Entries |
Document | Title | Date |
20080206793 | Ischemic Biomarkers and their Use to Predict Adverse Neurological Events from Surgery - Methods are provided for predicting the occurrence of adverse neurological events from surgery. Such adverse events include, for example, stroke, delirium and transient ischemic attach (TIA). The methods are based on the discovery that levels of circulating cerebral NMDA receptor peptides and antibodies can be used to identify patients who are likely to suffer from an adverse neurological event. Also provided are diagnostic procedures for practicing the predictive methods of the current invention, and interventional strategies for reducing the risk of adverse neurological events from surgery (FIG. | 08-28-2008 |
20080206794 | Systems And Methods For Characterizing Contrast Induced-Nephropathy - The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of contrast-induced nephropathy by detection of cytokines, cytokine-related compounds, and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat contrast-induce nephropathy. | 08-28-2008 |
20080206795 | Novel Supports, in Particular for Immunodetection of Molecules of Interest - The invention concerns supports or receptacles for solubilized or suspended biological entities whereof the walls are made of plastics surface-treated by an electromagnetic plasma followed by a polymer deposition. It can be in the form of tubes or multiple-well plates. It provides among other things the possibility of storing, transferring and performing reactions in the context of microassays of biological entities, more particularly the prion protein, with enhanced sensitivity. | 08-28-2008 |
20080206796 | Use of the Salivary Protein Cd14 as an Indicator of the Low Risk to Developing Dental Caries - It is generally accepted that salivary components are important for dental health, but till now no clear correlation has been found between one or more of said components and the onset of dental caries. The present invention relates to an assay method comprising analysing the presence and/or the content of the salivary soluble CD14 protein from a saliva sample of the individual subjected to examination; the absence of said protein from the salivary sample, or its presence in a reduced amount compared to a predetermined threshold value in caries-free individuals, is considered as a marker of susceptibility to developing caries and/or as a diagnostic element for the existence of ongoing carious lesions. | 08-28-2008 |
20080213807 | Methods of Using Bone Morphogenic Proteins as Biomarkers for Determining Cartilage Degeneration and Aging - Methods are provided for determining cartilage degeneration, regeneration, or aging in a joint tissue in a patient by measuring levels of osteogenic protein-1 (OP-1) protein and/or mRNA in synovial fluid or joint tissue. The methods according to the invention are useful for detecting, diagnosing, predicting, determining a predisposition for, or monitoring joint tissue degeneration, regeneration, or aging in a patient including inflammatory joint disease or age-related disorders. | 09-04-2008 |
20080220459 | Diagnosis of collagen IX destruction - A method for detecting or monitoring the presence of protein fragments, cleaved at novel cleaving sites near the N-terminal part of the collagen IX alpha 1 chain, close to the C-terminal part of the NC4 domain, and at the COL3 domain close to the NC3 domain. Neoepitope antibodies against the neoepitopes were created by the cleavages and an epitope in the cleaved N-terminal part of the NC4 domain unique to collagen IX. A diagnostic kit and antibodies useful in carrying out such methods are also presented | 09-11-2008 |
20080227125 | Secreted Polypeptide Species Reduced in Cardiovascular Disorders - The invention discloses human secreted polypeptides that circulate at a decreased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development. | 09-18-2008 |
20080227126 | OPTICAL WAVEGUIDE TYPE ANTIBODY CHIP AND METHOD OF MEASURING ANTIGEN CONCENTRATION - An optical waveguide type antibody chip includes a transparent substrate, an incident-side optical element and an emitting-side optical element placed at a distance from each other on a primary face of the substrate, a water repellent resin film formed on the primary face of the substrate including an optical waveguide layer formed between the optical elements, the water repellent resin film includes a reaction hole having exposed the optical waveguide layer on its bottom and a frame-shaped trench surrounding the reaction hole, a rectangular frame-shaped cell wall which is fixed in the trench of the water repellent resin film and which forms a cell capable of infusion and discharge of a specimen solution together with the reaction hole, and an antibody immobilization layer formed on the bottom of the reaction hole, the surface of the antibody immobilization layer being masked with at least a buffer agent and a salt. | 09-18-2008 |
20080227127 | Human NK3-Related Prostate Specific Gene-1 - The present invention relates to a novel member of the NK family of homeobox genes. In particular, isolated nucleic acid molecules are provided encoding the human NK-3 prostate specific gene 1 (NKX3.1) protein. NKX3.1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of NKX3.1 activity. Also provided are diagnostic methods for detecting prostate cancer and other cancers and therapeutic methods for prostate cancer and other cancers. | 09-18-2008 |
20080233600 | Method and Kit for the Measurement of Neutrophil Cell Activation - The present invention is related to accurate detection methods for the measurement only of myelopexidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them. | 09-25-2008 |
20080233601 | POLYMERIZABLE CHEMILUMINESCENT COMPOUNDS - Disclosed are compounds having the formula: | 09-25-2008 |
20080241863 | Biomarkers for liver diseases and method for using the same - Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity. | 10-02-2008 |
20080248506 | Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor - The present invention relates to the method of determining the anti-tumor activity of a histone deacetylase inhibitor by measuring the phosphorylation of the histone variant H2AX or the level of cytokeratin-18 fragment aa 387-397. | 10-09-2008 |
20080248507 | C-erbB-2 external domain: GP75 - Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden. | 10-09-2008 |
20080248508 | Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials - Chitosan is a natural product having wide range of applications in the food and cosmetic industries. Food and commodity grade chitosan are laden with pyrogens, such as endotoxins and proteins which limit its applicability in the biological and medical arenas, as minute amounts of endotoxins may induce adaptive and innate responses when contacted with mammalian tissue, pharmaceuticals and biomedical devices. Due to chitosan's ability to avidly bind endotoxin and other pyrogens, they are difficult to remove. The present invention is directed to methods for purifying chitosan from shells, food and commodity grade chitosan into ultra-pure, low endotoxin chitosan having biological and medical applicability. Additionally, the present invention is also directed to a method of determining the pyrogenicity of the ultra-pure low endotoxin chitosan. | 10-09-2008 |
20080254490 | Salivary Protease Assays for Identifying Increased Risk of Preterm Delivery Induced by Premature Rupture of Fetal Membranes - Assay methods for identifying an increased risk of preterm delivery induced by premature rupture of the fetal membranes are provided. More specifically, the invention provides salivary protease assays indicative of amniochorion and fetal membrane concentrations of proteases involved in the degradation of the fetal membranes leading to rupture. An increase in salivary protease levels beyond normal or individual baseline provides an indication that protease levels in fetal membranes and/or the amniotic fluid are abnormally elevated. Abnormally elevated protease levels define an increased risk of a premature delivery caused by rupture of the fetal membranes. Thus, abnormally high levels of salivary protease levels indicates elevated risk of PROM, and provides an indication for therapeutic intervention to prevent PROM-induced preterm labor. | 10-16-2008 |
20080261249 | Detecting and Quantifying Host Cell Proteins in Recombinant Protein Products - A single-step immunoassay method, kit, and reagents for detecting and quantifying contaminant host cell proteins in a recombinant protein sample are described. The method includes the step of adding to immobilized medium comprising a capture reagent including anti-host cell protein antibodies, both the recombinant protein sample and a detection reagent comprising anti-host cell protein antibodies and a detectable moeity. The recombinant protein sample and two reagents are added simultaneously. This single-step format provides greater interaction between the capture antibody, the contaminant host cell proteins that may be present in the recombinant protein sample, and the detection antibody. By providing the opportunity for both antibodies and HCPs to interact at the same time, the one step format allows the formation of the “capture antibody-HCP-detection antibody” complex with all possible HCPs present. Thus, the HCP assay sensitivity is significantly improved, and the possibility of a false negative is significantly reduced. In addition, the one step format shortens the assay turnaround time and provides a convenient tool for measuring the HCP in the product during the course of the entire purification procedure. Quality control of the process is increased and the protein purification efficiency during process development can be measured. | 10-23-2008 |
20080261250 | Methods for Assessing the Risk for Development of Cardiovascular Disease - The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease. | 10-23-2008 |
20080261251 | Monoclonal Antibodies, Hybridomas, Improved Method for Determining the Protein Ptx3 and Kit for Said Determination - Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody. | 10-23-2008 |
20080261252 | Soluble Interleukin-1 Receptor Accessory Molecule - The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein. IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are further provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists. | 10-23-2008 |
20080268476 | Nectin 4 (N4) as a Marker for Cancer Prognosis - The present invention relate for a method for prognosis cancer, in particular metastatic breast cancer comprising doing a dosage of Nectin 4, in a soluble form or in transmembrane form, in a sample, the presence of Nectin 4 being indicative of a cancer. | 10-30-2008 |
20080268477 | Antibody Reactive Specifically to Age Derived from 3,4-Dge - The present invention provides antibodies against AGEs derived from carbonyl compounds that are highly reactive with proteins or peptides, and methods of detecting the AGEs derived from the carbonyl compounds. 3,4-dideoxyglucosone-3-ene (3,4-DGE) is allowed to react with proteins, a host animal is immunized with the reaction product thereof, AGEs, and antibodies against the AGEs (anti-AGE antibodies) are isolated from serum recovered from the host animal. These anti-AGE antibodies thus isolated are allowed to react with a sample, and then the antigen-antibody reaction between the AGEs in the sample and the anti-AGE antibodies is detected. Thereby the presence or amount of the AGEs in the sample can be detected. | 10-30-2008 |
20080268478 | Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation - The invention disclosed herein relates to the detection or diagnosis of atherosclerosis by measuring the level of the protein eotaxin in an individual's serum. The presence of eotaxin above levels specified herein is indicative that atherosclerosis may be present. Detection of elevated eotaxin levels in serum may provide a means to diagnose atherosclerosis prior to the onset of symptoms. | 10-30-2008 |
20080268479 | FETUIN-A AS A BIOMARKER FOR MULTIPLE SCLEROSIS - Biomarkers are disclosed that facilitate the mechanisms associated with central nervous system disease worsening or activity, specifically multiple sclerosis. Methods are also disclosed for identification of biomarkers associated with disease worsening or activity in multiple sclerosis. | 10-30-2008 |
20080268480 | Methods of Evaluating Baff - The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject. | 10-30-2008 |
20080268481 | Sensitive Magnetic Catch Assay By Building a Strong Binding Couple - The invention relates to a sensor device for detecting a target in a sample suspected of comprising the target, which device is suitable for use in an assay such as a sandwich assay. The invention further relates to a method for detecting a target in a sample. The device comprises a sensor surface, which is functionalised with one moiety of a strong binding couple, which moiety preferably shows little or no cross reactivity with the target molecule. | 10-30-2008 |
20080274482 | BETA 1 INTEGRIN ACTIVATION AS A MARKER FOR ASTHMA - Methods are provided in which β | 11-06-2008 |
20080274483 | Method for Diagnosing Renal Disorder, Hemolytic Uremic Syndrome and Enterohemorrhagic Infectious Disease Caused by Escherichia Coli - Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic | 11-06-2008 |
20080274484 | Method for Diagnosing Renal Disorder, Hemolytic Uremic Syndrome and Enterohemorrhagic Infectious Disease Caused by Escherichia Coli - Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic | 11-06-2008 |
20080280310 | Testing for Blood Group Immunological Reaction Without the Use of Anti-Human Globulin - A method testing for blood antigens (known as forward blood grouping) is presented wherein known antibodies are attached to a solid surface and the red blood cell sample for immunological reaction is centrifuged to physically overcome the natural repellent force between two red cells (know in the industry as the zeta potential) and to allow for the antigen antibody reaction to occur more rapidly. A reverse blood grouping procedure utilizes synthetic or purified antigens, which are attached directly attached directly to a solid surface. The surface is then contacted with the patient's serum and then centrifuged to allow the antigen antibody reaction to occur. The cells are then washed and a second labeled antibody of known concentration is added as an indicator. This is a method of performing a major crossmatch that does not utilize anti-human immunoglobin. In an alternative major crossmatch procedure, a binder is used to attach red blood cell membranes from a blood donor and the serum from a recipient is allowed to undergo an immune reaction with these membranes on the solid surface. Antibody screening and antibody identification are carried out by attaching known antigen carrying cells to a solid surface. The solid surface is contacted with the unknown solution which will undergo an immune reaction to the extent that antibodies specific to the previously adhered antigens are present and will bind. Red blood cells or synthetic labeled particles are used as the indicator mechanism. | 11-13-2008 |
20080286817 | NOVEL ALLERGENS AND TREATMENT - The present invention is related to novel nucleotide sequences encoding a louse allergen and a methods for diagnosing, treating and preventing lice infestation and associated allergic disease with the nucleotide sequences and protein allergen of the invention. The present invention also relates to kits for diagnostic assays. | 11-20-2008 |
20080305505 | Method For Dissolution Testing of Pharmaceutical Products - The present invention relates to the field of dissolution measurement and, more particularly to methods for reproducible dissolution testing of pharmaceutical products such as allergen vaccines. | 12-11-2008 |
20080311599 | ANTIBODIES AGAINST CASPASE-8, THEIR PREPARATION AND USE - The invention relates to antibodies to a specific region in caspase-8, and to their use. | 12-18-2008 |
20080311600 | ROUNDWORM COPROANTIGEN DETECTION - A composition, device, kit and method for detecting the presence or absence of roundworm in a fecal sample. The composition, device, kit and method of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. | 12-18-2008 |
20080311601 | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy - The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors. | 12-18-2008 |
20080311602 | RAPID ELISA PROCESSES AND RELATED COMPOSITIONS - The present invention provides improved and rapid detection methods for an antigen such as a chemical compound, a peptide, a nucleic acid, or a protein released from cells or virus particles in situ. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional ELISA, and also Western blot or Dot blot assays. The improved ELISA method is rapid, economical, reproducible, simple and automatable. Also provided are compositions and kits for using the improved ELISA methods for the rapid detection of antigens. | 12-18-2008 |
20080311603 | Diagnostic Test for Inflammatory Endothelial Dysfunctions in Pregnancies - The present invention relates to a diagnostic test for inflammatory endothelial dysfunctions in pregnant women. Particularly, the present invention relates to a method of diagnosing or evaluating the risk of contracting an inflammatory endothelial dysfunction of the maternal compartment comprising the following steps: a) detecting the plasma levels of long pentraxin PTX3 in blood samples taken from a pregnant woman; b) comparing the PTX3 plasma level data, obtained according to step a), with statistically significant PTX3 plasma level data of normal pregnant population. | 12-18-2008 |
20080318257 | Polynucelotides encoding novel variants of the TRP channel family member, LTRPC3 - The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 12-25-2008 |
20090004678 | METHOD FOR SCREENING FERTILITY AND NEW COMPOUNDS OR MOLECULES, USING CRT OR ERP57 TRANSLOCATION - A screening method for testing the immunogenicity of new molecules and compounds and for testing fertility and sterility conditions. The method includes inducing a translocation of a calreticulin protein and/or an ERP57 protein, to a cellular membrane in order to determine the immunogenicity of the new molecules and compounds, or the fertility or sterility conditions. The method includes also the using of recombinant CRT and/or ERP57 to treat sterility. | 01-01-2009 |
20090004679 | METHOD FOR DETERMINING PLASMINOGEN ACTIVATOR INHIBITOR - A method is provided for determining active plasminogen activator inhibitor—Type 1 (PAI-1) in a biological fluid, the method comprising the steps of (i) providing a sample of a biological fluid; and (ii) measuring the amount of PAI-1/multimeric vitronectin complex in the sample to determine active PAI-1 in the sample. A kit for carrying out the method is also provided. | 01-01-2009 |
20090004680 | DETERMINING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY USING BOTULINUM TOXIN A PEPTIDES - The present invention provides BoNT/A peptide compositions, tolerogizing compositions, BoNT/A immune response inducing compositions and antibody compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of preventing or reducing immunoresistance to botulinum toxin therapy in an individual, methods of vaccinating an individual against botulinum toxin, methods of preparing anti-BoNT/A antibodies, methods of treating botulinum toxicity in an individual and methods of reducing anti-botulinum toxin antibodies in an individual. | 01-01-2009 |
20090011443 | METHODS FOR SIMULTANEOUSLY DETECTING BOTH MEMBERS OF A BINDING PAIR - Methods and kits for simultaneously measuring both members of a binding pair are described. | 01-08-2009 |
20090011444 | DETECTION AND DIAGNOSIS OF INFLAMMATORY DISORDERS - Soluble H4 (sH4) levels have been discovered to correlate with the stage or severity of inflammatory disorders including autoimmune disorders. In particular, circulating levels of sH4 can be used as a diagnostic for determining the severity of an inflammatory disorder or the propensity for developing an inflammatory disorder. The severity of an inflammatory disorder can be determined by assaying the levels of sH4 in a subject and comparing the levels of sH4 to reference sH4 concentrations that correlate to specific stages of an inflammatory disorder. The therapeutic efficacy of treatments for inflammatory disorders can also be determined by comparing levels of sH4 before and during treatment. Methods and devices for measuring sH4 are also provided. | 01-08-2009 |
20090011445 | METHOD AND APPARATUS FOR IN VIVO COLLECTION OF CIRCULATING BIOLOGICAL COMPONENTS - The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe. | 01-08-2009 |
20090017478 | HIGH-THROUGHPUT ENZYME-LINKED IMMUNO ABSORBENT ASSAY (ELISA) FOR DETERMINATION OF RHO-KINASE (ROK) ACTIVITY - The invention is referring to an assay for measuring the activity of a ROK (Rho Kinase) protein by means of a biotinylated peptide. | 01-15-2009 |
20090017479 | LY6H GENE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SEQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like. | 01-15-2009 |
20090023164 | COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies. | 01-22-2009 |
20090023165 | Methods for Early Diagnosis of Kidney Disease - The invention provides reagents and methods for diagnosing kidney disease in a human or animal. | 01-22-2009 |
20090023166 | Method For the in Vitro Diagnosis of Autoimmune Immune Response by Detection of Antibodies Directed Against The Pentraxin 3 Antigen - A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method. | 01-22-2009 |
20090035793 | Microchip for cell response evaluation - In a microchip which enables cell cultivation and accurate cell count measurement, fine particles affixed with cells are trapped within a passage by making the minimum width of a solution and fine particle inlet into a cell culture portion larger than the maximum diameter of the fine particles, and making the width of an outlet smaller than the maximum diameter of the fine particles. | 02-05-2009 |
20090035794 | METHOD FOR DETECTING, SCREENING, AND/OR MONITORING CANCER IN AN INDIVIDUAL - The invention relates to a method for screening and/or detecting and/or monitoring a cancer in an individual, said method comprising determining a first parameter represented by the concentration of TIMP-1 in at least one excreta, e.g. saliva, from the individual. The invention provides a method that without the need to use a blood sample is suitable for facilitating the early diagnosis of a cancer, monitoring the recurrence of a cancer, and/or monitoring the status of a cancer or the effect of cancer treatment in an individual. | 02-05-2009 |
20090042223 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS - Methods and reagents are disclosed for enhancing the bioavailability of a hydrophobic drug, and in some embodiments for determining a hydrophobic drug, in a sample suspected of containing a hydrophobic drug. A combination is formed in a medium where the combination comprises the sample, a hemolytic agent where a determination of the hydrophobic drug is conducted, and a bioavailability agent for the hydrophobic drug. The bioavailability agent comprises an ionic detergent comprising a chain of at least 10 carbon atoms or a non-ionic detergent comprising a chain of at least 15 repeating ethylene oxide units or propylene oxide units or a combination of ethylene oxide units and propylene oxide units. The concentration of the bioavailability agent in the medium is sufficient to enhance the bioavailability of the hydrophobic drug. The medium is incubated under conditions for enhancing the bioavailability of the hydrophobic drug, and in a determination of the hydrophobic drug under conditions for hemolyzing cells in the sample. For determination of the hydrophobic drug, reagents for determining the presence and/or amount of the hydrophobic drug in the sample are added to the medium. The reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug. The presence and/or amount of the complex indicates the presence and/or amount of the hydrophobic drug in the sample. | 02-12-2009 |
20090042224 | METHODS FOR DIAGNOSIS AND/OR PROGNOSIS OF OVARIAN CANCER - In one embodiment, methods are provided for assessing the presence of mesothelin-expressing tumor cells in a human subject. In another embodiment, methods are provided for monitoring the efficacy of treatment of a human cancer patient diagnosed with a mesothelin-expressing tumor. | 02-12-2009 |
20090042225 | Method for selecting therapeutic agents for cancer treatment - An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated. The tissue sample technique of the present invention is also useful in assaying expression and/or secretion of various markers, factors or antigens present on or produced by the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents. | 02-12-2009 |
20090042226 | Identification and cloning of a full-length human CLNK-related gene, MIST (MAST cell immunoreceptor signal transducer) - The present invention describes a newly discovered full-length polynucleotide encoding an SH2 domain-containing adapter protein, called human MIST, cloned, isolated and identified from a human spleen cDNA library. Also described are the MIST polypeptide sequence, expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Novel splice variant forms of human MIST are provided. Methods for screening for modulators, particularly inhibitors, of the MIST protein and use of the human MIST polynucleotide and polypeptide for therapeutics and diagnostics are described. | 02-12-2009 |
20090053742 | Capture and release based isotope tagged peptides and methods for using the same - The invention provides non-affinity based isotope tagged peptides, chemistries for making these peptides, and methods for using these peptides. In one aspect, tags comprise a reactive site (RS) for reacting with a molecule on a protein to form a stable association with the peptide (e.g., a covalent bond) and an anchoring site (AS) group for reversibly or removably anchoring the tag to a solid phase such as a resin support. Anchoring may be direct or indirect (e.g., through a linker molecule). Preferably, the anchoring site comprises a biotin compound. Preferably, the tag comprises a mass-altering label, such as a stable isotope, such that association of the tag with the peptide can be monitored by mass spectrometry. The reagents can be used for rapid and quantitative analysis of proteins or protein function in mixtures of proteins. | 02-26-2009 |
20090061465 | COMPOSITION FOR ANALYZING DIABETES MELLITUS AND/OR RETINAL VASCULAR DISEASE AND ANALYZING METHOD THEREOF - Disclosed are composition for diagnosing a diabetes mellitus and a retinal vascular disease, a kit for diagnosing the retinal vascular disease including the protein, a gene encoding the protein, and a method for analyzing an antibody prepared by the diabetes mellitus and/or the retinal vascular disease using the same. | 03-05-2009 |
20090061466 | ANTI-DRUG ANTIBODY ASSAY - The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at least two different antibody sites. | 03-05-2009 |
20090068687 | Screening platform for discovery of immunomodulatory activities in traditional medicine - The present invention relates to a method of screening traditional medicines for immunomodulating activity and anti-tumor activity. The method involves applying techniques and tools used in the field of proteomics, isolating an active ingredient from a natural ingredient historically used as a traditional medicine, stimulating splenocytes, and measuring and determining biomarker indicators resulting from such stimulation. | 03-12-2009 |
20090068688 | PVDF membranes - The invention provides a method of treating a polyvinyl difluoride (PVDF) membrane comprising: (a) contacting said membrane with an alcohol and a wetting agent; and (b) drying said membrane. | 03-12-2009 |
20090068689 | Molecular phenotyping of severe asthma - The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected. | 03-12-2009 |
20090068690 | METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF HAVING OVARIAN CANCER AND COMPOSITIONS THEREFOR - Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided. | 03-12-2009 |
20090068691 | Endothelial-monocyte activating polypeptide II, a biomarker for use in diagnosis and treatment of brain injury - A diagnostic tool and method of diagnosing brain injury and brain injury type (traumatic vs. ischemic) by detecting the level of expression of endothelial monocyte-activating polypeptide II (EMAP-II) and comparing to a control. An increase of EMAP-II indicates the presence of traumatic brain injury and a decrease of EMAP-II indicates the presence of ischemic brain injury. Detection of EMAP-II can be done in brain tissue, biofluids such as cerebrospinal fluid or blood (including plasma and serum) | 03-12-2009 |
20090075305 | Diagnostic serum antibody profiling - The invention is directed to a microarray assay procedure that can be used for profiling the antibodies present in serum, plasma or blood. The assay may be used to identify antibodies and antigens that are characteristic of particular diseases or conditions. In addition, the invention includes specific antigens that are associated with prostate cancer, progressive benign prostate hyperplasia (BPH) and ovarian cancer. | 03-19-2009 |
20090075306 | DIAGNOSTIC ASSAY FOR DETECTING AND MONITORING AGE RELATED AND NOISE INDUCED HEARING LOSS - A method of detecting age related and/or noise induced hearing loss in a subject includes detecting in a biological sample from the subject the presence of cochlin antibodies; and correlating the level of detected cochlin antibodies to the presence or absence of age related and/or noise induced hearing loss in the subject. | 03-19-2009 |
20090075307 | METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF HAVING OVARIAN CANCER AND COMPOSITIONS THEREFOR - Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided. | 03-19-2009 |
20090081712 | ATM-Dependent Phosphorylation of Sp1 Is Involved in the Cellular Response to DNA Damage and Enhances Cellular Survival After DNA Damage - The present invention is related to the discovery that phosphorylation of SP1 (SEQ ID NO.: 2) at serine residue 101 (known herein as phosphoserine | 03-26-2009 |
20090081713 | PEPTIDE BIOMARKERS PREDICTIVE OF RENAL FUNCTION DECLINE AND KIDNEY DISEASE - The presently-disclosed subject matter provides methods for diagnosing a kidney disease, or the risk thereof, in a subject. The methods comprise determining an amount of at least one peptide biomarker disclosed herein in a biological sample from the subject and comparing the amount of the at least one peptide in the sample with a control level, wherein if the amount determined is different than the control level, the subject is diagnosed as having, or at an increased risk of developing, the kidney disease. | 03-26-2009 |
20090093005 | PROTEIN-BASED BIOMARKERS FOR ABDOMINAL AORTIC ANEURYSM - The present invention encompasses compositions and methods useful for diagnosing subjects with abdominal aortic aneurysms. The invention relates to the use of protein biomarkers whose levels are different in subjects with abdominal aortic aneurysms relative to normal subjects. | 04-09-2009 |
20090098583 | METHODS OF DETECTING EARLY RENAL DISEASE IN ANIMALS - The present invention provides a method for the detection of early renal disease in animals. The method includes the steps of (a) obtaining a sample from an animal to be tested and (b) determining the amount of albumin in the sample. An amount of albumin in the range of from 10 μg/ml to about 300 μg/ml indicates the presence of early renal disease. The present invention also provides antibodies to canine, feline and equine albumin which can be used to detect the presence of early renal disease. | 04-16-2009 |
20090098584 | Biomarkers and Methods for Determining Sensitivity to Vascular Endothelial growth factor Receptor-2 Modulators - VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer. | 04-16-2009 |
20090104632 | MODIFIED TWO-STEP IMMUNOASSAY EXHIBITING INCREASED SENSITIVITY - The present invention relates to immunoassays for detecting or quantifying at least one analyte of interest in a test sample which exhibits improved sensitivity and/or a reduction in non-specific background compared to the immunoassay formats known in the art. | 04-23-2009 |
20090104633 | Kit for Highly Sensitive Detection Assays - The present invention relates to kits comprising 2,4-dichlorophenoxyacetate derivatives as well as antibodies that bind to these derivatives. Inter alia, the kits can be used to label biomolecules for analytical and diagnostic applications. Some of the compounds described here can be used to label biomolecules under physiological conditions and without having to apply in situ activation. Furthermore, the presence of spacers within the 2,4-dichlorophenoxyacetate derivatives improves their binding to antibodies. | 04-23-2009 |
20090104634 | ONE-STEP IMMUNOASSAYS EXHIBITING INCREASED SENSITIVITY AND SPECIFICITY - The present disclosure relates to immunoassays for detecting or quantifying at least one analyte of interest in a test sample which exhibits improved sensitivity and specificity compared to the immunoassay formats known in the art. | 04-23-2009 |
20090111130 | METHOD OF EXAMINING PREGNANCY TOXEMIA - It is intended to provide a method of detecting the onset of pregnancy toxemia whereby the onset risk of pregnancy toxemia can be adequately evaluated. Namely, a method of detecting the onset of pregnancy toxemia in a pregnant mammal which comprises the measurement step of measuring the concentration of angiopoietin-2 in a body fluid, the comparison step of comparing the angiopoietin-2 concentration obtained in the above measurement step with a normal level, and the judgment step of judging the presence or absence of the onset risk of pregnancy toxemia based on the results of the above comparison step. In the judgment step, it may be considered that the patient has a risk of the onset of pregnancy toxemia in the case where the angiopoietin-2 concentration obtained in the measurement step is lower than the normal level. | 04-30-2009 |
20090111131 | Method of detecting protein losing enteropathy in animals - The present invention provides a method and kit for the detection of Protein Losing Enteropathy (PLE) in animals. The method includes the steps of (a) obtaining a biological sample from an animal to be tested and (b) determining the absence or presence of albumin in the biological sample via a kit comprising an immunoassay utilizing a species-specific anti-albumin antibody. | 04-30-2009 |
20090123951 | Method Of Diagnosing A Body Weight Condition Or Predisposition - A method for diagnosing a body weight condition or predisposition to a body weight condition in an animal by determining observed level(s) of at least one biomarker in a tissue or biofluid sample from the animal and comparing the observed level(s) to reference level(s) for the biomarker; wherein the observed level(s) relative to the reference level(s) are individually or collectively indicative of the body weight condition or predisposition. | 05-14-2009 |
20090136971 | MULTIPLEX LIQUID TISSUE METHOD FOR INCREASED PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICAL SAMPLES, TISSUES, AND CELLS - The invention provides methods for multiplex analysis of biological samples of formalin-fixed tissue samples. The invention provides for a method to achieve a multiplexed, multi-staged plurality of Liquid Tissue preparations simultaneously from a single histopathologically processed biological sample, where the protocol for each Liquid Tissue preparation imparts a distinctive set of biochemical effects on biomolecules procured from histopathologically processed biological samples and which when each of the preparations is analyzed can render additive and complementary data about the same histopathologically processed biological sample. | 05-28-2009 |
20090142781 | Non-Liquid Phase Type Chemiluminescent Enzyme Immunoassay Method and Assay Kit - A chemiluminescent enzyme immunoassay method whereby a target substance such as a protein is assayed. This chemiluminescent enzyme immunoassay method comprises: the step of capturing an immune complex containing an enzyme-labeled antibody, which is labeled with an enzyme acting a chemiluminescent substrate, and the target substance on a support having no solution layer; the step of overlaying a support membrane containing the chemiluminescent substrate on the immune complex having been captured above; and the step of measuring the luminescence dose caused by the reaction between the enzyme-labeled antibody and the chemiluminescent substrate to thereby quantify the target substance. Since a highly sensitive chemiluminescent enzyme immunoassay is conducted by using a non-liquid phase type reaction system in the chemiluminescent enzyme immunoassay method as described above, multiple items can be assayed by using only a small amount of a specimen and, furthermore, the target substance can be assayed at a high sensitivity thereby without resorting to any troublesome procedures such as pipetting a reagent. | 06-04-2009 |
20090142782 | Identification of Actinobacillus actinomycetemcomitans Antigens for Use in the Diagnosis, Treatment, and Monitoring of Periodontal Diseases - Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by | 06-04-2009 |
20090155822 | Process for diagnosing rheumatic diseases - The invention relates to polypeptides reacting with rheumatism-associated autoantibodies. The invention moreover relates to a diagnostic agent comprising any of said polypeptides, to a diagnostic kit comprising said diagnostic agent and to a process for in vitro detection of rheumatic diseases. The invention furthermore relates to a medicament comprising any of said polypeptides and to the use of said polypeptides for preparing a medicament for the prophylaxis and/or treatment of rheumatic diseases. | 06-18-2009 |
20090155823 | Automated Immunoassay Apparatus - An automated immunoassay apparatus is disclosed comprising a single optical reading device ( | 06-18-2009 |
20090155824 | METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 06-18-2009 |
20090155825 | DETECTION OF ANAPLASMA PLATYS - The invention provides compositions and methods for the detection of | 06-18-2009 |
20090162876 | MYELOPEROXIDASE ASSAYS - The present invention relates to methods and kits for determining autoantibodies to myeloperoxidase or a myeloperoxidase fragment and myeloperoxidase or a myeloperoxidase fragment in a test sample. | 06-25-2009 |
20090170133 | Intact IGFBP-3 as a Colon Cancer Risk Factor in Patients With Inflammatory Bowel Disease - The subject invention provides a method for determining whether a human subject afflicted with long-lasting irritable bowel disease (IBD) has an increased risk for developing colon cancer comprising: (a) determining the concentration of intact IGFBP-3 in a suitable cell-free bodily fluid sample taken from the subject; and (b) determining whether the concentration of intact IGFBP-3 determined in step (a) is indicative of an increased risk of colon cancer in a human subject afflicted with long-lasting IBD. This invention also provides a kit for performing the instant method. | 07-02-2009 |
20090170134 | BIFUNCTIONAL AND TRIFUNCTIONAL NITRONE SPIN TRAPPING COMPOUNDS AND USES THEREOF - Methods and compositions for detecting free radicals, the compositions being spin trapping compounds comprising a nitrone having a detecting moiety and optionally having a targeting moiety for targeting the nitrone to an organ, a cell, an organelle or a molecule of interest for directly detecting free radicals, especially free radicals in biological samples. | 07-02-2009 |
20090170135 | DETERMINING FELINE proBNP - Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 20 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed. | 07-02-2009 |
20090170136 | DETERMINING FELINE proBNP - Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed. | 07-02-2009 |
20090170137 | DETERMINING CANINE proBNP - Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed. | 07-02-2009 |
20090170138 | DETERMINING CANINE proBNP - Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 32 to 48 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed. | 07-02-2009 |
20090176256 | Methods and Products for Evaluating an Immune Response to a Therapeutic Protein - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 07-09-2009 |
20090176257 | Methods and Biomarkers for Diagnosing and Monitoring Psychotic Disorders - The invention relates to methods of diagnosing or monitoring a psychotic disorder in a subject comprising providing a test biological sample from the subject, performing spectral analysis on said test biological sample to provide one or more spectra, and, comparing the one or more spectra with one or more control spectra. The invention also relates to methods for diagnosing or monitoring psychotic disorders such as schizophrenic or bipolar disorders, comprising measuring the level of one or more biomarkers present in a biological sample taken from a test subject, said biomarkers being selected from the group consisting of transthyretin, ApoA1: VLDL, LDL and aromatic species such as plasma proteins. The invention also relates to sensors, biosensors, multi-analyte panels, arrays, assays and kits for performing methods of the invention. | 07-09-2009 |
20090176258 | TEST FOR THE DETECTION OF PATHOLOGICAL PRIONS - The am of the invention is to create a method for detecting pathological prions which is highly sensitive, can be carried out quickly and at a low cost, and allows prions to be detected at an early stage of a disease. Said aim is achieved by the fact that immobilized capture antibodies bind the pathological and non-pathological form of the prion protein contained in a sample whereupon the bound non-pathological form is specifically divided by means of plasmin. The undivided, pathological form of the prion protein, which is bound by the immobilized capture antibodies, can then be easily detected with the aid of detection antibodies. The inventive method is used for detecting pathological prions. | 07-09-2009 |
20090197286 | Methods and Kit for Diagnosing T1DM - A method of diagnosing Type 1 Diabetes Mellitus (T1DM) in a subject in need thereof is provided. The method comprising determining a presence and/or a level of antibodies in a biological sample of the subject, wherein the presence or level above a predetermined threshold is indicative of T1DM, thereby diagnosing T1DM in the subject. Also provided are a kit for diagnosing T1DM and a method of monitoring anti diabetic treatment. | 08-06-2009 |
20090197287 | SYSTEMS AND METHODS FOR CHARACTERIZING KIDNEY DISEASE - The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders. | 08-06-2009 |
20090203053 | METHODS AND MATERIALS FOR AMPLIFICATION OF A SIGNAL IN AN IMMUNOASSAY - Ultrafine particles are provided having a core region that has a signal amplifying molecule and a shell region that surrounds the core region. The shell region has at least one antibody affixed to its surface that is specific for at least one antigen. Alternatively, the ultrafine particles may entrap the signal amplifying molecule within its matrix and may also have antibodies affixed to its surface for molecular recognition. Ultrafine particles are also provided having a matrix component that includes a signal amplifying molecule and at least one antibody specific for the antigen or biomaterial. The ultrafine particles of the present disclosure may be used in assays for the detection, including quantification, of one or more antigens present in a biological sample. | 08-13-2009 |
20090208982 | ASSAY METHOD FOR HUMAN OROTATE PHOSPHORIBOSYLTRANSFERASE PROTEIN - To establish an immunoassay method for human OPRT. | 08-20-2009 |
20090208983 | Diagnose device for measuring the ratio of proteins with similar structure - The present invention relates to a diagnostic device for measuring the ratio of similar structural proteins among the proteins secreted in a liquid test sample taken from diagnosis subject. In further detail, the test device according to the present invention comprises detection marker-antibody conjugate recognizing the same site on two or more similar structural proteins and a detection zone in which antibody specifically recognizes each of said proteins via formation of sandwich type complex, wherein said antibodies form a set, and the present Invention relates to a diagnostic device for early diagnosis of polycystic ovary syndrome, abnormal pregnancy, prostatic carcinoma etc. based on determination of the ratio of follicle stimulating hormone and luteinizing hormone in case of polycystic ovary syndrome, the ratio between hCG isomers in case of abnormal pregnancy, and the ratio of prostate-specific antigens (PSA) in case of prostatic carcinoma. | 08-20-2009 |
20090208984 | DETECTION OF FOOD SPECIFIC HUMAN IgG4 ANTIBODIES - This invention particularly discloses an improved immunoassay method for the sensitive and specific detection of food specific human IgG4 antibodies. A sample diluent comprising a chaotrophic agent is used to reduce the occurrence of nonspecific antibody-dietary antigen interactions. To reduce competition between IgE and IgG4 antibodies for specific epitopes on dietary antigens a heat denaturing step is included to inactivate IgE antibodies. Finally, a signal amplification step is included in the assay to reduce the amount of sample required to perform the assay. | 08-20-2009 |
20090208985 | Method Of Evaluating Degree Of Skin Sensitivity Using Squamous Cell Carcinoma Antigen As An Indicator Thereof - The present invention provides a method for evaluating the degree of skin sensitivity by using the expression of squamous cell carcinoma antigen (SCCA) in skin corneocytes as an indicator thereof. | 08-20-2009 |
20090208986 | Method and kit for diagnosing acute myocardial infarction - Disclosed herein are method and kit for diagnosing acute myocardial infarction which is capable of predicting and diagnosing whether coronary artery disease is proceed to myocardial infarction or not by using an increase in triglyceride level in high density lipoprotein (HDL) or low density lipoprotein (LDL), a decrease in cholesterol level in HDL, increase of interleukin-6, CETP (cholesteryl ester transfer protein) and apo (apolipoprotein) C-III as a biomarker that are characteristic changes occurred only in sera of myocardial infarction patients among patients with coronary artery disease. | 08-20-2009 |
20090208987 | Method and Composition for Stabilizing Liquid Reagents - The invention relates to methods and compositions for removing a dissociated species from a fluid medium solution during and after it has detached from a solid-phase immersed in said medium, thereby allowing the concentration of free species to remain close to zero, and for improving the signal to noise ratio in assays. This is achieved by employing a substrate, such as a scavenging solid-phase, having an attached binding partner or partners (“scavenger”) for the specifically binding species and which is present during storage. This substrate may also contain regions for binding signal generating components attached to the solid-phase. This substrate binds any free species bleeding off the solid phase, increasing the reliability and sensitivity of assays. A subset of the substrates in the invention additionally forms cross-linked networks of solid-phase particles that further increase the sensitivity of assays. | 08-20-2009 |
20090215094 | DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 08-27-2009 |
20090221008 | NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention. | 09-03-2009 |
20090233319 | Method for Evaluating Skin Condition Using Squamous Cell Carcinoma Antigen as Marker - The invention provides a method for evaluating skin condition using squamous cell carcinoma antigen (SCCA) expression in skin stratum corneum cells as a marker. | 09-17-2009 |
20090253154 | Blood and saliva test for detection of delayed food allergy and intolerance against modified foods - A method for determining the presence of delayed food allergy and intolerance against antigens extracted from modified foods. The method includes determining a level of antibodies against a modified dietary food antigen in blood and mucosal samples from the patient and comparing the level with normal levels of the antibodies. Dietary antigens that were tested include milk and modified milk products; eggs and modified egg products; meat and modified meat products; fish, mollusks, and crustaceans and their modified products; oils, fats and their modified products; grains and modified grain products; pulses, seeds kernels, nuts and their modified products; vegetables and modified vegetable products; fruits and modified fruit products; sugar, modified sugar products, modified chocolate products and confectionery; and spices and their modified forms. | 10-08-2009 |
20090253155 | Method For Diagnosing Irritable Bowel Syndrome and Monitoring Inflammatory Bowel Disease - A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease. | 10-08-2009 |
20090258377 | Method of Measuring Enzymatic Activity of Adsorbed Allergenic Enzyme - The invention relates to a method of measuring the immunological activity of a vaccine preparation in the form of a mixture of one or more allergenic enzyme(s) and an oxygen-containing metal salt adjuvant, wherein the mixture comprises a liquid phase and a solid phase, and wherein at least a part of the allergenic enzyme(s) is adsorbed to the solid phase, the method comprising the steps of measuring the enzymatic activity of the mixture in an enzyme activity assay, and using the measurement obtained as an indication of the immunological activity of the vaccine preparation, or using the measurement obtained for quantifying the amount of allergenic enzyme. | 10-15-2009 |
20090258378 | STRESS-INDUCED PHOSPHOPROTEIN 1 AS A BIOMARKER FOR THE DETECTION OF HUMAN OVARIAN CANCERS AND ENDOMETRIOSIS - Disclosed herein is a method for the detection, preliminary screening or monitoring of a gynecological disease selected form ovarian cancers and endometriosis, in which STIP1 is used as a biomarker for the gynecological disease. | 10-15-2009 |
20090258379 | ISOLATION OF MEMBRANE VESICLES FROM BIOLOGICAL FLUIDS AND METHODS OF USING SAME - Methods of isolating membrane vesicles from a biological fluid sample are provided. In some embodiments, the methods comprise providing a biological fluid sample comprising membrane vesicles; filtering the biological fluid sample through a filtration module comprising a filter having an average pore diameter of between about 0.01 um and about 0.15 um; and collecting from the filtration module a retentate comprising the membrane vesicles, thereby isolating the membrane vesicles from the biological fluid sample. | 10-15-2009 |
20090263837 | METHOD OF MINIMIZING REAGENT CONSUMPTION IN MICROPLATE-BASED REACTIONS - A method is provided for performing a reaction, such as the synthesis of concentrated cDNA, in the wells of a microplate while minimizing the volume of the solution of reagents required to perform the reaction. In the method, a pestle is inserted into the well of a microplate to which a substance has been immobilized. A volume of reagent solution is introduced into the well that is insufficient to cover the portion of the well onto which the substance is immobilized. The insertion of the pestle displaces reagent solution and increases the surface area of the solution in contact with the portion of the well to which the substance has been immobilized when the pestle is inserted. | 10-22-2009 |
20090263838 | Method for determining a lung cancer treatment and method for determining the effectiveness of an agent for treatment of lung cancer - The present invention provides a method of determining a lung cancer treatment, the method comprising: measuring an amount of KL-6 in a sample of body fluid from a subject, and determining the treatment based on the amount of KL-6 measured, and a method of determining the effectiveness of an agent for treatment of lung cancer on a subject, the method comprising: measuring an amount of KL-6 in a sample of body fluid from the subject, determining the effectiveness of an EGFR inhibitor on the subject should the EGFR inhibitor be administered as the agent for treatment of lung cancer, based on the amount of KL-6 measured. | 10-22-2009 |
20090269790 | Method and Apparatus for Determining Hemocompatibility - Provided herein are techniques for screening materials for hemocompatibility. Hemocompatible materials may be advantageous when incorporated into devices that may come into direct contact with blood or other bodily fluids. Such techniques take advantage of conformational changes in fibrinogen when adsorbed onto certain materials. As a result of conformational changes, the fibrinogen has altered responsiveness to cleavage by thrombin. Accordingly, the products of thrombin cleavage of fibrinogen may be assessed to determine the hemocompatibility of a material. | 10-29-2009 |
20090269791 | NON-PROTEOLYTIC METHOD FOR THE DETERMINATION OF ANALYTES IN KERATINIZED STRUCTURES - Methods that permit the rapid release of one or more analytes from head or body hair or other keratinized structures of an individual (who may previously have ingested one or more of the analytes) are provided. The methods can include contacting the keratinized structure with a reducing agent but not with a proteolytic agent. The methods can further include identification and quantification of the one or more analytes by known analytical techniques such as immunoassays. The described methods do not damage the analyte and do not cause harmful effects on a subsequently-used analyte detection probe (e.g., an antibody). | 10-29-2009 |
20090275059 | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same - Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage. | 11-05-2009 |
20090275060 | DETERMINATION OF SERUM ANTI-MULLERIAN HORMONE AS A DIAGNOSTIC TEST FOR SPAY IN COMPANION ANIMALS - This invention relates to non-surgical assays that can be used to determine whether an animal that has a non-postpartum anestrous period of three months or greater, such as a dog or a cat, has been spayed. In particular, the present invention relates to devices, kits and methods that allow correlation of levels of Anti-Müllerian Hormone with the state of being spayed. | 11-05-2009 |
20090275061 | METHOD TO MEASURE SERUM BIOMARKERS FOR THE DIAGNOSIS OF LIVER FIBROSIS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of different liver fibrosis-associated serum biomarkers in a serum sample, which can be used for the diagnosis of liver fibrosis. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antibodies used for the detection of liver fibrosis-associated serum biomarkers for the diagnosis of liver fibrosis. | 11-05-2009 |
20090275062 | METHOD OF TACROLIMUS EXTRACTION AND QUANTIFICATION USING AQUEOUS DETERGENTS - The present invention relates to a method of extracting tacrolimus in a test blood sample to use in a tacrolimus quantification assay. The method of the present invention extracts tacrolimus in non-precipitating, non-denaturing aqueous environment, avoiding cumbersome manual pretreatment procedures or the use of organic solvents. The method of the present invention permits full automation of tacrolimus quantification assays. | 11-05-2009 |
20090286267 | Methods for Determining Drug Responsiveness - The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the protein levels of a gene that responds to the drug, such as a steroid, to the protein levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid. | 11-19-2009 |
20090286268 | Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples - The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. | 11-19-2009 |
20090291461 | METHOD OF SELECTIVELY ASSAYING ADIPONECTIN MULTIMERS - Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody. | 11-26-2009 |
20090305314 | Upregulation of Adamts4 Protease Activity for the Treatment of Alzheimer's Disease - The invention provides methods of identifying compounds suitable for treating Alzheimer's disease and related conditions by means of modulation of ADAMTS4. | 12-10-2009 |
20090311724 | USE OF ADDITIVES FOR THE REDUCTION OF NON-SPECIFIC BINDING IN ASSAYS - A method for reducing non-specific binding in an assay is provided herein. The method includes (a) providing a reaction mixture, which includes or is suspected to include a first component and a second component capable of binding to each other in a specific binding reaction, and (b) adding non-physiological amounts of at least one additive to the reaction mixture before, during or after binding in a sufficient amount to reduce non-specific binding in the reaction mixture. The method further includes (c) monitoring or measuring the presence and/or concentration of at least one of the first and second components after step (b). | 12-17-2009 |
20090311725 | POLYPEPTIDE PRODUCING CELLS - The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor. | 12-17-2009 |
20090311726 | Methods and compositions for categorizing patients - The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data. | 12-17-2009 |
20090311727 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN - The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing on the solid support the gliadin fusion protein via the tag. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase. | 12-17-2009 |
20090317841 | Methods and Materials for the Detection of Leishmania Infection - The present invention provides rapid diagnostic assays for the detection of | 12-24-2009 |
20090317842 | Methods and Tools for The Therapy of Neurodegenerative Pathologies - The present invention concerns compositions and methods for the treatment of neurodegenerative diseases in which the cognitive functions are altered, such as observed in Alzheimer's disease. More particularly, the invention presents a strategy for human clinical monitoring of the activity and/or effectiveness of neuroprotective treatments, based on biochemical assay of certain platelet parameters, and thus can be done by blood sampling. The invention also concerns methods, tools, constructions and compositions suitable for implementing these strategies. | 12-24-2009 |
20090317843 | METHOD FOR MEASURING PLASMA LEVELS OF LONG PENTRAXIN PTX3 - The present invention relates to a method for measuring PTX3 in a biological fluid, particularly in human or animal plasma. Particularly, the present invention relates to a method for measuring PTX3 levels in a human or animal derived plasma sample, comprising a stage of the treatment of said plasma sample with a red blood cell agglutinating agent and a subsequent stage of determining the plasma levels of PTX3. | 12-24-2009 |
20090325204 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CHAGAS DISEASE - Compounds and methods are provided herein that provide for diagnosis and treatment of Chagas disease. | 12-31-2009 |
20100003707 | GLAUCOMA BIOMARKER - According the present invention, Brain Derived Neurotrophic Factor (BDNF) in the tears or blood is used as a biomarker for early detection and assessing the progression of POAG. A reduced level of BDNF compared to normal range can be the sign of POAG. Lower levels of BDNF represent more advanced cases of POAG. The invention includes both the method and the analytic kit for performing the method. | 01-07-2010 |
20100009391 | METHOD FOR EXTRACTING GLUTEN FROM PROCESSED AND UNPROCESSED FOODS BY MEANS OF HEAT BASED ON THE USE OF IONIC AND NON-IONIC DETERGENTS - The present invention relates the analysis of foods for celiac patients. In particular, the invention includes: a method for extracting gluten from foods, which is compatible with an enzyme-linked immunosorbent assay (ELISA) and with the Western Blot technique; compositions suitable for implementing this method; kits that comprise these compositions; a method for the quantification of the gluten present in a food. | 01-14-2010 |
20100009392 | USE OF MELANOMA INHIBITORY ACTIVITY (MIA) PROTEIN AS AN EARLY INDICATOR FOR THERAPEUTIC RESPONSE IN MELANOMA - The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent. | 01-14-2010 |
20100009393 | FACTOR H POLYMORPHISMS IN THE DIAGNOSIS AND THERAPY OF INFLAMMATORY DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION - The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases. | 01-14-2010 |
20100015644 | Potency assays for antibody drug substance binding to an fc receptor - The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor. | 01-21-2010 |
20100015645 | IL-8 AS BIOMARKER FOR THE DETECTION OF UROLITHIASIS - Disclosed herein is a method for the detection or preliminary screening of urolithiasis, comprising: detecting the IL-8 level and the creatinine level in a urine sample taken from a human subject suspected to have urolithiasis; obtaining a creatinine-normalized IL-8 level in the urine sample by normalizing the detected IL-8 level to the detected creatinine level; and comparing the creatinine-normalized IL-8 level in the urine sample with a predetermined standard; wherein an elevation of the creatinine-normalized IL-8 level in the urine sample as compared to the predetermined standard is indicative of urolithiasis. | 01-21-2010 |
20100015646 | PORTABLE, POINT-OF-CARE, USER-INITIATED FLUIDIC ASSAY METHODS AND SYSTEMS - Methods and systems to perform point-of-care, user-initiated fluidic assays, using substantially self-contained, portable, user-initiated fluidic assay systems. Exemplary assays include diagnostic assays and chemical detection assays. Diagnostic assays may include, without limitation, enzyme-linked immuno-sorbent assays (ELISA), and may include one or more sexually transmitted disease (STD) diagnostic assays. An exemplary assay system includes a housing having one or more fluid chambers, a fluid controller system to dispense fluid from the one or more fluid chambers, and a user-initiated actuator to control the fluid controller system. The actuator may be configured to move fluid controllers from functionally closed positions to functionally open positions, to control fluid flow from the fluid chambers. The fluid controller system may be configured to dispense fluids serially, and may be configured to mix a plurality of fluids. The housing may include one or more fluid paths amongst the fluid chambers and/or between the fluid chambers and an assay portion, and the fluid controller system may be configured to serially align fluid chamber outlets with corresponding fluid paths. The user-initiated actuator system may include an external user-operated trigger mechanism to initiate the actuator system. The actuator system may include a mechanical actuator system, and may include a compressible spring actuator system. The assay apparatus may include a display window to view assay results. Exemplary methods of preparing portable, user-initiated fluidic assay systems, and methods of using portable, user-initiated fluidic assay systems are disclosed. | 01-21-2010 |
20100015647 | METHOD AND KIT FOR THE DETECTION OF HEPARIN-DEPENDENT ANTIBODIES AND THE DIAGNOSIS OF IMMUNE OR AUTOIMMUNE PAHTOLOGIES POTENTIATED BY HEPARIN SUCH AS HEPARIN-INDUCED THROMBOCYTOPENIA - The invention relates to a method for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by a heparin substance, such as thrombocytopenia induced by heparin (HIT type II) as inducer drug. The invention is characterized in that said method comprises the steps consisting in: 1) reacting: at least one substance with high affinity for a heparin substance (SFA), consisting of any molecule or complex having a high affinity for a heparin substance, with at least one heparin substance (SH) so as to form a substance with high affinity for heparin-heparin substance (SFA-SH) complex, wherein the heparin substance is in slight or large excess, so as to be able to bind other substances with affinity for heparin; then with at least one potential antigenic substance capable of reacting with the heparin substance, thus forming a complex (Ag-SH; and, finally, with the plasma or the serum of a patient to be tested (preferably diluted to a dilution of the order of 1:100) potentially containing: an anti(Ag-SH) antibody material generated in the organism after administration of a heparin substance, and/or at least one immune complex consisting of an Ag-SH/anti(Ag-SH) antibody complex present in the plasma or serum of the patient capable of reacting with the substance with high affinity for the heparin substance-heparin substance (SFA-SH) complex, and then, 2) revealing the resulting (Ag-SH)-anti(Ag-SH) complex produced. | 01-21-2010 |
20100015648 | DETECTION OF NGAL IN CHRONIC RENAL DISEASE - Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 01-21-2010 |
20100021945 | DETERMINATION OF CHANGES IN CONCENTRATION - The invention relates to the field of macrocyclic host systems and fluorescent dyes. In particular, the invention relates to apparatuses and methods for determining a change in the concentration of an analyte, in particular as a result of a catalysed reaction, preferably an enzymatically catalysed reaction and preferably in an aqueous solution (>50% by weight water). | 01-28-2010 |
20100021946 | METHOD FOR PREPARING STANDARD SERUM MIXTURE FOR DETERMINING ALLERGEN ACTIVITY AND THE USE THEREOF - A method for preparing standardized serum mixture for determining allergen potency which comprises: 1) providing multiple serum samples from patients moderately hypersensitive to said allergen; 2) determining the relative content of sIgE against said allergen in each serum sample, obtaining the mean value of the relative content of sIgE of said multiple serum samples, and obtaining deviation value of the relative content of sIgE of each serum with respect to said mean value; 3) removing at least 5% of serum samples that have the largest and smallest deviation values respectively, and mixing the residual sera in the same volume. A serum mixture prepared by the method as well as the use of such serum mixture are also described. | 01-28-2010 |
20100028917 | A NEUROGLOBIN ENZYME-LINKED IMMUNOSORBENT ASSAY KIT AND THE USE OF IT - The invention discloses a Neuroglobin enzyme-linked immunosorbent assay kit and the use of it. The Neuroglobin enzyme-linked immunosorbent assay kit provided by the invention includes Neuroglobin polyclonal antibody, Neuroglobin monoclonal antibody and enzyme labeled antibody. Neuroglobin monoclonal antibody is produced through culturing hybridoma cells prepared by cell conjugation after inoculating mice with Neuroglobin antigen, whereas Neuroglobin polyclonal antibody is produced from animal antiserum after inoculating with Neuroglobin antigen. | 02-04-2010 |
20100028918 | GLUTAMINYL CYCLASE AS A DIAGNOSTIC/PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES - A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided. | 02-04-2010 |
20100028919 | METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 02-04-2010 |
20100035285 | RAPID ELISA - A step in the enzyme-linked immunosorbent assay (ELISA) is changed from a heterogeneous phase to a homogeneous phase, to give a much shorter overall completion time. The new assay comprises the steps of (i) mixing in a homogeneous phase a sample and a first binding partner to an analyte to form a first mixing product; and (ii) exposing the first mixing product to a second binding partner to the analyte. | 02-11-2010 |
20100041076 | Reagents, Methods and Kits for the Universal Rapid Immuno-Detection - This invention relates to a novel immuno-detection methods, kits and reagents. The Combination of this invention, combining at least two of the following reagents of a Non-specific Competitor, a Specific Indicator, a primary antibody and an antigen, provides a faster and easier method for an immuno-detection, combining at least two of the following steps of blocking, antigen binding, primary antibody binding and 2 | 02-18-2010 |
20100041077 | PESTICIDE BIOMARKER - Provided are methods, compositions and articles of manufacture for detecting biomarkers indicative of exposure of a mammal to organophosphate compounds. The interaction of such a biomarker with a receptor bound to a biopolymer results in an optical readout that reports the presence of the biomarker. | 02-18-2010 |
20100041078 | ANTIBODY-BASED GAMMA-HYDROXYBUTYRATE (GHB) DETECTION METHOD AND DEVICE - Gamma-hydroxybutyrate (GHB) can be used as a recreational party drug, aphrodisiac, and attenuator of other drugs and make a person a vulnerable target of robbery or rape. The present invention provides methods and kits for detection of GHB in a sample using an antibody-based assay. Antibodies that specifically bind to GHB or the conjugates of GHB and its derivatives to larger molecules and methods for detecting GHB or its derivatives in bodily fluids and non-alcoholic and alcoholic drinks by employing such antibodies in ELISA or RIA assays are provided by the present invention. | 02-18-2010 |
20100041079 | METHOD FOR PREDICTING CARDIOVASCULAR EVENTS - A novel method for assessing the risk of a cardiovascular event is provided. The concentration of 11-dehydro thromboxane in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event. | 02-18-2010 |
20100047829 | ACTIVATED HER3 AS A MARKER FOR PREDICTING THERAPEUTIC EFFICACY - The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed. | 02-25-2010 |
20100047830 | COMPOSITIONS AND METHODS FOR DETECTING CANCERS IN A SUBJECT - Disclosed are compositions and methods for detecting oral and gastrointestinal cancers in a subject. Autoantigen p90 was shown to be overexpressed in oral cancer cells, and this protein, as well as its companion autoantigen p62 and antibodies directed to both proteins, can be used as markers for detecting oral digestive and other cancers in a subject at an early stage. | 02-25-2010 |
20100055722 | Methods of Detecting A Neurological Condition Via Analysis of Circulating Phagocytes - The present invention features methods of monitoring or detecting a neurological or inflammatory condition in a patient. The method comprises (1) obtaining from the patient a fluid sample from outside of a brain tissue of the patient, wherein the fluid sample contains a circulating phagocyte, and (2) detecting for one or more biomarkers (e.g., a panel of biomarkers) inside the phagocyte, wherein the biomarker is associated with the respective neurological or inflammatory condition. | 03-04-2010 |
20100055723 | Galectin-3-Binding Protein as a Biomarker of Cardiovascular Disease - The present invention provides compositions and methods for using biomarkers to diagnose and monitor cardiovascular associated diseases and disorders. More specifically, the present invention provides Galectin-3-binding protein as a biomarker for disease. | 03-04-2010 |
20100055724 | METHODS OF DETECTING AUTOANTIBODIES FOR DIAGNOSING AND CHARACTERIZING DISORDERS - Methods for detecting and/or quantitating levels of autoantibodies in subjects are provided. Methods for diagnosing and/or characterizing a disorder associated with autoantibody production are further provided. In some embodiments, the disorder diagnosed and/or characterized can be a cancer or an infertility disorder. | 03-04-2010 |
20100062462 | IMMUNODEFICIENCY VIRUSES - This document relates to methods and materials involved in detecting, monitoring, and prognosing immunodeficiency virus infections. For example, methods and materials for determining whether or not a mammal (e.g., a human) has an immunodeficiency virus infection (e.g., an HIV infection), methods and materials for determining whether or not a mammal with an immunodeficiency virus infection is improving, and methods and materials for determining whether or not a mammal with an immunodeficiency virus infection has an advanced immunodeficiency virus infection are provided. | 03-11-2010 |
20100068735 | MICROFLUIDIC DEVICE INCLUDING UNIT FOR EVALUATING CAPTURE MATERIAL AND METHOD OF EVALUATING CAPTURE MATERIAL - Provided are a microfluidic device including a unit for evaluating a capture material and a method of evaluating a capture material. | 03-18-2010 |
20100068736 | Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Lung Cancer - Novel markers for lung cancer that are both sensitive and accurate. These markers are overexpressed in lung cancer specifically, as opposed to normal lung tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of lung cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between lung cancer and non-cancerous states. | 03-18-2010 |
20100068737 | Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin - The present invention relates to the use of hepcidin-specific antibodies for the detection of hepcidin in biological samples for the diagnosis of diseases and disorders related to iron metabolism. Kits useful in screening various subjects suspected of having diseases or disorders associated with iron metabolism are also provided. | 03-18-2010 |
20100075348 | METHOD FOR DIAGNOSIS OF A DISEASE INVOLVING AN ANTI-ENDOTHELIN-RECEPTOR ANTIBODY - The invention relates to a method for diagnosis of a disease, wherein presence or absence of an anti-endothelin-receptor antibody is determined in a sample from a patient to be diagnosed more in particular an anti-endothelin-receptor-A antibody. The disease according to the invention is in particular selected from diabetes, preferably type I diabetes, graft rejection, pre-eclampsia, hypertension, vasculitis, collagenosis, Raynaud-Syndrom (Morbus Raynaud), and inflammatory rheumatic disease and arteriosclerosis. The invention further relates to the use of an inhibitor of an anti-endothelin-receptor antibody or an inhibitor of an endothelin-receptor for the production of a medicament as well as a method for removing anti-endothelin-receptor antibodies from isolated blood by means of plasmapheresis. | 03-25-2010 |
20100075349 | RAPID ELISA PROCESSES AND RELATED COMPOSITIONS - The present invention provides improved and rapid detection methods for an antigen such as a chemical compound, a peptide, a nucleic acid, or a protein released from cells or virus particles in situ. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional ELISA, and also Western blot or Dot blot assays. The improved ELISA method is rapid, economical, reproducible, simple and automatable. Also provided are compositions and kits for using the improved ELISA methods for the rapid detection of antigens. | 03-25-2010 |
20100093005 | IDENTIFYING DUCT CANCERS - This document relates to methods and materials involved in identifying mammals that are likely to have duct cancer. For example, this document provides methods and materials related to using the presence of a variant form of the secretin receptor in a mammal's blood to identify the mammal (e.g., human) as being likely to have duct cancer. | 04-15-2010 |
20100099123 | Soluble Human M-CSF Receptor and Uses Thereof - Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease. | 04-22-2010 |
20100099124 | Method for Diagnosing Diseases Based on Levels of Anti-Glycan Antibodies - Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample. | 04-22-2010 |
20100105084 | METHODS AND KITS FOR THE RAPID DETERMINATION OF PATIENTS AT HIGH RISK OF DEATH DURING SEVERE SEPSIS AND SEPTIC SHOCK - The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis. | 04-29-2010 |
20100105085 | METHOD OF DIAGNOSING AND STRATIFYING ANTI-PHOSPHOLIPID SYNDROME - Disclosed are a method and reagents for diagnosis of anti phospholipid syndrome based on the levels of certain anti 1 can antibodies. | 04-29-2010 |
20100105086 | DIFFERENTIAL DIAGNOSIS FOR SCLERODERMA - Use of IFI16 protein, fragments or peptides thereof for differential diagnosis of the limited cutaneous form of scleroderma (Ic-SSc) in a subject suspected of or at risk of having an autoimmune disease and the corresponding method of diagnosis and kit. | 04-29-2010 |
20100105087 | BIOMARKERS FOR BREAST CANCER - Low molecular weight (LMW) peptides have been discovered that are indicative of breast cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting breast cancer and monitoring the progression of the disease, for example during treatment. The LMW peptides are particularly useful in detecting breast cancer during its early stages. | 04-29-2010 |
20100105088 | METHOD FOR DIAGNOSING ATHEROSCLEROTIC PLAQUES BY MEASUREMENT OF CD36 - The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed. | 04-29-2010 |
20100112605 | Biomarker for the Medicine and the Biology of the Reproduction - The present invention relates to a new biomarker for the medicine and the biology of reproduction, in particular for in vitro fertilization (IVF) outcome. It relates to methods for predicting IVF outcome and for selecting the subject for IVF. | 05-06-2010 |
20100112606 | MEASUREMENT AND ANALYSIS OF LEUKOTRIENES - The present invention provides a new analytical method for measuring leukotrienes in a clinical sample using liquid chromatography and tandem mass spectrometry (LCMSMS). The method provides a simple, rapid and low-cost assay for the measurement of leukotriene levels in a clinical sample with high accuracy and precision over the physiological range. The present invention further provides a method to determine the susceptibility of a subject to treatment with a leukotriene modifier, as wells as methods for diagnosis of a chronic obstructive disease of the airways and for predicting the risk of exacerbation of the same. | 05-06-2010 |
20100112607 | METHODS FOR DETERMINING ACTIVE INGREDIENTS IN PRO-DRUG PEG PROTEIN CONJUGATES WITH RELEASABLE PEG REAGENTS (IN VITRO DE-PEGYLATION) - The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA. | 05-06-2010 |
20100112608 | METHOD OF DIAGNOSING LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 05-06-2010 |
20100120074 | Methods and Kits for Detection of Cancer Metastasis - The invention provides a method of detecting metastasis of cancers in the body fluids from a mammal, the method comprising the steps of: (a) providing the body fluids from the mammal; and (b) the measurement of the CAS protein level or CAS polypeptide level in the body fluids to screen or diagnose the metastatic cancers. | 05-13-2010 |
20100129838 | METHODS FOR PREDICTION OF INFLAMMATORY BOWEL DISEASE (IBD) USING SEROLOGIC MARKERS - The present invention provides methods, systems, and code for accurately classifying whether a sample from a pediatric individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from a pediatric individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions. | 05-27-2010 |
20100136587 | Method of Identifying Risk for Thyroid Disorder - A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder. | 06-03-2010 |
20100136588 | Methods and Devices for Diagnosis of Appendicitis - A method is provided for determining the severity of appendicitis in a patient that includes testing a blood, serum or plasma sample from the patient for the quantity of MRP8/14 in the sample and comparing it with the quantity of MRP8/14 present in standard samples correlated with an appendicitis severity scoring system. A histologically-based appendicitis severity scoring system is also provided. Immunoassays and kits for performing the appendicitis assays of this invention are also provided, as are standard samples and data correlating MRP8/14 quantities present in patient samples to histologically-based appendicitis severity grades. The methods and immunoassay devices and kits of this invention are useful for managing the treatment of patients presenting with appendicitis symptoms. | 06-03-2010 |
20100136589 | Methods and Kits for Determining von Willebrand Factor Activity in the Absence of Ristocetin and for Determining the Activity of ADAMTS-13 Protease - Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin. | 06-03-2010 |
20100143950 | BINDING OF COMPLEMENT FACTOR H TO C-REACTIVE PROTEIN - The invention relates to a correlation between serum complement Factor H levels and binding to C-reactive protein (CRP) and risk of developing age-related macular degeneration. The invention provides methods for screening a subject to assess risk of developing AMD. The invention also provides methods for screening for agents useful to treat AMD. | 06-10-2010 |
20100143951 | NOVEL MARKERS FOR CHRONIC KIDNEY DISEASE - The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention. | 06-10-2010 |
20100143952 | BIOCHIP, AND METHOD FOR THE SELECTIVE IDENTIFICATION OF CHLAMYDIA TRACHOMATIS INFECTIONS - The present invention relates to a method for the selective identification of | 06-10-2010 |
20100151503 | METHOD OF DETECTING LIVER CANCER, DIAGNOSTIC FOR LIVER CANCER AND REMEDY FOR CANCER - Disclosed are a method for detecting liver cancer capable of detecting liver cancer with high specificity and a diagnostic therefor, as well as a novel therapeutic drug for cancer having an excellent anticancer effect. The method for detecting liver cancer cells in a sample utilizes as an index the expression of dlk gene. The expression of dlk gene may be measured by immunoassay using an anti-dlk antibody or by measuring mRNA of dlk gene. The therapeutic drug for cancer comprises as an effective ingredient an antibody which undergoes antigen-antibody reaction with Dlk expressing on surfaces of cancer cells and which exerts anticancer action against the cancer cells. | 06-17-2010 |
20100151504 | DIAGNOSIS AND RISK CLASSIFICATION OF ACUTE CORONARY SYNDROME BY MEANS OF CT-PROET-1 IN COMBINATION WITH NT-PROBNP - The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP. | 06-17-2010 |
20100159486 | BIOMARKERS FOR NEUROLOGICAL CONDITIONS - Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures. | 06-24-2010 |
20100159487 | Assay system - An assay apparatus comprising: i) an assay cartridge ( | 06-24-2010 |
20100159488 | METHOD FOR THE MULTIPLEX SEROLOGICAL DIAGNOSIS IN VITRO OF SPIROCHETE INFECTIONS - A method for the serological diagnosis, in vitro, of an infection with a spirochete bacterium which is pathogenic in humans, chosen from bacteria of the | 06-24-2010 |
20100159489 | PROMOTER - The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5′ shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers. | 06-24-2010 |
20100159490 | Multiplexed Assay Methods - The present invention is directed to methods for conducting multiplexed assays. The methods are particularly well suited for measuring a plurality of analytes that may be present in very different abundances. The invention also relates to systems, devices, equipment, kits and reagents for use in such methods. | 06-24-2010 |
20100167318 | Fluidic Structures Including Meandering and Wide Channels - The present invention relates generally to microfluidic structures, and more specifically, to microfluidic structures and methods including meandering and wide channels. Microfluidic systems can provide an advantageous environment for performing various reactions and analyses due to a reduction in sample and reagent quantities that are required, a reduction in the size of the operating system, and a decrease in reaction time compared to conventional systems. Unfortunately, the small size of microfluidic channels can sometimes result in difficulty in detecting a species without magnifying optics (such as a microscope or a photomultiplier). A series of tightly packed microchannels, i.e., a meandering region, or a wide channel having a dimension on the order of millimeters, can serve as a solution to this problem by creating a wide measurement area. Although this invention mainly describes the use of meandering and wide channels in heterogeneous immunoassays on a microfluidic chip, this invention could be used for amplifying optical signals for other types of reactions and/or assays. | 07-01-2010 |
20100167319 | Diagnose of Mycobacterial Infections by Determination of IFN-Gamma - The present invention provides a method for diagnosing a mycobacterial infection in a subject, involving the following steps: (i) collection of a sample from the subject; (ii) incubation of the sample from (i) with an antigen preparation for 12 hours or less; and (iii) analysis of γ-IFN in the sample from (ii). The invention also provides a diagnostic kit for use in such a method. | 07-01-2010 |
20100167320 | Compositions and Methods for Detecting and Quantifying Toxic Substances in Disease States - The present invention relates to compositions comprising synthetic aggregated peptides (SAPs). The present invention also relates to the use of these SAPs as standards in methods for quantifying substances in a sample. The present invention also relates to methods of detecting, diagnosing and monitoring the progression of an abnormal condition in a subject with the methods comprising determining levels of an aggregated biomarker in a subject by measuring levels of the aggregated biomarker in the subject and correlating these levels to a standard curve, where the standard curve is established using a SAP peptide as the standard. | 07-01-2010 |
20100167321 | EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP-CAM-SPECIFIC CTL AND USE OF THE SAME - A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402. | 07-01-2010 |
20100167322 | METHOD OF DETECTING CEREBRAL STROKE OR ASYMPTOMATIC CEREBRAL INFARCTION USING ACROLEIN, INTERLEUKIN-6 AND CRP CONTENTS, POLYAMINE OXIDASE ACTIVITY OR POLYAMINE OXIDASE PROTEIN CONTENT AND SUBJECT'S AGE AS INDICATORS - A method of detecting cerebral stroke or asymptomatic cerebral infarction is disclosed. The method comprises measuring the contents of aldehyde compounds formed from polyamines, interleukin-6 and C-reactive proteins, the polyamine oxidase activity or the polyamine oxidase protein content in a biological sample obtained from a subject and using the measurement data thus obtained and the age of the subject as indications. Also disclosed is a kit for conducting this detection method; and a system for detecting cerebral stroke or asymptomatic cerebral infarction which comprises this kit. | 07-01-2010 |
20100167323 | METHOD FOR STABILIZATION OF PROTEINS IN SOLUTION - The present invention relates to a method for stabilization of analytes in solutions of solubilized body samples. The method comprises the steps of solubilizing the body samples obtained from a subject in a suitable sample medium and stabilizing said body sample contained within the sample medium by heating said sample medium for a certain period of time. A further aspect of the invention is a method of a denaturing immunoassay of proteins in solution. The method comprises the steps of bringing a sample containing proteins into contact with a denaturing agent and heating said sample in the presence of the denaturing agent to allow the protein to be denatured. | 07-01-2010 |
20100173334 | CANCER EVALUATION METHOD USING HAPTOGLOBIN BETA-CHAIN DEFINED BY ANTIBODY RM2 - The object of the present invention is to identify a molecule that is specifically recognized by antibody RM2 in tissue or serum of a cancer patient, and provide a method for diagnosing cancer in a simple manner with high specificity using the molecule as an indicator. The present method comprises evaluating a risk or grade of malignancy of genitourinary cancer in a subject using the level of the haptoglobin β chain to which antibody RM2 specifically binds or a fragment thereof in tissue or body fluid isolated from the subject as an indicator. | 07-08-2010 |
20100184104 | NANOELECTRONIC-ENZYME LINKED IMMUNOSORBENT ASSAY SYSTEM AND METHOD - The present invention relates to a device and method for determining the presence of a specific compound in solution. The device includes a nanosensor having an electrically conducting pathway between at least a first and second contact. The device also includes a first receptor, suitable for binding a specific compound in the solution, attached to the nanosensor, and a second receptor also suitable for binding the specific compound while the specific compound is bound to the first receptor. The second receptor is attached to an enzyme added to the solution. When the solution having the second receptor is added to the device, and a second compound that is a substrate for the enzyme is subsequently added to the solution, a measured difference in an electrical property in the device before and after the application of the second compound is indicative of the presence of the specific compound in the solution. | 07-22-2010 |
20100184105 | ASSESSING NEURONAL DAMAGE FROM BLOOD SAMPLES - Neuronal damage is detected by providing a biological sample derived from the subject, detecting in the sample the presence of a neurofilament subunits or their breakdown products, and correlating the presence and level of the neurofilament subunits and their breakdown products detected with the degree of neuronal injury. | 07-22-2010 |
20100190190 | FOOD SENSITIVITY TESTING IN ANIMALS - Diagnosing an immunologic food sensitivity or intolerance in companion animals comprises collecting a sample; screening the sample to detect the presence of an antibody to a particular food ingredient or composition. The sample can be serum, saliva or other bodily fluid to detect the presence of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. The food ingredient for which sensitivity or intolerance is tested is contained in at least one of a preprocessed food composition, balanced diet or recipe. Offending ingredient(s) in a preprocessed food composition, balanced diet or recipe is determined. An assessment is made as to whether it is possible to use a different preprocessed food composition, balanced diet or recipe, or whether a special diet needs to be formulated without the offending ingredient(s). | 07-29-2010 |
20100190191 | MULTI-STAGE NUTRIGENOMIC DIAGNOSTIC FOOD SENSITIVITY TESTING IN ANIMALS - A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or other non-serum bodily fluid sample is collected. The screening the saliva or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly a biologically active nutrient in relation to the animal from a molecular dietary signature is determined. The molecular dietary signature for the animal is a variation of expression of a set of genes, proteins or metabolites which may differ for the genotype of each animal. | 07-29-2010 |
20100196933 | Recombinant Polypeptides for Diagnosing Infection with Trypanosoma Cruzi - Recombinant polypeptides are disclosed that are useful for diagnosing American trypanosomiasis, or Chagas disease, a disease caused by the infectious agent | 08-05-2010 |
20100196934 | PRION ASSAY - The invention relates to an assay method for detecting the presence of PrP | 08-05-2010 |
20100196935 | TREATING PRE-ECLEMPSIA AND CARDIOVASCULAR DISEASES - This document relates to methods and materials involved in identifying, predicting, and treating pre-eclampsia or a cardiovascular disease (e.g., atherosclerosis) in mammals. For example, methods and materials involved in using serum levels of HtrA polypeptides to identify pre-eclampsia or a cardiovascular disease, using HTRA polymorphisms to predict pre-eclampsia or a cardiovascular disease, and using HtrA antibodies to treat pre-eclampsia or a cardiovascular disease in mammals (e.g., humans) are provided. | 08-05-2010 |
20100196936 | METHOD AND KIT FOR DETECTING CANCER - A method for detecting cancer is disclosed. The method includes the steps of: (1) obtaining a test sample of body fluid from a subject; (2) measuring a calsyntenin-1 (CLSTN-1) level in the test sample of body fluid in vitro; and determining if the CLSTN-1 level in the test sample of body fluid is significantly higher than a normal CLSTN-1 level in a sample of body fluid from a healthy population of the same species as the subject, and if yes, indicating that the subject under test has cancer. Methods for monitoring therapeutic efficacy of a therapy or a medicament for treating a cancer patient and for identifying efficacy of a medicament in treatment of cancer are disclosed, and a kit for use in the aforesaid methods is also provided. | 08-05-2010 |
20100203558 | METHOD AND IMMUNE ABSORBENTS FOR THE SPECIFIC DETECTION AND ABSORPTION OF CELIAC DISEASE-AND HERPETIFORM DERMATITIS-ASSOCIATED ANTIBODIES - The present invention relates to fusion peptides that are derived from components of gliadin, to a method and reagents for the serological diagnosis of celiac disease or dermatitis herpetiformis by way of assaying antibodies that are directed against modified gliadin. The invention also relates to methods and pharmaceutical compositions for treating said diseases by specific immunoabsorption of these antibodies. | 08-12-2010 |
20100203559 | Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P | 08-12-2010 |
20100209947 | Free human serum IgE immunoenzymetric assay and methods of use - The present invention relates to the development of novel of free blood fluid IgE Immunoenzymetric assay that is specifically designed to evaluate the blood fluid of patients on therapeutic agents designed to reduce free serum IgE levels, such as Omalizumab. The assay displays the robustness required for clinical analysis of serum containing such agents as Omalizumab. | 08-19-2010 |
20100209948 | BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof. | 08-19-2010 |
20100216173 | CITRULLINATED FIBRIN-FILAGGRIN CHIMERIC POLYPEPTIDE CAPABLE OF DETECTING THE ANTIBODIES GENERATED IN RHEUMATOID ARTHRITIS - The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the α or β chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease. | 08-26-2010 |
20100227339 | DIFFERENTIAL IMMUNOASSAY FOR PRRS VACCINE ANTIBODY - The present invention relates to immunoassays for serologically differentiating animals naturally infected with PRRS virus from animals vaccinated against PRRS. The immunoassays provide detection of at least a portion of the N terminal region of the 2b portion of PRRSV. The immunoassay is preferably an enzyme-linked immunosorbent assay (ELISA). | 09-09-2010 |
20100227340 | METHOD OF ANALYSIS, DETECTION AND CORRECTION OF FOOD INTOLERANCE IN HUMANS - A method of detection and correction of latent food intolerance (LFI) in humans is described. The method allows, through utilizing a dynamic analysis of a specific test for LFI, assessing the degree of food intolerance and devising an individualized diet that excludes food items which cause latent food intolerance, as well as food items which cause classic allergic reactions. Thus, this method promotes health throughout an individual's life by avoiding and correcting the negative effects of food items that act as immune antagonists. | 09-09-2010 |
20100227341 | Diagnosing Pneumococcal Pneumonia - Compositions and methods for eliciting an immune response against | 09-09-2010 |
20100227342 | DIAGNOSIS OF PREECLAMPSIA - The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia. | 09-09-2010 |
20100233736 | DETECTION METHOD AND KIT - The present invention relates to a method of detection and/or quantification of an antigen linked to a metal salt. The antigen may be present within a mixture of different antigens, such as in a multivalent vaccine composition. The invention further provides a kit for use in the method of the invention. | 09-16-2010 |
20100233737 | MARKER SPECIFIC TO AN OXIDATIVE DEGRADATION OF TISSUES CONTAINING TYPE III COLLAGEN, MEANS AND METHODS AND KITS FOR THE DIAGNOSIS, MONITORING OR PROGNOSIS OF PATHOLOGIES TARGETED BY THIS MARKER - Novel peptide marker, specific to the oxidative degradation of tissues containing type III collagen, preferably to nitrosylation of the type III collagen. This marker is defined of at least one peptide sequence of 5 to 25 amino acids (AAs) including a sub-sequence QYDSYD in which at least one of the Ys is nitrosylated and Q corresponds not only to glutamine but also to pyroglutamic acid. This marker is simple, sensitive and reliable and expedites the clinical information for obtaining oxidative degradation of tissues containing type III collagen (O.D.T.Coll III) pathologies. This marker allows better monitoring, prognosis and treatment of the O.D.T.Coll III pathologies. This invention concerns also elements of detection of the marker, methods and kits which allow, on one hand, the early, reliable, efficient and economical diagnosis of the pathologies targeted and, on the other hand, improved monitoring and prognosis of the O.D.T.Coll III pathologies. | 09-16-2010 |
20100240076 | IMMUNOASSAY INVOLVING MUTANT ANTIGENS TO REDUCE UNSPECIFIC BINDING - A method for a quantitative in vitro analysis to diagnose, to categorise, to predict and/or to monitor the progression of a condition comprising the following steps: a) Obtaining a sample suspected of containing anti-A-antibodies from a subject to be analysed, b) Providing native and mutant antigen A, c) Contacting the sample suspected of containing anti-A-antibodies with mutant antigen A and with native antigen A, d) Detecting the amount of anti-A-antibodies bound to native antigen A after step c), wherein the presence of anti-A-antibodies bound to native antigen A allows the diagnosis, the categorisation, the prediction and/or the monitoring of the progression of a condition. | 09-23-2010 |
20100240077 | METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2 SEROLOGIC RESPONSE - The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti- | 09-23-2010 |
20100248269 | DETECTION OF FIBRIN AND FIBRINOGEN DEGRADATION PRODUCTS AND ASSOCIATED METHODS OF PRODUCTION AND USE FOR THE DETECTION AND MONITORING OF CANCER - Disclosed herein are methods, systems and kits for the detection of, or monitoring the progression of, cancer by simultaneously detecting the presence of six fibrin and fibrinogen degradation products (FDP) in a biological sample in a single assay system. | 09-30-2010 |
20100248270 | Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Cardiac Disease - Novel markers for cardiac disease that are both sensitive and accurate. These markers are differentially and/or specifically expressed in cardiac tissue, as opposed to other types of tissues, optionally and preferably including muscle tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of cardiac disease, including pathology and/or damage, including acute and/or chronic damage. The markers of the present invention, alone or in combination, show a high degree of differential detection between cardiac disease states and non-cardiac disease states. | 09-30-2010 |
20100248271 | Fibrinogen Alpha and Hemoglobin Polypeptides as Cancer Markers - The present invention provides methods of detecting cancer using biomarkers. | 09-30-2010 |
20100255513 | SEROLOGICAL MARKERS OF INFLAMMATORY BOWEL DISEASE PHENOTYPE AND DISEASE PROGRESSION - Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease. | 10-07-2010 |
20100255514 | TUMOR CELL-DERIVED MICROVESICLES - The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer. | 10-07-2010 |
20100255515 | ELISA FOR VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index. | 10-07-2010 |
20100261205 | MICROCHIPS, KITS, AND METHODS FOR IMMUNOASSAYS - An objective of the present invention is to provide immunoassay microchips in which microstructures of beads having a sufficient reaction area were constructed within microchannels while suppressing flow path resistance, and to provide simple and highly-sensitive immunoassay methods for microsamples. The objective was achieved by immunoassay microchips comprising microchannels with microstructures arranged in at least a portion of the microchannels, the microstructures retaining microbeads uniformly dispersed in photo-cured hydrophilic resins, and the microbeads having a primary antibody immobilized on their surfaces, and by immunoassay methods using the microchips. | 10-14-2010 |
20100261206 | Peptide fragments reacting specifically with antibodies against highly pathogenic newcastle disease virus and uses thereof - We disclose synthetic peptide fragments comprising amino acid sequences of specific antigen sites of pathogenic Newcastle disease virus in birds, and more particularly synthetic peptide fragments that comprise polybasic amino acid sequences at the cleavage site of the F protein of pathogenic Newcastle disease virus and that induce humoral immune responses in hosts while reacting only with antibodies to pathogenic Newcastle disease virus and are useful to differentiate infected individuals from vaccinated individuals. | 10-14-2010 |
20100261207 | NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention. | 10-14-2010 |
20100261208 | ELISPOT METHOD HAVING TWO FILTER SYSTEMS - An ELISPOT method for in vitro diagnosis and/or in vitro therapy monitoring of infections and/or infectious diseases comprising incubating eukaryotic cells with an antigen, measuring the number of immunocompetent cells which secrete at least two different cytokines as a reaction to the antigen, and in measuring the immunocompetent cells, visualizing the cells with the aid of at least two different dyes and at least two different filter sets, the filter sets comprising narrowband filters. | 10-14-2010 |
20100261209 | BIOMARKERS FOR LIVER DISEASES AND METHOD FOR USING THE SAME - Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity. | 10-14-2010 |
20100261210 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PROSTATE CANCER - A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject. | 10-14-2010 |
20100267060 | High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis - The present invention relates to methods and compositions for measuring secretagogin in test samples, particularly patient samples. Preferred methods comprise performing a sandwich immunoassay, most preferably using a pair of monoclonal antibodies that bind to secretagogin. | 10-21-2010 |
20100267061 | DETECTING PHOSPHOLIPIDOSIS AND DIAGNOSING LYSOSOMAL STORAGE DISORDERS - Disclosed are methods for evaluating the potential or activity of a test compound to induce phospholipidosis in a target subject, for managing patient treatment, and for diagnosing a lysosomal storage disorder in a human subject. | 10-21-2010 |
20100267062 | Osteopontin as Novel Prognostic Biomarker for Heart Failure - The present invention relates to methods for providing a diagnosis, prognosis and/or risk stratification of a subject with heart failure, comprising determining the concentration of osteopontin (OPN) in the biological sample, preferably in a plasma sample. An OPN cut-off value is discloses as a valuable reference value. The present invention furthermore relates to the use of osteopontin as marker for diagnosis, prognosis and/or risk stratification of a subject with heart failure, the use of the determination of the osteopontin plasma concentration in a biological sample of a subject for diagnosis, prognosis and/or risk stratification of heart failure as well as kits for performing the methods and uses of the invention. The present invention allows particularly for risk stratification of patients with heart failure, such as mortality prediction and prognosis of heart failure severity. | 10-21-2010 |
20100273192 | METHOD FOR DETECTION OF DISEASE HAVING INSULIN-RESISTANT CONDITIONS - Disclosed is a simple method for detecting a pathological condition of an insulin-resistant disease, particularly type-2 diabetes. The method comprises quantifying the ganglioside GM3 in a blood sample separated from a living body. More specifically, the method comprises the following steps (a) to (c): (a) separating a plasma or serum from the blood collected from a human; (b) quantifying the ganglioside GM3 in the plasma or serum; and (c) comparing the quantified ganglioside GM3 level to the mean ganglioside GM3 level determined in blood samples from healthy volunteers. | 10-28-2010 |
20100273193 | Triacetone Triperoxide and Diacetone Diperoxide Derivatives, Method for the Preparation and Use Thereof - This disclosure is drawn to a triacetone triperoxide derivative in accordance with the general formula (I) and a diacetone diperoxide derivative in accordance with the general formula (II) | 10-28-2010 |
20100273194 | IMMUNOREACTIVE EHRLICHIA P120/P140 EPITOPES AND USES THEREOF - Provided herein are immunoreactive peptides which can selectively bind | 10-28-2010 |
20100279325 | USE OF MODIFIED EXTRACELLULAR MATRIX PROTEINS IN DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS - The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as passive immunization against glycosylated or aldehydemodified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis. | 11-04-2010 |
20100285507 | PLASMA KALLIKREIN FRAGMENTS AS DIAGNOSTIC BIOMARKERS FOR LUNG CANCERS - Disclosed herein are diagnostic markers for lung cancer, isolated from serum glycoproteins. The disclosed diagnostic markers for lung cancer are specifically expressed only in the sera of lung cancer patients at high levels, and thus will be very useful for diagnosing lung cancer and estimating disease progression and treatment. | 11-11-2010 |
20100285508 | USE OF THE PROTEIN EM6 AS A PERFORMANCE MARKER FOR GERMINATION OF SEED LOTS AND APPLICATIONS THEREOF - The invention relates to the determination of the level, maintenance and/or performance of germination of a seed lot, by quantification of the protein EM6, belonging to the group of Late Embryogenesis Abundant (LEA) proteins. The present invention further relates to antibodies permitting the quantification of the protein EM6. | 11-11-2010 |
20100285509 | Melanoma-Associated Endogenous Retrovirus (MERV) Derived Peptide Sequences And Their Therapeutic/Diagnostic Use - The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines. | 11-11-2010 |
20100285510 | MARKER FOR INFLAMMATORY CONDITIONS - Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described. | 11-11-2010 |
20100291597 | SECRETOGRANIN AND VGF PEPTIDE BIOMARKERS AND USES THEREOF - Secretogranin II and VGF peptides are biomarkers for major depressive disorder. They are useful in methods of diagnosing, monitoring and screening. | 11-18-2010 |
20100291598 | PRION ELISA - Assays for detecting PrP | 11-18-2010 |
20100291599 | LARGE AREA SCANNING APPARATUS FOR ANALYTE QUANTIFICATION BY SURFACE ENHANCED RAMAN SPECTROSCOPY AND METHOD OF USE - Raman spectra of protein immunoblots or enzyme linked immunosorbant assay procedures are acquired with a scanning Raman spectrometer. The sensitivity of the measurement is increased by conjugating secondary antibodies used in the Western blot and ELISA methods to surface enhanced Raman Scattering (SERS) labels. The resulting blot or well plate is analyzed with a Raman system that has forms a pixel map of the sample. More specifically, the Raman system generates an effectively line-shaped illumination pattern and scans the sample in the direction perpendicular to the line while the signal is accumulating on the detector. Each pixel is therefore a rectangle defined by the length of the illumination and the distance traveled by the sample within the duration of signal accumulation on the detector. The pixels are sequentially acquired to generate a map of the sample. | 11-18-2010 |
20100291600 | Immunoassay - The present invention provides an immunoassay method for detecting or determining the amount of salvinorin A, salvinorin B and/or analogues thereof in an in vitro sample, an antibody for salvinorin A, salvinorin B and/or analogues thereof and a kit for detecting the presence of or determining the amount of salvinorin A, salvinorin B and its analogues thereof in a sample. | 11-18-2010 |
20100291601 | CARBOHYDRATE BINDING MODULE AND USE THEREOF - The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein. | 11-18-2010 |
20100291602 | CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS - The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO/2008/031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers. | 11-18-2010 |
20100297678 | BIOMARKERS FOR MULTIPLE SCLEROSIS - The present invention relates to the diagnosis of neurological disorders, more specifically to the diagnosis of multiple sclerosis. A biomarker panel is provided which can be used to detect if a subject has multiple sclerosis. Also described are methods of identification of such biomarkers. | 11-25-2010 |
20100297679 | IDENTIFICATION AND QUANTIFICATION OF BIOMARKERS FOR EVALUATING THE RISK OF PRETERM BIRTH - Described herein are methods for evaluating the risk of preterm birth in pregnant subjects. The methods involve detecting and quantifying one or more biomarkers associated with preterm birth in a biological sample from the subject. Also described herein are isolated biomarkers and kits useful in predicting the risk of preterm birth. | 11-25-2010 |
20100297680 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE - The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease. | 11-25-2010 |
20100304408 | USE OF THE ALPHA CHAIN OF BRAIN SPECTRIN AND FRAGMENTS THEREOF, FOR DIAGNOSING CEREBRAL DISEASES - The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed. | 12-02-2010 |
20100304409 | METHOD FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS AND A KIT FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS - The present invention provides a method for detecting senescence in tumor cells and a kit for detecting senescence in tumor cells. eEF1A1 and CD markers are provided, wherein changes in the levels of the markers are correlated with premature senescence of tumor cells. | 12-02-2010 |
20100304410 | METHOD OF ASSESSING COLORECTAL CANCER STATUS IN AN INDIVIDUAL - The invention relates to a method of screening a patient to identify and quantify risk of colorectal cancer, and thereby identify patients suitable for further invasive investigation such as a colonoscopy. The method employs auto-antibodies that are shown to correlate with colorectal cancer risk method and involves of assaying a biological sample from the individual for a combination of a plurality of biomarkers selected from SEQUENCE ID NO's: 1 to 12, where the combination of biomarkers is chosen such that detection of all biomarkers in the patient correlates to at least a 50% risk of the patient being positive for colorectal cancer. Detection of all of the combination of biomarkers indicates that the patient should undergo a colonoscopy. Kits for performing the method of the invention are also provided. | 12-02-2010 |
20100304411 | Endogenous Morphine or a Naturally Occurring Metabolite Thereof as a Marker for Infection - The invention relates to a method for detecting infection in a patient comprising measuring the concentration of endogenous morphine or a naturally occurring metabolite thereof in a biological sample obtained from said patient. | 12-02-2010 |
20100304412 | METHODS FOR DETERMINING THE RISK OF PRENATAL COMPLICATIONS - The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. | 12-02-2010 |
20100311089 | COMPOSITIONS AND METHODS FOR DIAGNOSING PATIENTS WITH ACUTE ATHEROSCLEROTIC SYNDROME - The present invention is in the field of autoimmunity. More specifically, the present invention relates to the detection of autoantibodies to domain 4 of beta 2-glycoprotein I (β | 12-09-2010 |
20100317038 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 12-16-2010 |
20100317039 | MOLDING WITH EMBEDDED COUPLING PARTICLES FOR BIOMOLECULES - The invention relates to a molding, comprising a matrix in a material, selected from the group consisting of metal, ceramic and polymer synthetic material, and coupling particles embedded in the matrix, wherein a proportion of the surface of the molding in a geometrical form or in a regular pattern and/or an area of the molding is completely or the entire surface of the molding is mechanically treated. | 12-16-2010 |
20100317040 | METHODS AND KITS FOR DIAGNOSING CANCER - A method of diagnosing oral cancer or oral pharyngeal cancer in a subject in need thereof is provided. The method comprising determining a level or activity of at least one marker in a saliva sample of the subject, wherein a significant alteration in the level or the activity of the marker with respect to an unaffected saliva sample is indicative of the cancer, wherein the saliva marker is selected from the group consisting of Cyclin D1, phospho-Src, 8-oxoguanine DNA glycosylase (OGG1), Maspin, KI67 and translocator protein 18 kDa (TSPO). | 12-16-2010 |
20100317041 | NEURAL PROTEINS AS BIOMARKERS FOR NERVOUS SYSTEM INJURY AND OTHER NEURAL DISORDERS - The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury. | 12-16-2010 |
20100323373 | METHOD FOR THE ASSESSMENT OF THE INHIBITORY ACTIVITY OF ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR - A method for the assessment of the inhibitory activity of an antibody for inhibiting the binding of IGF-1 and/or IGF-2 to IGF-1R in a lysed PBL sample of a mammal which has been treated with said antibody, characterized in that the IGF-1R protein level of said PBLs is measured as a measure for the inhibitory activity of said antibody. | 12-23-2010 |
20100323374 | Serum Biomarkers for Diagnosing Liver Fibrosis and Method for Measuring the Same - Disclosed are serum biomarkers for diagnosing liver fibrosis and methods for measuring the same. The serum biomarkers obtained from human serum include alpha2-macroglobulin (“A2M”), vitamin D binding protein (“VDBP”), apolipoprotein AI (“ApoAI”). The methods involve with immunoassay using specific antibodies to detect the biomarkers, including enzyme-linked immunosorbent assay (“ELISA”), radio immune assay (“RIA”) and flexible multi-analyte profiling (“xMAP”). ELISA, RIA or xMAP is used to measure changes of protein concentration for the specific protein biomarkers in serum for diagnosing liver fibrosis with suffering hepatitis B or C or other liver diseases. The measurement is safe and accurate. The method can be used before and after treatment of liver fibrosis. Thus, it is possible to achieve early diagnosis and treatment advocated in the preventive medicine. | 12-23-2010 |
20100323375 | AGENT AND METHOD FOR DIAGNOSIS ON THE OCCURRENCE OF ALZHEIMER'S DISEASE OR THE TENDENCY TO DEVELOP ALZHEIMER'S DISEASE - Disclosed are: an agent, an apparatus and a method for the diagnosis of a disease associated with the abnormality in γ-secretase; a method for providing information for the diagnosis of a disease associated with the abnormality in γ-secretase; a method for monitoring the condition or the degree of progression of a disease associated with the abnormality in γ-secretase; and a method for determining the therapeutic effect of a therapeutic agent on a disease associated with the abnormality in γ-secretase. More specifically disclosed are: a diagnostic agent for a disease associated with the abnormality in γ-secretase, which comprises an antibody capable of recognizing a digestion product of an alcadein with α-secretase or γ-secretase or a fragment of the antibody; and others. | 12-23-2010 |
20100323376 | Method for Measuring Lipoprotein-Specific Apolipoproteins - The present invention is directed to methods of measuring the concentration of lipoprotein particles and/or lipoprotein-specific apolipoproteins in a biological fluid using an immunoassay, without the need of preliminary physical separation of the various types of lipoprotein particles present in the biological fluid. | 12-23-2010 |
20100330595 | DIAGNOSTIC METHOD FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS AND THERAPEUTIC USES THEREFOR - The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin. | 12-30-2010 |
20110008804 | ANGIOPOIETIN-1 AND -2 BIOMARKERS FOR INFECTIOUS DISEASES THAT COMPROMISE ENDOTHELIAL INTEGRITY - The invention relates to a method of identifying a subject having, or at risk of developing, an infectious disease state wherein endothelial integrity is compromised comprising: (a) determining a test ANG-1 level in a sample from a subject; and (b) comparing the test ANG-1 level to a control level wherein lower test ANG-1 level compared to the control level is indicative of the subject developing said infectious disease state. | 01-13-2011 |
20110008805 | Markers Associate with Arteriovascular Events and Methods of Use Thereof - Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease. | 01-13-2011 |
20110008806 | METHOD AND KIT FOR QUANTIFYING OF ALLERGEN-SPECIFIC HUMAN IGG SUBCLASSES FOR THE CONTROL AND ATTENDANCE OF SPECIFIC IMMUNOTHERAPY - A method for quantifying the levels of allergen-specific human IgG antibody subclasses, particularly of IgG1, IgG2, IgG3 or IgG4 subclasses, using a reverse ELISA immunoenzymatic technique. Also provided is a kit comprising microtitration plates for ELISA already sensitized/covered with monoclonal antibodies, for example, anti-Der p 1 or anti-Der p 2, total extract from corresponding allergens, labeled secondary antibodies, enzymatic conjugate, enzymatic substrate, and chromogenic buffer, as well as reference positive and negative control sera. The method provides high sensitivity for the detection of specific IgG antibody subclasses and is a potential tool for the control and attendance of allergen-specific immunotherapy in patients with allergic respiratory disease. | 01-13-2011 |
20110008807 | Composition Related to Rapid ELISA Process - The present invention provides improved and rapid detection methods for an antigen such as a chemical compound, a peptide, a nucleic acid, or a protein released from cells or virus particles in situ. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional ELISA, and also Western blot or Dot blot assays. The improved ELISA method is rapid, economical, reproducible, simple and automatable. Also provided are compositions and kits for using the improved ELISA methods for the rapid detection of antigens. | 01-13-2011 |
20110008808 | BIOMARKERS - The invention provides binding agents and assays for ghrelin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention. | 01-13-2011 |
20110014638 | SOLUBLE FAS IN ACUTE CORONARY SYNDROMES DIAGNOSIS - The present technology provides methods and materials for the early clinical detection of acute coronary syndromes in a subject. The methods and materials comprise measuring the amount of soluble Fas in a sample obtained from a subject, comparing the amount of soluble sFas with a reference value and detecting the presence of acute coronary syndromes. | 01-20-2011 |
20110020846 | Oral cancer biomarker and inspection method using the same - The present invention discloses an oral cancer biomarker and an inspection method using the same. The biomarker is Mca-2 binding protein (Mac-2BP), which can be directly detected in the specimen of the body fluid of a testee, and which can realize a fast and effective clinical diagnosis of oral cancer. | 01-27-2011 |
20110020847 | Direct Enzyme Immunoassay and Kit for Measurement of Serum Progesterone Levels - Compositions, methods and kits for determining progesterone levels in mares are disclosed. | 01-27-2011 |
20110020848 | METHOD FOR DETECTION OF PNEUMOCOCCUS - To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody. | 01-27-2011 |
20110027810 | CHIMERIC RECOMBINANT ANTIGENS OF TOXOPLASMA GONDII - The invention described herein relates to a method for combining antigen fragments of | 02-03-2011 |
20110027811 | ASSAY SYSTEM FOR THE ASSESSMENT OF ONCOGENICITY, TUMOR PROGRESSION, AND TREATMENT EFFICACY - Systems and kits are provided which are capable of determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Such systems and kits utilize assays to examine the levels of apoptotic markers, angiogenesis markers, immunomodulation markers, and cell cycle markers and can compare samples from a patient taken at different times to determine the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Methods for determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment with such systems and kits are also provided. | 02-03-2011 |
20110027812 | ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS - A method of detecting an immune response to a paratuberculosis-specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis-specific antigen. The antigen may be obtained from a novel | 02-03-2011 |
20110027813 | Compositions for Binding to Assay Substrata and Methods of Using - Compositions and methods for binding to assay substrata in a stable and protective manner, thereby enhancing assay performance, are provided. The compositions comprise lyotropic materials (for example, lyotropic liquid and/or liquid crystalline materials) and may contain macromolecular standards, markers or capture compounds. The compositions are capable of binding to assay substrata such as that of chips that are employed for MALDI and SELDI mass spectroscopy analyses and plates that are used for ELISA type assays. | 02-03-2011 |
20110033876 | METHOD FOR DIAGNOSING PULMONARY ARTERY HYPERTENSION - The invention relates to an in vitro method for detecting pulmonary arterial hypertension (PAHT), or the risk of developing PAHT, which includes determining the presence and/or amount of anti-tenascin C antibodies in a biological sample from a patient. | 02-10-2011 |
20110033877 | Method for Evaluation or Selection of Adiponectin Secretion Regulator - Provided is a method for conveniently and rapidly evaluating or selecting an adiponectin secretion regulator. | 02-10-2011 |
20110039281 | METHOD OF IMMUNOLOGICAL ANALYSIS FOR DETECTION OF ANTIBODIES AGAINST HUMAN GSTT1 (ANTI-HGSTT1) - The subject of the present invention is a method of immunological analysis for detection in biological fluids of anti-bodies against human GSTT1 (anti-hGSTT1). The present invention also concerns the use of said immunological analysis method for the diagnosis, prognosis, follow-up and monitoring of pathological conditions associated with the presence of anti-GSTT1 in biological fluids, and also concerns a tool kit for putting said method into practice. | 02-17-2011 |
20110039282 | METHOD OF DETECTING CALCIFYING NANOPARTICLES AND SUSCEPTIBILITY TO CALCIFYING NANOPARTICLE INFORMATION - A method of measuring the susceptibility of a subject to calcifying nanoparticle formation is disclosed. The method can include obtaining a cell culture comprising peripheral blood mononuclear cells, immune cells, or both, from a peripheral blood mononuclear fraction of a subject in a complete culture media; extracting a first aliquot and a second aliquot from the cell culture; and dispensing the first and second aliquot in different wells. The surface of the well containing the first aliquot can include a calcifying nanoparticle biofilm, while the well containing the second aliquot does not. The first and second aliquots can be incubated and the concentration of osteopontin in each aliquot determined. An osteopontin factor can be calculated and compared to osteopontin factors from a representative sample of other subjects. The osteopontin factor can be defined as the osteopontin concentration in the first aliquot divided by the osteopontin concentration in the second aliquot. | 02-17-2011 |
20110045504 | Prognostic Prediction Method for Acute Coronary Syndrome - Problem is to provide a diagnostic marker for prognostic prediction of acute coronary syndrome. Means to solve the Problem is to make it possible to predict the risk of recurrence of acute coronary syndrome by measuring the concentration of soluble LOX-1 in the blood. | 02-24-2011 |
20110045505 | INTEGRATED SEPARATION AND DETECTION CARTRIDGE WITH MEANS AND METHOD FOR INCREASING SIGNAL TO NOISE RATIO - The present invention relates to a device and a method for quantitative detecting of the presence or absence of a target analyte in a liquid sample having a volume of less than 200 μl, the device comprising a reaction chamber in the form of a capillary channel, a first part comprising a sample inlet for the introduction of a sample containing an analyte, and a discharge outlet for the discharge of waste products; a second part comprising means for detection of the target analyte, and a solution inlet for introduction of washing solutions and reaction mixtures; and means for transferring an immobilized analyte from the first part to the second part of the chamber and vice versa, where the first and second parts are separated such that other liquid sample material may not enter the second part of the chamber and such that light may not be transferred from the first part of the chamber to the detector part of the second part of the chamber. | 02-24-2011 |
20110045506 | Chemiluminescent Enzyme Assay Method and Apparatus - A chemiluminescent enzyme immunoassay method for quantifying antigen or antibody using 1,1′-oxalyldiimidazole (ODI) derivative or 1,1′-oxalyldisodium benzoate (ODB) derivative chemiluminescence (CL) detection was developed. Also, various enzymes were quantified using ODI derivative or DOB derivative CL detection. Fluorescent compound formed from a substrate (non-fluorescent compound) through the enzyme assay methods emitted CL when the fluorescent compound received energy from high-energy intermediate formed in ODI derivative or ODB derivative CL reaction. | 02-24-2011 |
20110045507 | FSTL-1 AS A BIOMAKER OF INFLAMMATION - The invention provides methods and kits for diagnosing severity of particular types of inflammatory diseases, such as rheumatic diseases, by assessing protein levels of follistatin-like protein 1 (FSTL-1). The level of FSTL-1 protein present in the serum or synovial fluid of individuals suspected of having certain inflammatory disease (e.g, rheumatoid arthritis) is positively correlated with the severity of the disease. | 02-24-2011 |
20110045509 | Method For Determining The Type of an Inflammatory-Rheumatic Disease in Synovial Fluid - Disclosed is an in vitro method for determining the type of an inflammatory-rheumatic disease, wherein the presence or absence of the protein Hdj2 in synovial fluid is determined at an early stage of the disease. | 02-24-2011 |
20110045510 | PEGYLATED INSULIN-LIKE-GROWTH-FACTOR ASSAY - The current invention reports an immunoassay for the determination of PEGylated insulin-like-growth-factor employing an anti-(polyethylene glycol) antibody and an anti-digoxygenin antibody for the detection of an insulin-like-growth-factor/insulin-like-growth-factor-binding-protein-complex. | 02-24-2011 |
20110045511 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHOD - The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), the product of inorganic phosphorus and total calcium (P×tCa), osteopontin (OPN) and parathyroid hormone (PTH) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (FGFR) kinase activity, in particular its inhibition, and/or the occurrence of secondary effects of FGFR inhibition. The invention further provides methods and kits relating to these uses. | 02-24-2011 |
20110053188 | ENDOTOXIN DETECTION METHOD - The invention relates to a method for detecting endotoxins in a sample. | 03-03-2011 |
20110053189 | Type IV secretion system proteins in sero-detection of Anaplasma phagocytophium - Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in | 03-03-2011 |
20110053190 | Use of CFH or ApoH as a Biochemical Diagnostic Marker for Complete Remission in Acute Myeloid Leukemia - The present invention relates to a diagnostic method for acute myeloid leukemia, in particular, a method for using CFH or ApoH in patient sera as biochemical diagnostic markers to determine complete remission in acute myeloid leukemia. In accordance with this invention, CFH and ApoH are identified as a novel biochemical marker for understanding the biological mechanism and responsiveness to disease in AML patients after induction chemotherapy, and can be used as a biochemical marker for evaluating the prognosis of disease in patients after induction chemotherapy. | 03-03-2011 |
20110053191 | METHOD FOR RISK REDUCTION IN GLYCEMIC CONTROL - Disclosed is a method for identifying a subject being susceptible to a therapy for intensive glycemic control, the subject suffering from diabetes and being in need for a therapy for intensive glycemic control, based on determining the amount of PLGF (placental growth factor) in a sample of the subject and comparing the thus determined amount to a reference amount. In a preferred embodiment, the method further includes determining at least one further marker selected from the group consisting of a cardiac troponin and a natriuretic peptide and comparing the determined amount(s) to a reference amount (amounts). Moreover, disclosed is a method for predicting the risk of an acute cardiovascular event in a subject who suffers from diabetes and is on intensive glycemic control. Further disclosed is a kit and a device adapted to carry out the method of the present invention. | 03-03-2011 |
20110059472 | REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS - Antibodies that specifically bind to a peptide having an amino acid sequence as found at the N-terminus of the HA2 fusion peptide of the influenza A virus may be raised by inoculating a mammal with a conjugate of the peptide. In one embodiment, the conjugate comprises the peptide linked to a spacer (e.g. 6-aminocaproic acid) and a carrier protein (e.g. KLH). The antibodies may be used as a universal reagent for detecting HA proteins of influenza viruses. The antibodies are useful as versatile reagents for laboratory research and vaccine potency determination, especially in the event of pandemic influenza outbreaks. | 03-10-2011 |
20110059473 | PROTEINS WITH PTERIDINE GLYCOSYLTRANSFERASE ACTIVITY AND ANALYSIS METHOD USING THE SAME - The present invention relates to proteins with pteridine glycosyltransferase activity and an analysis method using the same. Since the proteins glycate tetrahydrobiopterin selectively through an enzyme reaction, the method enables quantitative analysis of tetrahydrobiopterin and oxides thereof at the same time or quantitative analysis of tetrabiopterin selectively. | 03-10-2011 |
20110065133 | O-ring Systems and Methods for Quantification of Multiplex Biomarkers in Multiple Samples - Kits and methods of using O-rings having apertures are provided herein. O-rings are useful for incubating with a sample fluid potentially having one or more biomarkers, in order to detect the presence of the biomarkers. O-rings can be readily organized in a trackable manner prior to and during incubation with the sample fluid. O-rings can also be readily transferred and organized into one or more trackable arrays for detecting the presence of bound biomarkers and measuring the signaling product generated by bound detect molecule-linked enzymes present in a homogeneous solution with a spectrophotometer. | 03-17-2011 |
20110065134 | SYNTHETIC PEPTIDES IMMUNO-REACTIVE WITH RHEUMATOID ARTHRITIS AUTO-ANTIBODIES - Embodiments of the present invention relate to a three dimensional matrix of selected, synthetic peptide mimic sequences that are preferentially recognized by auto-antibodies, specifically by autoimmune antibodies, to be detected in patients afflicted with rheumatic arthritis, enabling enhanced sensitivity and specificity in detection of these antibodies in pre-symptomatic patients, in patients showing symptoms as well as patients confirmed positive for rheumatoid arthritis. | 03-17-2011 |
20110076700 | ANTI-CRP ANTIBODY AND UTILIZATION OF THE SAME - It is intended to provide means capable of specifically recognizing CRP in a test sample and assaying it with high sensitivity. The present invention provides an anti-CRP antibody which reacts with a C-reactive protein (hereinafter referred to as CRP) and recognizes an epitope located at residues 147 to 172 in a CRP amino acid sequence represented by SEQ ID NO: 1. | 03-31-2011 |
20110076701 | MULTI-STAGE NUTRIGENOMIC DIAGNOSTIC FOOD SENSITIVITY TESTING IN ANIMALS - A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined. The molecular dietary signature for the animal is a variation of expression of a set of genes, proteins or metabolites which may differ for the genotype of each animal. | 03-31-2011 |
20110081667 | BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof. | 04-07-2011 |
20110081668 | BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof. | 04-07-2011 |
20110081669 | SYSTEMS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - Methods for diagnosing a cancer in a subject are provided that include determining an amount of autoantibodies immunoreactive to procathepsin D (pCD) in a sample obtained from the subject. Further provided are systems for diagnosing a cancer in a subject that include an autoantibody immunoreactive pCD antigen and a means for detecting binding of an autoantibody to the antigen. | 04-07-2011 |
20110086371 | URINE AND SERUM BIOMARKERS ASSOCIATED WITH DIABETIC NEPHROPATHY - Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof. | 04-14-2011 |
20110086372 | BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof. | 04-14-2011 |
20110091910 | NOVEL ASSAY - A novel method for detection of Aβ peptides, in particular in plasma, and to the use of Aβ peptides for diagnosis of Alzheimer's disease. | 04-21-2011 |
20110091911 | ANTIBODIES, SYSTEMS AND METHODS FOR DETERMINING RELATIVE HEMOLYTIC INDEX - Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient. | 04-21-2011 |
20110091912 | HIGH MOLECULAR WEIGHT NGAL AS A BIOMARKER FOR CHRONIC KIDNEY DISEASE - A high molecular weight form of Ngal is provided which can be used to diagnose chronic kidney disease. High molecular weight Ngal is about 75 kDa to about 350 kDa, and comprises non-Ngal proteins, such as polymeric immunoglobulin receptor, alpha-2-macroglobulin and immunoglobulin heavy chain. Methods are disclosed for assessing high molecular weight Ngal in a diagnostic sample from a subject. | 04-21-2011 |
20110091913 | DRUG SAFETY TEST USING PENTRAXIN-3 (PTX-3) - The invention relates to an in vitro method for assessing the immunogenicity of a compound of interest comprising the steps of: a) providing a whole blood sample, wherein said blood was exposed to said compound of interest, b) measuring the level of pentraxin-3 in said sample, and c) comparing the measured level of pentraxin-3 with a control. | 04-21-2011 |
20110097746 | Orthogonal Method for the Removal of Transmissible Spongiform Encephalopathy Agents from Biological Fluids - A method comprising contacting a biological fluid comprising hemoglobin and at least one pathogenic agent with a first filter and generating a first filtrate; contacting the first filtrate with a nanofiltration device and generating a second filtrate; contacting the second filtrate with a chromatographic material and isolating an eluted fraction; contacting the eluted fraction with a hydrophobic solvent and generating a hydrophobic and a hydrophilic phase; and isolating the hydrophilic phase wherein the biological fluids comprise components of interest of equal to or less than about 65 kDa. A method comprising contacting a biological fluid comprising high molecular weight components and at least one pathogenic agent with a first filter and generating a first filtrate; contacting the first filtrate with a hydrophilic membrane and generating a second filtrate; contacting the second filtrate with a chromatographic material and isolating an eluted fraction; contacting the eluted fraction with a hydrophobic solvent and generating a hydrophobic and a hydrophilic phase; and isolating the hydrophilic phase, wherein the high molecular weight components have molecular weights greater than about 65 kDa. A method comprising subjecting a biological fluid comprising hemoglobin and at least one pathogenic agent to at least two filtration steps and thereby reducing the amount of pathogenic agent associated with the biological fluid. A method comprising removing transmissible spongiform encephalopathy agents in a hemoglobin solution of human and/or animal origin by subjecting the hemoglobin solution to an orthogonal separation methodology comprising a plurality of filtration steps. | 04-28-2011 |
20110097747 | Monoclonal antibody binds antigen associated with human tumors - The present invention is concerned with a novel antigen associated with human tumors, including carcinomas of the colon, pancreas, and lung, as well as novel monoclonal antibodies which binds strongly to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. The novel antigen disclosed is a 60,000 Dalton glycoprotein found on the cell surface of human tumor cells. | 04-28-2011 |
20110097748 | USE OF CELL LINES TO DETERMINE LEVELS OF EFFICACY OF PHARMACEUTICAL FORMULATIONS - The present invention provides methods and assays for determining the efficacy of pharmaceutical compositions. Through the use of cell lines to measure efficacy of a formulation, one can better measure characteristics such as half life, release rate and release profile of a product that may be informative to the FDA. These methods and assays may, for example, be of use when measuring the effect of anti-inflammatory agents on cytokine production that is being considered for local administration. | 04-28-2011 |
20110097749 | PROCESS FOR PRODUCING HEPCIDIN - The present invention provides a novel method for producing biologically functional hepcidin in | 04-28-2011 |
20110097750 | METHOD OF QUANTITATIVE ASSESSMENT ON REPRODUCTIVE EFFORT OF BLACK-LIP PEARL OYSTERS USING ANTIBODY SPECIFIC THERETO - Disclosed are an antigen protein of black-lip pearl oyster egg extract, an antibody specific thereto, and a method of quantitative assessment of the reproductive effort of black-lip pearl oyster using the antibody. The method accomplishes quantitative assessment of reproductive effort of black-lip pearl oysters easily and accurately. In addition, the method provides important information for the study of life cycles of black-lip pearl oysters, and allows efficient management of black-lip pearl oysters. | 04-28-2011 |
20110097751 | GLP-1 RECEPTOR AGONIST BIOASSAYS - Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays. | 04-28-2011 |
20110097752 | COPD Diagnosis - The present invention relates to a method for diagnosing chronic obstructive pulmonary disease (COPD) in a human subject or the risk of a human subject to develop COPD comprising the steps of: —providing a sample from a human subject, —determining the amount of caspase-cleaved cytokeratin-18 (ccCK-18), histones, heat shock protein 27 (HSP27), heat shock protein 70 (HSP70) and/or heat shock protein 90 alpha (HSP90 alpha) in said sample, —diagnosing COPD when the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha is increased compared to the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha in healthy human subjects, or—diagnosing the risk to develop COPD when the amount of ccCK-18, histones and/or HSP70 is reduced compared to the amount of ccCK-18, histones and/or HSP70 in healthy human subjects. | 04-28-2011 |
20110104722 | METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2 - The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2. | 05-05-2011 |
20110104723 | BIOMARKERS - The invention provides binding agents and assays for insulin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention. | 05-05-2011 |
20110104724 | BIOMARKERS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE - A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein; | 05-05-2011 |
20110104725 | Method of Effecting Coagulation in a Droplet - The invention provides techniques for coagulating blood on a droplet actuator. The invention also provides methods of manipulating the coagulated blood including a variety of droplet operations that may be conducted using the coagulated blood. Further, the invention provides a variety of assays that make use of the coagulated blood or various blood samples as input. | 05-05-2011 |
20110111438 | METHOD AND DEVICE FOR IMMUNOASSAY - The present invention relates to a method and a device for determining a concentration of a biological active substance in a sample by the means of an enzyme-linked immunosorbent assay (ELISA). The device comprises a solid support within a tubing ( | 05-12-2011 |
20110111439 | Elevation of Induced Heat Shock Proteins in Patient's Cerebral Spinal Fluid: A Biomarker of Risk/Onset of Ischemia and/or Paralysis in Aortic Surgery - Provided are methods for intra-operatively predicting, detecting or diagnosing the risk or onset of spinal cord ischemia and/or associated permanent paralysis in a patient, based upon the stress-induced elevation of levels of heat shock proteins, specifically HSP70 and/or HSP27 in the cerebral spinal fluid of the patient, as measured during thoracic-aorta surgery, particularly thoracic aneurysm repair surgery, that will permit intra-operative medical intervention to try to prevent or attenuate severe, and often fatal, complications. Further provided are kits, assay devices and methods of analyzing biomarker data for use in pre-, intra- or post-operatively detecting the stress-induced elevations of the measured levels of HSP70 and/or HSP27, and the biomarker itself. | 05-12-2011 |
20110111440 | ELISA KIT FOR DETECTING LINCOMYCIN - The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride. The ELISA kit according to the present invention can be used for detecting the content of lincomycin remained in a sample such as an animal tissue (muscle, liver), honey, etc. | 05-12-2011 |
20110117582 | MULTI-BIOMARKER BIOSENSOR - Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described. | 05-19-2011 |
20110117584 | Detection of Chronic Kidney Disease Patients or Coronary Artery Disease Using Bone Morphogenic Protein-4 - The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4. | 05-19-2011 |
20110124018 | DETECTION OF PATHOGENIC POLYPEPTIDES USING AN EPITOPE PROTECTION ASSAY - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. | 05-26-2011 |
20110124019 | METHOD OF USING CARBONIC ANHYDRASE TO DETECT HEMOLYSIS - A method and a test for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and test detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis. Plasma carbonic anhydrase is used to determine the percentage hemolysis in plasma. Furthermore, CA is quantified with specificity to the isozyme present in the plasma. | 05-26-2011 |
20110129858 | Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof - A method for evaluating the cure level of a stroke patient comprises following steps: (1) obtaining isolated blood sample from said stroke patient; (2) determining the concentration of serum granulocyte colony-stimulating factor (G-CSF) of said blood sample; (3) comparing the relationship between said concentration of granulocyte colony-stimulating factor (G-CSF) and the stroke severity ranking of said stroke patient; wherein United State National Institute of Health Stroke Scale (NIHSS) or modified Ranking Scale (mRS) is used in said stroke severity ranking; and (4) Using said concentration of granulocyte colony-stimulating factor (G-CSF) to predict the possible cure level of said stroke patient. The invention further provides a prognosis biomarker for evaluating the cure level of a stroke patient, and a kit containing said prognosis biomarker. | 06-02-2011 |
20110129859 | BIOMARKER FOR DIAGNOSIS OF LIVER DISEASE - Disclosed are: a marker for the diagnosis of a liver disease, which can determine the disease in a simple manner; an antibody directed against the marker; a diagnostic agent; a diagnosis method; and a method for marker detection in blood or serum. Proteome analysis revealed that quantities of the full-length kininogen and three partial peptides thereof (sequence A: position-440 to position-456, sequence B: position-439 to position-456, and sequence C: position-438 to position-456) in sera of patients with non-alcoholic fatty liver disease are significantly different from those in sera of healthy individuals; and a diagnostic agent and a detecting method for the non-alcoholic fatty liver disease that can be conveniently used for medical examination are established. The use of a combination of a kininogen-based marker and a C4-based marker (the full length sequence or partial peptides thereof) enables identification of chronic hepatitis and an asymptomatic virus carrier, as well as non-alcoholic fatty liver disease. | 06-02-2011 |
20110129860 | CALPROTECTIN AND HEMOGLOBIN/HAPTOGLOBIN COMPLEX FROM STOOL SAMPLE TO ASSESS COLORECTAL CANCER - The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention. | 06-02-2011 |
20110136153 | Use of VEGF-D in the Diagnosis of Lymphangioleiomyomatosis (LAM) Disease - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided. | 06-09-2011 |
20110136154 | VOLTAGE-GATED METAL-ENHANCED FLUORESCENCE, CHEMILUMINESCENCE OR BIOLUMINESCENCE METHODS AND SYSTEMS - In the present invention, it is demonstrated for the first time, the influence of electrical current on the ability of surface plasmons to amplify fluorescence signatures. An applied direct current across silver island films (SiFs) of low electrical resistance perturbs the fluorescence enhancement of close-proximity fluorophores. For a given applied current, surface plasmons in “just-continuous” low resistance films are sparsely available for fluorophore dipole coupling and hence the enhanced fluorescence is gated as a function of the applied current. | 06-09-2011 |
20110136155 | PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to | 06-09-2011 |
20110143377 | Protein fragments of virB10 and sero-detection of anaplasma phagocytophium - Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in | 06-16-2011 |
20110143378 | MICROFLUIDIC METHOD AND APPARATUS FOR HIGH PERFORMANCE BIOLOGICAL ASSAYS - The present invention provides a disposable microfluidic assay cartridge ( | 06-16-2011 |
20110143379 | DETECTION AND QUANTITATION OF FULL-LENGTH THIOREDOXIN (TRX) AND TRUNCATED THIOREDOXIN (TRX 80) IN COMPLEX SAMPLES - The present invention relates, e.g., to a method for detecting a full-length protein and a truncated form (e.g., a naturally occurring cleavage product) thereof, in a sample, comprising
| 06-16-2011 |
20110143380 | ALZHEIMER'S DISEASE BIOMARKERS AND METHODS OF USE - The invention encompasses biomarkers for AD, a method for detecting AD, a method of monitoring AD, and a kit for quantifying biomarkers for AD. | 06-16-2011 |
20110143381 | DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 06-16-2011 |
20110151486 | METHODS AND SYSTEMS TO PREVENT GAS BUBBLES FROM INTERFERING WITH FLOW OF FLUID THROUGH A MEMBRANE REGION - Methods and systems to remove gas bubbles from liquids and to improve uniform fluid flow through a region of a membrane in a microfluidic device, including to reduce, remove, and/or prevent gas bubbles on a surface of a porous membrane. An example membrane bubble trap system may include a fluid channel connected to a bubble pathway that surrounds an opening sealed with a membrane. The bubble pathway may be configured to collect bubbles in fluid that passes through the membrane through buoyancy forces and through a directional feature of a curved surface placed above the membrane. | 06-23-2011 |
20110151487 | Compositions And Methods For The Treatment Of Cancer - Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention discloses inhibitors of the Fanconi anemia pathway and methods using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer. | 06-23-2011 |
20110151488 | DETECTION AND MONITORING OF LIVER DAMAGE - A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression. | 06-23-2011 |
20110151489 | MONITORING SKIN METABOLISM PRODUCTS FOR EVALUATING BURN INJURY - The present invention relates to methods and kits for evaluating the severity of a burn injury, which are based on the detection in a clinical fluid sample of skin metabolism products, such as collagen peptides which are released upon collagen degradation or synthesis. | 06-23-2011 |
20110151490 | Compositions for the Detection and Treatment of Colorectal Cancer - The invention provides methods of identifying proteins and polypeptides and their cognate polynucleotides that are expressed by cells under one environmental condition and not under a second environmental condition. The invention also provides compositions for the treatment and detection of cancer, including colorectal cancer. | 06-23-2011 |
20110159526 | METHODS FOR PRDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY - The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample. | 06-30-2011 |
20110159527 | METHODS AND KITS FOR DIAGNOSING NEURODEGENERATIVE DISEASE - Methods and diagnostic kits for determining whether a subject may develop a or for diagnosing a neurodegenerative disease. The method includes quantitating the amount of alpha-synuclein and total protein in a cerebrospinal fluid (CSF) sample obtained from the subject and calculating a ratio of alpha-synuclein to total protein content; comparing the ratio of alpha-synuclein to total protein content in the CSF sample with the alpha-synuclein to total protein content ratio in CSF samples obtained from healthy neurodegenerative disease-free subjects; and (c) determining from the comparison whether the subject has a likelihood to develop neurodegenerative disease or making a diagnosis of neurodegenerative disease in a subject. A difference in the ratio of alpha-synuclein to total protein content indicates that the subject has a likelihood to develop a neurodegenerative disease or has developed a neurodegenerative disease. | 06-30-2011 |
20110159528 | Methods and Materials for the Detection of Leishmania Infection - The present invention provides rapid diagnostic assays for the detection of | 06-30-2011 |
20110165598 | METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE - Aspects of the invention relate to methods and compositions for treating Alzheimer's disease (AD). In some embodiments, the invention provides methods for screening and identifying compounds that selectively inhibit the targeting of the insulin-Akt signaling pathway by Aβ oligomers. | 07-07-2011 |
20110165599 | MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER - The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer. | 07-07-2011 |
20110165600 | DIAGNOSIS METHOD AND DIAGNOSIS KIT FOR DERMATOMYOSITIS - An object of the present invention is to identify an antigen corresponding to anti-CADM-140 antibody, produce a recombinant protein, and establish an assay system by ELISA or the like. The present invention provides a kit for diagnosing dermatomyositis containing an MDA5 protein shown in SEQ ID NO: 4 or a fragment thereof that is recognized by anti-CADM-140 antibody. | 07-07-2011 |
20110171668 | Determination Of Equilibrium Constants In Solution By Multi-Step Kinetics - The invention relates to a method for determining a first equilibrium constant of a first equilibrium reaction via MSK analysis of a second equilibrium reaction, whereby the first and the second equilibrium reaction share at least one reactant. | 07-14-2011 |
20110177530 | Methods and Compositions for Detection of Biological Materials Using Microfluidic Devices - Provided herein are microfluidic devices and methods useful for sensitive detection of analytes. The methods and devices described herein are also useful for detecting direct or indirect binding of enzymes or catalysts to a surface, for example a surface having analytes bound thereon. Methods disclosed herein include embodiments utilizing a pre-concentration scheme to improve signal levels of corresponding reporter moieties. | 07-21-2011 |
20110177531 | Cell-Based Complement Activation Product Algorithm for Diagnosing Systemic Lupus Erythematosus - The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus by measuring cell-based complement activation products (CB-CAPS) in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products on the surfaces of red blood cells, white blood cells, and platelets (e.g., EC4d, BC4d, PC4d, and ECR1). A diagnostic algorithm utilizing the determined levels of CB-CAPS is also disclosed. | 07-21-2011 |
20110177532 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF - The invention is directed to β1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The β1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The β1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated β1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils. | 07-21-2011 |
20110177533 | ASBESTOS EXPOSUSRE, PLEURAL MESOTHELIOMA, AND OSTEOPONTIN LEVELS - The present invention provides prognostic and diagnostic methods related to pleural mesotheliomas based on levels of osteopontin in bodily fluids. | 07-21-2011 |
20110177534 | DIAGNOSTICS FOR MEMBRANOUS NEPHROPATHY - The invention relates to immunoassays, reagents, therapeutics and methods of diagnosing and prognosis evaluation of idiopathic membranous nephropathy (MN). Immunoassays comprise enzyme-linked immunoabsorbent assays and nephelometric immunoassays for serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R). Therapeutic methods include removal of the auto-antibodies by absorbance or administration of soluble PLA2R or fragments to sequester the auto-antibodies. | 07-21-2011 |
20110177535 | METHOD OF DETECTING OR MONITORING A MALIGNANT PLASMA CELL DISEASE - A method of detecting or monitoring a malignant plasma cell disease comprising detecting in a sample the ratio between the relative amounts of immunoglobulins having:
| 07-21-2011 |
20110177536 | NOVEL ANTIBODIES RECOGNIZING NATIVE ANNEXIN A3 - The present invention refers to novel antibodies recognizing native annexin A3. These antibodies are suitable for diagnostic and therapeutic applications. | 07-21-2011 |
20110183362 | COMPOSITIONS AND METHODS FOR MEASURING LEVELS OF BIOACTIVE HUMAN HEPCIDIN - The invention provides compositions and methods for measuring human serum hepcidin levels. The invention provides methods for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal. | 07-28-2011 |
20110183363 | ASSAYS FOR DETECTING ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE IN ANAPHYLAXIS - The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody. | 07-28-2011 |
20110183364 | ANALYTICAL METHOD FOR THE DETECTION OF LATENT HEPATITIS C, USE THEREOF AND CORRESPONDING DIAGNOSIS KIT - The invention relates to an improved analytical method for the detection of latent hepatitis C, to the use thereof and to the corresponding diagnosis kit. The analytical method is based on the immunoassay technique and the most suitable operating conditions for detecting latent hepatitis C have been determined. The invention also relates to a diagnosis kit complementary to the method. The invention is suitable for use in medicine, biomedical research and in the field of analytical techniques. | 07-28-2011 |
20110189704 | NON-SPECIFIC REACTION INHIBITOR - Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method. | 08-04-2011 |
20110189705 | Immunoassay - The invention provides a highly sensitive immunoassay for detection of a biological species. The immunoassay comprises exposing an electrode to an analyte liquid putatively containing the biological species so as to couple the biological species, if present in the analyte liquid, to a binding antibody on the electrode. The electrode comprises a binding antibody and an anchor group, each being coupled to an electrically conductive substrate, said binding antibody being capable of binding to the biological species and said anchor group being capable of binding to a redox polymer. The electrode is then exposed to an antibody-enzyme liquid comprising an antibody-enzyme species, said antibody-enzyme species comprising a detection antibody capable of binding to the biological species, said detection antibody being coupled to a redox enzyme, whereby, if the analyte liquid comprises the biological species, the redox enzyme couples to the electrode by means of the coupling of both the detection antibody and the binding antibody to the biological species. The electrode is then exposed to a polymer solution comprising the redox polymer and to an enzyme substrate, whereby if the redox enzyme is coupled to the anchor group on the electrode the redox polymer is reduced and couples to the anchor group on the electrode. A voltage is then applied between the electrode and a reference electrode and the electrode is exposed to an oxidisable species, whereby a magnitude of an electric current between said electrode and a reference electrode is indicative of the presence or absence of the biological species. | 08-04-2011 |
20110189706 | PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE - The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use. | 08-04-2011 |
20110189707 | Goodpasture Antigen Binding Protein and its Detection - The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use. | 08-04-2011 |
20110195437 | METHOD FOR CHARACTERIZING, IN PARTICULAR FOR QUANTIFYING, MOLECULAR MARKERS THAT ARE INTRACELLULARLY ABSORBED FROM TISSUES BY BLOOD MACROPHAGES THAT ARE RECIRCULATED FROM THE TISSUES INTO THE CIRCULATORY SYSTEM - The invention relates to a method for characterizing, in particular for quantifying molecular marker(s) that are intracellularly absorbed from tissues by blood macrophages that are recirculated from the tissues into the circulatory system, wherein the following steps are carried out: application of an agent to whole blood, said agent inhibiting coagulation and/or agglomeration of whole blood; selecting and/or enriching and/or separating blood macrophages or leukocyte populations that contain blood macrophages from whole blood; perforating and/or lysing the selected blood macrophages or leukocyte populations containing the blood macrophages, optionally after previous permeabilization thereof; qualitatively and quantitatively determining non blood macrophage markers, namely molecular markers arising from tissue, after previously perforating and/or lysing the blood macrophages or leukocyte populations containing the blood macrophages, and an apparatus for carrying out the method. | 08-11-2011 |
20110195438 | INSULIN ASSAY - The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs. | 08-11-2011 |
20110201033 | G IMMUNOGLOBULIN USED AGAINST ANTHRAX TOXINS - An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes:
| 08-18-2011 |
20110201034 | METHOD AND KIT FOR DETECTING ANTIBODY TO AVIBACTERIUM PARAGALLINARUM - A method and a kit for detecting an antibody to | 08-18-2011 |
20110201035 | COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods or the detection of immunodeficiency virs infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies. | 08-18-2011 |
20110201036 | ENDOMETRIOSIS MARKERS - The present invention relates to methods for determining a risk or identifying a condition associated with the presence of endometriosis in a subject as well as testing a candidate compound for a therapeutic activity for the treatment of endometriosis and sorting patients based on the risk of having endometriosis. Specifically, the methods utilize novel markers for assessing the risk of the patient having endometriosis. | 08-18-2011 |
20110207152 | GELSOLIN BINDING AGENT COMPOSITIONS AND USES OF SAME - The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention. | 08-25-2011 |
20110207153 | METHODS FOR DETECTING THE PRESENCE OF EXPANDED CGG REPEATS IN THE FMR1 GENE 5' UNTRANSLATED REGION - The invention provides improved methods for detecting the presence of expanded CGG repeats in the fragile X mental retardation 1 (FMR1) gene and for quantifying the amount of protein produced by the gene. | 08-25-2011 |
20110207154 | METHOD FOR DETERMINATION OF MARINOBUFAGENIN LEVELS AND COMPOUNDS EMPLOYABLE IN SUCH METHOD - The present invention is directed toward a method for determination of marinobufagenin concentration in a body specimen through conjugation of marinobufagenin to a suitable protein, thereby creating a conjugate which will trigger an antibody response in a host. The conjugated marinobufagenin is immunogenic. The antibodies so produced may be employed in an ELISA test to ascertain the concentration of marinobufagenin in a body specimen. A number of unique compounds are created in the process and are disclosed. An ELISA assay may be employed. | 08-25-2011 |
20110207155 | Method for the preparation of immunoconjugates and use thereof - The present invention concerns a method for the preparation of molecular conjugates comprising immunoglobulins and biomarkers occurring in neoplastic diseases characterized by high levels of reproducibility. | 08-25-2011 |
20110207156 | Biomarkers for Diagnosis of Breast Cancer - The present invention provides methods and kits for determining breast cancer. The invention includes the identification and use of biomarkers that are present in different amount or differentially expressed in breast cancer versus normal controls. | 08-25-2011 |
20110212470 | BIOMARKERS FOR RHEUMATOID ARTHRITIS - The present invention relates to the diagnosis of autoimmune disorders, more specifically to the diagnosis of rheumatoid disorders, chronic autoimmune arthritis and even more specifically to the diagnosis of rheumatoid arthritis. A biomarker panel is provided which can be used to detect if a subject has rheumatoid arthritis. Also described are methods of identification of such biomarkers. | 09-01-2011 |
20110212471 | METHOD FOR DIAGNOSING ATHEROSCLEROTIC PLAQUES BY MEASUREMENT OF CD36 - The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed. | 09-01-2011 |
20110212472 | Asbestos Exposure, Pleural Mesothelioma and Osteopontin Levels - The present invention provides diagnostic and disease progression or recurrence prediction methods based on osteopontin levels in a biological sample. | 09-01-2011 |
20110212473 | MMP ACTIVATION PEPTIDE DETECTION IN BIOLOGICAL SAMPLES - A method is provided along with related reagent kits for aiding the diagnosis of IPF or other interstitial lung diseases, as well as for potential monitoring of disease progression or therapeutic response to treatment. | 09-01-2011 |
20110223621 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS - The invention features pharmaceutical compositions that include dipyridamole and a corticosteroid. | 09-15-2011 |
20110223622 | Methods and Kits for Predicting the Onset of Labour - The present invention relates to methods and kits useful for predicting the time of onset of labour in a pregnant subject. In particular, the invention relates to methods and kits for predicting the time of onset of labour wherein the levels of at least two hormones, selected from estriol, estradiol and progesterone, are determined and a ratio of said levels is calculated, and wherein the time of onset of labour is predicted by comparison of said ratio with a predetermined ratio. The invention further contemplates methods for preventing preterm delivery of an infant/offspring. | 09-15-2011 |
20110223623 | METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS - The invention provides methods for prognosis of patients afflicted with cancer, comprising determining the level of GP88 expression in a biological sample obtained from said patient. | 09-15-2011 |
20110229914 | Use of Antibody Secreting Cell Elispot To Assess Antibody Responses Following Antigen Exposure - Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies. | 09-22-2011 |
20110229915 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin-1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries. | 09-22-2011 |
20110236912 | SYSTEMS AND METHODS FOR CHARACTERIZING LUPUS ERYTHEMATOSUS - The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (SLE) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of SLE subjects for determining nephritic disease states and kidney damage in SLE subjects and the efficacy of agents and interventions used to treat lupus nephritis. | 09-29-2011 |
20110236913 | COMPOSTION AND KIT FOR DIAGNOSING IMMUNOGLOBULIN A NEPHROPATHY AND TGBM NEPHROPATHY - Disclosed is the development of a protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. The disclosed development relates to a diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein. The protein level is increased or decreased in urine from a patient with IgA nephropathy or TGBM nephropathy compared to urine from a normal patient. According to the disclosed development, the degree of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). As well, the monoclonal antibody is used in early diagnosis and progress detection of IgA nephropathy and development of a novel drug for the purpose of treatment. | 09-29-2011 |
20110236914 | RECORDING ASSAY DEVICE - A method for assaying a sample involves an assessment device having an assay part and a detachable recording part, which are disposed on separable portions of a substrate. The sample to be assayed is received in a sample application well on the assay element, where it contacts a measuring element, generally after being mixed with an assay reagent. Assay information relating to the sample is transferred from the measuring element to data recording element on the recording part. After the information transfer, the assay part and the recording are separated, so that the assay part can no longer transfer information to the data recording element. | 09-29-2011 |
20110236915 | ZAP-70 EXPRESSION AS A MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) - It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein. | 09-29-2011 |
20110244488 | CHITIN-INDUCED IMMUNE RESPONSE BASED METHOD FOR DIAGNOSING ALLERGIC ASTHMA IN PATIENTS - A method of diagnosing allergic asthma in patients, including the steps of: obtaining from a subject a first sample of peripheral blood immune cells and a second sample of peripheral blood immune cells; adding chitin to the first sample; measuring the average amount of IFN-γ in both the first sample and the second sample to get a first value and a second value respectively; and dividing the first value with the second value to get a ratio, wherein if the ratio is smaller than a threshold value, the subject is diagnosed as an allergic asthma patient. | 10-06-2011 |
20110244489 | METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 10-06-2011 |
20110244490 | DETECTION AND MONITORING OF LIVER DAMAGE - A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression. | 10-06-2011 |
20110244491 | PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES - The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject. | 10-06-2011 |
20110244492 | IMMUNOASSAYS FOR CITRULLINATED PROTEINS - Methods and kits are provided for assessing radiation injury and exposure in a mammal. The methods comprise the steps of: obtaining one or more test samples from the mammal, contacting the test samples with an antibody immunoreactive with a citrullinated protein to form an immunocomplex; and detecting the immunocomplex with an ELISA; wherein a decrease in the quantity of the immunocomplex in the test samples, as compared to the quantity of immunocomplexes formed under identical conditions with the same antibody and a control sample from one or more mammals known to have a lower degree of radiation injury or exposure, indicates a higher degree of radiation injury and exposure to the mammal. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the mammal, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis. | 10-06-2011 |
20110244493 | CELL-BASED DETECTION OF APF THROUGH ITS INTERACTION WITH CKAP4 FOR DIAGNOSIS OF INTERSTITIAL CYSTITIS - An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC. | 10-06-2011 |
20110244494 | REAGENTS, METHODS AND KITS FOR THE UNIVERSAL RAPID IMMUNO-DETECTION - Novel immuno-detection methods, kits and reagents are provided. The Combination of this invention, combining at least two of the following reagents of a Non-specific Competitor, a Specific Indicator, a primary antibody and an antigen, provides a faster and easier method for an immuno-detection, combining at least two of the following steps of blocking, antigen binding, primary antibody binding and 2 | 10-06-2011 |
20110250622 | METHOD FOR DIAGNOSING AUTO-IMMUNE CHRONIC URTICARIA - In certain embodiments, the present invention relates to methods, compositions, and kits for diagnosing autoimmune chronic urticaria. For example, in certain embodiments, such methods generally comprise detecting the presence of auto-antibodies to cell-surface IgE receptors or cell-bound IgE in a patient. Such auto-antibodies may be detected by (a) obtaining donor basophils and associated leukocytes from one or more donors, (b) challenging the donor basophils and associated leukocytes with control serum and quantifying the amount of histamine released by the donor basophils and associated leukocytes, (c) calculating a normalized baseline of histamine release, wherein the normalized baseline of histamine release represents a mean percentage of histamine released by the basophils and associated leukocytes of an individual donor plus a specified amount above such mean, (d) reacting patient serum with the donor basophils and associated leukocytes, (e) measuring the percentage of histamine released by the donor basophils and associated leukocytes in response to the patient serum, and (f) comparing the percentage of histamine released by the donor basophils and associated leukocytes in response to the patient serum to the normalized baseline of histamine release. | 10-13-2011 |
20110250623 | BIOMARKER AND METHOD FOR DETECTING A CHRONIC INFLAMMATORY-ASSOCIATED DISEASE - The present invention in one embodiment uses detection of isoforms of CAP37 as an early detection marker for a chronic inflammatory-associated disease. Chronic inflammatory-related diseases may include, for example, atherosclerosis, psoriasis, and osteoarthritis. The invention is also directed to isoforms of CAP37 protein having apparent molecular weights of about 135 kDa (±15 kDa) and about 100 kDa (±15 kDa) as assessed by SDS PAGE under reducing conditions, and their use as biomarkers for the presence of a chronic inflammatory-associated disease in a subject. The invention is also directed to monoclonal and/or polyclonal antibodies raised against such isoforms of CAP37 protein and kits and diagnostic tests comprising these antibodies. | 10-13-2011 |
20110250624 | ELISA ASSAY FOR DETECTING ANTIBODIES AGAINST BLV SURFACE ANTIGEN GP 51 IN BOVINE SERUM - The subject of the present invention is a method of obtaining purified BLV gp | 10-13-2011 |
20110250625 | GAMMA SECRETASE NOTCH BIOMARKERS - The present invention relates to the biomarker TFF-3 that measures γ-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage. | 10-13-2011 |
20110256559 | Method for Detecting Soluble Amyloid Precursor Protein (APP) Alpha and/or Soluble APP Beta - The present invention relates to a method for detection or quantification of sAPPα and/or sAPPβ in a sample and their use for diagnosing and/or monitoring a neurodegenerative disease in a subject in need thereof and kit for use in said method. | 10-20-2011 |
20110256560 | METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER - Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject. | 10-20-2011 |
20110256561 | LIVER DISEASE MARKER, METHOD AND APPARATUS FOR MEASURING THE SAME, AND METHOD FOR ASSAYING PHARMACEUTICAL PREPARATION - A normal person (i.e. a control) and liver diseases such as drug induced liver injury, an asymptomatic hepatitis B carrier, an asymptomatic hepatitis C carrier, chronic hepatitis B, chronic hepatitis C, liver cancer, a nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and simple steatosis (SS) are identified by measuring the concentrations of γ-Glu-X (X represents an amino acid or an amine) peptides or the levels of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value. | 10-20-2011 |
20110262939 | METHODS AND ASSAYS FOR CLASSIFYING FOODSTUFF AND/OR BEVERAGE AND/OR DIET AND/OR NUTRITION REGIMEN AND/OR MEDICAMENT IN VIEW OF AN EFFECT ON THE CARDIOVASCULAR SYSTEM - Subject of the present invention is an in vitro-method for classifying a foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system of a subject, comprising determining the relative level of one or more cardiovascular markers. | 10-27-2011 |
20110269157 | Immunological Test For Detecting Autoantibodies Against Testicular Antigens - The present invention discloses an immunological test for the detection and specific determination of autoantibodies against testicular antigens which are associated with inflammation-related fertility disorders of male mammals in a biological sample of a male mammal, in particular the detection of testicular ER-60 autoantibodies and/or transferrin autoantibodies. The immunological test is utilized to detect the presence of immunologically-caused and infection-related infertility in male mammals, particularly in humans. | 11-03-2011 |
20110269158 | USE OF S-ERBB-3 AS A MARKER FOR CANCER - The present invention relates to a method aiding in the assessment of cancer. It discloses the use of s-ErbB-3 as a universal marker of different cancer types. Measurement of s-ErbB-3 can, e.g., be used in the early detection or diagnosis of cancer or in the surveillance of patients who undergo surgery. | 11-03-2011 |
20110275098 | Method for Evaluating The Immunogenicity of Proteins - The invention relates to a method for evaluating the immunogenicity of proteins in humans or animals, comprising analysing the CD4+ T lymphocyte response specific to the protein to be tested in individuals of the (human or animal) species in which the immunogenicity of said cell is analysed. | 11-10-2011 |
20110275099 | DIAGNOSTIC METHOD FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS AND THERAPEUTIC USES THEREFOR - The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. | 11-10-2011 |
20110275100 | SERPIN B 13 AS A MARKER FOR SQUAMOUS CELL CARCINOMA OF THE LUNG - Disclosed is a method aiding in the assessment of squamous cell carcinoma (SCC). It involves the use of the protein serpin B13 as a marker of SCC. Furthermore, the disclosure relates to a method for assessing lung cancer in a tissue sample derived from a patient having non-small cell lung carcinoma (NSCLC) and for differentiating SCC from adenocarcinoma or large cell carcinoma of the lung. | 11-10-2011 |
20110281284 | NOVEL LIVER CANCER MARKER - According to the present invention, HDGF in the blood of patients with chronic liver disease is measured to diagnose whether the patients have liver cancer. A measurement kit for the diagnosis is also provided. | 11-17-2011 |
20110281285 | Assay for Detecting Cathepsin K Activty in Bone, Cartilage and/or Soft Tissue - There is provided a method for detecting cathepsin K activity in bone, cartilage and/or connective tissue, the method comprising providing a biological sample, contacting the sample with an antibody having binding specificity for a neoepitope comprising EAGKPG (SEQ ID NO: 9), and detecting an immunocomplex formed between the antibody and the neoepitope, wherein presence of the immunocomplex is indicative of cathepsin K activity in bone, cartilage and/or connective tissue. There is also provided a kit for detecting cathepsin K activity in bone, cartilage and/or connective tissue. | 11-17-2011 |
20110287453 | ANTIBODY BINDING SPECIFICALLY TO TDP-43 AGGREGATE - The present invention provides an antibody that specifically binds to an abnormal TDP-43 protein aggregate, an agent comprising the antibody for detecting a TDP-43 proteinopathy lesion, and a method for detecting or diagnosing a TDP-43 proteinopathy lesion by using the antibody. | 11-24-2011 |
20110287454 | METHODS FOR MONOCLONAL ANTIBODY PRODUCTION - This invention provides improved methods for production of monoclonal antibodies against a protein of interest. The present methods are based on immunization of an animal with a fusion protein between a protein of interest and a Th2 cytokine such as IL-4, IL-5, IL-13 and IL-31. | 11-24-2011 |
20110287455 | Methods, Devices and Kits for Detecting or Monitoring Acute Kidney Injury - Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment. | 11-24-2011 |
20110287456 | SYNTHETIC PEPTIDES, METHODS AND KITS FOR DIAGNOSING AUTOIMMUNE DISEASES - Provided herein are synthetic peptides, methods and kits for easy detecting or diagnosing an autoimmune disease, particularly, Henoch-Schönlein purpura (HSP), based on the detection of autoimmune antibodies with peptides derived from β-2-glycoprotein-1 (β2-GPI). | 11-24-2011 |
20110287457 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject. | 11-24-2011 |
20110294144 | SCREENING METHOD - The present invention provides a cell model system capable of sufficiently reproducing a series of tau lesions, and provides a screening method for a prophylactic or therapeutic drug for a neurodegenerative disease using phosphorylation, insolubilization or aggregation of tau, or neurite denaturation or cell death in the cell model as an index. | 12-01-2011 |
20110294145 | REAGENTS AND METHODS FOR DETECTING A POLYMORPHIC PROTEIN - The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications. | 12-01-2011 |
20110294146 | Identification of Actinobacillus actinomycetemcomitans Antigens for Use in the Diagnosis, Treatment, and Monitoring of Periodontal Diseases - Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by | 12-01-2011 |
20110294147 | SEROLOGICAL SCREENING FOR HHV-8 INFECTION USING ANTIGEN MIXTURES - The invention provides compositions, methods, and kits for the diagnosis or detection of active, latent, or prior infection with human herpesvirus 8 in a subject sample. | 12-01-2011 |
20110300562 | GDF15 AS A DIFFERENTIAL MARKER FOR SPONDYLOARTHROPATHY - In vitro methods for differential diagnosis of spondyloarthropathy are disclosed which involve determining the levels of GDF15 in biological samples. | 12-08-2011 |
20110300563 | METHODS OF PREPARING AND OPERATING PORTABLE, POINT-OF-CARE, USER-INITIATED FLUIDIC ASSAY SYSTEMS - Methods of preparing assays and of assaying, using substantially self-contained, portable, user-initiated fluidic assay systems. Example assays include diagnostic assays and chemical detection assays. Diagnostic assays may include, without limitation, enzyme-linked immuno-sorbent assays (ELISA), and may include one or more sexually transmitted disease (STD) diagnostic assays. An assay system may include one or more fluid chambers, one or more fluid paths amongst the fluid chambers and/or between the fluid chambers, a sample portion, and/or an assay portion. The assay system may include a fluid controller system to dispense fluid from the one or more fluid chambers, and a user-initiated actuator to control the fluid controller system. The fluid controller system may be configured to dispense fluids serially, and may be configured to mix a plurality of fluids. The user-initiated actuator system may include an external user-operated trigger mechanism. The assay apparatus may include a display window to view assay results. | 12-08-2011 |
20110300564 | DIAGNOSIS OF PRE-ECLAMPSIA - The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (PlGF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin. | 12-08-2011 |
20110306067 | Antibody Profiles Characteristic of Tuberculosis State - Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination at least three | 12-15-2011 |
20110306068 | Method For Detecting And Removing Endotoxin - The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca | 12-15-2011 |
20110306069 | Corin As A Marker For Heart Failure - The invention is a method of assessing whether an individual is afflicted with congestive heart failure (CHF) comprising comparing the level of corin or portion thereof in the individual to the level of corin or portion thereof in a control, wherein a decrease in the level of corin or portion thereof in the individual compared to the level of corin or portion thereof in the control indicates that the individual is afflicted with CHF. The methods described herein can be also be used to determine the severity of CHF in an individual, whether an individual's treatment for CHF is effective and whether an individual is at risk of developing CHF. | 12-15-2011 |
20110311994 | AVIAN VACCINES POSSESSING A POSITIVE MARKER GENE - The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine comprising the recombinant turkey herpesvirus provided in the present invention can elicit serological immune responses to the marker gene product that may be detected by serological assays such as enzyme-linked immunosorbent assay and serum agglutination test, thus enabling easy identification and tracking of vaccinated animals. | 12-22-2011 |
20110311995 | METHOD FOR THE DIAGNOSIS OF SYSTEMIC SCLERODERMA OR OF PULMONARY ARTERIAL HYPERTENSION - The invention relates to an in vitro method for detecting systemic scleroderma (SSc) and/or pulmonary arterial hypertension (PAH), or a risk of developing SSc or PAH, which comprises determining the presence and/or the amount of antibodies in a biological sample originating from a patient. | 12-22-2011 |
20110311996 | OPTICAL PARTICLE DETECTOR AND DETECTION METHOD - A particle detector apparatus for optically ascertaining a number of particles arranged on a surface, for example, a particle filter. The particle detector apparatus includes a light source, an optical focusing device, a spatially resolving light detector and an evaluation device. The light source emits source light onto the surface. The optical focusing device focuses image light that is emitted from the surface in response to the source light onto the spatically resolving light detector. The spatially resolving light detector includes light sensors that measure brightness values based on the image light, such that the light detector produces image data based on the brightness values delivered by the light sensors. The evaluation device then ascertains the number of particles based on the image data. | 12-22-2011 |
20110311997 | METHODS FOR ESTIMATING PRION CONCENTRATION IN FLUIDS AND TISSUE BY QUANTITATIVE PMCA - The present embodiments disclose methods for estimating PrP | 12-22-2011 |
20110311998 | A+ Biomarker Assays - Disclosed herein assay methods which comprise detecting the presence, absence or amount of at least one antibody which specifically binds a first biomarker or an epitope thereof and at least one second biomarker in a sample which comprises a single reaction step whereby both a first capture reagent for the antibody and a second capture reagent for the second biomarker are together contacted with the sample, and detecting the presence, absence or amount of the antibody, and detecting the presence, absence or amount of the second biomarker. Also disclosed are assay methods for prostate cancer. | 12-22-2011 |
20110311999 | DIAGNOSTIC PREDICTION OF RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention pertains to a diagnostic assay for the diagnosis of an autoimmune disease. The present invention provides an improved diagnostic assay for the diagnosis of an autoimmune disease, particularly rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). In particular the invention pertains to a method of determining in a sample of a subject the presence of two or more antibodies comprising the step of determining whether an antibody is present in a sample that specifically recognizes a hnRNP-DL polypeptide or a fragment thereof or a splice variant thereof and the further step of determining whether at least one further antibody is present in the sample that specifically recognizes a at least one other hnRNP polypeptide which is not sequence homologue to said hnRNP-DL polypeptide or fragments thereof or splice variants thereof, and/or said CCP peptide and/or a polypeptide comprising at least the Fc-part of IgG, respectively. The invention also relates to polypeptides, protein sets and antibodies that may be used in such methods and assays and for therapeutic use in RA and SLE patients. | 12-22-2011 |
20110318758 | HUMAN MONOCLONAL ANTIBODIES AND METHODS FOR PRODUCING THE SAME - The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer. | 12-29-2011 |
20110318759 | METHOD FOR ASSAYING KERATAN SULFATE, ASSAY KIT THEREFOR AND METHOD FOR DETECTING JOINT DISEASE BY USING THE SAME - The inventions provides a method for immunologically determining a keratan sulfate level which method includes bringing an anti-keratan sulfate monoclonal antibody into contact with a biological sample, the anti-keratan sulfate monoclonal antibody exhibiting a relative reaction specificity between keratan sulfate-I and keratan sulfate-II represented by IC50 | 12-29-2011 |
20110318760 | METHOD FOR THE IN VITRO DIAGNOSIS OF AN AUTOIMMUNE RESPONSE ASSOCIATED WITH THE EXISTENCE OF AN ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES-ASSOCIATED VASCULITIS BY DETECTION OF ANTIBODIES DIRECTED AGAINST THE PENTRAXIN 3 ANTIGEN - A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method. | 12-29-2011 |
20110318761 | METHODS AND KITS FOR PREDICTING A RESPONSE TO AN ERYTHROPOIETIC AGENT - Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17. | 12-29-2011 |
20110318762 | Graft-Versus-Host Disease Predicting Marker and Use Thereof - A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1 concentration of a patient of hematopoietic stem cell transplantation from bone marrow or the like over a period after the transplantation to provide data concerning the transition of the concentration to an abnormally high level deviating from the normal range, whereby the probability of the development of acute graft-versus-host disease is predicted, the risk of the development is estimated, or therapeutic effects after the development are evaluated. Concerning the molecular targeted therapy and pharmaceutical preparation used therefor wherein blood DNAM-1 of a GVHD patient or a graft recipient that is a possible patient is used as a target molecule, GVHD is treated or prevented by administering an anti-DNAM-1 antibody that is a neutralizing antibody. | 12-29-2011 |
20110318763 | DETECTION OF CANCER BY ELEVATED LEVELS OF BCL-2 - The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid. | 12-29-2011 |
20110318764 | METHOD FOR DETECTING MUSCLE DEGENERATIVE DISEASES, AND METHOD FOR DETERMINING THERAPEUTIC EFFICACY ON THE DISEASES - Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject. | 12-29-2011 |
20120003671 | METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 01-05-2012 |
20120003672 | IN VITRO-METHOD FOR THE DIAGNOSIS, PROGNOSIS, MONITORING AND THERAPY FOLLOW-UP OF DISORDERS ASSOCIATED WITH THE METABOLIC SYNDROME, A CARDIOVASCULAR DISEASE AND/OR INSULIN RESISTANCE - The present invention relates to an in vitro-method for diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in a subject, comprising the determination of the relative level of one or more cardiovascular markers in a sample of a subject and the use of the determined relative level of said one or more cardiovascular peptides for the diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in said subject. | 01-05-2012 |
20120003673 | Screening method, composition containing substance selected by the screening method, and binding substance - Disclosed is a screening method which can select a substance having an influence on the binding between thioredoxin and MIF. The screening method is characterized in that a test substance capable of enhancing the binding between a polypeptide belonging to the thioredoxin family and a macrophage migration inhibitory factor is selected through the steps of mixing at least one binding substance selected from the substances (1) to (4) shown below with the test substance, allowing the binding substance to bind to the macrophage migration inhibitory factor, and confirming the binding between the binding substance and the macrophage migration inhibitory factor: (1) a polypeptide belonging to the thioredoxin family; (2) a protein which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in an amino acid sequence for a polypeptide belonging to the thioredoxin family and has the same activity as that of a polypeptide belonging to the thioredoxin family; (3) a gene encoding the polypeptide (1); and (4) a gene encoding the protein (2). | 01-05-2012 |
20120003674 | Chloral Hydrate Detection - The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure. | 01-05-2012 |
20120009603 | METHOD FOR INCREASING AND REGULATING LIGHT EMISSION FROM A CHEMILUMINESCENT REACTION - Method for increasing and regulating the emission of light from a chemiluminescent reaction including luminol, a peroxidase enzyme, an oxidant and an electron mediator (primary enhancer) through the use of an acylation catalyst (secondary enhancer) belonging to the class of N-azoles., i.e., a class of five-membered nitrogen heteroaromatic ring compounds containing at least one other atom of nitrogen. N-azoles, which are especially useful as secondary enhancers are imidazole, 1-methylimidazole, 1,2,3-triazole and 1,2,4-triazole. The invention also describes the use in diagnostic assays of chemiluminescent substrates containing said N-azoles, as secondary enhancers. | 01-12-2012 |
20120009604 | USE OF GRF1 PROTEIN FOR SCREENING MOLECULES - The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease. | 01-12-2012 |
20120009605 | NEW ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate. | 01-12-2012 |
20120009606 | PEPTIDE BIOMARKERS PREDICTIVE OF RENAL FUNCTION DECLINE AND KIDNEY DISEASE - The presently-disclosed subject matter provides methods for diagnosing a kidney disease, or the risk thereof, in a subject. The methods comprise determining an amount of at least one peptide biomarker disclosed herein in a biological sample from the subject and comparing the amount of the at least one peptide in the sample with a control level, wherein if the amount determined is different than the control level, the subject is diagnosed as having, or at an increased risk of developing, the kidney disease. | 01-12-2012 |
20120009607 | DIFFERENTIATING CARDIAC- AND DIABETES MELLITUS-BASED CAUSES OF KIDNEY DAMAGE - Disclosed is a method for differentiating in a subject suffering from kidney damage between kidney damage caused by (i) heart failure and/or (ii) diabetes mellitus type 1 or type 2 including the steps of: a) determining the amount of liver-type fatty acid binding protein (L-FABP) and the amount of kidney injury molecule 1 (KIM-1) in a urine-sample of a subject and forming the L-FABP/KIM-1 ratio; b) determining the amount of adiponectin in a urine-sample of said subject; and c) comparing the ratio determined in a) and the amount determined in b) with reference amounts, and establishing the predominant cause of the kidney damage. Also disclosed are a device and a kit for carrying out the method. | 01-12-2012 |
20120015380 | ANTI-POLYETHYLENE GLYCOL ANTIBODY EXPRESSING CELL QUANTIFY ANY FREE POLYETHYLENE GLYCOL AND POLYETHYLENE GLYCOL-DERIVATIZED MOLECULES - In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH | 01-19-2012 |
20120015381 | Methods and kits for the differential diagnosis of Alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia, comprising FAS-L and CK 18 as biomarkers - The invention relates to methods and kits for the differential diagnosis of Alzheimer's disease (AD) versus frontotemporal dementia (FTD), using biomarkers TNF-α, FAS-L and CK18, taken from a biological sample. Differences in biomarker levels can be used to distinguish between AD and FTD The invention is based on a discovered correlation between FTD and markers FAS-L and CK18. Therefore the invention also relates to the diagnosis of FTD using FAS-L and CK18. The serum concentrations of these biomarkers can further be used as an index of the severity of disease, and may occur in conjunction with clinical-based diagnostic testing and neuro-imaging assessment. | 01-19-2012 |
20120015382 | DROPLET-BASED SELECTION - The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like. | 01-19-2012 |
20120015383 | NOVEL DIAGNOSTIC MARKER FOR TYPE 1 DIABETES MELLITUS - The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample. | 01-19-2012 |
20120015384 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 01-19-2012 |
20120015385 | DOXORUBICIN IMMUNOASSAY - Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids. | 01-19-2012 |
20120015386 | IP-10 BASED IMMUNOLOGICAL MONITORING - The present invention relates to an immunological method and, more particularly, a method for measuring cell-mediated immune reactivity (CMI) in mammals based on the production of IP-10. The invention further discloses an assay and a kit for measuring CMI to an antigen using whole blood or other suitable biological samples. The methods of the present invention are useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications, thus the invention further relates to a method for diagnosing an infection in a mammal. | 01-19-2012 |
20120021441 | IN-PROCESS CONTROL IN A METHOD FOR PRODUCING EPO - The invention relates to a method for determining the isoform composition of erythropoietin, comprising the following steps:
| 01-26-2012 |
20120021442 | MARKERS FOR DETECTION OF COMPLICATIONS RESULTING FROM IN UTERO ENCOUNTERS - Described herein are biomarkers, such as protein biomarkers, which are diagnostic of and predictive for complications that result from an in utero encounter, such as an infection by the fetus, that can lead to premature birth (PTB). The biomarkers can be used to identify fetuses and newborns at risk for complications of PTB, such as (Early Onset Neonatal Sepsis) EONS, intra-ventricular hemorrhage (IVH) and other poor outcomes. | 01-26-2012 |
20120021443 | DIRECTIONAL SURFACE PLASMON COUPLED FLUORESCENCE AND CHEMILUMINESCENCE FROM THIN FILMS OF NICKEL, IRON OR PALLADIUM AND USES THEREOF - Nickel, iron and palladium thin films thermally evaporated onto glass supports are used to demonstrate surface plasmon coupled fluorescence (SPCF) and surface plasmon couple chemiluminescence (SPCC) over a broad wavelength range (400-800 nm) for potential assays or other detection systems. Nickel, iron and palladium thin films used in SPCF and SPCC convert otherwise isotropic emission into highly directional and polarized emission, an attractive concept for surface assays. The emission angles of detected emissions occur over a 10 degree range for tested emitted wavelengths. | 01-26-2012 |
20120028278 | CELL LINES EXPRESSING GUANYLATE CYCLASE-C AND METHODS OF USING THEM - Cell lines that stably express GC-C and methods for using those cell lines are disclosed herein. The invention includes cell lines that express GC-C and techniques for creating cell lines. The GC-C-expressing cell lines are highly sensitive, physiologically relevant and produce consistent results in cell-based assays, e.g., high throughput screening assays. | 02-02-2012 |
20120028279 | BIOMARKER FOR MONITORING PATIENTS - The present invention is in the field of immunotherapy and relates to methods for determining the efficacy of certain immunotherapy treatments. The methods of the invention include measuring special biomarker at some time following the initiation of immunotherapy treatment to evaluate the clinical outcome of the said treatment. The invention thus has applications to the field of medicine. | 02-02-2012 |
20120028280 | XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO - The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: | 02-02-2012 |
20120034629 | PREDICTION OF NON-FATAL AND FATAL ATHEROTHROMBOTIC EVENTS - The present invention relates to methods and systems for the prediction of atherothrombotic events in human subjects. Preferably the human subjects are afflicted with a cardiovascular disease, such as end-stage renal disease. Methods and systems of the invention are particularly suited to predict atherothrombotic events in patients on hemodialysis. | 02-09-2012 |
20120034630 | Circovirus Sequences Associated With Piglet Weight Loss Disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 02-09-2012 |
20120040376 | LUNG CANCER DIAGNOSTIC POLYPEPTIDE, METHOD FOR DETECTING LUNG CANCER, AND METHOD FOR EVALUATING THERAPEUTIC EFFECT - A novel biomarker for use in lung cancer diagnosis is provided. | 02-16-2012 |
20120040377 | RECOGNITION OF CYP2E1 EPITOPES - A critical epitope of human cytochrome P4502E1 (CYP2E1) associated with the development of hepatic autoimmune disease, including methods and kits for diagnosis and prognosis using the critical epitope as a biomarker for hepatic autoimmune disease. | 02-16-2012 |
20120040379 | METHODS FOR DIFFERENTIATING PLASMA- DERIVED PROTEIN FROM RECOMBINANT PROTEIN IN A SAMPLE - The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein. | 02-16-2012 |
20120045778 | ELISA FOR HAPTOGLOBIN-MATRIX METALLOPROTEINASE 9 COMPLEX AS A DIAGNOSTIC TEST FOR CONDITIONS INCLUDING ACUTE INFLAMMATION - A method for detecting a haptoglobin-matrix metalloproteinase 9 (Hp-MMP9) complex in a biological sample. The sample includes incubating the biological sample with a capture reagent immobilized on a solid support to bind Hp-MMP9 to the capture reagent. The capture reagent includes a monoclonal antibody that binds MMP9. The method detects Hp-MMP9 bound to the immobilized capture reagent by contacting the bound Hp-MMP9 with a detectable antibody that binds to Hp. | 02-23-2012 |
20120045779 | METHOD FOR DIAGNOSING ENDOMETRIOSIS AND DIAGNOSTIC KIT FOR ENDOMETRIOSIS - It is an object of the present invention to provide: a method for determining endometriosis, in which a blood sample from a subject can be used, and which is capable of determining endometriosis with higher sensitivity and higher precision than those of a conventional method using only a conventional endometriosis marker such as CA125; and a diagnostic kit for carrying out the method of the present invention. The method for determining endometriosis according to the present invention comprises: a step of analyzing an expression of at least one selected from among an anti-syntaxin autoantibody, an anti-PDIK1L autoantibody and an anti-enolase autoantibody; and a step of determining the presence or absence of the onset of endometriosis based on results of said expression analysis. | 02-23-2012 |
20120045780 | SIGNAL BIOMARKERS - Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefor. | 02-23-2012 |
20120045781 | PATHOLOGY BIOMARKER ASSAY - Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described. | 02-23-2012 |
20120058495 | Recombinant fragments and synthetic peptides of 17-kDa polypeptide useful in detecting Bartonella henselae - The present disclosure describes recombinant and synthetic polypeptides of | 03-08-2012 |
20120058496 | PHYSIOLOGICALLY ACTIVE SUBSTANCE COLLECTING DEVICE AND BIOLOGICAL INFORMATION ACQUISITION METHOD - A physiologically active substance collecting device, includes: a collecting section brought into contact with a body surface of a living organism to acquire a physiologically active substance from the body surface; and a liquid sending means for sending a solvent to the collecting section, the collecting section having an aperture at which the solvent flown by being sent from the liquid sending means contacts the body surface. | 03-08-2012 |
20120058497 | DIAGNOSTIC REAGENT FOR CROHN'S DISEASE - The present invention provides a reagent and a method of safely, conveniently, and specifically diagnosing Crohn's disease. Provided are a diagnostic method for Crohn's disease in a subject, including measuring antibodies against one kind or more of dietary components selected from the group consisting of grapefruit, alfalfa, avocado, cabbage, green pepper, lettuce, onion, potato (white), spinach, tomato, oat, pecan, yeast, cane sugar, celery, buckwheat, corn, rice and soy, and a diagnostic reagent or kit for Crohn's disease, containing the above-mentioned preparation of a dietary component. | 03-08-2012 |
20120058498 | Compositions and Methods for Characterizing Arthritic Conditions - The present invention relates to autoantibodies against 14-3-3 proteins or circulating immune complexes thereof and the detection of such for the diagnosis and prognosis of an arthritic condition. | 03-08-2012 |
20120064547 | DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 03-15-2012 |
20120064548 | NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CERVICAL CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided. | 03-15-2012 |
20120064549 | Lenalidomide and Thalidomide Immunoassays - Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids. | 03-15-2012 |
20120064550 | METHOD FOR MEASUREMENT OF EQUOL IN BIOLOGICAL SAMPLE BY IMMUNOASSAY, KIT FOR THE MEASUREMENT, AND METHOD FOR DETERMINATION OF EQUOL PRODUCTION ABILITY OF SUBJECT - An object of the present invention is to provide a method for measuring equol in a biological sample by an immunological method, a kit for the measurement, and a method for determining equol-producing ability of a subject. | 03-15-2012 |
20120070853 | YKL-40 AS A MARKER FOR GASTROINTESTINAL CANCERS - The present invention relates to gastrointestinal cancers and methods for selecting a treatment for said gastrointestinal cancer in a subject. The present invention further relates to a methods of diagnosing the presence of and/or classifying the severity of a gastrointestinal cancer; together with methods for determining the effect of a therapy administered and/or the prognosis for a subject suffering from a gastrointestinal cancer, before, during or after administering the treatment. For all the methods applies that a determined level of YKL-40 above one or more reference levels indicates the treatment, the severity of the disease, the effect of the treatment and/or the prognosis of the subject. The reference level is typically a level obtained from healthy individuals or a level previously obtained from the same subject. The subject may suffer from any one or more gastrointestinal cancers, such as upper gastrointestinal cancers, and metastatic colorectal cancer. The present invention further relates to a kit and a device that may be used in the method of the present invention. | 03-22-2012 |
20120070854 | HNRNP A3 Related Peptides and Use Thereof for Diagnosis of Rheumatoid Arthritis - The invention relates to a peptide and retro or retro-inverso peptide thereof, with a length of ≦25 amino acid residues, characterized in that the peptide comprises at least one citrulline residue, and exhibits a sequence identity over the whole sequence of the peptide of ≧70% compared to human hnRNP A3 protein (SEQ ID No. 1) and uses thereof. | 03-22-2012 |
20120070855 | METHOD FOR IN VITRO ASSAY OF SOLUBLE FIBRIN BY GENERATING SPECIFIC DEGRADATION PRODUCTS - The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp. | 03-22-2012 |
20120083008 | Methods for obtaining molecules with reduced immunogenicity - The invention provides a method for reducing immunogenicity of a peptide, protein or protein complex in an individual comprising introducing at least one cross-link between two amino acids in the peptide, protein or protein complex that is stable or irreversible in vivo, wherein the at least one cross-link reduces the immunogenicity of the peptide, protein or protein complex in the individual compared to an identical peptide, protein or protein complex not so cross-linked. | 04-05-2012 |
20120083009 | Rheumatoid Arthritis Test Method And Treating Method - To evaluate the prognosis of rheumatoid arthritis based on the evaluation of the disease severity of the patient to select a treatment method suitable for each rheumatoid arthritis patients, and to measure HSC71 protein levels of the patients before and after the administrations of therapeutic agents to determine the efficacy of various therapeutic agents for each of rheumatoid arthritis patients and to use thereof as a remedy for preventing onset and progression of rheumatoid arthritis. | 04-05-2012 |
20120088255 | HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 10 | 04-12-2012 |
20120088256 | Anaplasma translocated substrate-1 (ATS-1) and sero-detection of anaplasma phagocytophilum - Disclosed is the use of isolated Ats-1 protein in | 04-12-2012 |
20120088257 | METHOD FOR DIAGNOSING VASCULITIS - The invention relates to a method for the in vitro detection of vasculitis or the risk of developing vasculitis, including determining the presence and/or the amount of anti-endothelial cell antibodies (AECA) or anti-vascular smooth muscle cell (VSMC) antibodies in a biological sample from a patient. | 04-12-2012 |
20120088258 | INTEGRATED DEVICE FOR SURFACE-CONTACT SAMPLING, EXTRACTION AND ELECTROCHEMICAL MEASUREMENTS - The invention relates to a device and method for non-invasive detection of an analyte in a fluid sample. In one embodiment, the device comprises: a collection chamber containing an absorbent hydrogel material; a fluidic channel connected to the collection chamber; a sensing chamber connected to the fluidic channel, wherein the device is comprised of a compressible housing that allows transfer of fluid collected by the collection chamber to be transferred to be extracted and withdrawn to the sensing chamber upon compression of the device, wherein the sensing chamber contains a material that specifically detects the analyte and wherein the sensing chamber is operably linked to a processor containing a potentiostat that allows detection of the analyte using electrochemical sensing. | 04-12-2012 |
20120088259 | Post-Translation Modified Cardiac Troponin T As A Biomarker Of A Risk For Heart Failure - The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker. | 04-12-2012 |
20120094314 | DIAGNOSIS OF SEPTIC COMPLICATIONS - The invention describes a method for diagnosing of septic complications in polytraumatised human or animal patients, said patients being free of traumatic brain injury, by determining the level of the C-type natriuretic peptide (CNP), its precursors or fragments thereof, especially the precursor of the C-type natriuretic peptide (NT-proCNP), in this patient and diagnosing the patient a having septic complications or being at risk of developing septic complications, if the level of CNP, its precursors or fragments thereof, especially NT-proCNP, is increased compared to normal levels. | 04-19-2012 |
20120094315 | BIOMARKERS FOR THE DIAGNOSIS AND/OR PREDICTION OF SUSCEPTIBILITY TO MENTAL AND NEURODEGENERATIVE DISORDERS - Provided herein are, inter alia, methods for predicting the susceptibility of a subject to a mental or neurodegenerative disorder, the method comprising obtaining one or more biological samples from the subject; determining the levels of one or more biomarkers in the sample, wherein the biomarkers are selected from pyrroles, histamine, methionine adenosyltransferase (MAT) activity, homocysteine, copper and zinc; and comparing the level(s) of the biomarker(s) determined in (b) with the level(s) of said biomarker(s) from one or more control samples, wherein abnormal levels of the one or more biomarkers in the sample(s) from the subject compared to the one or more control samples is predictive of susceptibility of the subject to a mental or neurodegenerative disorder. | 04-19-2012 |
20120094316 | Drug Detection - The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds. | 04-19-2012 |
20120094317 | Method and Apparatus for Detecting an Analyte - In one aspect, this disclosure provides a substrate for determining the concentration of an analyte within a sample. The substrate includes a conductive region and a recognition layer, the conductive region including at least one particle and having a first surface operatively coupled with the recognition layer, the recognition layer comprising at least one recognition molecule. The distance between the first surface of the conductive region and the recognition molecule is selected such that when the analyte is bound to the recognition layer the combination of the at least one particle and the analyte exhibits at least one of the following effects when radiation is directed through the conductive region and the recognition layer: (i) a particle plasmon effect, (ii) a particle bulk interband absorption, (iii) analyte molecular absorption, and (iv) absorption by the analyte-particle combination. | 04-19-2012 |
20120094318 | E-CADHERIN AS A BIOMARKER OF GASTROESOPHAGEAL REFLUX DISEASE - The present invention provides methods of diagnosing and identifying subjects as having GERD comprising detecting E-cadherin fragments in a biological sample from the subject. The invention further provides methods for identifying subjects as having heartburn that is responsive to proton pump inhibitor therapy and subjects having an increased likelihood of a rapid relapse of GERD after reducing the dosage of PPIs or terminating PPI therapy. In addition, the present invention provides methods for monitoring the healing of erosive and nonerosive esophagitis of GERD without the need for esophagogastroduodenoscopy or esophagogastroduodenoscopy and biopsy, respectively. | 04-19-2012 |
20120100562 | METHODS AND COMPOSITIONS FOR MODULATING THE WNT PATHWAY - The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6. | 04-26-2012 |
20120107841 | Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease - A laboratory method for screening, diagnosing, monitoring and/or staging early onset Alzheimer's disease which consists of mild cognitive impairment entails conducting a blood test after an oxidative exposure of serum to assay for the presence of an elevated level of redox-reactive autoantibodies. | 05-03-2012 |
20120107842 | METHOD FOR DETECTING ANTIBODY AGAINST SITH-1 IN BIOLOGICAL SAMPLE - The present invention provides a method for detecting an antibody against a small protein encoded by the intermediate stage transcript of HHV-6 (SITH-1) in a biological sample. | 05-03-2012 |
20120107843 | ANTI BONE-LOSS AND ANTI ATTACHMENT-LOSS EFFECTS OF AN ORAL COMPOSITION - Methods for identifying compounds useful for treating diseases and conditions of the oral cavity are described herein. | 05-03-2012 |
20120107844 | IMMUNOSORBENT ASSAY SUPPORT AND METHOD OF USE - Embodiments of the present invention provide an immunosorbent assay support immobilized with an intermediate binding antibody and their method of use in an improved immunoassay format. | 05-03-2012 |
20120107845 | Disrupting FCRN-Albumin Interactions - Provided herein are, inter alia, methods for identifying a candidate compound for treating the toxic effects of compounds or molecules that bind to albumin in a subject. The methods include identifying test compounds that inhibit the binding between FcRn and albumin. | 05-03-2012 |
20120107846 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 05-03-2012 |
20120107847 | TESTING EFFICACY FOR CELIAC DISEASE - We describe a method to determine effectiveness of a compound or composition in treatment of celiac disease or gluten intolerance, the method comprising:
| 05-03-2012 |
20120115168 | BIOASSAY AND PEPTIDES FOR USE THEREIN - The invention provides a bioassay for detection of | 05-10-2012 |
20120115169 | HYDROXYCHOLESTEROL IMMUNOASSAY - Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective. | 05-10-2012 |
20120115170 | SERUM MG53 AS A DIAGNOSTIC MARKER FOR TISSUE INJURY - Disclosed herein are compositions and methods for measuring the level of MG53 found in a biological fluid as a biomarker for a disease or disorder, e.g., tissue damage, exercise capacity or a muscle-related disease or disorder. In addition, the invention relates to targeting the native MG53 found in the blood as a therapeutic approach. | 05-10-2012 |
20120115171 | Method For Diagnosing Thrombophilia - The invention relates to a method for diagnosing thrombophilia in a subject suffering from HIV or from a systemic auto-immune disease, said method comprising determining in a blood sample obtained from said subject the level of free Protein S having Activated Protein C (APC) cofactor activity and the level of total Protein S. | 05-10-2012 |
20120115172 | PTEN/AKT METHODS AND COMPOSITIONS RELATING TO BMP - The present invention relates to a purified molecules, including antibodies, that bind specifically to murine β-catenin phosphorylated at amino acid position Serine | 05-10-2012 |
20120115173 | BIOMARKERS FOR MOTOR NEURON DISEASE - The invention provides methods of determining a diagnosis or prognosis of motor neuron disease in a mammal comprising determining the expression level of one or more proteins or polypeptides of the renin-angiotensin system in a sample taken from a subject. Similarly, aberrant post-translational modification of the proteins or polypeptides as compared to a negative control indicates a diagnosis of disease. | 05-10-2012 |
20120122123 | DETECTION OF ANTHRAX PATHOGENICITY FACTORS - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples. | 05-17-2012 |
20120122124 | NEW BACTERIOPHAGE ADHESION PROTEINS - The present invention relates to bacteriophage adhesion proteins binding to the O-antigen of gram negative bacteria, lacking the ability of binding to a bacteriophage and of hydrolysing lipopolysaccharides. The invention further relates to nucleic acid molecules comprising a sequence encoding the proteins according to the present invention. In addition, the present invention relates to a method for generating bacteriophage adhesion proteins according to the present invention. The invention further relates to the use of said proteins and methods of detection, purification and enrichment of bacteria. | 05-17-2012 |
20120122125 | ANTI-T. CRUZI ANTIBODIES AND METHODS OF USE - The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of | 05-17-2012 |
20120122126 | ANTI-PSK ANTIBODY - An antibody which recognizes PSK is provided. | 05-17-2012 |
20120122127 | Cleavage Sensitive Antibodies and Methods of use thereof - We disclose cleavage-sensitive antibodies with epitopes spanning the scissile bond of the toxins molecular target protein, enabling toxin-associated proteolysis to be measured in a variety of assay formats. | 05-17-2012 |
20120129195 | Method of quick laboratory diagnosis if illnesses based on the discovery of specific proteins and equipment for its implementation - A method of quick laboratory diagnosis of diseases, based on the discovery of specific protein targets characteristic to the disease in the reaction of their specific interaction with other protein reagents, distinct in that specific protein targets for the given disease are hydrolyzed with proteolytic enzymes and then the chemical structure of the oligopeptide formula created is modified in such a way that its charge is changed to the opposite. This method of quick laboratory diagnosis of illnesses based on the discovery of specific proteins, and the equipment for its implementation, may be applied for the discovery of viral and microbial antigens in various human biological fluids. The method may also be used for the detection of new and little-studied infectious diseases in connection with the ease of diagnostic preparation. | 05-24-2012 |
20120129196 | HIGHLY SENSITIVE MONOCLONAL ANTIBODY RESIDUAL DETECTION ASSAY - The present invention relates to compositions and highly sensitive methods for the detection of biotechnology product residual when monitoring product carry over and/or for cleaning verification in the manufacture of biotechnology products. In particular, the present invention is directed to immunoassays wherein one or more capture antibodies, or antigen binding fragments thereof, are used to detect residuals associated with the production of biotechnology products. | 05-24-2012 |
20120129197 | Immunomodulation of Functional T Cell Assays for Diagnosis of Infectious or Autoimmune Disorders - Improved assays for detecting the presence of a specific cell-mediated immune response in an individual are provided, where a sample comprising T cells and other cells of the immune system, usually a blood sample or derivative thereof, is contacted with test antigen(s) of interest in the presence of a pattern recognition receptor (PRR) agonist. The sample is incubated for a period of time sufficient to activate effector T cells; and release of immune effector molecule(s) is then detected. In some embodiments, the PRR is an agonist of a toll-like receptor (TLR) expressed by mature antigen presenting cells, including without limitation agonists TLR3 and TLR7, such as LPS, poly I:C, imiquimod, etc. | 05-24-2012 |
20120129198 | NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS - Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. | 05-24-2012 |
20120129199 | COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS - Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional APCs (PAPCs) result in the generation of autologous APCs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic T lymphocyte (CTL) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to APCs for assessing the immunogenicity of drugs and biologics. The composition, kits, assays and methods involve the combined use of MHC targeting, universal DR binding peptides (e.g., PADRE, HA) with charged (e.g., positively-charged) highly branched polymeric dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs, giving rise to a new nanoparticle-based method for assessing the immune response (CTL response) to a vaccination or other therapy or intervention, or for assessing the immunogenicity of a biologic or drug. Targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs for effective expression and processing generates more physiologically relevant target antigens for evaluation of cell-mediated immune responses to vaccination, for example, and provides a low-cost approach for rapid generation of reagents and development of assay systems for more accurate profiling of immunological responses to infection, immunization, and other therapies or interventions. Immunoevaluation kits using targeted nanoparticle-based antigen delivery are described herein. | 05-24-2012 |
20120135425 | ELISA for Haptoglobin-Matrix Metalloproteinase 9 Complex as a Diagnostic Test for Conditions Including Acute Inflammation - A method for detecting a haptoglobin-matrix metalloproteinase 9 (Hp-MMP 9) complex in a biological sample. The sample includes incubating the biological sample with a capture reagent immobilized on a solid support to bind Hp-MMP 9 to the capture reagent. The capture reagent includes a monoclonal antibody that binds MMP9. The method detects Hp-MMP 9 bound to the immobilized capture reagent by contacting the bound Hp-MMP 9 with a detectable antibody that binds to Hp. | 05-31-2012 |
20120135426 | Method for quantifying phosphokinase activity on proteins - The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins. | 05-31-2012 |
20120135427 | METHODS FOR DETERMINING MATERNAL HEALTH RISKS - The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin. | 05-31-2012 |
20120135428 | NOVEL MARKERS FOR CHRONIC KIDNEY DISEASE - The present invention relates to a method for determining the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention. | 05-31-2012 |
20120135429 | PRO-GRP AS A SURROGATE MARKER TO PREDICT AND MONITOR RESPONSE TO BCL-2 INHIBITOR THERAPY - A method for classifying cancer patients as eligible to receive cancer therapy with a Bcl-2 inhibitor comprising determination of the presence or absence in a patient tissue sample of levels of pro-GRP, as a surrogate marker for the presence of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon pro-GRP levels as a surrogate for the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy with a Bcl-2 family inhibitor, either as monotherapy or as part of combination therapy, and to monitor patient response to such therapy using a peripheral blood sample. | 05-31-2012 |
20120135430 | COMPLEMENT ASSAYS AND USES THEREOF - The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods. | 05-31-2012 |
20120135431 | TYPE IV COLLAGEN-LIKE IMMUNOREACTIVE PEPTIDE - A type IV collagen-like immunoreactive peptide and an antibody thereof which are useful for detecting nephritis, a method for selecting a type IV collagen-like immunoreactive peptide, a method for screening an immunoreactive antibody and an immunoreactive peptide, a nephritis model, a method for detecting chronic nephritis, a vaccine, and a therapeutic agent for nephritis are provided. | 05-31-2012 |
20120135432 | DIAGNOSTIC METHOD FOR DETERMINING THE SUSCEPTIBILITY TO DELIVERY AND REAGENT KIT FOR USE THEREOF - The invention relates to a diagnostic method for detecting susceptibility to delivery, and to a test kit for this purpose. A low, but higher than baseline level concentration of Insulin-like Growth Factor Binding Protein 1 (IGFBP-1), which is due to leakage from decidual cells, is detected by an immunological assay in a vaginal secretion sample. | 05-31-2012 |
20120135433 | PROGNOSIS DIAGNOSIS METHOD AND PROGNOSIS DIAGNOSIS KIT FOR SEPSIS OR MULTIPLE ORGAN FAILURE - Disclosed are: a prognosis diagnosis method which can diagnose the prognosis of a patient suffering from sepsis or sepsis-related multiple organ failure in a simple manner and with high accuracy and a prognosis diagnosis kit for use in the prognosis diagnosis method. The prognosis diagnosis method comprises: a first detection step of detecting a liver fatty acid-binding protein contained in urine collected from a subject with a specific antibody; a second detection step of treating the urine with a Redox reagent such as hemin and detecting a liver fatty acid-binding protein contained in the treated urine with the specific antibody; and a comparison step of comparing a detection value obtained in the first step with a detection value obtained in the second step. It is determined that the larger the detection value obtained in the second step compared to that in the first step, the worse the prognosis. | 05-31-2012 |
20120142033 | METHOD FOR EXTRACTION AND PURIFICATION OF RECOMBINANT PROTEINS FROM TRANSGENIC PLANTS - Extraction and purification of recombinant proteins rendered difficult to extract from transgenic plants by using an extraction solution containing reducing agents and surfactants or an extraction solution containing reducing agents and organic solvents. | 06-07-2012 |
20120142034 | PVDF MEMBRANES - The invention provides a method of treating a polyvinyl difluoride (PVDF) membrane comprising:
| 06-07-2012 |
20120142035 | Calibrator/Control for Simultaneous Assay of Proteins Capable of Complexing With One Another - Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest. | 06-07-2012 |
20120149038 | DIAGNOSIS OF AUTISM - A method for diagnosing autism in a subject is performed by determining the presence and concentration of specific peptides in the body fluid. The peptides have the amino acid sequences SKITHRIHWESASLL, SSKITHRIHWESASLL, and SSKITHRIHWESASLLR with the molecular masses 1779+/−1 Da, 1865+/−1 Da and 2022+/−1 Da, respectively. | 06-14-2012 |
20120149039 | DIAGNOSTIC APPARATUS FOR ORGANIC SAMPLE ANALYSIS - A diagnostic apparatus for organic-sample analyses including a fluid sucking and ejecting device to enable suction and inner storage or ejection to the outside of the fluid, a feeding needle that can be secured to the sucking device including an inner channel for passage of the fluids and to be inserted into containers for intaking or ejecting a given amount of the fluid, an actuating device, including a carriage, to spatially move the carriage along three axes, the carriage being susceptible of connection with the sucking and ejecting device, a first replacement station to house a plurality of feeding needles of the disposable type and suitable to enable automatic fastening and removal of one of the disposable feeding needles to and from the sucking device connected to the carriage, and a second replacement station to allow automatic fastening and removal of a precision feeding needle to and from the carriage. | 06-14-2012 |
20120149040 | Adam12, A Novel Marker For Abnormal Cell Function - The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum. The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and/or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate. | 06-14-2012 |
20120149041 | IDENTIFICATION AND QUANTIFICATION OF BIOMARKERS FOR EVALUATING THE RISK OF PRETERM BIRTH - Described herein are methods for evaluating the risk of preterm birth in pregnant subjects. The methods involve detecting and quantifying a first biomarker and a second biomarker associated with preterm birth in a biological sample from the subject. Also described herein are isolated biomarkers and kits useful in predicting the risk of preterm birth. | 06-14-2012 |
20120156700 | DETECTION AND QUANTITATION OF URINE GELSOLIN - The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide in a test sample. In particular, the gelsolin binding agents are useful in assays of urine samples to diagnose a gelsolin-related medical condition. Kits to detect gelsolin in biological samples are also provided by the present disclosure. | 06-21-2012 |
20120156701 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-X-C motif chemokines-1, -2, and -3 as diagnostic and prognostic biomarker assays in renal injuries. | 06-21-2012 |
20120156702 | CMYBP-C AND MLC2 AS DIAGNOSTIC MARKERS OF CARDIAC INJURY - The invention relates to markers for acute myocardial infarction (AMI), particularly markers that may be used in the rapid and accurate diagnosis of AMI or reinfarction. A method of diagnosing cardiac injury comprising identifying an elevated concentration of cardiac myosin binding protein C (cMyBP-C) or a fragment thereof or myosin regulatory light chain 2 (MLC2) or a fragment thereof in a sample obtained from a subject. | 06-21-2012 |
20120156703 | USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE - The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan. | 06-21-2012 |
20120156704 | IN VITRO METHOD FOR DETECTING GP91PHOX AS A MARKER OF OXIDATIVE STRESS - The invention relates to an in vitro method for detecting the activation of NADPH oxidase by measuring gp91 | 06-21-2012 |
20120164667 | METHOD FOR TEST ON DIABETIC NEPHROPATHY - Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin. | 06-28-2012 |
20120164668 | ULTRASOUND ASSISTED IMMUNOASSAY - The invention relates to methods, devices and systems for an enhanced, ultrasound assisted immunoassay (such as a Western blot immunoassay). In particular, there are provided methods, devices and system for the automated and enhanced processing of a membrane having proteins associated therewith, wherein the processing includes the use of ultrasonic energy. | 06-28-2012 |
20120171702 | QUANTITATIVE AND SELF-CALIBRATING CHEMICAL ANALYSIS USING PAPER-BASED MICROFLUIDIC SYSTEMS - A method of determining the concentration of a test fluid sample using a paper-based microfluidic system having a plurality of hydrophilic testing zones, including: a) depositing said test fluid sample on at least one said testing zone; b) depositing a plurality of standard fluid samples or reactives of differing known concentrations on other said testing zones; c) introducing an indicator solution to each said test zone to thereby react with the deposited fluid sample and result in a colour intensity change which is a function of the fluid sample concentration; and d) comparing the differences in colour intensity between the test fluid sample and the standard fluid samples or reactives to thereby determine the concentration of said test fluid sample. | 07-05-2012 |
20120171703 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE - The present invention relates to compound of formula I: and their use as chemiluminescent and/or bioluminescent reagents. | 07-05-2012 |
20120178105 | DETECTION OF GLOBOTRIAOSYLCERAMIDE (GLC) IN HUMAN URINE SAMPLES USING AN ANTIBODY SANDWICH - Applicant has developed an assay for the detection of GL3 in human samples using a sandwich based immunoassay in which utilizes a pair of GL3 specific monoclonal antibodies, one for capture and one for detection, to create an antibody “sandwich” around the GL3 ligand. To further increase sensitivity, Applicant has modified traditional sandwich based assays by complexing the capture antibody with GL3 before adding the sample or detector antibody, providing an inhibition based assay. | 07-12-2012 |
20120178106 | ANTIGEN BINDING MOLECULES THAT BIND EGFR, VECTORS ENCODING SAME, AND USES THEREOF - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 07-12-2012 |
20120178107 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 07-12-2012 |
20120178108 | IMMUNODETECTABILITY - In the present disclosure, there is provided a method for improving the immunodetectability of at least one protein in an optionally diluted sample of blood, serum or plasma, comprising a step of heating the sample to a temperature of 64-85° C. prior to a contact between the sample and at least one affinity ligand for detection and/or quantification of the at least one protein. | 07-12-2012 |
20120178109 | DIAGNOSIS OF A PARASITIC DISEASE SUCH AS LEISHMANIASIS USING RIBOSOMAL PROTEIN EXTRACT (RPE) - The invention relates to a diagnosis method for | 07-12-2012 |
20120178110 | SCREENING OF PROTEIN CANDIDATES - Successful application of an engineered protein as therapeutics or in other industries would require the protein to have good expression level, good biophysical properties and often desired affinity to its target. The present invention provides a method of screening large numbers of protein candidates (PCs) in all three aspects simultaneously. PCs are fused to a protein anchor, which is captured by the target/antigen. The captured PCs are evaluated for their expression levels, biophysical properties and affinities using conventional methods. | 07-12-2012 |
20120178111 | METHODS AND COMPOSITIONS FOR THE DETECTION OF LUNG CANCERS - A method of screening for, diagnosing or detecting lung cancer in a subject, the method comprising: a) determining a level of a biomarker or a plurality of biomarkers in a sample from the subject, wherein the biomarker(s) is/are selected from the biomarkers listed in Table 8, and b) comparing the level of each biomarker in the sample with a control; wherein an increased level of any one of the biomarkers compared to the control is indicative that the subject has lung cancer Biomarkers were identified by shot-gun proteomics analysis of lung cancer cell-lines H1688, H520, H460 and H23. These lines are of differing histo-types, and were grown on serum-free media. | 07-12-2012 |
20120183977 | SAMPLE PLATE SYSTEMS AND METHODS - A sample plate comprising a sample well is disclosed. The sample well can comprise one or more bead retaining chambers. A method of using the sample plate and a kit comprising the sample plate is also disclosed. | 07-19-2012 |
20120183978 | ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY - Methods aiding in the diagnosis of certain neuropathies are disclosed, in which the titer of antibodies to a disulfated heparin disaccharide is assessed in a test sample from an subject. Also disclosed are apparatus and kits that can be used in the methods of the invention. | 07-19-2012 |
20120183979 | PROTEIN FRAGMENTS OF VIRB10 AND SERO-DETECTION OF ANAPLASMA PHAGOCYTOPHILUM - Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in | 07-19-2012 |
20120190050 | CANCER BIOMARKER AND THE USE THEREOF - Gastric cancer is one of the leading causes of cancer-related death worldwide. To date no specific marker is available for gastric cancer screening. The expression profile of 37 proteins was identified to be consistently different between the plasma of normal and gastric cancer subjects. The expression of complement component C9 protein was validated to be significantly higher in the plasma of gastric cancer compared to normal subjects. This was independent of the gastritis and | 07-26-2012 |
20120196303 | CYBP AS A MARKER FOR LUNG CANCER - The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer. | 08-02-2012 |
20120196304 | DETECTION APPARATUS - The present invention relates to, in part, methods, reagents and apparatuses for the detection of agents. The present invention also relates, in part, to compositions including, but not limited to, flow cells, assay chambers, reagent reservoir delivery units and devices for holding an assay chamber. The present invention also provides various components and combinations of components for various detection apparatuses. The present invention also relates to a portable agent detection apparatus that can be used in the field or at a point of care and is not limited to specialized laboratories or limited to use by highly skilled users. | 08-02-2012 |
20120196305 | Detection of a specific DEK isoform as a urine-based biomarker for bladder cancer - The present invention is directed to a method of detecting a DEK protein isoform 2 in a human urine sample using ELISA. Methods and compositions for detection of DEK isoform 2 in human urine are provided herein. The presence of DEK isoform 2 in urine is shown to correlate with bladder cancer in humans. | 08-02-2012 |
20120196306 | COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies. | 08-02-2012 |
20120196307 | SYNAPTOTAGMIN AND COLLAPSIN RESPONSE MEDIATOR PROTEIN AS BIOMARKERS FOR TRAUMATIC BRAIN INJURY - Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological samples after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (biological samples). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury. | 08-02-2012 |
20120196308 | Methods and Kits for Measuring Von Willebrand Factor - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Iba having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Iba and von Willebrand factor. | 08-02-2012 |
20120202226 | METHOD AND SYSTEM FOR THE DETECTION OF CANCER - Disclosed are a method and kit of diagnosis of cancer in a body sample of a subject, comprising contacting the sample with at least two different suitable antigens to form at least two different complexes with antibodies present in the sample, determining the actual levels of each of said antigen-antibody complexes in said sample and establishing the ratio between the levels of the different complexes in said subject; and comparing the ratio to a predetermined ratio between antigen-antibody complexes levels formed between the same at least two antigens and samples from healthy subjects, whereby if said ratio determined in step higher or lower than a predetermined cutoff point pre-established for healthy subjects, said subject is diagnosed with cancer. The method and kit can be used for diagnosing various types of cancer, including breast, ovary, lung, prostate and colon cancer. | 08-09-2012 |
20120202227 | Babesia microti Genomic Clones Containing Novel Antigens Useful in the Diagnosis of Babesiosis - Disclosed are the cloning and expression of novel antigens in | 08-09-2012 |
20120202228 | Antibody Profiles Characteristic of Tuberculosis State - Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination at least three | 08-09-2012 |
20120208212 | METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2, OMPC AND ASCA SEROLOGIC RESPONSE - The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti- | 08-16-2012 |
20120208213 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. | 08-16-2012 |
20120208214 | RAPID SACCHARIDE BIOMARKER ASSAY - The present invention includes compositions, methods, kits and diagnostics for biosugar profiling of biological samples from a patient suspected of having a disease associated with changes in the biosugar profile. The biosugar profile from the patient sample is compared to a healthy biosugar profile from the same type of biological sample to evaluate disease potential and progression. | 08-16-2012 |
20120208215 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same - Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. | 08-16-2012 |
20120208216 | NON-CROSS-REACTIVE ANTI IGG ANTIBODIES - Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG | 08-16-2012 |
20120214178 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors - Mesenchymal stern cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 | 08-23-2012 |
20120214179 | METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid. | 08-23-2012 |
20120214180 | NT-pro ANP and SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS - The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient. | 08-23-2012 |
20120214181 | ASSAY FOR PCSK9 INHIBITORS - The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders. | 08-23-2012 |
20120214182 | SYSTEM FOR DETERMINING UNPROCESSED AND PARTIALLY PROCESSED NEUROTOXIN TYPE A - The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed Botulinum neurotoxin A polypeptide (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A comprising the steps of contacting a sample of the solution with a capture antibody which specifically binds to the partially processed and unprocessed BoNT/A under conditions which allow for binding of the antibody to the partially processed and unprocessed BoNT/A, whereby a complex is formed, and determining the amount of the formed complex, whereby the amount of the complex is indicative for the amount of the partially processed and/or unprocessed BoNT/A in the solution. Moreover, the present invention contemplates a device and a kit for carrying out the method. | 08-23-2012 |
20120214183 | METHODS FOR EVALUATING RISK OF MOTHER'S MILK OR FOOD INDUCING AN ONSET OF ATOPIC DERMATITIS, AND MOTHER'S MILK OR FOOD WITH REDUCED RISK OF INDUCING AN ONSET OF ATOPIC DERMATITIS - An entity of a Th2 adjuvant activity in mother's milk has been revealed as coenzyme A by HPLC and mass spectrometry. The followings have been found out that: a risk of developing atopic dermatitis can be evaluated by targeting coenzyme A; and any one of a food and mother's milk with a reduced risk of developing atopic dermatitis can be prepared by removing or inactivating coenzyme A. | 08-23-2012 |
20120219972 | DIAGNOSIS AND TREATMENT OF EHRLICHIOSIS - The present invention provides an isolated | 08-30-2012 |
20120219973 | IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases. | 08-30-2012 |
20120219974 | DISTINGUISHING ASSAY - The current invention comprises a method for determining of an antibody against a drug antibody in a sample using an immunoassay comprising a capture drug antibody and a tracer drug antibody, wherein the method comprises providing i) a capture drug antibody, which is the drug antibody conjugated to a solid phase, ii) a tracer drug antibody, which is the drug antibody conjugated to a detectable label, contacting the capture drug antibody separately with i) the sample, ii) the sample, to which the drug antibody in monomeric form has been added, iii) the sample, to which the drug antibody in oligomeric form has been added, and determining an antibody against the drug antibody in the sample by a positive immunoassay in i) and a negative immunoassay in ii) and iii). | 08-30-2012 |
20120219975 | Galactose-Alpha-1,3-Galactose-Macromolecule Conjugates And Methods Employing Same - Methods and reagents are disclosed for conducting assays for IgE. Embodiments of the present reagents comprise a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. Embodiments of the present methods are directed to determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample. A combination is provided in a medium, which comprises the sample and a reagent for determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample wherein the reagent comprises a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. The combination is subjected to conditions for binding of the IgE to the reagent to form a complex. The presence and/or amount of the complex are detected and the amount of the complex is related to the presence and/or amount of IgE in the sample. | 08-30-2012 |
20120219976 | REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION - The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. | 08-30-2012 |
20120225440 | HEPATOCELLULAR CARCINOMA PROTEIN MARKER, AND METHOD FOR DETECTION OF HEPATOCELLULAR CARCINOMA USING THE SAME - A method of detecting hepatocellular carcinoma includes using an isolated protein including an amino acid sequence represented by SEQ ID NO: 1. | 09-06-2012 |
20120225441 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 09-06-2012 |
20120225442 | New Markers for the Diagnosis of Celiac Disease - The invention relates to new peptides and to their use in the diagnosis of celiac disease. | 09-06-2012 |
20120231479 | COMBINATION METHODS OF DIAGNOSING CANCER IN A PATIENT - The present disclosure relates to methods for determining the presence, activity, and/or concentrations of certain cancer biomarkers and their use in determining the presence of cancer. | 09-13-2012 |
20120231480 | MATERIALS AND METHODS FOR THE DIFFERENTIAL DIAGNOSIS OF PACREATIC LESIONS - Levels of VEGF-A, VEGF-C and PGE | 09-13-2012 |
20120231481 | METHODS OF EVALUATING BAFF - The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject. | 09-13-2012 |
20120231482 | METHOD, KIT OR DIAGNOSTIC FOR THE DETECTION OF REAGENTS WHICH INDUCE ALTERED CONTRACTILITY - A method of screening for compounds that enhance or depress contractile function, based on measuring the formation of heterodimers of contractile fibers (e.g. Tm and actin, myosin heavy and myosin light chains), for example through disulfide bond formation. Diagnostic and prognostic methods and kits are also provided. | 09-13-2012 |
20120237956 | TREPONEMA PALLIDUM TRIPLET ANTIGEN | 09-20-2012 |
20120237957 | Method For Enhancing Enzyme Assays - Additives capable of controlling the reaction rate between substrate and enzyme to form a dye in enzyme assays with absorbance, chemiluminescence, and fluorescence are effective tools for optimizing enzyme assays. A dye can be formed rapidly from the reaction between enzyme and substrate in the presence of a catalyst. Using relatively high concentration of dye formed from the rapid reaction, trace levels of analytical materials can be quantified using absorbance, chemiluminecence and fluorescence detection. A dye can be formed from a relatively slow reaction between enzyme and substrate in the presence of a surfactant such as Triton X-100 and β-cyclodextrin. Using relatively low concentration of dye from the slow reaction, a high concentration of analytical material can be quantified without any dilution using absorbance, chemiluminescence, and fluorescence. | 09-20-2012 |
20120237958 | METHODS FOR IDENTIFYING ANIMALS WITH A REDUCED ABILITY TO DIGEST LIPID AND PROTEIN - The invention provides methods for identifying animals with a reduced ability to digest fat or protein by determining various blood and physical factors for the animals and comparing the determined values to standard values that are indicative of a reduced ability to digest fat and protein. | 09-20-2012 |
20120244557 | IMMUNOASSAYS USING ANTIBODIES SPECIFIC TO CARBAMAZEPINE - The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies. | 09-27-2012 |
20120244558 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E | 09-27-2012 |
20120244559 | Nanobeads covered with plasminogen as a direct support for cyclic amplification of the prion protein PrPSC - The present invention relates to an in vitro method for detecting a pathogenic conformational isomer of the prion protein in a sample, said method comprising a preliminary step for capturing the pathogenic conformational isomer by putting the sample into contact with nanobeads covered with a ligand of the pathogenic conformational isomer, and then applying a cyclic amplification of the misfolded prion protein directly on the solid support having captured the pathogenic conformational isomer, and detecting the presence of the pathogenic conformational isomer. The invention also relates to a kit for applying this method and to a method for decontaminating a biological sample. | 09-27-2012 |
20120244560 | MONOCLONAL ANTIBODY AGAINST HUMAN HIG-1 POLYPEPTIDE - This invention relates to a monoclonal antibody against a human HIG-1 polypeptide, the antibody binding to at least one epitope included in the amino acid sequence at positions 1-19 of a human HIG-1 polypeptide; an antibody fragment derived from the antibody; a DNA comprising a base sequence encoding a variable region of the antibody; an expression vector comprising the DNA; a cell line producing the antibody; a reagent for detecting a human HIG-1 polypeptide comprising the antibody or the antibody fragment, and a method for detecting a human HIG-1 polypeptide using the antibody or the antibody fragment. | 09-27-2012 |
20120244561 | BIOCHEMICAL SERUM MARKER - The present invention relates to a method for detecting the presence and/or concentration of the soluble BAG3 protein in an unknown biological sample and the assay is preferably carried by ELISA assay with antibodies, preferably monoclonal antibodies. The presence of said protein in a soluble form is associated with heart disease or with the presence of pancreatic tumors. | 09-27-2012 |
20120252039 | PLASMA KALLIKREIN FRAGMENTS AS DIAGNOSTIC BIOMARKERS FOR LUNG CANCERS - Disclosed herein are diagnostic markers for lung cancer, isolated from serum glycoproteins. The disclosed diagnostic markers for lung cancer are specifically expressed only in the sera of lung cancer patients at high levels, and thus will be very useful for diagnosing lung cancer and estimating disease progression and treatment. | 10-04-2012 |
20120252040 | KIT FOR DIAGNOSING PROSTATE CANCER AND DIAGNOSIS METHOD - The present invention relates to a kit and method for diagnosing prostate cancer, which use an antibody to prostate-specific antigen (PSA) to detect PSA in human urine. More specifically, the invention relates to a kit for diagnosing prostate cancer, which comprises an antibody to PSA and uses human urine as a sample, and to a method for diagnosing prostate cancer, which comprises brining a human urine sample into contact with an antibody to PSA in order to detect PSA in the sample. | 10-04-2012 |
20120258477 | FECAL NEOPTERIN CONCENTRATION MEASUREMENT AS AN INDICATOR OF DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE - Disclosed are methods for determining disease activity in a patient having or at risk for developing inflammatory bowel disease (IBD) which include measuring neopterin concentration in a fecal sample from the patient. | 10-11-2012 |
20120258478 | METHOD OF COLLECTING SPECIMEN AND METHOD OF DIAGNOSING SUBJECT TO DETECT UPPER DIGESTIVE SYSTEM DISEASE - A method of collecting a specimen of the present invention detects upper digestive system disease. The method of collecting a specimen includes: a step of administering a stimulant of pancreatic juice secretion or a stimulant of bile secretion to a subject; a step of positioning sampling equipment in the duodenum of the subject into which duodenal juice is secreted, the sampling equipment being used to collect and store the duodenal juice; a step of starting collection of the duodenal juice by the sampling equipment within five minutes from the administration of the stimulant of pancreatic juice secretion or the stimulant of bile secretion; and a step of stopping collection of the duodenal juice such that collection time for the duodenal juice is within five minutes from the start of collection. | 10-11-2012 |
20120258479 | Assay Device Having Rhombus-Shaped Projections - An assay device includes: a liquid sample receiving zone; a capture zone in fluid communication with the sample receiving zone having capture elements bound thereto, the capture zone having a substrate and projections which extend substantially vertically from the substrate, the projections having a rhombus-shaped cross-section and the projections arranged on the substrate with the corners of the projections facing upstream in a direction toward the sample receiving zone. The projections have a height, cross-section and a distance between one another that defines a capillary space between the projections capable of generating capillary flow parallel to the substrate surface; and a sink in fluid communication with the capture zone having a capacity to receive liquid sample flowing from the capture zone. The sample receiving zone, the capture zone and the sink define a fluid flow path. Preferably, the rhombus-shaped cross-section is a square or a diamond. | 10-11-2012 |
20120264143 | CYTOKINE-LIKE PROTEINS - A full-length cDNA corresponding to an EST (AA418955), which does not show any homology to other proteins in the database but has a weak homology to G-CSF, has been successfully isolated by synthesizing primers based on the EST sequence, and effecting PCR-cloning from a human fetal spleen library. Sequencing of the thus-isolated cDNA and analysis of its structure revealed that the cDNA has typical characteristics of a factor belonging to the IL-6/G-CSF/MGF family. It is also found out that the culture supernatant of said sequence-transfected CHO cells shows a proliferation supporting activity towards bone marrow cells in the coexistence of kit ligand. | 10-18-2012 |
20120264144 | METHOD FOR BINDING A RECOMBINANT POLYPEPTIDE TO A CARRIER - The present invention refers to a method for binding a recombinant polypeptide to a carrier, wherein a layer is bound to a carrier, and the layer comprises a recombinant polypeptide on the surface distal to the carrier. | 10-18-2012 |
20120264145 | Assay for Soluble CD200 - The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200. | 10-18-2012 |
20120264146 | COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: -measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), -combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 10-18-2012 |
20120264147 | Diagnostic Marker for Hepatocellular Carcinoma Comprising Anti-FASN Autoantibodies and a Diagnostic Composition for Hepatocellular Carcinoma Comprising Antigens Thereof - The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody. | 10-18-2012 |
20120270243 | Diagnosing and Managing Venous Thromboembolism and Intracardiac Thrombi Using a Provoked D-dimer Test - The present invention provides methods for diagnosing a venous thromboembolism or intracardiac thrombi in an individual in need of such treatment. A representative method of the present invention comprises the steps of: obtaining a plasma sample from said individual; determining the baseline level of D-dimer in said sample; contacting said sample with a compound that catalyzes the conversion of plasminogen into plasmin; and measuring the level of D-dimer is said sample after administering or contacting said sample with a compound that catalyzes the conversion of plasminogen into plasmin, wherein a significantly greater concentration of D-dimer after contact with a compound that catalyzes the conversion of plasminogen into plasmin than prior to contact with a compound that catalyzes the conversion of plasminogen into plasmin indicates that said individual has pulmonary embolism or venous thromboembolism. | 10-25-2012 |
20120270244 | Means and Methods for Diagnosing and/or Treating a Subject at Risk of Developing Heart Failure - The present invention relates to a method for identifying a subject at risk of developing heart failure, comprising: (a) determining the level of one or more biological markers in a biological sample of the subject; (b) comparing the level of the biological marker to a standard level of the same biological marker; and (c) determining whether the level of the marker is indicative of a risk for developing heart failure, wherein the biological marker is Krüppel-Like Factor 15 (KLF-15) and/or lysosomal integral membrane protein-2 (LIMP-2) and/or fragments and/or variants thereof, and/or wherein the biological marker is a gene coding for KLF 15 and/or LIMP-2, and/or fragments and/or variants thereof. The invention further relates to use of the KLF15 and/or LIMP-2 protein, and/or the gene coding for KLF15 and/or LIMP2, and/or fragments, and/or variants of the genes and/or proteins, for the preparation of a medicament for a prophylactic and/or a therapeutic medicament for prevention and/or treatment of heart failure. | 10-25-2012 |
20120270245 | DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis. | 10-25-2012 |
20120276559 | Thrombospondin Fragments and Uses Thereof In Clinical Assays for Cancer and Generation of Antibodies and Other Binding Agents - The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility; and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer. | 11-01-2012 |
20120276560 | BIOMARKERS FOR ASSESSING SIALIC ACID DEFICIENCIES - The present invention relates to methods of diagnosing, monitoring and assessing conditions of sialic acid deficiency such as Hereditary Inclusion Body Myopathy (HIBM) and to methods of predicting/determining responsiveness to treatment. | 11-01-2012 |
20120276561 | MARKER PROTEIN FOR TYPE-2 DIABETES - The present invention provides a marker protein for the early detection of type II diabetes, antibodies directed to the marker protein and their use in a diagnostic method for type II diabetes and in drug development. | 11-01-2012 |
20120282636 | Diagnostic Device - The invention provides for rapid response analysis through lateral flow chromatographic assays of specific antigens present in human or animal fluids, or in agricultural, microbial or biological products, with an audio and visual result of the analysis and when needed, an electronic surge to provide heat for rapid results. A lateral flow device for conducting the analysis includes a plurality of components, and a method for making the device forms components of the device on an elongate, ribbon-like substrate of dielectric material, then folds the substrate into shorter lengths which are then secured together to establish a multiple-layered, self-sustaining structure. | 11-08-2012 |
20120282637 | POLYPEPTIDES FOR BINDING TO THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS AS WELL AS COMPOSITIONS AND METHODS INVOLVING - The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the “receptor for advanced glycation endproducts” (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder. | 11-08-2012 |
20120282638 | METHOD FOR IMMUNOASSAY OF AUTOANTIBODY AGAINST KU86, KIT FOR USE IN SAME, AND METHOD FOR DETERMINATION OF PRIMARY HEPATOCELLULAR CARCINOMA USING SAME - An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma. | 11-08-2012 |
20120288879 | METHODS FOR DEVELOPING AND ASSESSING THERAPEUTIC AGENTS - Assays are provided that can effectively assess tumor response to one or more therapeutic agents. Preferred assays of the invention include assessment of posttranslation modification and expression of target proteins. | 11-15-2012 |
20120288880 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OR PROGNOSIS OF CARDIOVASCULAR DISEASE - The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an EMT subfraction, or in a complex containing apoA-I or apoA-III isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject. | 11-15-2012 |
20120288881 | Method for Evaluating the Cure Level of Stroke - A method for evaluating the cure level of a stroke patient comprises following steps: (1) obtaining isolated blood sample from said stroke patient; (2) determining the concentration of serum granulocyte colony-stimulating factor (G-CSF) of said blood sample; (3) comparing the relationship between said concentration of granulocyte colony-stimulating factor (G-CSF) and the stroke severity ranking of said stroke patient; wherein United State National Institute of Health Stroke Scale (NIHSS) or modified Ranking Scale (mRS) is used in said stroke severity ranking ; and (4) Using said concentration of granulocyte colony-stimulating factor (G-CSF) to predict the possible cure level of said stroke patient. The invention further provide a prognosis biomarker for evaluating the cure level of a stroke patient, and a kit containing said prognosis biomarker. | 11-15-2012 |
20120288882 | TYPE IV SECRETION SYSTEM PROTEINS IN SERO-DETECTION OF ANAPLASMA PHAGOCYTOPHILUM - Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in | 11-15-2012 |
20120295286 | Methods for the Diagnosis, Prognosis and Monitoring of Cancer Therapy Using BP1 - The invention described herein relates to method for diagnosing or monitoring the progression of a cancer, e.g., breast cancer, prostate cancer or brain cancer, in a subject by determining the amount of one or more biomarkers in a bodily fluid sample, where the biomarkers comprise pBP1. The invention described herein also relates to method for assessing the efficacy of a treatment of a subject having or suspected of having a cancer, by determining the amount of one or more biomarkers in a bodily fluid sample. | 11-22-2012 |
20120301901 | GEMCITABINE IMMUNOASSAY - The present invention comprises novel analogs of gemcitabine and novel gemcitabine immunogens leased out of, i.e., derived from, the 5′-hydroxy position of gemcitabine. The invention also comprises unique monoclonal antibodies generated using gemcitabine linked immunogens as well as unique conjugates and tracers which antibodies, conjugates, and tracers are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids. | 11-29-2012 |
20120301902 | Gemcitabine Immunoassay - The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids. | 11-29-2012 |
20120301903 | Microfluidic Devices and Methods of Manufacture and Use - Series of bio-detection elements, shown as short hollow transparent reaction vessels ( | 11-29-2012 |
20120301904 | MULTIPROTEIN ASSEMBLIES - The present invention provides compositions and methods of use in investigations of the formation of mulitprotein assemblies implicated in disease. Also provided are assays for screening candidate compounds of potential utility in preventing and/or treating such diseases by preventing the assembly of or disrupting the function of multiprotein assemblies. | 11-29-2012 |
20120309032 | Animal Model Having a Chimeric Human Liver and Suceptible to Human Hepatitis C Virus Infection - The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids. | 12-06-2012 |
20120309033 | METHOD FOR DETECTING AN ANTIGEN - The present invention relates to a method for detecting an antigen with use of an antibody and an enzyme. Specifically, the present invention provides a method for detecting an antigen without use of a labeled-antibody. the method comprises immersing particles in a first buffer solution which is predicted to contain the antigen; wherein an antibody and a multi-copper oxidase CueO are immobilized on each surface of the particles, and the antibody reacts specifically with the antigen. The method further comprises the following steps recovering the obtained particles; mixing the particles recovered, an oxidation-reduction indicator (reductant), and a second buffer solution so as to prepare a reaction solution; measuring an activity degree of the multi-copper oxidase CueO contained in the reaction solution; determining that the first buffer solution contains the antigen based on the above activity degree. | 12-06-2012 |
20120309034 | METHOD FOR MEASURING IMMUNITY OF COMPLEX OF Ku86 AND AUTOANTIBODY THEREOF, KIT USED THEREFOR, AND METHOD FOR DETERMINING CANCER USING SAME - A reaginic antibody of Ku86 and a substance capable of binding with the autoantibody of Ku86 are acted on a complex of Ku86 and the autoantibody thereof in a subject. Said complex can be measured by measuring the obtained immune complex of the aforementioned complex, reaginic antibody, and substance capable of binding with the autoantibody of Ku86. As a consequence, it is possible to determine whether the cancer is a primary hepatoma, colon cancer, stomach cancer, pancreatic cancer, breast cancer, lung cancer, or an esophageal cancer. | 12-06-2012 |
20120322087 | METHOD FOR EXAMINING ACUTE RENAL DISORDER - Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful. | 12-20-2012 |
20120322088 | METHODS FOR THE DIAGNOSIS, RISK ASSESSMENT, AND MONITORING OF AUTISM SPECTRUM DISORDERS - Methods for the diagnosis, risk assessment, and monitoring of Autism Spectrum Disorder (ASD) are disclosed. More specifically the present invention relates to the measurement of small molecules (metabolites) in human plasma that are found to have different abundances between persons with a clinical manifestation of ASD and subjects not expressing symptoms of ASD. Further, this invention relates to the monitoring of putative therapeutic strategies designed to ameliorate the biochemical abnormalities associated with ASD. | 12-20-2012 |
20120329077 | METHODS AND COMPOSITIONS FOR CATEGORIZING PATIENTS - The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data. | 12-27-2012 |
20120329078 | METHOD OF DIAGNOSING CANCER USING G-CSF PROTEIN HAVING A DELETION OF AN AMINO ACID SEQUENCE CORRESPONDING TO EXON 3 AS A DIAGNOSTIC CANCER MARKER - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker. | 12-27-2012 |
20130004971 | CYSTATIN C, beta2 MICROGLOBULIN, alpha1 MICROGLOBULIN AND GENES FOR SAME, ANTIBODY, AND KIT AND METHOD FOR DIAGNOSIS OF FELINE NEPHROPATHY - Proteins respectively having the amino acid sequences represented by SEQ ID NOs: 1, 17 and 32; structural genes respectively encoding the proteins, preferably respectively having the nucleotide sequences represented by SEQ ID NOs: 2, 18 and 33; an antibody capable of specifically binding to feline-derived cystatin C, feline-derived β2 microglobulin or feline-derived α1 microglobulin; a kit for diagnosing feline nephropathy, containing the antibody of the present invention; and a method for diagnosing feline nephropathy using the antibody of the present invention. | 01-03-2013 |
20130004972 | METHOD FOR THE DETECTION OF PREDIABETES - Provided is a method for prediabetes screening by means of methylglyoxal-modified arginine derivative assay, with which it is possible to treat many samples as simply and as safely as with blood sugar assay, and to collect a blood sample taken during a primary health screening in one procedure without imposing any time restraints, complications or risks on the subject. The method for prediabetes screening by means of methylglyoxal-modified arginine derivative assay comprises assaying the methylglyoxal-modified arginine derivative in blood using an assay system which employs an antibody that specifically recognizes methylglyoxal-modified arginine derivative. | 01-03-2013 |
20130004973 | METHODS OF USE FOR AN IMMUNOASSAY DETECTING FRAGMENT Ba - Methods, compositions and kits for detecting the complement Factor B cleavage product Ba in a biological sample are described. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of or ruling out pre-eclampsia in a pregnant human subject. | 01-03-2013 |
20130004974 | EXTRACELLULAR AND MEMBRANE-ASSOCIATED PROSTATE CANCER MARKERS - This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein. | 01-03-2013 |
20130004975 | Method of Stabilizing Heme Protein and Storage Solution Therefor - A method of stabilizing a hem protein which is effective against the denaturation and degradation of a hem protein typified by hemoglobin and a storage solution therefor. A method of stabilizing a hem protein and a storage solution therefor characterized in that an iminocarboxylic acid or its salt is made to coexist in a sample containing the hem protein, wherein the above-described iminocarboxylic acid is a compound represented by the following general formula (1) wherein R represents a hydrogen atom or a hydroxyl group; and X's represent each a hydrogen atom, an alkali metal or an ammonium group. | 01-03-2013 |
20130011863 | Follistatin-Like Protein-1 as a Biomarker for Sepsis - The present invention relates to methods and kits for diagnosing systemic inflammatory response syndrome or sepsis using levels of FSTL-1. | 01-10-2013 |
20130011864 | PHOTOLUMINESCENT NANOPARTICLE, PREPARATION, AND APPLICATION THEREOF - Luminescent nanoparticles, preparation, and application thereof are disclosed. The luminescent nanoparticle consists of matrix, which is a macromolecular compound containing carboxyl group, and a rare-earth luminescent dye dispersed in the matrix. The preparation method of the luminescent nanoparticle comprises: dissolving the rare-earth complex luminescent dye and the macromolecular compound in organic solvent miscible with water, adding the solution into water, and forming the luminescent nanoparticle by coprecipitation-selfassembly process. The prepared luminescent nanoparticle has excellent long-wave excitational luminescent properties and good stability, and can be used in coupling the surface carboxyl group of a biomolecule. The biological probes based on such luminescent nanoparticles have wide application prospects on the aspects of high-sensitivity luminescent immunoassay, biological imaging and the like. | 01-10-2013 |
20130011865 | MARKER FOR DETECTING GASTRIC CANCER AND METHOD FOR DETECTING GASTRIC CANCER - It is intended to provide a method for detecting gastric cancer, which is low invasive to a human test subject and has high detection sensitivity and accuracy. The present invention provides a method comprising measuring in vitro the amount of Cofilin 1 protein, a variant thereof, and/or a fragment thereof in a body fluid sample derived from a human test subject, and detecting the presence or absence of gastric cancer affecting the test subject on the basis of the amount, and a kit for gastric cancer diagnosis comprising an antibody capable of specifically binding to the protein. | 01-10-2013 |
20130011866 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen. | 01-10-2013 |
20130011867 | BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME - A bladder cancer biomarker and a test method using the same are provided. The biomarker contains serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect. | 01-10-2013 |
20130011868 | NOVEL PLATELET ACTIVATION MARKER AND METHOD FOR DETERMINATION THEREOF - The present invention provides a convenient and highly sensitive method of determining sGPVI present in plasma; this is accomplished by establishing a plurality of mouse hybridomas that produce antibody against GPVI and combining the antibodies produced therefrom. Provided thereby are a novel platelet activation marker, a reagent and method for determining this novel platelet activation marker, and novel applications of this marker in, for example, the diagnosis of diseases associated with platelet activation/vascular endothelial injury. | 01-10-2013 |
20130011869 | NOVEL MONOCLONAL ANTIBODIES AND METHOD OF IMMUNOLOGICAL ANALYSIS OF D-DIMER - Provided are an antibody capable of specifically and accurately measuring digested products of stabilized fibrin (D-dimer), and a method and a reagent for measuring D-dimer using the antibody. The antibody specifically reacts with D-dimer, which is plasmin-digested products of stabilized fibrin, but does not react with fibrinogen or plasmin-digested products of fibrinogen, which include fragment X, fragment Y, fragment D1, and fragment E3, and does not react with dissociation products of DD/E monomer, which include fragment DD, fragment E1, and fragment E2. | 01-10-2013 |
20130017561 | Lateral Flow Device for Diagnosing Microbial Infections - Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of | 01-17-2013 |
20130017562 | Assay for Vascular CalcificationAANM Shanahan; Catherine M.AACI LondonAACO GBAAGP Shanahan; Catherine M. London GBAANM Kapustin; Alexander N.AACI LondonAACO GBAAGP Kapustin; Alexander N. London GB - An assay for identifying an individual having or at risk of developing vascular calcification, said assay comprising obtaining a blood sample from an individual and measuring the level of a vesicular compound in a matrix vesicle present in the blood sample from said individual; wherein an increased level of said compound indicates an individual at risk of developing vascular calcification. | 01-17-2013 |
20130029359 | MONOCLONAL ANTIBODIES AND DIAGNOSTIC USES THEREOF - The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies. | 01-31-2013 |
20130029360 | DIMERIC CORE-SHELL NANOSTRUCTURE LABELED WITH RAMAN ACTIVE MOLECULE LOCALIZED AT INTERPARTICLE JUNCTION, USE THEREOF, AND METHOD FOR PREPARING THE SAME - The present invention relates to a nanoparticle dimer in which Raman-active molecules are located at a binding portion of the nanoparticle dimer, and more particularly, to a core-shell nanoparticle dimer comprising: a gold or silver core having a surface to which oligonucleotides are bonded; and a gold or silver shell covering the core. In addition, the present invention relates to the core-shell nanoparticle dimer, to a method for preparing same, and to the use thereof. | 01-31-2013 |
20130029361 | DISC-SHAPED ANALYSIS CHIP - A disc-shaped analysis chip has an internal space. The internal space includes: a first reservoir for accommodating a first liquid; a second reservoir and a third reservoir arranged nearer to an outer peripheral portion of the analysis chip than the first reservoir; a fourth reservoir, a fifth reservoir and a sixth reservoir for accommodating a second liquid, a third liquid and a fourth liquid, respectively, and being arranged nearer to the outer peripheral portion of the analysis chip than the second and the third reservoir; a seventh reservoir arranged nearer to the outer peripheral portion of the analysis chip than the fourth to the sixth reservoir; an eighth reservoir arranged nearer to the outer peripheral portion of the analysis chip than the seventh reservoir; and a first to an eighth flow path for appropriately interconnecting the first to the eighth reservoir. | 01-31-2013 |
20130029362 | MARKERS AND ASSAYS FOR DETECTION OF NEUROTOXICITY - A process and assay for diagnosing neurotoxicity in a subject is provided. The extent of a neurotoxic insult to a subject is assessed through the measurement of one or more biomarkers in a biological fluid, such as CSF or serum. Other uses and advantages afforded include pre-market drug discovery, monitoring, drug neurotoxicity screening and post market assessment of safety and monitoring for drug of known potential neurotoxicity. | 01-31-2013 |
20130034867 | METHODS FOR ISOTOPICALLY LABELING BIOMOLECULES USING MAMMALIAN CELL-FREE EXTRACTS - Methods for producing an isotope-labeled mammalian, including a human, biomolecule, such as polypeptides and proteins, in a cell-free protein synthesis system. A biomolecule standard is produced having at least one isotope different in abundance than that of the naturally occurring isotopes in the biomolecule. Methods for quantifying biomolecules standards expressed using mammalian cell-free extracts are disclosed. Methods for producing such standards, kits, systems and reagents, relating to the use of isotope-labeled biomolecule as quantification standards in mass spectrometric and nuclear magnetic resonance analysis. | 02-07-2013 |
20130034868 | METHOD AND USE FOR ASSESSING RADIATION THERAPY IN ACCORDANCE WITH SAA - A method for assessing a subject to receive radiation therapy in accordance with the present invention includes the steps of obtaining a body fluid sample from the subject, measuring the concentration of serum amyloid A proteins of the body fluid sample and comparing the concentration of the serum amyloid A proteins with a range of values to determine whether the subject is suitable to receive radiation therapy. Additionally, the present invention also provides a use of serum amyloid A proteins for assessing whether a subject is suitable to receive radiation therapy. | 02-07-2013 |
20130034869 | DEVICES AND METHODS FOR MULTIPLEXED ASSAYS - The disclosure provides low cost, portable three-dimensional devices for performing multiplexed assays. The devices comprise at least two substantially planar layers disposed in parallel planes, wherein one of the layers is movable relative to each other parallel to the planes to permit the establishment of fluid flow communication serially between the two layers. | 02-07-2013 |
20130040319 | DETECTION OF INFECTIOUS PRION PROTEIN BY SEEDED CONVERSION OF RECOMBINANT PRION PROTEIN - The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrP | 02-14-2013 |
20130040320 | Method for Diagnosing Gram-Negative Infections - The invention concerns an in vitro method for determining if an individual is infected by a gram-negative bacterium preferably on prosthesis comprising: (i) detection of antibodies directed against a polypeptide of sequence SEQ ID NO: 2 and antibodies directed against a polypeptide of sequence SEQ ID NO: 4, in a biological sample of the individual, and (ii) deduction therefrom that the individual is infected by a gram-negative bacterium. The invention further concerns the kit for diagnosing of such an infection. | 02-14-2013 |
20130040321 | Method for Diagnosing Streptococcus, Enterococcus and Pepstostreptococcus Genera Infections - The invention concerns a method to determine if an individual is infected by a bacterium selected from the group consisting | 02-14-2013 |
20130040322 | Method of Diagnosing Sjogren's Disease - Provided are methods and compositions for determining whether an individual has Sjögren's disease (SD). The method entails determining in a biological sample from the individual the presence of antibodies directed to salivary gland protein 1 (SP-I), parotid secretory protein (PSP), carbonic anhydrase 6 (C A6), or determining a combination of the antibodies. Determining that the individual has SD is based on the presence of the antibodies. The method provides for detection of early SD. Kits for antibody detection containing the antigens to which the antibodies of SD patients are directed are also provided. | 02-14-2013 |
20130040323 | DETECTION KIT CONTAINING A NOVEL RECOMBINANT 15-kDA POLYPEPTIDE USEFUL FOR DETECTING HUMAN INFECTION WITH BARTONELLA HENSELAE - Disclosed are the cloning and expression of a novel antigen of | 02-14-2013 |
20130040324 | PERIFUSION DEVICE - A perifusion device includes at least one sample container for cells, the sample container having an inlet and an outlet. The container receives test liquid through the inlet and discharges the liquid through the outlet. A manifold having a plurality of liquid inlets, control valves, and liquid outlets can be provided. A receptacle housing has a plurality of receptacles. A drive is connected to the receptacle housing for moving the receptacle housing. A programmable controller can be provided to control movement of the receptacle housing. The test liquid includes at least one stimuli for the cells. The liquid collected in the receptacles is analyzed to determine the response of the cells to the stimuli. | 02-14-2013 |
20130045492 | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided. | 02-21-2013 |
20130052665 | METHODS FOR DIAGNOSIS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - Methods for diagnosis of systemic juvenile idiopathic arthritis (SJIA) are disclosed. In particular, the invention relates to the use of biomarkers for diagnosis of SJIA, which can be used to distinguish SJIA from other inflammatory diseases, including infectious illness, acute febrile illness, Kawasaki disease, and similar juvenile idiopathic arthritis (JIA) disease subtypes, and to predict inflammatory flares in SJIA patients in advance of clinical symptoms. | 02-28-2013 |
20130052666 | ANTIBODY AGAINST HUMAN TSH AND CANINE TSH - It is an object of the present invention to provide an antibody that recognizes a canine TSH and binds thereto, without obtaining a large amount of canine TSH antigen. The present invention provides a monoclonal antibody produced by a hybridoma having Accession No. FERM BP-11490. | 02-28-2013 |
20130065254 | NOVEL EPIGENETIC MECHANISMS RELATED TO DNA DAMAGE AND AGING - This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided. | 03-14-2013 |
20130065255 | Biomarker to Measure Drug Efficacy in Enteropathic Disease - The diagnosis of a patient with an enteropathic disease or the response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, serum breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label. | 03-14-2013 |
20130065256 | ASSAY SYSTEM - An assay apparatus comprising: i) an assay cartridge ( | 03-14-2013 |
20130065257 | ENZYME-LOGIC BIOSENSING - Techniques, apparatus and systems are disclosed for implementing enzyme-logic based diagnosis that uses patterns of multiple markers and biochemical processing of the signal information for reliably identifying cardiac abnormalities and providing a final digital binary answer. In one aspect, a biochemical logic sensing system includes a network of enzyme-biocatalyzed logic gates adapted to receive biomarker input signals and perform an enzyme-biocatalyzed reaction resembling a Boolean logic operation using the received biomarker input signals to generate an output signal of the enzyme-biocatalyzed reaction. A signal processing unit is connected to the network of enzyme-biocatalyzed logic gates. The signal processing unit processes the generated output signal of the enzyme-biocatalyzed reaction and generates a digital binary output having a value of zero or one. The generated digital binary output indicates a type of an injury. | 03-14-2013 |
20130065258 | COLORECTAL CANCER MARKER GALECTIN, METHOD FOR ANALYZING GALECTIN CONCENTRATION IN BLOOD SAMPLE, AND KIT FOR DETECTING COLORECTAL CANCER MARKER GALECTIN - The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody. | 03-14-2013 |
20130071861 | METHODS AND KITS FOR DETECTING ITA IN A BIOLOGICAL SAMPLE - Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention. | 03-21-2013 |
20130071862 | FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the | 03-21-2013 |
20130071863 | Sulfur-Containing Amino Acid Derivative - The present invention provides a method of measuring an endogenous low-molecular-weight compound specifically and conveniently with high sensitivity. Using the particular sulfur-containing amino acid derivative, a method of measuring an endogenous low-molecular-weight compound specifically and conveniently with high sensitivity can be provided. | 03-21-2013 |
20130071864 | COLORECTAL CANCER MARKER VITRONECTIN AND METHOD FOR ANALYZING VITRONECTIN CONCENTRATION IN BLOOD SAMPLE - The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA | 03-21-2013 |
20130078651 | INDIVIDUAL INFORMATION DETERMINING METHOD, INDIVIDUAL INFORMATION DETERMINING DEVICE, ELECTRONIC APPARATUS, AND INDIVIDUAL INFORMATION DETERMINING PROGRAM - Disclosed in an individual information determining method in which individual information of a subject is determined based on one or a plurality of pieces of biomolecule data collected from a surface of a body surface of the subject. | 03-28-2013 |
20130078652 | METHODS AND KITS FOR DETERMINING VON WILLEBRAND FACTOR ACTIVITY IN THE ABSENCE OF RISTOCETIN AND FOR DETERMINING THE ACTIVITY OF ADAMTS-13 PROTEASE - Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin. | 03-28-2013 |
20130078653 | ANTIBODIES, COMPOSITIONS, AND ASSAYS FOR DETECTION OF CARDIAC DISEASE - The present invention provides antibodies, devices, and immunoassays for detection of ischemic cardiac events (unstable angina and heart attack) in patients experiencing chest pain. The invention allows for rapid determination of the cause of chest pain, and allows for differentiation of chest pain due to ischemic cardiac events and other causes. The invention provides antibodies that specifically bind to the epitope f-MII and the epitope f-MLF. | 03-28-2013 |
20130078654 | Methods For Diagnosing Rheumatoid Arthritis - The present invention relates to methods of diagnosing, prognosing, preventing or delaying onset of or treating rheumatoid arthritis, methods of distinguishing between different types or stages of rheumatoid arthritis, of identifying an individual at risk of developing rheumatoid arthritis, and of monitoring efficacy of a treatment regime in an individual being treated for rheumatoid arthritis, using a citrullinated enolase peptide to detect or capture antibodies associated with rheumatoid arthritis. | 03-28-2013 |
20130084584 | METHOD TO DETECT TISSUE DEGRADATION LEADING TO INFLAMMATION - This invention relates generally to a method, an assay and a kit for determining a tissue degradation process that leads to inflammatory responses opening up for a vicious circle of increased tissue destruction. More specifically the invention relates to kits and methods for an assay that can analyzee human samples, for the presence of a COMP fragment complex that have activated complement exemplified by the complex between COMP and complement factor C3b or natural breakdown fragments of C3b. | 04-04-2013 |
20130084585 | IMMUNOASSAY FOR CHROMOGRANIN A, ANTIBODIES AND KIT - The invention relates to monoclonal antibodies which are reactive with an epitope in the polypeptide represented by amino acid sequence 236 to 251 or 264 to 279 of the human CGA amino acid sequence. The invention further relates to the use of these monoclonal antibodies in an immunoassay for CGA, to immunoreagents comprising any of these two antibodies, and to test kits for the determination of CGA containing immunoreagents based on both of the monoclonal antibodies. | 04-04-2013 |
20130089874 | RECIRCULATING FLUIDIC NETWORK AND METHODS FOR USING THE SAME - The present invention provides a variety of microfluidic devices and methods for conducting assays and syntheses. The devices include a solid substrate layer having a surface that is capable of attaching ligand and or anti-ligand, and an elastomeric layer attached to said surface. Preferred embodiments have deflectable membrane valves and pumps, for example, rotary pumps associated therewith. | 04-11-2013 |
20130089875 | PEGylated insulin-like-growth-factor assay - The current invention reports an immunoassay for the determination of PEGylated insulin-like-growth-factor employing an anti-(polyethylene glycol) antibody and an anti-digoxygenin antibody for the detection of an insulin-like-growth-factor/insulin-like-growth-factor-binding-protein-complex. | 04-11-2013 |
20130089876 | CAPILLARY BIOSENSOR SYSTEM AND ITS METHOD OF USE - A portable biosensor system includes at least one capillary tube extending longitudinally along a major axis between a proximal inlet end and a distal end. The at least one capillary tube has an interior surface coated with a capture material and forms a waveguide. At least one collimated light emitting diode is disposed proximate and perpendicular to the major axis of the at least one capillary tube and is positioned relative to the at least one capillary tube so that energy enters the at least one capillary tube from its exterior along the entire length of the at least one capillary tube to project a line of energy along substantially the entire longitudinal extent of the at least one capillary tube. A photosensor is disposed proximate the distal end of the at least one capillary tube for receiving emissive radiation therefrom. The photosensor generates an output voltage (or, optical output) representative of the emissive radiation, and a means for measuring the output voltage is provided. Also disclosed is a method of detecting target molecules in a sample using the biosensor of the present invention. | 04-11-2013 |
20130089877 | THE NOVEL ABETA22(pE)-42 PEPTIDE THAT BINDS TO AMYLOID-BETA ANTIBODY SPECIFICALLY IN BLOOD AND PHARMACEUTICAL COMPOSITION FOR THE DIAGNOSIS OF DEMENTIA DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present inventors screened peptides having a specific sequence specifically binding to amyloid-beta antibody and accordingly confirmed that Aβ22(pE)-42 peptide showed higher reactivity to amyloid-beta antibody in serum of Alzheimer's disease patients. Therefore, the said Aβ22(pE)-42 peptide can be used as an active ingredient for the kit for diagnosing dementia and thus it can be said that the peptide can be effectively used for the diagnosis of dementia whose early diagnosis is hardly possible. | 04-11-2013 |
20130089878 | GLP-1 RECEPTOR AGONIST BIOASSAY - Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays. | 04-11-2013 |
20130089879 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND MONITORING DISEASE AND TREATMENT VIA ANTIGEN-SPECIFIC MOLECULES - This document provides methods and materials related to compositions and methods for diagnosing and monitoring treatment for sensitivity to an antigen. Compositions of substantially pure polypeptides, or antigenic fragments thereof, and methods of using such compositions for diagnosing Lyme disease, infections, exposure to toxic environmental agents, and food sensitivities, and monitoring a subject's response to treatment of the same are provided. | 04-11-2013 |
20130095506 | METHODS OF MAKING A DIAGNOSTIC DEVICE BY INTERWEAVING HYDROPHOBIC AND HYDROPHILIC FIBERS, AND DIAGNOSTIC DEVICE THEREFROM - In one aspect, the invention provides a method for making a hydrophilic-silk composition. The method includes providing at least one strand of silk fiber, treating the silk fiber with an alkaline solution to provide at least one strand of degummed silk fiber, and treating the degummed silk fiber with a treatment solution to provide a hydrophilic-silk composition. The degummed silk fiber or the hydrophilic-silk composition is further immobilized with at least one reagent to make a silk-based diagnostic composition. The invention provides a silk-based diagnostic composition made by the method of the invention, and a diagnostic device that comprises the silk-based diagnostic composition. In another aspect, the invention provides a method of making a diagnostic device. The method includes providing at least one strand of a diagnostic-fiber composition, providing at least one strand of a hydrophobic-fiber composition, inter-weaving the at least one strand of the diagnostic-fiber composition and the at least one strand of the hydrophobic-fiber composition. In one embodiment, the diagnostic-fiber composition and the hydrophobic-fiber composition are both based on silk. | 04-18-2013 |
20130095507 | Method Of Identifying Risk For Thyroid Disorder - A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder. | 04-18-2013 |
20130102013 | MATERIALS AND METHODS TO DETECT PYRIMIDINE-PYRIMIDINE DIMER FORMATION - Disclosed are methods and apparatuses pertaining to measuring DNA damage due to exposure to ultraviolet light, as measured by formation of pyrimidine-pyrimidine dimers in a polynucleotide. The apparatuses can be in the form of a patch which can be particularly useful in measuring the effectiveness of a sunscreen. The apparatuses can further include a reporter agent for instant determination of the pyrimidine-pyrimidine dimer formation. | 04-25-2013 |
20130102014 | FLUORINATED RESORUFIN COMPOUNDS AND THEIR APPLICATION - The invention provides novel fluorinated resorufin compounds that are of use in a variety of assay formats. Also provided are methods of using the compounds and kits that include a compound of the invention and instructions detailing the use of the compound in one or more assay formats. | 04-25-2013 |
20130109033 | Method, Particularly Enzyme-Linked Immunosorbent Assay (ELISA), for In Vitro Detection of Amyloid Beta Autoantibodies, Microtiter Plate, and Test Kit | 05-02-2013 |
20130109034 | Compositions and Methods for Determining Celiac Disease | 05-02-2013 |
20130109035 | DETECTION OF HIGH-RISK INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM AND PANCREATIC ADENOCARCINOMA | 05-02-2013 |
20130115631 | Methods For Measuring High Molecular Weight Complexes Of Fibrinogen With Fibronectin And Fibulin-1 - A method of detecting MSDX Complex-1, the method introducing a first antibody to a sample to create an antibody-sample mixture, wherein the first antibody is specific for one of fibrinogen, fibronectin, or fibulin-1, the first antibody having a label molecule; providing a well coated with a second antibody, the second antibody is specific for one of fibrinogen, fibronectin, or fibulin-1; introducing the antibody-sample mixture to the well; and introducing a substrate to the antibody-sample mixture in the well, wherein the label molecule and the substrate interact to provide a signal, wherein when the signal is detected then MSDX Complex-1 is detected. | 05-09-2013 |
20130115632 | HIGHLY SENSITIVE METHOD FOR ASSAYING TROPONIN I - A highly sensitive method of assaying an analyte present in a sample using protamine is provided, as well as an immunoassay reagent and biosensor that reduces non-specific binding by electrostatic interaction of protamine with fibrinogen present in the sample. | 05-09-2013 |
20130115633 | Methods & Devices for Diagnosing Cardiac Disorders - A method for diagnosing a cardiac disorder by detecting levels of cardiac-specific membrane polypeptides in tissue samples. | 05-09-2013 |
20130115634 | PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to | 05-09-2013 |
20130115635 | EPITOPE TAG FOR AFFINITY-BASED APPLICATIONS - Described is an epitope tag useful in affinity-based applications. The invention further includes fusion proteins, methods for preparing fusion proteins, nucleic acid molecules encoding these fusion proteins and recombinant host cells that contain these nucleic acid molecules. The invention also relates to nanobodies and other affinity ligands specifically recognizing the epitope tag, and uses thereof in affinity-based applications. | 05-09-2013 |
20130115636 | HISTONE CITRULLINATED PEPTIDES AND USES THEREOF - The present invention refers to citrullinated synthetic peptides derived from the histone H4 protein and their use in the diagnosis of autoimmune diseases,particularly Rheumatoid Arthritis (RA). | 05-09-2013 |
20130115637 | Efficiency of Prion Conversion in vitro and Sensitivity of Prion Detection - The present invention relates to improved methods and kits for the amplification detection of pathogenic prion proteins in samples. In some aspects of the invention, the method comprises: i) contacting the sample with a source of PrP | 05-09-2013 |
20130122526 | METHOD OF PREPARING A FUSION PROTEIN FOR THE INHIBITION OR REDUCTION OF SECRETION OF AN EXTRACELLULAR MEDIATOR FROM A TARGET CELL - The present invention provides a method for designing a re-targeted toxin conjugate for use in treating a medical condition or disease. Also provided, is the use of said conjugates in the manufacture of a medicament for treating medical conditions or diseases. The conjugates include a Targeting Moiety, which directs the conjugate to a desired target cell, and are characterised by a Targeting Moiety that increases exocytic fusion in the target cell. The present invention also provides methods for identifying agonists suitable for use as Targeting Moieties, and methods for preparing conjugates comprising said Targeting Moieties. | 05-16-2013 |
20130122527 | Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 05-16-2013 |
20130122528 | COMPOSITIONS AND METHODS FOR ASSESSING APPENDICITIS - The invention relates to methods, devices and systems for assessing appendicitis in a subject. More particularly, this invention relates to methods, devices and systems for assessing appendicitis in a subject by evaluating multiple biomarkers in a sample from the subject and comparing the values of the biomarker to a reference value from a group having high or low risk for appendicitis, or combining the values of the biomarkers using a mathematical algorithm to produce a numerical test score, and comparing the test score to a reference value to assess appendicitis in the subject. | 05-16-2013 |
20130130283 | Methods for Identifying Inhibitors of the Type III Secretion System - A method for determining whether a test compound has the ability to inhibit the function of the type 3 secretion system. In a first step, the compound is tested for its ability to inhibit secretion of an effector and/or a translocator protein, in a second step, it is further tested for its ability to inhibit the assembly of the structural components to form the needle complex. By this method, drug candidates can be identified that are highly specific anti-bacterial agents for treating diseases caused by Gram-negative bacteria with a T3SS. | 05-23-2013 |
20130130284 | ENZYME-FIBER MATRIX COMPOSITE OF THREE-DIMENSIONAL NETWORK STRUCTURE, PREPARATION METHOD THEREOF, AND USE THEREOF - Disclosed is a composite of enzyme and fiber matrix with three-dimensional structure. The composite of enzyme and fiber matrix with three-dimensional structure includes a significantly large amount of an enzyme loaded in and immobilized in/onto a matrix when compared to conventional composites. In addition, the immobilized enzyme is prevented from leaching from the matrix when an external impact is applied to the composite of enzyme and fiber matrix with three-dimensional structure. Therefore, the stability of the composite of enzyme and fiber matrix with three-dimensional structure of the present invention is maintained even after a long period passes since a remarkably great amount of enzymes compared with a known composite can be supported and immobilized to a matrix, and the immobilized enzyme is not easily released by an external impact. In addition, it is possible to stably immobilize a great amount of enzymes even if a functional group covalently bonding to enzymes is hardly present on the surface of fiber. Therefore, it is possible to remarkably improve performance by using the composite of enzyme and fiber matrix with three-dimensional structure of the present invention in a biosensor, a bio-fuel cell and the like, compared with the case using a known matrix composite. | 05-23-2013 |
20130130285 | Markers for Renal Disease - This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein. | 05-23-2013 |
20130130286 | METHODS FOR ASSESSING THE IMMUNE SYSTEM IN A PATIENT - Methods of determining the onset or susceptibility of an immunological disease are provided herein. Also provided are immunoassay techniques for carrying out such methods. | 05-23-2013 |
20130137120 | AMYLOID B MEASUREMENT METHOD - Disclosed herein is an Aβ measurement method capable of accurately measuring the concentration of Aβ in a sample even when the sample contains a very low level (about several pM) of Aβ. The amyloid β measurement method includes: a sample preparation step | 05-30-2013 |
20130137121 | Method And Device For Assay Determination - A device and method for determining the assay result is disclosed. The device includes a photoelectric detection circuit and a processor, and an optical detection device which is set with a detection zone and a blank zone for measuring assay results, and the photoelectric detection circuit detects the light-reflection intensity signal, and feeds back the detected information to the processor, and the processor is preset with a threshold value changing with time, and determined value processed by the processor is compared with the preset threshold value to obtain the result of assay. The method for determining the assay result display the result when confirmed determined value is bigger than the preset threshold value or can not reach preset threshold value within a fixed time or detected signal can not be determined, wherein the threshold value changes with the time. The device and method for determining the assay result work more efficiently, measure more accurately and cost less than the prior art. | 05-30-2013 |
20130137122 | DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 05-30-2013 |
20130137123 | USE OF HMGB1 AS A BIOLOGICAL MARKER OF BOWEL INFLAMMATORY CONDITIONS, NON-INVASIVE METHOD FOR ITS DETECTION IN FECAL SAMPLES AND KIT THEREOF - A non-invasive method for measuring a bowel inflammatory condition in humans through the presence of HMGB1 protein in fecal extracts and the involvement of such protein in the pathogenesis of chronic inflammatory bowel diseases, more specifically of Crohn's Disease (CD) and of ulcerative colitis (UC), including an analysis protocol to detect the HMGB1 presence in feces through Western blot assay or ELISA assay using an appropriate antigen-antibody. The invention also includes the colorimetric kit for implementing such a method. | 05-30-2013 |
20130143239 | Melittin Peptide Conjugates And Methods Employing Same - Methods and reagents are disclosed for conducting assays for IgE specific for honey bee venom allergen. A reagent comprises a conjugate of a small molecule linked to a terminal glycine amino acid of a synthetic 26 amino acid melittin peptide. In the method a combination is provided that comprises a sample and the aforementioned reagent. The combination is subjected to conditions for binding of IgE specific for honey bee venom allergen to the reagent to form a complex. One or both of the presence and amount of the complex is detected and related to one or both of the presence and amount in the sample of IgE specific for honey bee venom allergen. | 06-06-2013 |
20130143240 | HOMOARGININE AS A BIOMARKER FOR THE RISK OF MORTALITY - The present invention relates to the field of laboratory diagnostics. Specifically, means and methods for determining the risk of mortality in a patient based on homoarginine and to reduce the risk of mortality by administration of homoarginine are disclosed. Moreover, the present invention relates to the use of homoarginine for the preparation of a medicament for the treatment of a patient having an increased risk of mortality caused by stroke or a cardiac cause. Furthermore, the present application relates to a pharmaceutical composition comprising homoarginine and a composition for foodstuff supplement comprising homoarginine. | 06-06-2013 |
20130143241 | IMMUNOASSAY FOR FREE VITAMIN D - Disclosed is the invention to conduct immuno-adsorption of free 25(OH) vitamin D from blood or blood components, notably serum or plasma, after which the absorbed material is measured. A fluoro-alkyl surfactant is used to enhance the solubility of Vitamin D and allow the measurement of free Vitamin D. The invention thus employs a binding protein to absorb the free 25(OH) vitamin D. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound, preferably radiolabeled, fluorescent labeled, luminescent labeled, biotin labeled, gold labeled or enzyme labeled. Alternatively the immunocaptured 25-OH vitamin D can be quantitated by mass spectrometry. | 06-06-2013 |
20130143242 | MONOCLONAL ANTIBODY AGAINST GROUP 2 ALLERGEN OF DERMATOPHAGOIDES PTERONYSSIUNS, HYBRIDOMA CELL LINE PRODUCING THEREOF, STRIP, KIT AND METHOD USING SAID MONOCLONAL ANTIBODY FOR DUST MITE ASSAY - This present invention discloses a monoclonal antibody which specifically recognizes and binds to a epitope of group 2 allergen of | 06-06-2013 |
20130143243 | REAGENT AND REAGENT KIT FOR MEASUREMENT OF FDP, AND MEASUREMENT METHOD - The present invention relates to a reagent for the measurement of FDP comprising a carrier sensitized with at least two monoclonal antibodies selected from three monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent kit comprising the reagent and a method for measurement of FDP using the reagent or reagent kit. | 06-06-2013 |
20130143244 | SOX9 AS A MARKER FOR AGGRESSIVE CANCER - The invention provides methods for determining whether a cancer is or is likely to become aggressive, by detecting the presence of the transcription factor SOX9 in the cytoplasm of cells of the cancer, provided the cancer is not solid pseudopapillary tumor or a melanoma. | 06-06-2013 |
20130149720 | DETECTION OF SOLUBLE ADIPONECTIN RECEPTOR PEPTIDES AND USE IN DIAGNOSIS AND THERAPEUTICS - The present invention relates to soluble C-terminal fragments of the adiponectin receptor and their use in the diagnosis and management of disorders. | 06-13-2013 |
20130149721 | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation - Compositions and uses of mGluR | 06-13-2013 |
20130149722 | System and Method for Quantifying Fragile X Mental Retardiation 1 Protein in Tissue and Blood Samples - A system and method for the detection and quantification of fragile X mental retardation protein (FMRP) in human tissue and blood samples. The system includes several high avidity monoclonal antibodies that may be provided on Xmap microspheres to capture FMRP from a tissue or blood specimen. The resulting complex is reacted with a polyclonal anti-FMRP rabbit antibody and then mixed with an anti-rabbit IgG antibody conjugated to phycoerythrin. Fluorescence emitted from the resulting complex is a function of the amount of FMRP present in the specimen. | 06-13-2013 |
20130149723 | Method of controlling insect pests in cotton - An assay system is provided in which gossypol is used as a biological marker to detect evolved resistance of insects to Bt cotton. Detection of gossypol using a monoclonal antibody ELISA-based protocol enables at risk populations of insects to be evaluated for evolved resistance to Bt present in a genetically modified cotton. | 06-13-2013 |
20130149724 | SYSTEMS, DEVICES AND METHODS FOR MICROFLUIDIC CULTURING, MANIPULATION AND ANALYSIS OF TISSUES AND CELLS - Microfluidic devices for dissociating tissue, culturing, separating, manipulating, and assaying cells and methods for using the device are disclosed. Individual modules for tissue dissociation, cell, protein and particle separation, cell adhesion to functionalized, permissive micro- and nano-substrates, cell culturing, cell manipulation, cell and extracellular component assaying via metabolic and therapeutic compounds, compound titration, cell transfection, and micro-ELISA are described. Specialized micro- and nano-substrates and their methods of fabrication are also described. An integrated device is also disclosed. The devices and methods can be used for diagnostic applications, monitoring of disease progression, analysis of disease recurrence, compound discovery, compound validation, drug efficacy screening, and cell-based assays. | 06-13-2013 |
20130157290 | SOLUBLE ST2 AS A MARKER FOR DISEASE - The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality. | 06-20-2013 |
20130157291 | DIAGNOSTIC MARKER FOR LUNG CANCER COMPRISING HPaR AS ACTIVE INGREDIENT - Disclosed is a diagnostic marker for lung cancer comprising HpαR as an active ingredient. Because blood, which is relatively easy to sample, is employed as a specimen, the diagnostic kit and marker for lung cancer is very simple and does not subject patients to a load compared to conventional methods that are directed to a biopsy. In addition, the kit and marker of the present invention is useful in the early diagnosis of lung cancer thanks to its high diagnostic sensitivity and selectivity. | 06-20-2013 |
20130157292 | COMPOSITION FOR THE DIAGNOSIS OF OVARIAN CANCER OR PNEUMONIA COMPRISING THIOREDOXIN 1 AS ACTIVE INGREDIENT AND USE THEREOF - Disclosed are a composition for the diagnosis of ovarian cancer and/or pneumonia, comprising thioredoxin 1 as an active ingredient, and the use thereof. Also, a diagnostic kit for ovarian and/or pneumonia and a diagnosis method are provided. Because blood, which is relatively easy to be sampled, is employed as a specimen, the diagnostic method is very simple and does not impose a load on patients compared to conventional methods that are directed to a biopsy. In addition, the method is useful in the early diagnosis of ovarian cancer thanks to the high diagnostic sensitivity and selectivity thereof. Thioredoxin 1 can be used as a diagnostic marker for pneumonia, which is characterized by a decreased serum level, with high selectivity for pneumonia, thereby readily discriminating pneumonia from cancer as well as diseases other than cancer. | 06-20-2013 |
20130157293 | PHARMACEUTICAL MANUFACTURING METHODS - The invention describes methods for manufacturing oligoadenylate synthetase (OAS) proteins for use as active pharmaceutical ingredients in pharmaceutical compositions. A manufacturing method is described that produces large quantities of concentrated, highly active OAS protein for use in pharmaceutical compositions for the treatment of a variety of diseases including viral infection. Methods for monitoring and validating the manufacturing process are also described. | 06-20-2013 |
20130157294 | Methods and Compositions for the Diagnosis of Cancer Susceptibilities and Defective DNA Repair Mechanisms and Treatment Thereof - Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway. | 06-20-2013 |
20130157295 | XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO - The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: | 06-20-2013 |
20130164764 | Methods of Detection of Coccidioides Species in Bodily Fluid - Coccidioidomycosis (Valley Fever) is currently diagnosed by relying on infected individuals (humans, dogs, etc.) to generate antibodies against the fungus. Since the immune response against Valley Fever can be delayed or absent in many cases, methods that detect a polypeptide or peptide component of the | 06-27-2013 |
20130164765 | METHOD AND SYSTEM FOR DIAGNOSIS OF LAWSONIA INTRACELLULARIS - A method, system, and kit are provided for diagnosing | 06-27-2013 |
20130164766 | Isolation and Application of BAD-1 For Diagnosing Infections With Blastomyces Dermatitidis - Methods for obtaining highly pure native, recombinant or modified BAD-1 protein include the steps of culturing a population of microbes expressing BAD-1 protein in a culture medium, collecting the population of microbes from the culture medium, obtaining a BAD-1 protein-containing solution, and purifying the BAD-1 protein from the solution by combining the BAD-1 protein-containing solution with a nickel-chelating resin, washing the nickel-chelating resin to remove unbound matter, and eluting the BAD-1 protein from the nickel-chelating resin. Highly pure native BAD-1 protein may be used in diagnostic kits for detecting | 06-27-2013 |
20130164767 | ASSAYS FOR HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE, HUMAN PRO B-TYPE NATRIURETIC PEPTIDE AND HUMAN B-TYPE NATRIURETIC PEPTIDE - The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide in a test sample. | 06-27-2013 |
20130171669 | POROUS MEMBRANES HAVING A HYDROPHILIC COATING AND METHODS FOR THEIR PREPARATION AND USE - A modified porous membrane comprising a polymeric hydrophilic coating bonded to a porous membrane is described. The polymeric hydrophilic coatings grafted to the porous membranes comprise, for example, a PEG moiety such as a PEGMA, a PEGDA, or a TMPET, wherein the polymeric hydrophilic coating on the porous membrane decreases non-specific binding of unwanted material to the porous membrane and increases the signal to noise ratio in immunoassays, in vitro diagnostic tests, and point of care tests. Methods of making these modified porous membranes are also disclosed. | 07-04-2013 |
20130171670 | DIAGNOSIS AND MONITORING OF INFLAMMATION, ISCHEMIA AND APPENDICITIS - The invention provides methods and kits for diagnosing and monitoring inflammation and/or ischemia in an animal. The methods comprise determining the quantity of a post-translationally modified protein, other than phosphorylated tau, present in a body fluid from an animal. | 07-04-2013 |
20130171671 | METHODS FOR MODELING PROTEIN STABILITY - The present invention relates to a method for determining the highest temperature that is suitable for performing accelerated protein stability studies, as well as to a method for modeling real-time protein stability from accelerated stability data generated at said temperature. | 07-04-2013 |
20130177928 | NORMALIZATION OF PLATELET BIOMARKERS - Described herein are methods useful for normalizing any biomarker in platelets. This has application in any method in which one wishes to ascertain or compare the level of a biomarker, e.g., for diagnostic or prognostic methods relating to a biomarker of interest. Using such an approach can permit the assessment of disease status (e.g., angiogenic status) of an individual with less error than an expression value that is not normalized or that is normalized to total protein levels. Also provided are methods for selecting a normalizing protein for normalizing biomarkers in a sample, e.g., a platelet sample. | 07-11-2013 |
20130177929 | METHOD FOR THE THREE-DIMENSIONAL CO- CULTURE OF PODOCYTES AND ENDOTHELIAL CELLS AND RELATIVE IN VITRO CO- CULTURE SYSTEM - The present invention relates to a new three-dimensional co-culture method of podocytes and endothelial cells, and a relative co-culture system. Furthermore, the invention relates to the use of said co-culture system as an in vitro study model of pathologies affecting the kidneys, and in particular the renal glomerular filtration barrier. | 07-11-2013 |
20130177930 | Methods for measuring protein content - A process for measuring the amount of an antigen in a sample comprising the steps of binding the antigen to a solid phase, forming an antigen-antibody immunocomplex on the solid phase by applying a detection antibody that is specific for the antigen, liberating the detection antibody from the immunocomplex by applying a competing molecule that disrupts the immunocomplex by competing against the antigen for binding to the detection antibody, collecting the liberated detection antibody; and quantifying the liberated detection antibody to measure the amount of the antigen in the sample. | 07-11-2013 |
20130177931 | SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. | 07-11-2013 |
20130177932 | EX-VIVO METHOD FOR THE EARLY DIAGNOSIS OF MINIMAL HEPATIC ENCEPHALOPATHY BY MEANS OF THE DETERMINATION OF THE 3-NITROTYROSINE IN SERUM - An ex-vivo method for the early diagnosis of minimal hepatic encephalopathy by means of determining serum 3-nitrotyrosine relates to an ex-vivo method for the detection and early diagnosis of minimal hepatic encephalopathy (MHE) in patients with liver diseases, including cirrhosis, based on the presence of specific serum biomarkers, specifically by means of determining 3-nitrotyrosine (3-NT), which comprises obtaining serum or plasma obtained from the blood of patients and controls, and determining whether or not the measurement of the concentration of 3-nitrotyrosine obtained is greater than a specific level. | 07-11-2013 |
20130183687 | METHODS OF DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS (NASH) - Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods. | 07-18-2013 |
20130183688 | TIM-3 LIGANDS AND METHODS THEREOF - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses. | 07-18-2013 |
20130183689 | METHOD FOR DETECTING AND REMOVING ENDOTOXIN - The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca | 07-18-2013 |
20130183690 | HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF - Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor. | 07-18-2013 |
20130183691 | POLYPEPTIDE MARKER FOR DIAGNOSIS OF ARTERIOSCLEROSIS, METHOD FOR DETECTION OF ARTERIOSCLEROSIS BY USING THE MAKER OR THE LIKE, AND KIT FOR DIAGNOSIS OF ARTERIOSCLEROSIS - Disclosed are: a polypeptide marker for diagnosing arteriosclerosis; a gene marker for diagnosing arteriosclerosis; an antibody; a probe for detecting an arteriosclerosis marker gene; a DNA microarray or a DNA chip for detecting an arteriosclerosis marker gene; a method for detecting arteriosclerosis; and a kit for diagnosing arteriosclerosis; with which an arteriosclerotic lesion can be detected with much improved accuracy. Specifically disclosed are: a polypeptide marker for diagnosing arteriosclerosis, which comprises a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35 of the Sequence Listing, or a partial amino acid sequence thereof; a gene which encodes the amino acid sequence; a probe for detecting the gene; a DNA microarray or a DNA chip comprising the probe; an antibody bindable to the polypeptide as an antigen; a kit comprising any one of the above-mentioned items; and a method for detecting arteriosclerosis by using any one of the above-mentioned items. | 07-18-2013 |
20130183692 | INTOLERANCE TESTING FOR INGREDIENTS IN NUTRIENTS, FLAVORINGS AND THERAPEUTICS - Diagnosing an ingredient sensitivity or intolerance in companion animals comprises collecting a sample; screening the sample to detect the presence of an antibody to a particular ingredient. The sample can be saliva or other bodily fluid to detect the presence of an IgA, or IgM antibody to a particular ingredient or composition. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, or IgM antibody to a particular food ingredient or composition. Thirdly, a biologically active nutrient in relation to the animal is determined. | 07-18-2013 |
20130183693 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 07-18-2013 |
20130183694 | Method For Analyzing A Sample - The invention relates to a method of analysing a sample, comprising the analysis of clinical-chemical parameters and the analysis of immunodiagnostic parameters in a fully automatic analysis apparatus, wherein the analysis apparatus comprises a pipetting apparatus, at least one holder for a reagent cartridge containing the components necessary for carrying out the analysis, a holding apparatus for a measurement cell, at least one measurement cell, with each reagent cartridge being associated with a measurement cell, a holding apparatus for a sample container containing sample, and a photometric or spectrometric measurement device. On the basis of a sample it is possible here for a plurality of different clinical-chemical and/or immunodiagnostic parameters to be determined, to which end a dedicated reagent cartridge is inserted into a holding apparatus of the analysis apparatus for each clinical-chemical or immunodiagnostic parameter to be determined. | 07-18-2013 |
20130183695 | BIOMECHANICAL-BASED METHODS OF DIAGNOSING SCOLIOSIS - Methods for diagnosing a scoliosis (e.g., adolescent idiopathic scoliosis (AIS)) and/or a predisposition to developing a scoliosis based on the determination of the variation of osteopontin (OPN) levels induced by mechanical forces/stimuli are described. | 07-18-2013 |
20130183696 | METHODS OF USE AND KIT FOR MEASUREMENT OF LIPOPOLYSACCHARIDE WITH A TIME RESOLVED FLUORESCENCE BASED ASSAY - The present invention relates to the methods of use for measurement of lipopolysaccharide (LPS) and methods of use for diagnosis of sepsis and LPS-related conditions. Specifically the present invention relates to a time resolved fluorescence (TRF) based assay for the measurement of LPS and methods of use for the measurement of LPS to diagnose sepsis, Gram-negative bacterial infections, and LPS-related conditions. | 07-18-2013 |
20130183697 | Methods And Compositions For Detecting Fungi And Mycotoxins - The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient. | 07-18-2013 |
20130189715 | Hemolysin and its Protein Fragments in Sero-Detection of Anaplasma Phagocytophilum - Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in | 07-25-2013 |
20130189716 | METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2 - The present invention relates to a method for identifying a subject at risk of developing hypertensive and organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2. | 07-25-2013 |
20130196353 | DETECTION OF SOLUBLE ADIPONECTIN RECEPTOR PEPTIDES AND USE IN DIAGNOSIS AND THERAPEUTICS - The present invention relates to soluble C-terminal fragments of the adiponectin receptor and their use in the diagnosis and management of disorders. | 08-01-2013 |
20130196354 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits. | 08-01-2013 |
20130196355 | Method and a kit to quantify and qualify exosomes for diagnosis of prostate cancer and prostate hyperplasia - A method and a kit are provided to quantify and qualify exosomes. Specifically the method and the kit quantify PSA-carrying exosomes for a purpose to diagnose prostate cancer and to distinguish between patients having a tumor and those having a benign prostate condition with increased blood levels of PSA. The method and the kit provide a fast, easy to use and accurate method for clinical settings. | 08-01-2013 |
20130196356 | Assay for Prions - The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits. | 08-01-2013 |
20130203083 | SERUM CLUSTERIN LEVELS IN SYSTEMIC AMYLOIDOSIS FEATURING CARDIOMYOPATHY - The present invention relates generally to diagnostic methods, systems, assays and kits for identification of subjects with cardiac amyloid deposits, where a low level of clusterin protein in a peripheral fluid sample, e.g., a serum sample from the subject, indicates the subject likely has cardiac amyloid deposits. Other aspects relate to methods of treatment of diseases or disorders characterized by cardiac amyloid deposits and transthyretin (TTR) amyloidosis, and more particularly to methods of treatment of cardiac-related amyloidosis and cardiac amyloid deposits in subjects with familial transthyretin (TTR), senile systemic amyloidosis (SSA), or familial amyloidodic polyneuropathy (FAP), or immunoglobulin light chain (AL) amyloidosis. Other aspects relate to methods and compositions comprising clusterin (CLU) or a clusterin agent (e.g. an agonist of clusterin activity or a biologically active fragment or derivative thereof), and their use in methods to treat a disease or disorder characterized by transthyretin (TTR) amyloidosis, e.g. senile systemic amyloidosis (SSA) or familial amyloidodic polyneuropathy (FAP), and their use in methods to treat amyloidotic cardiomyopathy associated with transthyretin (TTR) amyloidosis. | 08-08-2013 |
20130203084 | SPECIFIC DETECTION OF HUMAN CHORIONIC GONADOTROPIN BETA SUBUNIT TYPE II PRODUCED BY TROPHOBLASTIC AND NEOPLASTIC CELLS - The present invention provides a novel method to distinguish between HCG β type I and type II gene expression using specific antibody. The specific recognition of HCGβ encoded by type II genes and expressed by trophoblastic and neoplastic cells might improve the clinical usefulness of assays aimed at either diagnosing tumors or screening Down's syndrome. The present invention also provides a diagnostic kit for determining the amount of HCGβ type II in a biological sample. The present invention additionally provides process of preparation and screening hybridoma capable of specifically recognizing HCGβ type II and recombinant antibody thereof. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample. | 08-08-2013 |
20130203085 | ANTIGENIC STRUCTURE AND USES THEREOF FOR SCREENING TRYPANOSOMIASES IN HUMANS AND ANIMALS - The invention relates to an antigenic structure that contains a tryptophan epitope, characterised in that said structure is made up of a tryptophan pattern W or a peptide of 3 or 4 amino acids comprising a pattern W, coupled with glutaraldehyde. The invention can he used for screening trypanosomiasis in humans or animals. | 08-08-2013 |
20130203086 | MICROFLUIDIC DEVICE FOR GENERATING NEURAL CELLS TO SIMULATE POST-STROKE CONDITIONS - This application provides devices for modeling ischemic stroke conditions. The devices can be used to culture neurons and to subject a first population of the neurons to low-oxygen conditions and a second population of neurons to normoxic conditions. The neurons are cultured on a porous barrier, and on the other side of the barrier run one or more fluid-filled channels. By flowing fluid with different oxygen levels through the channels, one can deliver desired oxygen concentrations to the cells nearest those channels. | 08-08-2013 |
20130203087 | DIAGNOSTIC REAGENTS - There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a | 08-08-2013 |
20130203088 | METHODS AND MEANS FOR DIAGNOSING SPONDYLARTHRITIS USING AUTOANTIBODY MARKERS - The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis. In particular, detection of the presence of autoantibodies against CD74 and/or IKBKB allows early diagnosis of Spa, in particular, AS and undifferentiated spondyloarthritis. | 08-08-2013 |
20130203089 | Filtered Adapter for Pipettors - The present invention relates to an adapter containing a filter that can be used with pipetting devices, particularly robotic pipetting devices, to efficiently connect the pipetting device to pipette tips with minimal distortion of the pipette tip. The present invention also relates to a process and a system of using an adapter containing a filter that can be used with pipetting devices, particularly robotic pipetting devices, to assemble the adapter together with an unfiltered pipette tip on the site of application. The adapter and pipette tip are each stackable for saving space at the work station. | 08-08-2013 |
20130203090 | SYSTEMS AND METHODS FOR DETERMINING ANTIBODY-MEDIATED RISK INDEX - Disclosed herein are systems and methods for assessing the risk of risk of hemolytic disease of the fetus or neonate, neonatal alloimmune thrombocytopenic purpura, or transfusion-associated lung injury in a patient or transfusion recipient. | 08-08-2013 |
20130203091 | MOESIN FRAGMENTS ASSOCIATED WITH APLASTIC ANEMIA - The present application provides compositions and methods useful for detecting and monitoring acquired aplastic anemia. | 08-08-2013 |
20130210035 | CHIP AND METHOD FOR DETECTING GLYCOSYLATED HEMOGLOBIN - The present invention relates to a chip and a method for detecting HbA1c. The detection chip comprises: a substrate; and a biomolecular layer disposed on the substrate, wherein the biomolecular layer comprises a first anti-hemoglobin antibody. The biomolecular layer can bind both the glycosylated hemoglobin and the hemoglobin in the blood sample. The method for detecting HbA1c of the present invention comprises the use of a bio-detection layer that comprises anti-glycosylated hemoglobin antibody and a second hemoglobin antibody with different epitope to differentiate the glycosylated hemoglobin from the total hemoglobin. Thus, the relative amount of glycosylated hemoglobin to hemoglobin can be detected by using the detection chip and the detection method of the present invention. | 08-15-2013 |
20130210036 | Controlling Fluid Flow Through An Assay Device - An assay device includes: a detection zone which includes a first set of projections which are capable of generating capillary flow. A wicking zone (WZ) has a capacity to receive liquid sample flowing from the detection zone and includes a second set of projections which are capable of generating capillary flow. The WZ is rectangular in shape and the longer side of the rectangle extends in the direction of flow to thereby reduce the pressure gradient in the assay device which increases the total flow time of liquid sample compared to a WZ having equal length sides and same volume. At least a portion of the second set of projections have at least one dimension selected from a diameter, a center-to-center spacing, or a gap between projections that is different from the first set of projections, and is selected to increase the total flow time of the sample. | 08-15-2013 |
20130210037 | METHODS OF DIAGNOSING AND TREATING AUTISM - The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR). The invention further provides methods of preventing or reducing the risk of a fetus or child developing an ASD by administering to the mother an agent that blocks the binding of maternal antibodies to the one or more fetal biomarkers listed above or by removing from the mother antibodies that bind to the one or more fetal biomarkers. | 08-15-2013 |
20130210038 | Novel Method for Diagnosing Q-fever Using a Cellular Immunological Test - The present invention relates to a method for diagnosing Q-fever in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of a | 08-15-2013 |
20130210039 | BLOOD INSULIN RESISTANCE AND DIABETES MARKER PROGRANULIN, METHOD FOR ANALYZING CONCENTRATION OF PROGRANULIN IN BLOOD SAMPLE, AND METHOD FOR SCREENING FOR SUBSTANCE THAT IMPROVES INSULIN RESISTANCE AND IMPROVES OR SUPPRESSES DIABETES - The present invention provides a marker capable of detecting insulin resistance and diabetes in a collected blood sample, a method for analyzing said marker, a method for screening a substance improving insulin resistance, and improving or suppressing diabetes. A blood insulin resistance marker and a blood diabetes marker, which comprises a polypeptide comprising at least 15 continuous amino acids in an amino acid sequence constituting progranulin. A method for analyzing a blood marker, which comprises the steps of: measuring a concentration of an insulin resistance marker or a diabetes marker in a collected blood sample; and comparing the measured concentration with a normal blood concentration of the marker. A method for screening a substance improving insulin resistance, and improving or suppressing diabetes, which comprises the steps of: administering a candidate substance to a living body expressing insulin resistance or suffering from diabetes; measuring a blood concentration of a marker in the living body after administration; and comparing the measured concentration of the marker with a blood concentration of the marker not administered with the candidate substance. | 08-15-2013 |
20130217043 | HUMANIZED TRANSGENIC MOUSE MODEL - Provided is a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multitransgenic animal. Also disclosed are methods for screening compositions for human vaccine development. More specifically, a mouse model capable of expressing human leukocyte antigen DR4, and human costimulatory molecules (CD80) upon infusion of human HLA-matched hematopoietic stem cells, which can develop into a functional man immune system is provided. | 08-22-2013 |
20130217044 | FACTOR INVOLVED IN LATENT INFECTION WITH HERPESVIRUS, AND USE THEREOF - Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder. | 08-22-2013 |
20130217045 | Use of Functional Autoantibodies in Alzheimer Disease - Provided herein is a method for diagnosing Alzheimer's disease in a subject comprising detecting an increase in an amyloidogenic Aβ | 08-22-2013 |
20130217046 | METHOD FOR DETERMINING PREDISPOSITION TO ESOPHAGEAL-RELATED DISORDERS - Provided herein are methods and materials for diagnosing an esophageal or esophageal-related disorder, or a predisposition for such disorders, in a subject. The methods center on detecting a genetic or protein esophageal marker. An esophageal marker has been identified in the PLCE1 gene and may be useful in predicting disease progression and assessing the subject's response to therapy. | 08-22-2013 |
20130217047 | KITS FOR DETECTING BREAST OR OVARIAN CANCER IN A BODY FLUID SAMPLE AND USE THEREOF - The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method. | 08-22-2013 |
20130217048 | Immunizing Compositions and Methods of Use - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 08-22-2013 |
20130224769 | METHODS OF USING CHEMOKINE PANEC-1 ANTIBODIES - The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein. | 08-29-2013 |
20130224770 | Antibody Diluent Buffer - The compositions described include an antibody diluent buffer that minimizes the amount of antibody required for immunoassays and further improves the performance of antibody-based assays. The claimed antibody diluent buffer comprises a high-molecular weight neutral polymer and an antibody that specifically binds to an antigen of interest, wherein the antibody remains in solution in the presence of the polymer. Methods for the use of the antibody diluent buffer to detect an antigen, even trace amounts of an antigen, in an antibody-based assay are also disclosed herein. | 08-29-2013 |
20130224771 | ANTI-MULLERIAN HORMONE DETECTION IN WHOLE BLOOD - The present invention provides methods, kits, compositions, and devices for detecting Anti-Mullerian hormone (AMH) in whole blood samples. In certain embodiments, the methods, kits, compositions, and devices employ immunoassays that generate a colorimetric or fluorescent signal (e.g., using antibodies conjugated to gold nanoparticles or fluorescent particles) where the signal generated is proportional to the approximate concentration of AMH in a whole blood sample. In particular embodiments, the present invention provides quantitative or semi-quantitative lateral flow immunoassay devices and kits for detecting AMH at home (e.g., in order for women to estimate their ovarian age or diagnose polycystic ovarian syndrome). | 08-29-2013 |
20130224772 | METHOD FOR DETECTING ANTI-HE4 ANTIBODIES AND METHODS OF DIAGNOSIS AND/OR PROGNOSIS OF CONDITIONS ASSOCIATED WITH HE4-EXPRESSING CELLS - The present invention features, inter alia, compositions and methods related to the detection of HE4-expressing tumor cells in a subject. The methods include detection of anti-HE4 antibodies in a biological sample obtained from the subject. The methods are useful for diagnosis and monitoring the efficacy of treatments for cancers in which HE4 is expressed, for example, ovarian cancer. | 08-29-2013 |
20130224773 | Method for Rapid Growth, Detection and Identification of Live Microorganisms Immobilized on Permeable Membranes by Antibodies - A method is provided for rapid growth, detection and identification of one or more live target microorganisms grown on a nutrient-rich medium. Grown microcolonies of the one or more live microorganisms attach to permeable membrane having immobilized antibodies thereon specific for the one or more live target microorganisms. The permeable membrane is contacted with at least one type of antibody-enzyme conjugate specific to antigens of the one or more live target microorganisms. Non-specific cells are washed from the permeable membrane and the membrane is stained to allow coloration and subsequent identification of the one or more live targeted microorganisms. The entire method allows for the rapid growth, detection and identification of live microorganisms in about 5 hours or less. | 08-29-2013 |
20130224774 | METHODS AND MATERIALS FOR AMPLIFICATION OF A SIGNAL IN AN IMMUNOASSAY - Ultrafine particles are provided having a core region that has a signal amplifying molecule and a shell region that surrounds the core region. The shell region has at least one antibody affixed to its surface that is specific for at least one antigen. Alternatively, the ultrafine particles may entrap the signal amplifying molecule within its matrix and may also have antibodies affixed to its surface for molecular recognition. Ultrafine particles are also provided having a matrix component that includes a signal amplifying molecule and at least one antibody specific for the antigen or biomaterial. The ultrafine particles of the present disclosure may be used in assays for the detection, including quantification, of one or more antigens present in a biological sample. | 08-29-2013 |
20130224775 | Apparatus and Methods for Analyte Measurement Immunoassay - The present invention relates to methods for measuring an amount of an analyte using an electrochemical assay in a conduit comprising a sensor, wherein said sensor comprises an electrode having a surface layer of immobilized antibody that binds said analyte, and a counter/reference electrode disposed within said conduit. A solution comprising a substrate for said enzyme and at least one air segment contacts the sensor to remove unbound analyte and labeled antibody from a region of the sensor. The disclosed invention is adaptable to the point-of-care clinical diagnostic field, including use in accident sites, emergency rooms, surgery, nursing homes, intensive care units, and non-medical environments. | 08-29-2013 |
20130230868 | Screening process for finding samples having a functionality disorder of the GPIb-von Willebrand factor interaction - The invention relates to a screening process for determining a disordered von Willebrand factor (VWF)-GPIb interaction in a patient's sample. This comprises contacting the sample with isolated GPIbα protein, with VWF protein and with a solid phase associated with an antibody specific for said isolated GPIbα protein, and determining complex formation. | 09-05-2013 |
20130230869 | ANTIBODY AGAINST COLORECTAL CANCER MARKER - The purpose of the present invention is to provide a novel monoclonal antibody which binds to SLC6A6 or an extracellular domain thereof. The present invention relates to a monoclonal antibody which recognizes native SLC6A6 or a polypeptide of an extracellular domain of SLC6A6. | 09-05-2013 |
20130236916 | D-DIMER, TROPONIN, AND NT-PROBNP FOR PULMONARY EMBOLISM - The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy. | 09-12-2013 |
20130236917 | ALBUMIN-BOUND PROTEIN/PEPTIDE COMPLEX AS A BIOMARKER FOR DISEASE - Methods and kits provide for diagnosis and prognosis of ischemia by using biomarkers comprising albumin-bound protein/peptide complex (ABPPC). | 09-12-2013 |
20130244258 | Sensitive and Specific Assay for Babesia spp. - The invention is directed to methods of using novel | 09-19-2013 |
20130244259 | NOVEL TESTING METHOD AND TESTING REAGENT FOR ANGIITIS - [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. | 09-19-2013 |
20130244260 | METHOD FOR DISCRIMINATING BETWEEN EARLY AND ADVANCED STAGE LUNG CARCINOMA - The present invention relates to a method for discriminating between early and advanced stage lung carcinoma in an individual suffering from lung carcinoma comprising the steps of a) providing a sample of an individual suffering from lung carcinoma, b) determining the level of heat shock protein 27 (HSP27) in said sample, c) comparing the determined level of HSP27 in said sample with a reference range of HSP27 measured in samples of control individuals with an early stage lung carcinoma and/or with advanced stage lung carcinoma, d) diagnosing early stage lung carcinoma in said individual when the level of HSP27 in sample a) is below the reference range of HSP27 in samples of control individuals with advanced stage lung carcinoma or within the reference range of control individuals with early stage lung carcinoma and diagnosing advanced stage lung carcinoma when the level of HSP27 in sample a) is above the reference range of HSP27 in samples of control individuals with early stage lung carcinoma or within the reference range of control individuals with advanced stage lung carcinoma. | 09-19-2013 |
20130252263 | METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF - The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma. | 09-26-2013 |
20130252264 | METHODS AND COMPOSITIONS FOR THE EVALUATION OF RENAL INJURY USING HYALURONIC ACID - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of hyaluronic acid (HA) as diagnostic and prognostic biomarker assays in renal injuries. | 09-26-2013 |
20130252265 | METHOD FOR TESTING FOR CEREBRAL INFARCTION VIA CARTILAGE ACIDIC PROTEIN 1 - A test method for diagnosing cerebral infarction, a test method for diagnosing the disease type of cerebral infarction, and a test method for predicting prognosis of cerebral infarction in a subject animal, which test methods comprise the step of measuring the amount of cartilage acidic protein 1 in a blood sample collected from the animal. | 09-26-2013 |
20130252266 | P-SELECTIN ASSOCIATED WITH EOSINOPHILS AS A MARKER FOR ASTHMA AND CORRELATING WITH B-1 INTEGRIN ACTIVATION - Methods are provided for the detection of P-selectin associated with eosinophils and for the use of P-selectin as a biological marker for asthma. In one embodiment, the present invention relates to methods for detecting P-selectin in a sample containing eosinophils and quantifying the total number of eosinophils. In another embodiment, the present invention relates a method for determining the proportion of eosinophils that are P-selectin positive and positive for at least partially activated β-1 integrin. In yet another embodiment, the present invention relates to kits for the detection of P-selectin and for the detection of eosinophils that are both P-selectin positive and positive for at least partially activated β-1 integrin. In still yet another embodiment, the invention relates to a method for monitoring a biological condition. | 09-26-2013 |
20130260397 | APPARATUS FOR SAMPLING OF A REPRESENTATIVE AND NON-DESTRUCTIVE SAMPLE OF PARTICLES FROM BULK MATERIAL AS WELL AS A METHOD FOR SAMPLING USING THE APPARATUS - The present invention relates a method for the detection of at least one mycotoxin contamination from bulk ware, an apparatus for taking a sample of particles from bulk ware as well as a method for taking particles from bulk ware using the apparatus according to the invention and the use of the apparatus according to the invention. | 10-03-2013 |
20130260398 | PHOSPHOHISTIDINE ANALOGS - The present invention relates to the phosphohistidine analogs of the present invention which of the formula (I) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine. | 10-03-2013 |
20130260399 | BIOMARKERS FOR DETERMINING BREAST CANCER BONE METASTASIS - The invention provides biomarkers and biomarker profiles that discriminate between a subject with breast cancer that has metastasized to the bone and a subject with breast cancer that has not metastasized to the bone. In particular, the biomarker and biomarker profile include polypeptides present or present at higher levels in the circulatory system of subjects having breast cancer bone metastasis compared to subjects having breast cancer without bone metastasis. | 10-03-2013 |
20130260400 | ASSAY FOR A TYPE II COLLAGEN BIOMARKER - An assay for Type II collagen fragments in serum, plasma, or synovial fluid obtains a quantitative measure of the concentration of all protein fragments in a serum, plasma, or synovial fluid sample that are reactive with an antibody, or immunoreactive antibody fragment, having specific reactivity with a C-terminal epitope present in the amino acid sequence GPPGRDGAAG and lacking specific reactivity with an amino acid sequence comprising the amino acid sequence GPPGRDGAAGV, which may be Mab NB44-3C1 as produced by the cell line deposited in HPA Culture Collection Logistics Office with Accession Number 10091402. | 10-03-2013 |
20130260401 | DAIKENCHUTO BIOASSAY METHOD AND QUALITY MANAGEMENT METHOD USING SAME - The invention intends to provide a bioassay method using a simple in-vitro test for Daikinchuto, and further to provide a more highly accurate method for quality control of Daikenchuto using the same. These methods are a bioassay method for the pharmacological activity of Daikenchuto, characterized in that a test sample containing Daikenchuto is added to cultured serotonin-producing cells, and the serotonin content in the culture supernatant is subsequently measured; and a quality control method for Daikenchuto preparations in which the pharmacological activity of a test preparation and a reference preparation for which the pharmacological effect as Daikenchuto has been clinically confirmed are evaluated under the same conditions, and the equivalence of the reference preparation and testing preparation is evaluated. | 10-03-2013 |
20130266968 | DETECTION OF INFLUENZA VIRUS - The present application describes methods for detecting influenza A and/or influenza B and/or distinguishing between pathogenic and seasonal influenza A subtypes. Many of these preferred formats employ pan-specific antibodies (i.e., that react with all or at least multiple strains within an influenza type) to detect presence of influenza A and/or influenza B and PDZ domains in combination with panspecific antibodies to influenza A to distinguish pathogenic and seasonal influenza A subtypes. | 10-10-2013 |
20130266969 | METHOD OF AND SYSTEM FOR PRINTING IN-WELL CALIBRATION FEATURES - An apparatus and a method are disclosed for printing in-well calibration features onto assay substrates. An apparatus includes a testing substrate; a plurality of capture compound features in a well of the testing substrate; a calibration feature on one of the capture compound features in the well of the testing substrate, where the calibration feature has a known concentration of a compound that is capable of binding to the capture compound; and at least one additional capture compound feature in the same well of the testing substrate, where the at least one additional capture compound feature does not have a calibration feature printed onto the at least one additional capture compound feature. Methods for using the same are disclosed. | 10-10-2013 |
20130266970 | PLASMA BIOMARKER FOR DISTAL METASTASIS IN COLORECTAL CANCER - The present invention proposes secretory gelsolin (pGSN) as a plasma biomarker for evaluating distal metastasis of colorectal cancer. The present invention uses a special amino acid sequence of pGSN to fabricate a pGSN-specific polyclonal antibody. The present invention further uses the pGSN-specific polyclonal antibody to develop a high-specificity ELISA method and an assay kit thereof for evaluating distal metastasis of colorectal cancer. | 10-10-2013 |
20130266971 | POLYSACCHARIDE AND DERIVATIVES THEREOF, SHOWING AFFINITY TO FICOLIN-3, METHOD OF PREPARATION AND USE - The invention relates to bacterial lipopolysaccharide and its components, especially native and chemically modified polysaccharides isolated from | 10-10-2013 |
20130266972 | METHOD OF DETECTING PROTEIN LOSING ENTEROPATHY IN ANIMALS - The present invention provides a method and kit for the detection of Protein Losing Enteropathy (PLE) in animals. The method includes the steps of (a) obtaining a biological sample from an animal to be tested and (b) determining the absence or presence of albumin in the biological sample via a kit comprising an immunoassay utilizing a species-specific anti-albumin antibody. | 10-10-2013 |
20130266973 | IDIOTYPIC ANTIBODIES AND USES THEREOF - The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same. | 10-10-2013 |
20130266974 | METHOD FOR DIAGNOSING HYPERTENSION AS WELL AS CARDIOMYOPATHIES - A method for diagnosis and/or prediction of hypertension and/or cardiovascular end-organ damage is disclosed. The method disclosed comprises the determination of the presence of soluble pro-renin receptor in samples derived from a subject. Furthermore, the use of anti-sPRR antibodies in diagnosis and/or prediction of cardiovascular end-organ damage is encompassed. | 10-10-2013 |
20130266975 | Body Fluid BIN1 as a Marker of Cardiac Health - The present disclosure provides methods involving use of BIN1 protein levels in biological fluid of a subject in evaluating cardiac health of the subject. The method provided herein may be used to predict a risk of a poor outcome in a subject. The methods also find use in evaluating subjects for assessing patients diagnosed with heart failure. These methods are also useful in assessing therapy options and efficacy of treatment in heart failure patients. | 10-10-2013 |
20130266976 | BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof. | 10-10-2013 |
20130273573 | AMYLOID BETA AGGREGATES IN CEREBRO SPINAL FLUID AS BIOMARKERS FOR ALZHEIMER'S DISEASE - The invention provides methods for assessing increased probability of having Alzheimer's disease in a subject under assessment including a step of obtaining a measurement of Aβ40 aggregates in a biological sample from the subject, where the biological sample does not include brain tissue, a fraction of brain tissue, or brain homogenate. In some embodiments, the invention relates to methods of assessing increased probability of early stage Alzheimer's disease. The invention further provides methods of assessing increased probability of not having Alzheimer's disease, methods of monitoring disease progression in a subject with Alzheimer's disease, and methods of assigning disease stage for a subject with Alzheimer's disease, and methods of assessing increased probability of MCI progressing to Alzheimer's disease. | 10-17-2013 |
20130273574 | OLIGOMERIC A-BETA IN THE DIAGNOSIS, PROGNOSIS, AND MONITORING OF ALZHEIMER'S DISEASE - The invention provides methods for diagnosis, prognosis and monitoring of Alzheimer's disease. The methods involve measuring the amounts of combined monomeric and oligomeric Aβ and amount of monomeric Aβ in samples obtained from a subject, and determining a ratio. The ratio can be used in diagnosing, prognosing, and/or monitoring Alzheimer's disease. | 10-17-2013 |
20130273575 | Method for Assaying Fibroblast Growth Factor-23 and Assay Reagent - A method for measuring fibroblast growth factor-23 (FGF-23) in a sample, which comprise the following steps:
| 10-17-2013 |
20130273576 | REAGENTS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS - Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors. | 10-17-2013 |
20130273577 | DETECTION OF DYSPLASTIC OR NEOPLASTIC CELLS USING ANTI-MCM3 ANTIBODIES - Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma. | 10-17-2013 |
20130273578 | METHOD OF DETECTING CALCIFYING NANOPARTICLES AND SUSCEPTIBILITY TO CALCIFYING NANOPARTICLE FORMATION - A method of measuring the susceptibility of a subject to calcifying nanoparticle formation is disclosed. The method can include obtaining a cell culture comprising peripheral blood mononuclear cells, immune cells, or both, from a peripheral blood mononuclear fraction of a subject in a complete culture media; extracting a first aliquot and a second aliquot from the cell culture; and dispensing the first and second aliquot in different wells. The surface of the well containing the first aliquot can include a calcifying nanoparticle biofilm, while the well containing the second aliquot does not. The first and second aliquots can be incubated and the concentration of osteopontin in each aliquot determined. An osteopontin factor can be calculated and compared to osteopontin factors from a representative sample of other subjects. The osteopontin factor can be defined as the osteopontin concentration in the first aliquot divided by the osteopontin concentration in the second aliquot. | 10-17-2013 |
20130273579 | METHOD FOR ANALYZING PROTEINS CONTRIBUTING TO AUTOIMMUNE DISEASES, AND METHOD FOR TESTING FOR SAID DISEASES - Provided are a detection method for a myriad of proteins involved in an autoimmune disease with high sensitivity and high efficiency, and an analysis method for data resulting from the detection method. In order to construct the detection method and analysis method, there is provided means for comprehensively analyzing the proteins involved in an autoimmune disease by bringing a mammal-derived protein expressed in a cell-free protein synthesis system into contact with a sample derived from a patient with an autoimmune disease to detect autoantibody production, and subjecting the detected data to statistical analysis processing, and further, gene ontology analysis and/or pathway analysis. | 10-17-2013 |
20130280736 | REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-ALPHA - The invention relates to reagents and methods for detecting, diagnosing and screening for conditions associated with hydroxylated hypoxia inducible factor 1-α (HIF-1α). The invention also relates to novel monoclonal antibodies specific for hydroxylated HIF-1α, or binding fragments thereof, and related nucleic acids, vectors, cells and compositions, as well as methods of using the antibodies in methods of the invention. | 10-24-2013 |
20130280737 | CHEMILUMINESCENCE COMPACT IMAGING SCANNER - Systems, devices, and methods for accurately imaging chemiluminescence and other luminescence are disclosed. A compact, flat-bed scanner having a light-tight enclosure, one or more detector bars of linear charge-coupled device (CCD) or complementary metal oxide semiconductor (CMOS) imaging chips, and high working numerical aperture (NA) optics scans closely over a sample in one direction and then the opposite direction. Averages or other combinations of intensity readings for each pixel location (x, y) between the two or more passes are averaged together in order to compensate for luminescence that varies over time. On-chip pixel binning and multiple clock frequencies can be used to maximize the signal to noise ratio in a CCD-based scanner. | 10-24-2013 |
20130280738 | DIAGNOSTICS FOR MEMBRANOUS NEPHROPATHY - The invention provides immunoassays for detecting serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R) and uses thereof for diagnosis and prognosis evaluation of idiopathic membranous nephropathy (MN). | 10-24-2013 |
20130280739 | DETERMINATION OF THE EFFICACY OF AN ANTI-MYCOBACTERIAL VACCINATION - The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine. | 10-24-2013 |
20130288274 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN - The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a hexamer of a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing the gliadin fusion protein on the solid support. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase. | 10-31-2013 |
20130288275 | COMPOSITIONS AND METHODS FOR DETECTING ACETYLATED SUMO PROTEINS - The invention is directed to methods of using antibodies or antibody fragments that specifically bind to an acetylation domain of a small ubiquitin-like modifier protein (SUMO protein) when the acetylation domain is at least partially acetylated. The invention is also directed towards antibodies or antibody fragments that specifically bind to an acetylation domain of a small ubiquitin-like modifier protein (SUMO protein) when the acetylation domain is at least partially acetylated. | 10-31-2013 |
20130288276 | METHOD FOR PREDICTION OF PROGNOSIS OF SEPSIS - Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients. | 10-31-2013 |
20130288277 | IMMUNOASSAY OF COFILIN 1 PROTEIN - An object of the present invention is to realize an antibody or a fragment thereof specifically recognizing a cofilin 1 protein, and a method for detecting and testing gastrointestinal cancer with high detection performance, which comprises performing immunoassay of the cofilin 1 protein using the antibody or a fragment thereof. An immunoassay of cofilin 1 protein is characterized by measuring cofilin 1 or a fragment thereof in a sample using 2 or more types of anti-cofilin 1 monoclonal antibody or fragments thereof specifically recognizing different peptide regions in the amino acid sequence constituting the cofilin 1 protein. | 10-31-2013 |
20130288278 | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR - The object of the present invention is to provide a method for screening a substance that affects gelatinase-mediated EphA4 processing. The present invention provides a method for screening a substance that affects gelatinase-mediated EphA4 processing, which comprises the steps of: (a) allowing a first biological composition containing gelatinase or a biologically active fragment thereof to be contacted with a second biological composition containing EphA4 in the presence and absence of a candidate substance; (b) measuring the presence or amount of the EphA4 ectodomain and/or endodomain fragment; and (c) selecting the candidate substance as a substance that affects gelatinase-mediated EphA4 processing if the results of the step (b) measured in the presence of the candidate substance are changed in comparison with the results of the step (b) measured in the absence of the candidate substance. | 10-31-2013 |
20130295589 | NGAL FOR DIAGNOSIS OF RENAL CONDITIONS - Use of serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker, alone or in conjunction with creatinine to aid in the diagnosis of renal conditions such as acute tubular necrosis and acute renal failure, and a method and a kit for assigning a diagnosis of acute tubular necrosis or acute renal failure to a subject based on the correlation between the levels of NGAL and optionally creatinine in a sample obtained from a subject when compared to a sample obtained from a normal subject not experiencing acute tubular necrosis or acute renal failure. | 11-07-2013 |
20130295590 | FOXA1 AS A MARKER FOR INVASIVE BLADDER CANCER - The present invention provides for a proteomic approach to predicting, diagnosing and staging invasive bladder cancer, and for predicting patient survival and therapeutic efficacy. More specifically, the target being analyzed for reduced expression is FOXA1, and optionally including analysis of increased FOXA2 expression. | 11-07-2013 |
20130295591 | SYSTEMS FOR IMMUNOASSAY TESTS - This invention relates to a cartridge for an immunoassay test. The cartridge comprises (a) a probe well comprising a probe and a cap, the cap being in a closed position to enclose the probe in the probe well, wherein the probe has a bottom tip coated with analyte-binding molecules; (b) a sample well to receive a sample; (c) one or more reagent wells; (d) a plurality of wash wells each containing a first aqueous solution; and (e) a measurement well having a light transmissive bottom, the measurement well containing a second aqueous solution; wherein the openings of the sample well, reagent well, measurement well and wash wells are sealed. The present invention also relates to an apparatus for loading and releasing a probe. The apparatus comprises a push pin and a groove to load and transfer the probe to a plurality of locations, such as different wells in the above-mentioned cartridge, to conduct the immunoassay test. | 11-07-2013 |
20130302830 | ROTORS FOR IMMUNOASSAYS - The present invention provides an analyte detection system for detecting target analytes in a sample. In particular, the invention provides a detection system in a rotor or disc format that utilizes a centrifugal force to move the sample through the detection system. Methods of using the rotor detection system to detect analytes in samples, particularly biological samples, and kits comprising the rotor detection system are also disclosed. | 11-14-2013 |
20130302831 | METHODS AND KITS FOR DETECTING AND DIAGNOSING NEUROTRAUMA - Methods and kits for detecting and diagnosing neurotrauma (e.g., traumatic brain injury, stroke, or spinal cord injury) are provided. These methods rely on the determination of lysophosphatidic acid (LPA) and/or LPA metabolite levels in patient samples following suspected injury. | 11-14-2013 |
20130302832 | METHOD FOR ELECTRICAL DETECTION OF BIOMOLECULES BY METAL DISSOLUTION AND ASSAY KIT THEREFORE - The present invention relates to a method for detecting a target molecule in a sample by metal dissolution as described in the specification, said method using an electrical readout; to kits adapted for this method and to electrodes suitable for such kits and methods. | 11-14-2013 |
20130302833 | METHOD FOR CONTROL OF INVASION AND USE OF ADIPONECTIN - Physical condition under stress can be controlled by using adiponectin in blood as a stress marker and measuring a level thereof. Moreover, endotoxin activity can be inhibited by using adiponectin. | 11-14-2013 |
20130302834 | METHOD FOR EVALUATING REGENERATED CARTILAGE - A method, according to an embodiment, for evaluating a regenerated cartilage includes allowing a group of cells containing auricular chondrocytes to stand in the presence of a culture medium, subsequently collecting at least a portion of a liquid component from the culture medium, measuring the GFAP content of the collected liquid component, and determining whether a regenerated cartilage that has been obtained or can be obtained from the group of cells is suitable for transplantation based on the GFAP content. | 11-14-2013 |
20130302835 | ANTIBODIES DIRECTED AGAINST PYROGLUTAMATE MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1 N1pE) - Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE). | 11-14-2013 |
20130302836 | COMMON LIGHT CHAIN MOUSE - A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments. | 11-14-2013 |
20130302837 | Immunoassay for Direct Determination of Antigen Content of Products Comprising Adjuvant-Coupled-Antigen Particles - The present invention relates to methods for the direct determination of the antigen content of products comprising adjuvant-coupled-antigen particles. Specifically, the present invention relates to a method for determining the antigen content of a product comprising antigen-coupled-adjuvant particles, the method comprises the steps of: a) contacting the product comprising antigen-coupled-adjuvant particles with immunoglobulin molecules capable of recognizing the antigen under conditions allowing antigen-immunoglobulin binding; b) providing a surface with the antigen, without the adjuvant, immobilized thereon; c) contacting the immunoglobulin contacted product of step (a) with the surface of step (b) under conditions allowing antigen-immunoglobulin binding; d) removing non-bound immunoglobulin molecules and antigen-coupled-adjuvant particles bound immunoglobulin molecules; e) detecting antigen-bound immunoglobulin molecules thereby determining the antigen content of a product comprising antigen-coupled-adjuvant particles. | 11-14-2013 |
20130302838 | BIOMARKER FOR AMYLOID-B-RELATED NEUROLOGICAL DISORDERS - A novel biomarker for diagnosing amyloid β-related neuropathy such as Alzheimer's disease is provided. Disclosed is a method for diagnosing Alzheimer's disease comprising measuring the level of a MFG-E8 protein in a blood, serum or plasma sample obtained from a human or animal subject, wherein the measured value is used as a marker for diagnosis of Alzheimer's disease. The MFG-E8 protein is found to bind to phosphatidylserine in a Ca | 11-14-2013 |
20130309694 | HYBRIDOMA CELL LINE FOR PRODUCING ANTIBODY FOR TYPE II COLLAGEN - The present invention provides a hybridoma cell line (DSM ACC3145), wherein the hybridoma cell line produces an antibody which specifically binds to an amino acid sequence of type II collagen comprising: K-G-E-P-G-D-D-G-P-S-C (as set forth in SEQ ID NO. 1); and a method for detecting osteoarthritis, by identifying a presence of type II collagen in a urine sample through containing the urine sample with the said antibody. | 11-21-2013 |
20130309695 | METHODS OF DIAGNOSING ASTHMA - A method of detecting a risk for or presence of asthma in a subject. The method comprises obtaining a biological sample comprising human airway smooth muscle cells from a subject and testing the biological sample for the presence of a pentraxin-3 (PTX3) polypeptide. The presence and/or quantity of PTX3 polypeptide in the biological sample correlates with the risk for or presence of asthma in the subject. | 11-21-2013 |
20130309696 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE - The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphorylcholine conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof. | 11-21-2013 |
20130309697 | BIOMARKERS FOR PROSTATE CANCER AND METHODS USING THE SAME - Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer. | 11-21-2013 |
20130309698 | Methods for Diagnosing Systemic Lupus Erythematosus - The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus. | 11-21-2013 |
20130316377 | METHODS FOR PREDICTING AND TREATING MYOCARDIAL DAMAGE - A method for predicting myocardial damage in a subject having or at risk of cardiac disease includes determining a level of apolipoprotein AI (ApoAI) and a level of Coenzyme Q | 11-28-2013 |
20130316378 | METHODS OF DIAGNOSING ACUTE CARDIAC DISORDERS USING BNP-SP - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection. | 11-28-2013 |
20130316379 | MOESIN FRAGMENTS ASSOCIATED WITH IMMUNE THROMBOCYTOPENIA - The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia. | 11-28-2013 |
20130316380 | Methods and Assays for Measuring p95 and/or p95 Complexes in a Sample and Antibodies Specific for p95 - The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95. | 11-28-2013 |
20130316381 | METHOD AND REAGENT DEVICE FOR DETERMINING ANTI-RA33 ANTIBODY IGG - The present invention provides a method for determining anti-RA33 antibody by ELISA based on a special device. The device comprises a substrate, wherein 8 wells are formed on the substrate, and one end of the substrate is provided with a handle and the handle is adhered with a bar-shaped code with the information of detecting reagent. By using the method and device of present invention, detection reagents can be placed in a single analysis device, thus the operation is simple and it is not easy to go wrong so that the correctness of the detection result is ensured. | 11-28-2013 |
20130323759 | SPINAL MUSCULAR ATROPHY DIAGNOSTIC METHODS - The present invention relates to the discovery of the human survival motor-neuron gene or SMD gene, which is a chromosome 5-SMA (Spinal Muscular Atrophy) determining gene. The present invention further relates to the nucleotide sequence encoding the SMN gene and corresponding amino acid sequence, a vector containing the gene encoding the SMN protein or a DNA sequence corresponding to the gene and transformant strains containing the SMN gene or a DNA sequence corresponding to the gene. | 12-05-2013 |
20130323760 | COMPOSITION OF DIAGNOSTIC BIOMARKER FOR STOMACH CANCER AND METHOD OF DIAGNOSING STOMACH CANCER USING THE COMPOSITION - Provided are a composition of a diagnostic biomarker for stomach cancer and a method of diagnosing stomach cancer using the same. The composition of a diagnostic biomarker for stomach cancer and the method of diagnosing stomach cancer using the same may be useful to determine stomach cancer from a patient with suspected stomach cancer. | 12-05-2013 |
20130323761 | BIOMARKERS AND THERAPEUTIC TARGETS FOR TREATING CARDIOMYOPATHIES AND CONGESTIVE HEART FAILURE - In alternative embodiments, the invention provides methods for predicting or diagnosing a heart disease or a defect in cardiac muscle contractility in an individual, or a defect in rate of cardiac muscle twitch relaxation and/or ventricular torsion, or detecting a cardiac trauma, in an individual or in a cardiac cell, or (by testing) a serum or a blood sample. In alternative embodiments, the invention provides methods for screening for a composition that can treat, ameliorate, prevent or reverse a heart disease or a congestive heart failure in an individual, or a defect in cardiac muscle contractility, or a defect in rate of cardiac muscle twitch relaxation and/or ventricular torsion in an individual or a cardiac muscle cell. | 12-05-2013 |
20130323762 | ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID BETA PEPTIDE - The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid β peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid β peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid β peptide. | 12-05-2013 |
20130323763 | METHOD FOR DIAGNOSING ACUTE LUNG INJURY - The present invention provides a useful examination method and diagnostic reagent, which are capable of diagnosing acute lung injury in clear distinction from chronic progressive interstitial pneumonia. Specifically, the present invention provides a method of determining whether or not a test subject is affected with acute lung injury, which comprises quantifying heat shock protein 47 in a biological sample derived from the test subject. | 12-05-2013 |
20130330744 | NITRATED CARDIAC TROPONIN I AS A BIOMARKER OF CARDIAC ISCHEMIA - The present invention relates to the identification of a novel biomarker for cardiac ischemia: nitrated cardiac troponin I. The present invention also provides methods for the identification and use of a nitrated cardiac troponin as a biomarker for the diagnosis, prognosis and treatment management of myocardial ischemia, with and without necrosis of heart muscle. | 12-12-2013 |
20130330745 | METHODS OF PROGNOSIS AND DIAGNOSIS IN SEPSIS - The present disclosure provides methods of diagnosing sepsis in patients by detecting the presence and amounts of biomarkers of sepsis in samples from the patients. Such biomarkers may be used to develop a more accurate prognosis for a patient with sepsis, or to accurately diagnose a patient suspected of having sepsis. | 12-12-2013 |
20130330746 | BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER, AND METHODS THEREOF - The present invention describes a method for predicting a health-state indicative of the presence of prostate cancer. The method measures the intensities of specific small biochemicals, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to the intensities observed in a population of healthy individuals and/or to the intensities previously observed in a population of confirmed prostate cancer-positive individuals. The method enables a practitioner to determine the probability that a screened patient is positive for prostate cancer. | 12-12-2013 |
20130330747 | MULTI-BIOMARKER BIOSENSOR - Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described. | 12-12-2013 |
20130330748 | FLUIDIC STRUCTURES INCLUDING MEANDERING AND WIDE CHANNELS - The present invention relates generally to microfluidic structures, and more specifically, to microfluidic structures and methods including meandering and wide channels. Microfluidic systems can provide an advantageous environment for performing various reactions and analyses due to a reduction in sample and reagent quantities that are required, a reduction in the size of the operating system, and a decrease in reaction time compared to conventional systems. Unfortunately, the small size of microfluidic channels can sometimes result in difficulty in detecting a species without magnifying optics (such as a microscope or a photomultiplier). A series of tightly packed microchannels, i.e., a meandering region, or a wide channel having a dimension on the order of millimeters, can serve as a solution to this problem by creating a wide measurement area. Although this invention mainly describes the use of meandering and wide channels in heterogeneous immunoassays on a microfluidic chip, this invention could be used for amplifying optical signals for other types of reactions and/or assays. | 12-12-2013 |
20130330749 | METHOD AND APPARATUS FOR DETECTING LIVER DISEASE, AND METHOD FOR ASSAYING PHARMACEUTICAL PREPARATION - A normal person (i.e. a control) and liver diseases such as drug induced liver injury, an asymptomatic hepatitis B carrier, an asymptomatic hepatitis C carrier, chronic hepatitis B, chronic hepatitis C, liver cancer, a nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and simple steatosis (SS) are identified by measuring the concentrations of γ-Glu-X (X represents an amino acid or an amine) peptides or the levels of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value. | 12-12-2013 |
20130330750 | SOLID SUPPORT AND METHOD OF ENHANCING THE RECOVERY OF BIOLOGICAL MATERIAL THEREFROM - The present invention relates to solid supports that are used for the storage and further processing of biological materials. The invention is particularly concerned with solid supports which have at least one surface coated with a chemical that enhances the recovery of the biological material from the support. Methods of preparing and using the solid supports are also described. | 12-12-2013 |
20130330751 | SAMPLE PRESERVATION METHOD AND SAMPLE APPLICATION SUBSTRATE - The invention discloses a sample preservation method which comprises the following steps: a) providing a paper substrate comprising ligands, where the ligands comprise charged groups, b) applying a sample comprising at least one analyte and at least one contaminant on the paper substrate, c) drying the sample on the paper substrate and, d) extracting at least part of the paper substrate to provide a solution of the analyte. | 12-12-2013 |
20130337477 | Distributable Chemical Sampling and Sensing System Process - The present invention relates to the use of a distributable sampling and sensing system for the determination of volatile components of consumable foods and other agricultural products. This process is used to separate and concentrate the chemicals of interest from samples at remote locations onto a target substrate that can be analyzed on-site or at a central lab. The chemicals deposited onto the substrate can be analyzed on-site with specific sensors (e.g., electrochemical sensors) or the target substrate can be sent to a central lab where the components adsorbed within are analyzed with conventional chemical instrumental methods (e.g., GC-MS). This process provides sufficient flexibility to enable the chemical analysis of a wide range of chemical species of interest in target materials in remote locations. | 12-19-2013 |
20130337478 | Antigen-Binding Protein Directed Against Epitope in the CH1 Domain of Human IgG Antibodies - The present disclosure relates to a method for the purification of a human IgG-CH1 domain comprising molecule using an antigen-binding protein that is capable of binding to an epitope that is comprised in the CH1 domain of each of human IgG1, human IgG2, human IgG3 and human IgG4. The disclosure further relates to the antigen-binding proteins that can be used in the method of the disclosure. The frame-work regions of the antigen-binding proteins of the invention preferably correspond to those of antibodies that naturally are devoid of light chains as may e.g. be found in camelids. The disclosure further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, and to the uses of such immunoadsorbent materials for the purification of IgG-CH1 domain containing molecules from a variety of species. | 12-19-2013 |
20130337479 | BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER - The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker. | 12-19-2013 |
20130344513 | RISK STRATIFICATION FOR ACUTE CORONARY SYNDROME BY MEANS OF FRAGMENTS/PARTIAL PEPTIDES OF PROVASOPRESSIN, ESPECIALLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis. | 12-26-2013 |
20130344514 | REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION - The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. | 12-26-2013 |
20130344515 | RADIAL FLOW IMMUNOASSAY AND METHODS OF PRODUCTION AND USE THEREOF - A radial flow immunoassay includes a membrane having a plurality of immobilized distinct antigens disposed thereon. Methods of producing the immunoassay, and methods of utilizing same to detect immunoglobulin present in a biological sample, are also disclosed. | 12-26-2013 |
20140004539 | SYSTEMS AND METHODS FOR MULTIPLEX SOLUTION ASSAYS | 01-02-2014 |
20140004540 | METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT | 01-02-2014 |
20140004541 | METHOD FOR THE DETERMINATION OF BOTULINUM NEUROTOXIN BIOLOGICAL ACTIVITY | 01-02-2014 |
20140004542 | Systems and Methods for Anti-PAX8 Antibodies | 01-02-2014 |
20140004543 | ASC AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | 01-02-2014 |
20140004544 | FEN1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | 01-02-2014 |
20140017709 | MICROFLUIDICS BASED ASSAY DEVICE - A subtractive corrective assay device and methodology, whereby ail required binding and label detection reagents are initially located within the detection zone. Application of a magnetic field is used to selectively remove bound label from the detection zone by means of paramagnetic particles. The relationship between measured label concentration before and after the application of a magnetic field within the detection zone is used to accurately measure analyte concentration within the sample. | 01-16-2014 |
20140017710 | PROCESS AND KIT FOR IN VITRO DIAGNOSIS OF A PROSTATE CANCER - The object of the present invention is a process for in vitro diagnosis of a prostate cancer, according to which a urine sample to be analysed is contacted with two antibodies, a capture antibody and a detection antibody, one of the two antibodies being directed against the first repeat domain of native human Annexin A3 identified as SEQ ID NO: 1, and the other of the two antibodies being directed against the fourth repeat domain of native human Annexin A3, identified as SEQ ID NO: 2, as well as a kit for implementing the process. | 01-16-2014 |
20140017711 | METHODS OF DIAGNOSING ULCERATIVE COLITIS AND CROHN'S DISEASE - The present invention relates to methods of prognosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of risk serological marker ANCA is indicative of an aggressive form of ulcerative colitis. In another embodiment, the present invention relates to methods of diagnosing a Crohn's disease subtype in an individual, where the presence of risk variants and serological markers I2, OmpC and/or Cbir1 are indicative of the Crohn's disease subtype. | 01-16-2014 |
20140017712 | IMMUNOLOGICAL MEASURING METHOD AND MEASURING KIT FOR WHOLE BLOOD SAMPLE - In a known method of measuring a target substance, comprising: providing a sample solution containing the target substance, a first reaction solution, and a second reaction solution; sequentially aspirating the sample solution and the first reaction solution, using a measuring apparatus equipped with a dispensing unit, into the dispensing unit; discharging them at a time from the dispensing unit, to bring them into contact with the second reaction solution, and to form a complex of the target substance and a first partner which is contained in at least one of the first reaction solution or the second reaction solution and reacts specifically with the target substance; and analyzing the resulting complex, an improved method capable of inhibiting a reaction which adversely affects measurement results is provided. In this improved method, the specific gravity of the sample solution is different from the specific gravity of the first reaction solution; and the sample solution and the first reaction solution are aspirated into the dispensing unit in an overlaid state. | 01-16-2014 |
20140024050 | ANTIBODIES WHICH DETECT PIVKAII AND METHODS OF USE THEREOF - The present invention relates to antibodies or binding proteins which bind to PIVKA II and may be used, for example, in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions. | 01-23-2014 |
20140024051 | Methods and Compositions for Biomarkers of Fatigue - The present invention provides methods and compositions for identifying fatigue, disease states associated with fatigue, recovery from fatigue and/or physical performance capability in a subject. | 01-23-2014 |
20140024052 | SEQUENCE-SPECIFIC EXTRACTION AND ANALYSIS OF DNA-BOUND PROTEINS - An automated protein preparation technology that may use magnetic microparticles to isolate proteins in their native state from specific genomic loci of interest via the chromatin to which they are bound is described. After extraction, the targeted proteins may be purified for down-stream analysis by quantitative mass spectrometry or ELISA. The identification of DNA-bound proteins, histones and their post-translational modification is of high scientific and pharmaceutical importance due to the role of DNA-binding proteins in the causation and development of human disease; in particular, cancer. | 01-23-2014 |
20140024053 | METHODS, KITS AND DEVICES FOR DETECTING BII-SPECTRIN, AND BREAKDOWN PRODUCTS THEREOF, AS BIOMARKERS FOR THE DIAGNOSIS OF NEURAL INJURY - The present invention identifies biomarkers that are diagnostic of neural injury, neuronal disorder or neurotoxicity and is related to the discovery that proteases are selectively activated in subjects suffering from nervous system damage as compared to healthy subjects. Breakdown products reflecting protease activation are produced and detection of these different biomarkers of the invention is also diagnostic of the degree of severity and type of nerve damage in a subject. | 01-23-2014 |
20140024054 | ANTIBODY, KIT AND METHOD FOR DETERMINING AMYLOID PEPTIDES - The invention relates to the field of immunoassays which allow the detection of Aβ 17 peptides by virtue of the use of an anti-Aβ 17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease. | 01-23-2014 |
20140024055 | ANTIHUMAN BAFF ANTIBODY - An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody. | 01-23-2014 |
20140030739 | MONOCLONAL ANTIBODIES AGAINST GMF-B ANTIGENS, AND USES THEREFOR - The disclosure relates to anti-glial maturation factor beta (“GMF-B”) monoclonal antibodies (mAbs) and fragments thereof, as well as hybridoma lines that secrete antibodies or fragments. Therapeutic and diagnostic uses of such antibodies, including treatment and detection of cancer and dementia, and methods and kits for detecting cells or samples expressing GMF-B, including soluble GMF-B, are also encompassed. | 01-30-2014 |
20140030740 | Rapid Bioluminescence Detection System - An assay is provided for detecting the activity of a reporter kinase comprising (i) adding said reporter kinase to an assay mixture wherein said reporter kinase is contacted with bioluminescent reagent no more than 5 minutes after being contacted with ADP, and wherein, prior to contacting the reporter kinase with ADP, the assay mixture is substantially free from kinase other than reporter kinase; and (ii) detecting light output from the assay mixture. Methods for detecting the presence of an analyte in a sample and methods for validating a treatment process using the above assay are also provided. Further provided are devices for conducting these assays and methods. | 01-30-2014 |
20140030741 | In Vitro Method for Determining Presence of Type II Pyrethroids - A method of determining the presence of type II pyrethroid compounds in a sample. | 01-30-2014 |
20140030742 | ANTIBODY REACTING WITH NATIVE COCHLIN-TOMOPROTEIN (CTP) AND METHOD FOR MEASURING CTP USING SAME - An immunological measurement is performed using anti-CTP antibody characterized by recognizing an antigenic determinant included in the polypeptide represented by amino acid numbers 118-132 of SEQ ID NO: 1, and reacting with native Cochlin-tomoprotein (CTP). | 01-30-2014 |
20140030743 | MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided. | 01-30-2014 |
20140030744 | Means and Methods for Diagnosing Gastric Bypass and Conditions Related Thereto - The present invention relates to the field of diagnostic measures. Specifically, it contemplates a method for assessing whether gastric bypass therapy was successful in a subject, a method of predicting whether gastric bypass therapy will be beneficial for a subject in need thereof, and a method of diagnosing whether a supportive therapy accompanying gastric bypass has beneficial effects on a subject in need thereof. Further provided are diagnostic methods for diabetes and body lean mass. Furthermore, the invention relates to a method for identifying a treatment against diabetes and/or obesity. | 01-30-2014 |
20140038209 | Apparatus and Methodology to Carry Out Biochemical Testing on a Centrifugal Platform Using Flow Splitting Technique - The invention provides an apparatus and methodology to carry out biochemical testing on a centrifugal platform using flow splitting technique. In conventional biochemical testing, reagents need to be loaded individually into each reservoir. By using the flow splitting technique in this invention, one reagent only need to be loaded once, then, it can be evenly distributed into each reaction chambers in single or multiple layers format. The invention greatly reduces the required manpower when large numbers of assays are integrated on one platform. Because of the invention, many medical examinations can be performed efficiently, thus reduce the waste of manpower, time and cost. | 02-06-2014 |
20140038210 | ANTI-HUMAN IgG1 ANTIBODY - Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays. | 02-06-2014 |
20140038211 | BREAST CANCER DIAGNOSIS USING NIPPLE DISCHARGE - A panel of biomarkers for the prediction of breast cancer using nipple discharge, as well as method and kits for using the same. Nipple discharge may be nipple aspirate fluid or spontaneous discharge. The panel has been selected to optimize predictive ability while minimizing the number of markers to be screened. As observed, the panel approaches one hundred percent accuracy for predicting breast cancer without the need for invasive biopsy. | 02-06-2014 |
20140038212 | IMMUNOASSAY METHODS - The application generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding. | 02-06-2014 |
20140038213 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 02-06-2014 |
20140045195 | Activatable Binding Polypeptides and Methods of Identification and Use Thereof - Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use. | 02-13-2014 |
20140045196 | METHODS OF PROGNOSIS AND DIAGNOSIS OF CANCER - Provided are methods of diagnosing cancer in a patient by detecting the presence and/or amount of a biomarker of cancer in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having cancer or suspected of having cancer, or to accurately diagnose a patient having, or suspected of having cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a cancer therapy. | 02-13-2014 |
20140045197 | BIOMARKERS USED TO DETECT AND MONITOR NEUROLOGICAL AUTOIMMUNE DISEASES - Biomarkers of neurological autoimmune diseases are described, and methods of using such biomarkers also are described. | 02-13-2014 |
20140045198 | METHOD OF PREDICTING THE EVOLUTION OF A PATIENT SUFFERING OF STROKE - The invention is a method of predicting the evolution of a patient suffering of a neurovascular disease, preferably stroke, comprising obtaining a biological sample of said patient, assessing in said biological sample the level of endostatin and FasL, determining whether said levels of endostatin and FasL together are above or below predetermined cut-off levels and predicting the functional outcome of said neurovascular disease on said patient evaluating the result of the previous step. The combination of endostatin and FasL is a more powerful predictor that any clinical prognostic tool and adds significant prognostic value to all other clinical variables of the art. | 02-13-2014 |
20140045199 | ANTI-VE-CADHERIN AUTOANTIBODIES AS A BIOMARKER OF VASCULAR ALTERATIONS ASSOCIATED WITH DISORDERS - The present invention relates to a method for predicting and/or diagnosing vascular alterations associated with a disorder in a patient, comprising a step of detecting or quantifying the presence of anti-VE-cadherin autoantibodies in a biological sample obtained from said patient as well as a kit suitable for carrying out such method. | 02-13-2014 |
20140051096 | NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS - The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. | 02-20-2014 |
20140051097 | METHODS FOR DETECTING CONTAMINANTS IN SOLUTIONS CONTAINING GLUCOSE POLYMERS - The invention relates to a method for detecting contaminants of glucose polymers, said contaminants being capable of acting in synergy with one another so as to trigger an inflammatory reaction, characterized in that it comprises an in vitro inflammatory response test using modified cell lines. | 02-20-2014 |
20140057292 | Immunochromatographic Device - The present invention is directed to provide a highly quantitative immunochromatographic device. | 02-27-2014 |
20140057293 | CONJUGATES OF 1,4,7-TRIAZACYCLONONANES, DINUCLEAR METAL COMPLEXES OF SUCH CONJUGATES, AND METHODS OF USE FOR BOTH 1,4,7-TRIAZACYCLONONANES AND CONJUGATES - Conjugates of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes with a variety of conjugating members are used in the formation of dinuclear metal complexes which bind to phosphate esters. By virtue of their conjugated forms, the complexes are incorporated into chromatographic media, affinity binding reagents, and dyes, which make the complexes useful in a wide range of assays, separations, and purifications. In addition, dinuclear metal complexes of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes that are not so conjugated are used in the detection of phosphate esters of biological species by either MALDI-TOF mass spectrometry or by dye displacement. | 02-27-2014 |
20140057294 | A HYBRIDOMA CELL LINE 10G4 AND A MONOCLONAL ANTIBODY AGAINST THE TOTAL OF AFLATOXIN B1, B2, G1 AND G2 - Hybridoma cell line 10G4 and monoclonal antibody against total aflatoxins produced by the hybridoma cell line 10G4. The hybridoma cell line 10G4 is used to produce the monoclonal antibody that binds specifically total aflatoxin B1, B2, G1 and G2. The titer of the mouse ascites antibody produced by the 10G4 treated mouse is determined through non-competitive enzyme-linked immunosorbent assay and the titer can reach up to 5.12×10 | 02-27-2014 |
20140057295 | ANTI-MULLERIAN HORMONE CHANGES IN PREGNANCY AND PREDICTION OF ADVERSE PREGNANCY OUTCOMES AND GENDER - The present invention provides for methods for evaluating the risk of an adverse pregnancy outcome in a subject and methods for treating subjects evaluated as being high risk. In some aspects, the present invention provides a method of evaluating the risk of an adverse pregnancy outcome in a subject, where if the subject does have an abnormal level of AMH as compared to a predetermined normal level the subject is more likely to have an adverse pregnancy outcome, and if the subject does not have an abnormal level of AMH the subject is less likely to have an adverse pregnancy outcome. In other aspects, the present invention provides a method of determining the gender of a fetus comprising obtaining information regarding the level of AMH in a sample from a pregnant subject. | 02-27-2014 |
20140057296 | ASSAYS FOR ANTIBODIES WHICH BIND TO THERAPEUTIC AGENTS - Methods and kits for determining the presence in a patient biological sample of an antibody which binds to an agent (e.g., an enzyme administered in the course of ERT), and optionally determining the neutralizing effect or lack thereof of the antibody on the agent are disclosed. | 02-27-2014 |
20140065646 | ASSAY SYSTEM - An assay apparatus comprising: i) an assay cartridge ( | 03-06-2014 |
20140065647 | SYSTEM AND METHOD FOR SPATIOTEMPORALLY ANALYZED RAPID ASSAYS - The invention relates to methods of reliably and quantitatively determining the amount of an analyte of interest in a fluid sample using a flow-induced assay, such as an immunochromatographic assay, in which spatiotemporal measurements are recorded during the course of the assay reaction, generating a spatiotemporal dataset, and subsequently analyzed. The invention also relates to a system incorporating instruments for recording spatiotemporal datasets (spatiotemporal data recorders), devices comprised of flow-induced assays configured for analysis on a spatiotemporal recorder, and programs for analyzing the recorded spatiotemporal datasets. | 03-06-2014 |
20140072986 | AMYLOID PROTEIN OLIGOMER-BINDING APTAMER - An aptamer having a G-quartet structure and being at least one selected from the group consisting of the following polynucleotides, the aptamer having a binding ability to an amyloid protein oligomer: (1) a polynucleotide comprising a base sequence represented by any one of SEQ ID NO:1 to SEQ ID NO:18; (2) a polynucleotide comprising a base sequence that includes at least four sets of at least two consecutive guanosine nucleotides and in which one or several bases has been deleted, substituted, or added in a base sequence represented by any one of SEQ ID NO:18; and (3) a polynucleotide that is a multimer including the polynucleotide of (1) or (2) as a structural unit. | 03-13-2014 |
20140072987 | METHODS OF DETECING BLADDER CANCER - The disclosure relates to methods of detecting bladder cancer including assaying a patient sample for the levels of certain combinations of biomarkers. The disclosure also relates to methods for determining the efficacy of a drug for the treatment of bladder cancer. | 03-13-2014 |
20140072988 | DETERMINATION OF VITAMIN D METABOLITES IN DRIED BLOOD - Method and test kit for quantitative determination of Vitamin D metabolites in blood, wherein a predetermined amount of blood is pre-analytically immobilised on a solid sorption material. Thereby, hemolysis of the blood has no effect on the analysis of vitamin D metabolites. For quantitative analysis the dried blood spot on the sorption material is dissolved with an aqueous solvent buffer containing detergent, pH 7.0 to 10.0, and the vitamin D metabolites are eluted with a protic organic solution having a permittivity of less than 35. The eluate is analysed for vitamin D metabolites using conventional methods. | 03-13-2014 |
20140080151 | ANTI-HIMF ANTIBODIES TO TREAT LUNG DISEASES - Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by a BTK inhibitor. In vivo studies revealed that HIMF can stimulate angiogenesis in the hypoxic tissue. Our results indicate that HIMF may act as a chemotactic molecule in stimulating the migration of leukocytes/EPCs from bone marrow to targeted tissues through activation of the BTK pathway. | 03-20-2014 |
20140080152 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 03-20-2014 |
20140080153 | METHOD FOR IMPROVING PHYSICAL PROPERTIES OF ANTIBODY - The present inventors discovered that physicochemical properties of a polypeptide can be improved by reducing the extracellular matrix-binding activity of the polypeptide. | 03-20-2014 |
20140080154 | IMMUNODIAGNOSTIC METHOD FOR DIAGNOSING AUTO-IMMUNE SYSTEMIC SCLEROSIS (SSC) AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - The invention relates to a method for the identification of patients affected by Systemic Sclerosis (SSc) (early, limited cutaneous, diffuse forms) or Systemic Lupus Erythematosus (SLE). Among SSc and SLE patients, this method allows identification of presence of vascular ulcerations in SSc, and Raynaud's phenomenon in SLE, respectively. | 03-20-2014 |
20140080155 | DETECTION OF NGAL IN CHRONIC RENAL DISEASE - Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 03-20-2014 |
20140080156 | MEANS AND METHODS FOR DIAGNOSING AND TREATING MULTIPLE SCLEROSIS - This invention relates to a peptide comprising or consisting of at least 8 consecutive amino acid residues of the sequence set forth in SEQ ID NO: 3, provided that said peptide does not consist of the sequence set forth in SEQ ID NO: 3, or a corresponding peptidomimetic, wherein said peptide or peptidomimetic binds to an anti-KIR4.1 antibody comprised in a sample from a patient, said patient having multiple sclerosis or a predisposition therefor, wherein preferably (i) said at least 8 consecutive amino acid residues are a subsequence of an extracellular domain of KIR4.1, said extracellular domain consisting of the sequence set forth in SEQ ID NO: 1 or 2; or (ii) said peptide comprises or consists of the sequence of SEQ ID NO: 1 or 2. The present invention furthermore relates to a method for diagnosing multiple sclerosis or a predisposition for multiple sclerosis in a subject, the method comprising determining the presence of an anti-KIR4.1 antibody in a sample obtained from said subject, wherein the presence of an anti-KIR4.1 antibody in said sample is indicative of multiple sclerosis or a predisposition for multiple sclerosis. Also provided are novel means and methods for the therapy of multiple sclerosis. | 03-20-2014 |
20140087396 | Health Diagnostic Compact Disc - A modified health diagnostic compact disc (HDCD) comprising (a) a protective layer; (b) a reflective layer; (c) a dye layer (d) a polycarbonate layer; and (e) a micro fluidic layer. In a certain aspect, the polycarbonate layer of the HDCD contains a data layer. The micro fluidic layer of the HDCD is composed of polydimethylsiloxane (PDMS). The micro fluidic layer of the HDCD contains one or more donut-shaped trenches. The micro fluidic layer of the HDCD is associated with conjugated microparticles in solution. The HDCD further comprises integrated microneedles. The modified health diagnostic compact disc can be used by methods of the invention to identify and/or measure the presence of biologic cells utilizing a standard computer compact disk drive. | 03-27-2014 |
20140087397 | BIOMARKERS FOR FANCONI ANEMIA - A method for adjusting therapy given to a patient having cancer by diagnosing Fanconi Anemia (FA), and/or predicting bone marrow failure (BMF) or predicting cancer susceptibility in the patient by determining a level of at least one biomarker. In one embodiment the biomarker is at least one of 3-hydroxyisovalerate, acetate, isopropanol, glycerol-3-phosphocholine, choline, histamine, glutamate, alanine, glycine, isoleucine, lysine, phenylalanine, threonine, tyrosine, vitamin A, vitamin D, cholesterol, ketone bodies, acetone, and/or acetoacetate/acetoacetaldehyde. The biomarker level is assessed in a biological sample obtained from the patient, and an altered level of the biomarker, increased or decreased, compared to a family member not having FA or to a healthy control subject, is indicative of FA and/or predictive of BMF and cancer susceptibility. The information is used to adjust the patient's therapy based on the diagnosis of FA and/or prediction of BMF and cancer susceptibility in the patient. | 03-27-2014 |
20140087398 | OXIDIZED CARDIOLIPIN AND USES TO DETECT CARDIOLIPIN ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies (such as IgG and IgM antibodies) in subjects, for example, when used in ELISA plates. ELISA plates are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples. | 03-27-2014 |
20140087399 | ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS - A method of assaying for peptide-specific T-cells comprises adding peptide to a fluid sample of fresh peripheral blood mononuclear cells, and detecting a cytokine such as interferon-y produced by T-cells that have been pre-sensitised to the peptide. The assay method is quick and cheap and is expected to be useful for the study of various disease states including Hepatitis B, Hepatitis C, tuberculosis, malaria, HIV and influenza. | 03-27-2014 |
20140087400 | DIAGNOSIS AND PROGNOSIS OF TRIPLE NEGATIVE BREAST AND OVARIAN CANCER - In one aspect, the present disclosure provides a method of predicting disease progression comprising: (a) obtaining a sample of breast tissue that is estrogen receptor negative, progesterone receptor negative and does not over-express human epidermal growth factor 2 receptor protein; and (b) determining the expression of glia maturation factor beta, wherein expression of glia maturation factor beta is indicative of lymph node metastatis. In another aspect, the present disclosure provides a method of predicting disease progression comprising: (a) obtaining a sample of breast tissue that is estrogen receptor negative, progesterone receptor negative and does not over-express human epidermal growth factor 2 receptor protein; and (b) determining the expression of glia maturation factor beta, wherein expression of glia maturation factor beta is indicative of an untreated or treated prognosis that is reduced compared to an absence of the expression. | 03-27-2014 |
20140087401 | Biomarkers for Assessment of the Molecular Quality in Biospecimens - The present invention provides compositions and methods for assessing the amount of degradation in a biospecimen. The invention relates to the discovery that dynamic changes in protein biomarkers correlate to the amount of degradation in a biospecimen. The present invention also provides kits for assessing the amount of degradation in a biospecimen. | 03-27-2014 |
20140093892 | MARKER COMPRISING ANTI-CK8/18 COMPLEX AUTOANTIBODY AND ITS USE FOR DIAGNOSING CANCER - The present invention relates to a cytokeratin 8/18 complex-specific autoantibody or a fragment comprising an antigen-binding site (paratope) thereof, the use thereof in the diagnosis of breast cancer, a polypeptide having an amino acid sequence of an epitope specifically binding to the autoantibody, a composition for diagnosing breast cancer comprising an agent capable of measuring an expression level of the autoantibody or the fragment comprising an antigen-binding site thereof, a hybridoma cell line producing the autoantibody, and a kit for diagnosing breast cancer comprising the composition of the present invention. Further, the present invention relates to a method for diagnosing breast cancer, comprising the step of detecting the cytokeratin 8/18 complex-specific autoantibody or the fragment comprising the antigen-binding site thereof using the composition of the present invention, and a method for screening a therapeutic agent for breast cancer using the autoantibody. | 04-03-2014 |
20140093893 | IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING METHOD - An automated in situ heat induced antigen recovery and staining method and apparatus for treating a plurality of microscope slides. The process of heat induced antigen recovery and the process of staining the biological sample on the microscope slide are conducted in the same apparatus, wherein the microscope slides do not need to be physically removed from one apparatus to another. The reaction conditions for treating a slide can preferably be controlled independently, including the individualized application of reagents to each slide and the individualized treatment of each slide. | 04-03-2014 |
20140106378 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS - The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy. | 04-17-2014 |
20140106379 | Immunological Test for Detecting Autoantibodies Against Testicular Antigens - The present invention discloses an immunological test for the detection and specific determination of autoantibodies against testicular antigens which are associated with inflammation-related fertility disorders of male mammals in a biological sample of a male mammal, in particular the detection of testicular ER-60 autoantibodies and/or transferrin autoantibodies. | 04-17-2014 |
20140106380 | METHODS FOR IDENTIFYING INHIBITORS OF ABETA42 OLIGOMERS - The invention herein is directed to immunoassays for the detection of Aβ42 oligomers. The inventive assays are based on the observations herein that the presence of Aβ42 oligomers in a preparation is directly related to a decrease in a C-terminal (CT) immunosignal and a correlated increase in an N-terminal (NT) immunosignal, relative to the immunosignal generated in the absence of Aβ42 oligomers, in an Aβ42 CT and NT ELISA assay and an Aβ42 CT AlphaLISA assay. The invention herein involves the use of these assays alone or in combination to screen for inhibitors of Aβ42 oligomerization. | 04-17-2014 |
20140106381 | METHOD FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS - The present invention refers to the use of citrullinated synthetic peptides for the diagnosis of rheumatoid arthritis (RA). | 04-17-2014 |
20140113317 | POLYCLONAL ANTIBODIES TO CLONED FUNGAL POLYPEPTIDE TARGETS - Described herein are processes for preparing a polyclonal antibody which specifically binds to a cDNA derived fungal allergen. Such antibodies, for example, polyclonal antibodies specific for cloned Alt a | 04-24-2014 |
20140113318 | Novel Biomarkers - Provided herein are, inter alia, methods for predicting the susceptibility of a subject to a mental or neurodegenerative disorder, the method comprising obtaining one or more biological samples from the subject; determining the levels of one or more biomarkers in the sample, wherein the biomarkers are selected from pyrroles, histamine, methionine adenosyltransferase (MAT) activity, homocysteine, copper and zinc; and comparing the level(s) of the biomarker(s) determined in (b) with the level(s) of said biomarker(s) from one or more control samples, wherein abnormal levels of the one or more biomarkers in the sample(s) from the subject compared to the one or more control samples is predictive of susceptibility of the subject to a mental or neurodegenerative disorder. | 04-24-2014 |
20140113319 | METHODS FOR DETERMINING THE RISK OF PRENATAL COMPLICATIONS - The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. | 04-24-2014 |
20140113320 | METHODS FOR DETERMINING THE RISK OF PRENATAL COMPLICATIONS - The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. | 04-24-2014 |
20140120559 | DIABETES PANEL - The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if the level exceeds a predetermined threshold. | 05-01-2014 |
20140120560 | GENERATION OF NEW PANCREATIC BETA CELLS - The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within. | 05-01-2014 |
20140120561 | ANTIBODY SPECIFICALLY BINDING TO INSULIN-LIKE GROWTH FACTOR-1 - Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample. | 05-01-2014 |
20140120562 | METHODS FOR THE PROGNOSTIC AND/OR DIAGNOSTIC OF NEURODEGENERATIVE DISEASE, METHODS TO IDENTIFY CANDIDATE COMPOUNDS AND COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASE - The present invention provides methods and uses for the diagnostic of a subject predisposed or suspected of developing a neurodegenerative disease or suffering from a neurodegenerative disease. The present invention also relates to methods and uses for identifying candidate compounds and to compounds for treating neurodegenerative disease. The present invention also relates to an animal model for neurodegenerative disease. | 05-01-2014 |
20140127719 | DETECTION OF ANALYTES - The present disclosure relates to a one-step immunoassay, in which a solid substrate is pre-coated with an immobilisation agent, and whereby the capture agent, the analyte and the detection agent are added to the solid substrate together, followed by a wash step prior to detection. Methods and kits for detecting an analyte in a sample are disclosed. The capture agent can bind the analyte and comprises a ligand for an immobilisation agent. Certain embodiments are directed to antibody capture agents and/or antibody detectable agents. Certain embodiments are directed to a ligand comprising a peptide tag and an immobilisation agent comprising an anti-peptide tag antibody. Certain embodiments are directed to detection of more than one analyte. | 05-08-2014 |
20140127720 | HUMAN AUTOANTIBODIES SPECIFIC FOR PAD3 WHICH ARE CROSS-REACTIVE WITH PAD4 AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED DISEASES - In one or more embodiments, the present invention provides a novel biomarker which provides a link between a distinct clinical phenotype and a biochemical effect of an autoantibody on an enzyme implicated in disease pathogenesis. In particular, the present invention provides an isolated or purified human autoantibody to PAD3 protein. Methods of diagnosis of subjects for rheumatoid arthritis (RA) using these antibodies as well as diagnosis of the severity of RA in the subject, and methods for monitoring treatment of a subject with RA are also provided. The biomarkers provided herein are also useful in the diagnosis of connective tissue-interstitial lung disease (CT-ILD) in patients having or suspected of having RA. | 05-08-2014 |
20140127721 | Immunoreactive Protein Orthologs of Ehrlichia canis and E. chaffeensis - The present invention concerns gp36 immunoreactive compositions for | 05-08-2014 |
20140127722 | MOLECULAR ARCHITECTURE ON MAGNETIC PARTICLES FOR AFFINITY ASSAYS WITH LOW NON-SPECIFIC BINDING - The present invention relates to a coating for preventing non-specific binding of molecules to a surface layer comprising an affinity molecule, said coating comprises single layer comprising non-affine spacer molecules forming a mesh; or a shell structure, wherein said shell structure comprises a first layer comprising one or more affinity molecules and further a second layer, which is coupled to the first layer, and wherein said first and second layer comprise non-affine spacer molecules forming a mesh. The present invention further relates to a particle, a flat structure or a matrix comprising such a coating. In a further aspect the present invention relates to the use of the coating, coated particle, coated flat structure or coated matrix for detection and/or purification of a specific target biomolecule from a sample and/or determination of the concentration of the specific target biomolecule. The present invention further relates to an assay for the detection of specific target biomolecules from a sample and/or determination of the concentration of specific target biomolecules comprising the use of such coating, coated particle, coated flat structure or coated matrix, in particular coated nanoparticles. | 05-08-2014 |
20140127723 | METHOD FOR DETERMINING RISK OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention provides a method of determining a risk for amyotrophic lateral sclerosis (ALS) in a subject, comprising the following steps: (1) measuring a concentration of an autoantibody against HMGB1 in a biological sample from the subject; and (2) comparing the measured concentration of the autoantibody against HMGB1 with a control value for autoantibody against HMGB1; wherein a difference between the measured concentration of the autoantibody against HMGB1 from the biological sample and the control value for autoantibody against HMGB1 is indicative of the risk of ALS in the subject. | 05-08-2014 |
20140127724 | System and Method for Quantifying Fragile X Mental Retardiation 1 Protein in Tissue and Blood Samples - A system and method for the detection and quantification of fragile X mental retardation protein (FMRP) in human tissue and blood samples. The system includes several high avidity monoclonal antibodies that may be provided on Xmap microspheres to capture FMRP from a tissue or blood specimen. The resulting complex is reacted with a polyclonal anti-FMRP rabbit antibody and then mixed with an anti-rabbit IgG antibody conjugated to phycoerythrin. Fluorescence emitted from the resulting complex is a function of the amount of FMRP present in the specimen. | 05-08-2014 |
20140134650 | INDUCED INTERCELLULAR COMMUNICATION - The present invention provides an approach for the determination of the activation state of discrete cell populations and/or the state of one or more cellular networks in an individual, when modulated with a modulator that acts on one cell population to communicate with other cell populations in the network. The status of discrete cell populations and/or the state of one or more cellular networks can be correlated with the diagnosis, prognosis, choice or modification of treatment, and/or monitoring of a condition, and with screening of agents. | 05-15-2014 |
20140134651 | Stable Discrete PEG Based Peroxidase Biological Conjugates - Disclosed is an analytical composition of a peroxidase discrete polyethylene glycol (PEG) conjugate, which conjugate is capable of providing a detectable condition in the presence of peroxidase and hydrogen peroxide. | 05-15-2014 |
20140134652 | Methods of and Systems for Improved Detection Sensitivity of Assays - Systems and methods are disclosed for improved detection sensitivity of assays. The systems include an upper plate that is inserted into a well of testing well, such as a base microtiter plate. For bottom detection, a coating, including polymer coatings or membrane coatings, is applied to an insert portion of the upper plate, and the base plate includes transparent windows. In bottom detection, a detector will image from below the base plate. Alternatively, for top detection, the coating is applied to the well of the base plate, and the upper plate includes transparent windows. In top detection, a detector will image from above the upper plate. Analysis features, including capture antibody features or antigen features, can be printed on the coating surface for forward-phase assays or reverse-phase assays, respectively. Methods for making and using the same are disclosed. | 05-15-2014 |
20140134653 | Calibrating Assays Using Reaction Time - A method for performing an assay on a liquid sample for the detection of one or more analytes of interest in an assay device having a flow path which includes a sample zone and detection zone thereon includes: dispensing the sample onto the sample zone; combining the sample and a reagent, wherein the sample and reagent may be combined prior to addition of the sample to the sample zone or on the assay device, flowing the combined sample/reagent by capillary action into and through the detection zone having capture elements bound thereto, wherein a signal at least partially representative of the presence or concentration of analyte(s) is produced and detected; determining a reaction time or reaction volume; and determining the concentration of the analyte by using both the detected signal and the reaction time or reaction volume. | 05-15-2014 |
20140141456 | PAPP-A2 AS A MARKER FOR MONITORING, PREDICTING AND DIAGNOSING PREECLAMPSIA - PAPP-A2 is used as a marker for monitoring, predicting and diagnosing preeclampsia in pregnant women. PAPP-A2 levels in pregnant women with preeclampsia are higher than PAPP-A2 levels in normal pregnant women. This is especially true of PAPP-A2 levels that are measured later on in the pregnancy. PAPP-A2 levels may be measured early in pregnancy in order to predict the likelihood of the patient having preeclampsia. Preeclampsia may also be diagnosed at later gestational ages when the levels of PAPP-A2 are more pronounced than normal PAPP-A2 levels at the same gestational age. The present invention relates to methods of assessing, predicting and diagnosing preeclampsia as well as a kit-of-parts for assessing, predicting and diagnosing preeclampsia. | 05-22-2014 |
20140141457 | DETECTION KIT CONTAINING A NOVEL RECOMBINANT 15-kDA POLYPEPTIDE USEFUL FOR DETECTING HUMAN INFECTION WITH BARTONELLA HENSELAE - Disclosed are the cloning and expression of a novel antigen of | 05-22-2014 |
20140141458 | ASSAY REAGENTS FOR A NEUROGRANIN DIAGNOSTIC KIT - The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin. | 05-22-2014 |
20140147863 | METHODS AND DEVICES FOR DIAGNOSING ALZHEIMERS DISEASE - Methods and devices for predicting, diagnosing, monitoring, or determining Alzheimer's disease in a human are described. In particular, methods and devices for predicting diagnosing, monitoring, or determining AD using measured concentrations of a combination of three or more analytes in a test sample taken from the human are described. | 05-29-2014 |
20140147864 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Proheparin-binding EGF-like growth factor, Tenascin C, Angiopoietin-related protein 4, Fibroblast growth factor 19, Fibroblast growth factor 21, Heparin-binding growth factor 1, Angiopoietin-related protein 6, Proepiregulin, Probetacellulin, Amphiregulin, Angiogenin, Thrombospondin-2, and Collagen alpha-1 (XVIII) chain as diagnostic and prognostic biomarkers in renal injuries. | 05-29-2014 |
20140147865 | METHODS FOR DIAGNOSING DEGENERATIVE JOINT DISEASE - The invention provides methods for diagnosing degenerative joint disease in an animal by collecting a saliva sample from an animal; determining the amount of at least one diagnostic agent selected from the group consisting of interferon gamma, interferoninducible protein-10, interleukin-2, and total saliva protein in the saliva sample; comparing the amount of diagnostic agent found in the saliva sample to a corresponding amount of the same diagnostic agent found in a saliva sample from one or more comparable control animals that do not suffer from degenerative joint disease; and diagnosing that the animal is susceptible to or suffering from degenerative joint disease if the amount of diagnostic agent in the saliva sample from the animal is greater than the amount of same diagnostic agent found in the saliva sample from the one or more comparable control animals. | 05-29-2014 |
20140147866 | COMPOUND FOR INHIBITING SNAIL-P53 BINDING AND THERAPEUTIC AGENT FOR CANCER INCLUDING THE COMPOUND AS EFFECTIVE COMPONENT - Provided are compounds for inhibiting Snail-p53 binding and therapeutic agents for cancer including the compounds as an effective component. The Snail-p53 binding inhibitors induce expression of p53 in K-Ras mutant cell lines, thereby enabling effective treatment or prevention of K-Ras mutant cancer, such as, pancreatic cancer, lung cancer, cholangioma, and colon cancer, of which diagnosis or treatment is not easy. | 05-29-2014 |
20140154705 | ANTIBODIES TO OXIDIZED LDL - A method is described for obtaining antibodies binding specifically to an epitope resulting from in vivo modification of a biomolecule or biomolecular complex, where the in vivo modification results from expression of a transgene in an animal. An example of such a biomolecule or biomolecular complex is LDL and an example of such a transgene is human myeloperoxidase. Resulting antibodies and methods of using the antibodies are also described. | 06-05-2014 |
20140154706 | Compounds and Methods for Determination of FKBP-Binding Immunosuppressant Drugs - Compositions are disclosed for releasing an FKBP-binding immunosuppressant drug from endogenous binding substances in a sample suspected of containing the FKBP-binding immunosuppressant drug. The compositions include sirolimus derivatives that are modified with a bulky organic radical in the triene portion of the sirolimus molecule. The compositions may be employed in conjunction with assays for an FKBP-binding immunosuppressant drug in a sample suspected of containing the drug. | 06-05-2014 |
20140154707 | N-GLYCOSYLATION IN TRANSFORMED PHAEODACTYLUM TRICORNUTUM - Transformed | 06-05-2014 |
20140154708 | REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample. | 06-05-2014 |
20140154709 | METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF - The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma. | 06-05-2014 |
20140154710 | GLYCOPROTEIN CANCER BIOMARKER - The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics. | 06-05-2014 |
20140154711 | DETECTION OF DEFENSINS TO DIAGNOSE CANCER - Non-invasive methods of detecting and providing an early diagnosis of cancer, in particular breast cancer are provided herein. The methods include obtaining a sample, suitably an ocular wash sample, from a subject and determining the level of α-Defensin 1, α-Defensin 2 and/or α-Defensin 3 in the sample. Increased levels of any of these proteins as compared to a negative control or non-cancerous subject are indicative of cancer in the subject from which the sample was obtained. Kits for performing the methods described herein are also provided. | 06-05-2014 |
20140154712 | ASSAY OF CELL MEDIATED IMMUNE RESPONSIVENESS - This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management. | 06-05-2014 |
20140154713 | ASSAY METHOD USING MAGNETIC SILICA PARTICLES AND REAGENT FOR SAID ASSAY METHOD - In the method of assaying an analyte in a sample of the present invention, magnetic silica particles are used. The magnetic silica particles include: silica particles containing 60 to 95% by weight of a superparamagnetic metal oxide that has an average particle size of 1 to 15 nm; and the analyte, an analog of the analyte, or a substance capable of specifically binding to the analyte immobilized on the surface of the silica particles. | 06-05-2014 |
20140154714 | Detection of Intraamniotic Infection - The present invention concerns the identification of biomarkers and groups or combinations of biomarkers that can be used for non-invasive diagnosis of intra-amniotic infection, and diagnostic assays using such biomarkers. | 06-05-2014 |
20140154715 | MONOCLONAL ANTIBODIES SPECIFIC FOR BETA-AMYLOID X-37 AND USES THEREOF - The present invention provides monoclonal antibodies which specifically recognize the shorter Aβ peptides obtained after cleavage of the APP protein mediated by γ-secretase, i.e. the Aβ-peptide fragments Aβ1-37, Aβ3-37, Aβ3p-37, Aβ1-37 and Aβ11p-37, and other like fragments ending at the 37 | 06-05-2014 |
20140162294 | METHODS AND COMPOSITIONS FOR ASSAYING VITAMIN D - The present invention provides methods for assaying a vitamin D moiety in a sample, using a water miscible organic solvent, a specific binding partner that specifically binds to said vitamin D moiety, the binding partner being different from a natural vitamin D binding protein for the vitamin D moiety, and a water soluble polymer that facilitates binding between the specific binding partner and the vitamin D moiety. Kits and reaction mixtures for assaying a vitamin D moiety in a sample are also provided. | 06-12-2014 |
20140162295 | Method and Biomarker for Detecting of Acute Kidney Injury - A method and a biomarker for detecting of acute kidney injury is provided, wherein the method of the present comprises the following steps: detecting a soluble form of hemojuvelin in a sample obtained from a subject, wherein when the soluble form of hemojuvelin is present in the sample, the subject is identified as having acute kidney injury. | 06-12-2014 |
20140162296 | Novel Read-Through Fusion Polynucleotides and Polypeptides and Uses Thereof - The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts. | 06-12-2014 |
20140162297 | ANTI-CARBAMYLATED PROTEIN ANTIBODIES AND THE RISK FOR ARTHRITIS - Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis. | 06-12-2014 |
20140170682 | BIOMARKERS OF IONIZING RADIATION - The present invention provides novel radiation associated markers. The radiation associated markers may be one or more of albumin, LTGF-β, or any protein or peptide listed in any one of Tables 1, 2, 3, 4, 5, and 6 provided herein. The present invention also provides methods of assessing exposure to ionizing radiation by determining the presence of one or more radiation associated markers. The methods may optionally include quantifying one or more of the radiation associated markers. The methods may further include comparing the amount of one or more radiation associated markers in the sample determined to be present in the sample with either (i) the amount determined for temporally matched, normal samples or (ii) the amount determined for samples obtained from individuals or subjects that have not been exposed to an elevated level of ionizing radiation. | 06-19-2014 |
20140170683 | CITRULLINATED PEPTIDES FOR DIAGNOSING AND PROGNOSING RHEUMATOID ARTHRITIS - The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided. | 06-19-2014 |
20140170684 | Methods, Devices, Kits and Compositions for Detecting Roundworm - Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated. | 06-19-2014 |
20140170685 | BIOMARKER OF ASBESTOS EXPOSURE AND MESOTHELIOMA - Several embodiments provided herein relate to methods of diagnosing asbestos exposure or mesothelioma. Several embodiments also relate to methods of differentiating whether a tumor of the lung is lung cancer or mesothelioma. | 06-19-2014 |
20140178903 | DETERMINATION OF LEVELS OF IMMUNOGENIC GLUTEN PEPTIDES IN HUMAN SAMPLES - The present invention, fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of said immunogenic peptides is controlled by immunological assays based on reactive antibodies against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques as ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease, in cases in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification. | 06-26-2014 |
20140178904 | Biochemical Markers of Red Blood Cell Storage and Toxicity - Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided. | 06-26-2014 |
20140178905 | ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS - Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics. | 06-26-2014 |
20140178906 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens. | 06-26-2014 |
20140178907 | Treponema Pallidum Triplet Antigen | 06-26-2014 |
20140186860 | NOVEL IMMUNOGENIC PROTEINS OF LEPTOSPIRA - The invention provides novel immunogenic proteins LigA and LigB from | 07-03-2014 |
20140186861 | SOLUBLE TREPONEMA PALLIDUM PROTEIN TP0453, TP0453-TP0326 FUSION PROTEIN, AND USE IN SYPHILIS DIAGNOSIS - The present application provides methods of producing soluble | 07-03-2014 |
20140186862 | SYSTEMS AND METHODS FOR DETERMINING THE PERCENTAGE OF GLYCATED HEMOGLOBIN - Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample. | 07-03-2014 |
20140186863 | METHOD FOR DETECTING PANCREATIC DISEASE MARKER - The present invention relates to a method for detecting a marker for pancreatic disease for obtaining highly reliable results while reducing the risk of complications. It also relates to a method for a detecting a marker for pancreatic disease comprising: measuring the concentration of a marker for pancreatic disease in duodenal juice that is collected from a subject and contains spontaneously discharged pancreatic juice, by a measurement method including detecting antigen or antibody immobilized on a solid phase using an antigen-antibody reaction, and the aforementioned method for detecting a marker for pancreatic disease further including judging the subject to have the possibility of being afflicted with a pancreatic disease in the case the concentration of the marker for pancreatic disease is equal to or greater than a prescribed threshold value. | 07-03-2014 |
20140193838 | METHOD FOR MEASURING SIALIC ACID IN IMMUNOGLOBULIN G AND IMMUNOGLOBULIN G ANTI-DOUBLE-STRANDED DNA ANTIBODIES - A method for measuring the amount of sialic acid in immunoglobulin G and immunoglobulin G anti-ds DNA antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin G in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin G. Also, using a mouse monoclonal antibody immunoglobulin G as a standard, which is diluted from 1000 ng/ml to 15.625 ng/ml in phosphate buffered saline (PBS), produces good results. The method for measuring the amount of sialic acid in immunoglobulin G anti-ds DNA antibodies has never been done and the present invention produces good results as well. | 07-10-2014 |
20140193839 | Smartphone Biosensor - A mobile computing device that includes an image sensor may be used to detect the result of a biomolecular assay. The biomolecular assay may be performed in an optical assay medium that provides an optical output in response to light from a light source, with the optical output indicating result. A wavelength-dispersive element may be used to disperse the optical output into spatially-separated wavelength components. The mobile computing device may be positioned relative to the wavelength-dispersive element such that different wavelength components are received at different locations on the image sensor. With the mobile computing device positioned in this way, the image sensor may be used to obtain one or more images that include the separated wavelength components of the optical output. A wavelength spectrum of the optical output may be determined from the one or more images, and the result may be determined from the wavelength spectrum. | 07-10-2014 |
20140193840 | CHROMATOGRAPHY FILTER PAPER-BASED ELISA - A chromatography filter paper-based ELISA includes following steps: providing a chromatography filter paper plate provided with a plurality of independent hydrophilic regions defined by at least one hydrophobic region; immobilizing an antigen of a sample onto one of the hydrophilic regions of the chromatography filter paper plate; and detecting the antigen with an ELISA process, wherein an antibody used in the ELISA process is a monoclonal antibody. The present invention has advantages in lower amount of loaded sample, higher sensitivity and rapid analysis in comparison to conventional ELISA. | 07-10-2014 |
20140193841 | FLUOROGENIC SEMICONDUCTOR NANOCRYSTALS - Fluorogenic semiconductor nanocrystals and compositions thereof are provided herein, including kits, assay systems and methods for their preparation and use. | 07-10-2014 |
20140193842 | NON-SPECIFIC REACTION INHIBITOR, METHOD FOR INHIBITING NON-SPECIFIC REACTION, AND KIT - Provided is a non-specific reaction inhibitor for achieving the accurate detection and quantitation of a trace component (a target substance) contained in a sample, in an immunoassay, by simply and effectively inhibiting a non-specific reaction associated with the measurement. | 07-10-2014 |
20140193843 | USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER - The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use. | 07-10-2014 |
20140193844 | Biomarkers for Ankylosing Spondylitis - There is described herein methods and peptides for detecting autoantibodies to NOG and/or SOST in a patient sample in order to diagnose of prognosticate Ankylosing Spondylitis in the patient. | 07-10-2014 |
20140206021 | PRION PROTEIN LIGANDS AND METHODS OF USE - Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject | 07-24-2014 |
20140206022 | THREE-DIMENSIONAL CELL CULTURE METHODS FOR TEST MATERIAL ASSESSMENT OF CELL DIFFERENTIATION - The present specification discloses three-dimensional in vitro cell-based methods to assess a test matrix polymer ability to support differentiation of a population of cells methods of screening a material for its ability to stimulate cell growth and/or differentiation. | 07-24-2014 |
20140206023 | Methods, Kits & Antibodies for Detecting Intact Fibroblast Growth Factor 21 - Disclosed are methods, compositions and kits related to immunoassays for detection of FGF21 using antibodies specific to the N-terminal and/or C-terminal of FGF21. The present invention provides antibodies specific to N-terminal or C-terminal peptide of FGF21. Also provided are immunoassays for specifically measuring intact FGF21 or FGF21 with an untruncated N- or C-terminal region. | 07-24-2014 |
20140212897 | METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY - The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample. | 07-31-2014 |
20140212898 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to | 07-31-2014 |
20140212899 | METHOD FOR NONINVASIVE PREDICTION OR DIAGNOSIS OF INFLAMMATION AND INFECTION IN AMNIOTIC FLUID OF PATIENTS WITH PREMATURE RUPTURE OF MEMBRANES - Provided is a method for noninvasive prediction or diagnosis of inflammation and/or infection in amniotic fluid leaked through the cervix into the vagina to predict the concentration of inflammatory markers in the amniotic fluid inside uterus by measuring the concentration of inflammatory markers (various cytokines). Further provided is a method for prediction or diagnosis of inflammation and/or infection in amniotic fluid by measuring the concentration of markers (IL-6, IL-1β IL-8, MCP-1, GRO-α) in the amniotic fluid leaked through the cervix into the vagina in patients with premature rupture of membranes. The method can be performed more stably on pregnant women, as compared to the conventional method for prediction or diagnosis of inflammation and/or infection using invasively collected amniotic fluid. | 07-31-2014 |
20140220601 | CELL MEDIATED IMMUNE RESPONSE ASSAY WITH ENHANCED SENSITIVITY - This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity. Lymphocytes from a subject are contacted with at least a first set of peptides comprising at least one peptide of from 7 to 14 amino acid residues in length and a second set comprising at least one peptide of 16 amino acid residues or greater and the presence or elevation of an immune molecule is detected. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management. | 08-07-2014 |
20140220602 | VACCINIA VIRUS POLYPEPTIDES - This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., polypeptides that can be isolated from naturally processed and presented class I polypeptides originating from vaccinia virus, a member of the Orthopoxvirus family). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided. | 08-07-2014 |
20140220603 | COMPOSITIONS AND METHODS FOR DETECTING MICROBIAL INFECTIONS - Provided herein are vaccine compositions for control of | 08-07-2014 |
20140220604 | TROPONIN AND BNP BASED DIAGNOSIS OF RISK PATIENTS AND CAUSE OF STROKE - Method for early differentiation of whether a subject suffers from cardioembolic stroke or from non-cardioembolic ischemic stroke based on the determination of the amount of a cardiac Troponin in a sample from a subject who is suffering from ischemic stroke, the sample obtained not more than 24 hours after the onset of symptoms of ischemic stroke. Kits and devices adapted to carry out the methods are also provided. | 08-07-2014 |
20140220605 | VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA SPECIES AND STRAINS - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic | 08-07-2014 |
20140234871 | METHOD OF EXTRACTION OF AN ENZYME FROM PLANT OR ANIMAL TISSUE - This invention provides a method for the extraction and detection of a peptide from transgenic plant tissues wherein a non-immunogenic solubility-promoting compound is used to release the enzyme into the solution fraction during the purification process. In some embodiments, this invention provides a method for the extraction and detection of the enzyme Amy797E, which is a heterologous thermo-tolerant α-amylase, from the tissues of corn event 3272 using a non-immunogenic amylase during the purification process. This invention allows for a limit of detection of 1:1000 of Amy797E in an enzyme-linked immunosorbent assay (ELISA). | 08-21-2014 |
20140234872 | TARGET OF THE PHOSPHOINOSITIDE 3-KINASE PATHWAY - The present disclosure generally relates to tyrosine phosphorylation sites of an Akt enhancer, and methods for the detection of the phosphorylated tyrosine residues. In particular, anti-phosphotyrosine antibodies and binding proteins find use in the compositions and methods of the present disclosure. | 08-21-2014 |
20140234873 | APPARATUS FOR PROCESSING A SAMPLE IN A LIQUID DROPLET AND METHOD OF USING THE SAME - A device for processing a sample in a liquid droplet containing a hydrophilic liquid is described. The device includes: a circumferential wall and a base including an immobilisation member. The circumferential wall and the base define a reservoir adapted to accommodate a hydrophobic medium immiscible with the liquid droplet. The medium is of a lower surface energy than a liquid of the liquid droplet. The immobilisation member includes a surface with a plurality of hydrophilic immobilisation areas and a hydrophobic area. The plurality of hydrophilic immobilisation areas is: (a) of a higher surface energy than the medium, (b) of a higher surface energy than the hydrophobic area, and (c) of a sufficient surface energy and a sufficient width to allow, in the medium, immobilisation of liquid droplets on the hydrophilic immobilisation areas via interfacial interactions. Methods of using and rinsing the device are also described. | 08-21-2014 |
20140234874 | COMPOSITIONS AND METHODS FOR IN VITRO DIAGNOSTIC TESTS INCLUDING SULFONIC ACID - The invention provides compositions, kits, and methods for performing colorimetric analysis. A substrate is reacted to generate a chromogenic reaction product, and a reaction stop reagent that is a sulfonic acid is added to stop and stabilize the reaction product. The absorbance properties of the chromogenic reaction product can be maintained over significantly longer periods of time of that of conventional reagents and methods. The sulfonic acid can be used in assays such as ELISAs in order to provide a more accurate and safer detection of analytes in a biological sample. | 08-21-2014 |
20140234875 | Methods Predicting Risk of an Adverse Clinical Outcome - Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject. | 08-21-2014 |
20140234876 | Method And System For Detection Of Natural High Intensity Sweeteners That Contain Hydroxyl Groups - The present invention provides a hapten derivative and conjugate of a natural high intensity sweetener containing hydroxyl groups. The conjugate can be used to produce antibodies specific against the natural high intensity sweetener. The present invention further provides a kit and method for detecting and quantifying the natural high intensity sweetener in a sample. | 08-21-2014 |
20140234877 | METHOD FOR DETECTING A BETA-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE - Disclosed is a method for detecting Aβ-specific antibodies in a biological sample comprising the following steps:—contacting the sample with Aβ-aggregates or with particles comprising Aβ-aggregate like surfaces and allowing the Aβ-specific antibodies to bind to the Aβ-aggregates, and -detecting the Aβ-specific antibodies bound to the Aβ-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting FACS. | 08-21-2014 |
20140242614 | MAGNETIC AGGREGATING AND WASHING DEVICE FOR IN VITRO ASSAYS AND METHODS OF USE THEREOF - Provided herein are magnetic aggregating and washing devices. Further provided herein are methods using magnetic aggregation to aggregate and wash sample molecules in an in vitro assay. | 08-28-2014 |
20140242615 | Methods and Reagents for Determining Isomeric Analytes - Methods include determining in a sample an amount of a first isomeric analyte and a second isomeric analyte. A first measurement value and a second measurement value are determined. The first measurement value represents a total amount of the first isomeric analyte and the second isomeric analyte. The second measurement value represents an amount of the second isomeric analyte only. The second measurement value is subtracted from the first measurement value to obtain a resulting value and the resulting value is equated to an amount of the first isomeric analyte in the sample. | 08-28-2014 |
20140242616 | FREE NGAL AS A BIOMARKER FOR CANCER - Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer. | 08-28-2014 |
20140242617 | Immunoassay for Detecting Kratom, its Constituents and their Use - The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites. | 08-28-2014 |
20140242618 | Ritalinic Acid Immunoassay - The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies. | 08-28-2014 |
20140242619 | EQUINE PARASITE DETECTION - The present invention provides a method of diagnosing a | 08-28-2014 |
20140242620 | METHOD OF INHIBITING NON-SPECIFIC BINDING IN STEP OF DETECTING SUBSTANCE IN BIOLOGICAL SAMPLE, AND AGENT FOR USE IN THE METHOD - The present invention provides a method of inhibiting non-specific binding in a step of detecting a substance in a biological sample. The invention provides a method of inhibiting non-specific binding in a step of detecting a substance in a biological sample, the method comprising:
| 08-28-2014 |
20140248640 | METHODS FOR TESTING AN IMMUNE RESPONSE USING CULTURES OF T CELLS, B CELLS, DENDRITIC CELLS AND FOLLICULAR DENDRITIC CELLS - The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising T cells, B cells and antigen-primed dendritic cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. | 09-04-2014 |
20140248641 | CLONED GLUCAGON-LIKE PEPTIDE-2 RECEPTORS - The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications. | 09-04-2014 |
20140248642 | APPARATUS AND METHOD FOR LATERAL FLOW AFFINITY ASSAYS - The invention provides apparatus for the quantitative analysis of an analyte in a sample, comprising (i) a solid phase; and (ii) a detector, wherein the surface of the solid phase comprises (a)a first position for sample application, and (b)a second position, distant from the first position, wherein a first molecule that binds to the analyte and is capable of releasing a detectable species is either deposited at the first position or is added to the sample prior to application to the LF membrane, and wherein a second molecule that binds to the analyte is immobilised at the second position, and wherein an enzyme is immobilised, co-located with the immobilised molecule at the second position, and wherein the detector is located in close proximity to the immobilised molecule at the second position. | 09-04-2014 |
20140255955 | METHOD OF DIAGNOSING SJOGREN'S DISEASE - Provided are methods and compositions for determining whether an individual has Sjögren's disease (SD). The method entails determining in a biological sample from the individual the presence of antibodies directed to salivary gland protein 1 (SP-1), parotid secretory protein (PSP), carbonic anhydrase 6 (CA6), or determining a combination of the antibodies. Determining that the individual has SD is based on the presence of the antibodies. The method provides for detection of early SD. Kits for antibody detection containing the antigens to which the antibodies of SD patients are directed are also provided. | 09-11-2014 |
20140255956 | DIAGNOSIS OF MYOCARDIAL AUTOIMMUNITY IN HEART DISEASE - Provided herein are, inter alia, methods of diagnosing myocardial autoimmunity in subjects by detecting the presence of autoantibodies to cardiac antigens in the subjects. | 09-11-2014 |
20140255957 | Antigens Derived from Citrullinated 14-3-3 and Uses Thereof in the Diagnosis of Rheumatoid Arthritis - The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis. | 09-11-2014 |
20140273022 | BIOMARKERS FOR DETECTING THE PRESENCE OF BACTERIA - In some aspects, provided are methods relating to the use of bacterial N-methyl-2 superfamily proteins as a biomarker for the presence of bacteria in a sample. The invention also relates to novel methods of diagnosis of the presence of bacteria in a liquid or solid sample, detection of bacterial infections in humans or animals, and use of antibodies or other specific binding molecules capable of binding to N-methyl-2 superfamily proteins. | 09-18-2014 |
20140273023 | GEMCITABINE IMMUNOASSAY - The present invention comprises novel analogs of gemcitabine and novel gemcitabine immunogens teased out of, i.e., derived from, the 5′-hydroxy position of gemcitabine. The invention also comprises unique monoclonal antibodies generated using gemcitabine linked immunogens as well as unique conjugates and tracers which antibodies, conjugates, and tracers are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids. | 09-18-2014 |
20140273024 | SYSTEM AND METHOD FOR DETERMINING RISK OF DIABETES BASED ON BIOCHEMICAL MARKER ANALYSIS - A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM. | 09-18-2014 |
20140273025 | SYSTEM AND METHOD FOR DETERMINING RISK OF PRE-ECLAMPSIA BASED ON BIOCHEMICAL MARKER ANALYSIS - A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing pre-eclampsia. | 09-18-2014 |
20140273026 | Methods for Detecting Ehrlichia Infection - The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against | 09-18-2014 |
20140273027 | Serological Methods and Diagnostic Tests for Syphilis Antibodies - A non-treponemal diagnostic test for syphilis infection includes initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin, permitting a volume of the antigen solution to evaporate in place within a container, rinsing the coated container with buffered saline, stabilizing the antigen coating by overcoating the antigen coating with an inert protein dissolved in buffered saline, decanting the overcoat solution, air-drying the container, and sealing the container in vapor-proof pouches with desiccant, providing an enzyme-labeled conjugate component of a syphilis infection test that is formulated to be compatible with a lipid nature of the cholesterol, the cardiolipin, and the lecithin VDRL antigens, providing a sample diluent that is formulated to be compatible with the lipid nature of the VDRL antigens, and providing a wash fluid that is formulated to be compatible with the lipid nature of the VDRL antigens. | 09-18-2014 |
20140273028 | PREGNANCY TESTING - A method of determining the stage (gestation) of a pregnancy—comprising the steps of quantifying the amount of the hormone hPL or a fragment thereof in a body fluid sample derived from a human female selected from a blood, plasma, serum and/or urine sample, and establishing the stage of pregnancy corresponding thereto. The disclosure also extends to a device adapted to detect the levels/amount of hPL or a fragment thereof in a body fluid sample, derived from a human female, selected from a blood, plasma, serum and/or urine sample, for establishing the stage of pregnancy. | 09-18-2014 |
20140273029 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNOASSAYS - Embodiments of the methods, compositions, and systems provided herein relate to enzymatic enhancement of immunoassays using photonic sensor arrays. | 09-18-2014 |
20140273030 | HUMAN BIOMARKER TEST FOR MAJOR DEPRESSIVE DISORDER - Materials and methods related to diagnosing depression disorders, using a multi-parameter biomarker system and algorithms related thereto. | 09-18-2014 |
20140273031 | IN-VITRO METHOD FOR MONOCLONAL ANTIBODY PRODUCTION - A method of producing an IgG type monoclonal antibody in vitro is described. The method includes the steps of: (A) providing B-cells obtained from a transgenic non-human mammal whose genome comprises a disruption of an Act1 gene; (B) contacting the B cells with an antigen under conditions which result in formation of an antibody specific to the antigen by the B cells; (C) fusing the B cells with one or more immortal cells, to produce one or more hybridomas which express IgG type monoclonal antibodies that specifically bind to the antigen; (D) selecting a hybridoma which expresses an antibody specific to the antigen; and (E) obtaining monoclonal antibody produced by the selected hybridoma. Kits for carrying out the method of producing an IgG type monoclonal antibody are also described. | 09-18-2014 |
20140273032 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OF SCHIZOPHRENIA - Provided is a method for diagnosis of schizophrenia, which comprises: detecting G72 gene product in a body fluid sample from a subject by an assay to determine G72 expression level; comparing said G72 expression level to a baseline G72 expression; and relating the G72 expression level to the patient's risk of schizophrenia by assigning an increased risk of schizophrenia when said G72 expression level is greater than said baseline G72 expression. Through detecting G72 expression level in a peripheral sample, the method can be simply performed by an in vitro assay and accurately predict or diagnose a subject with schizophrenia. | 09-18-2014 |
20140273033 | BIOMARKERS FOR MULTIPLE SCLEROSIS - Described is the diagnosis of neurological disorders, more specifically, the diagnosis of multiple sclerosis. A biomarker panel is provided that can be used to detect if a subject has multiple sclerosis. Also described are methods of identification of such biomarkers. | 09-18-2014 |
20140287440 | Melittin Peptide Conjugates and Methods Employing Same - Methods and reagents are disclosed for conducting assays for IgE specific for honey bee venom allergen. A reagent comprises a conjugate of a small molecule linked to a terminal glycine amino acid of a synthetic 26 amino acid melittin peptide. In the method a combination is provided that comprises a sample and the aforementioned reagent. The combination is subjected to conditions for binding of IgE specific for honey bee venom allergen to the reagent to form a complex. One or both of the presence and amount of the complex is detected and related to one or both of the presence and amount in the sample of IgE specific for honey bee venom allergen. | 09-25-2014 |
20140287441 | IMMUNOASSAY FOR CYCLOPROPYLINDOLE BASED SYNTHETIC CANNABINOIDS, METABOLITES AND DERIVATIVES THEREOF - The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites. | 09-25-2014 |
20140287442 | METHOD FOR DETERMINING DEGREE OF MODIFIED POTENCY OF BIPATHIC MEDICAMENT - The invention comprises a method for determining degree of modified potency of a bipathic medicament. A bipathic medicine is a medicament comprising a therapeutic component and a homeopathic component, wherein the homeopathic component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated-potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form. Further, the claimed analytical measurement of at least one characteristic parameter of the therapeutic form prior to its interaction with the activated-potentiated form and again after such interaction serves to quantify the degree of modifying potency associated with the activated-potentiated form in relative dimensionless activity units (release activity). | 09-25-2014 |
20140287443 | CHARACTERIZATION OF CHO-MIF GENE AND PROTEIN, AND USE THEREOF - The present invention is concerned with the specific and highly sensitive detection of specific CHO-MIF (macrophage migration inhibitory factor from Chinese Ovarian Hamster cell line) complexes in the production of anti-MIF antibodies. The present invention is further concerned with the provision of specific antibodies which can be used for a CHO-MIF detection method. The present invention is also concerned with a CHO MIF knockout cell line and use thereof. The present invention also provides preparations obtained from recombinant production in CHO cell lines which are essentially free of CHO-MIF. | 09-25-2014 |
20140295461 | Method for Determining Lung Injury Using Desmosine and Isodesmosine as Biomarkers - The subject invention is directed to a method for biochemically determining the extent of emphysematous changes in the lung. This method is entirely novel in that it links a biochemical parameter (the ratio of free to peptide-bound desmosine and isodesmosine [DID]) to specific morphological changes in lung tissue consisting of airspace enlargement and rupture of alveolar walls. While the total amount of DID in blood, urine, and sputum have been previously used to measure the rate of breakdown of lung elastic fibers, recent insights using percolation theory, have shown that the ratio of free to peptide-bound DID specifically reflects the total amount of elastic fiber damage in the lung, and is therefore a sensitive measure of emphysematous changes in the lung (which are the direct result of elastic fiber breakdown in alveolar septa). Furthermore, this new method establishes a relatively narrow range of values for normal individuals (without lung disease), which has not been previously possible by measuring total levels of DID (due to their large variability). The technique may be used to determine the amount of pulmonary emphysema in patients with chronic obstructive lung disease, and may also serve as a screening test for healthy smokers and other asymptomatic individuals (e.g. those with alpha-1 antitrypsin deficiency) who are at risk for developing pulmonary emphysema. Early detection of lung elastic fiber injury will result in more timely therapeutic intervention to slow the progression of the disease. | 10-02-2014 |
20140295462 | RBM3 Protein in Colorectal Cancer Prognostics - The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and | 10-02-2014 |
20140295463 | ELISA Detection of Urine DEK to Predict and Diagnose Bladder Cancer in Humans - The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans. | 10-02-2014 |
20140295464 | Detection of Degradation Products of Feline NT-proBNP - A method for determining the amount of NT-proBNP in blood samples from felines. The method includes detecting degradation products of feline NT-proBNP by various methods, including using antibodies, kits and devices. | 10-02-2014 |
20140295465 | USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN - This disclosure relates to the use of anti-α-synuclein antibody to diagnose an elevated level of α-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of α-synuclein in a blood plasma or CSF following administration to the test subject of an anti-α-synuclein antibody or antigen-binding fragment thereof, which can bind α-synuclein with sufficient activity to alter the net efflux of α-synuclein from brain to blood, or from brain to CSF. | 10-02-2014 |
20140295466 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 10-02-2014 |
20140295467 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 10-02-2014 |
20140302532 | METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT'S RECOVERY FROM A BRAIN INJURY - The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein. | 10-09-2014 |
20140302533 | ADVANCED DETECTION OF SEPSIS - The present invention relates to methods, monitors and systems, useful, for example, for advanced detection of sepsis in a subject. | 10-09-2014 |
20140302534 | ANTI-CANINE N-TERMINAL PRO-ATRIAL NATRIURETIC PEPTIDE ANTIBODY, AND IMMUNOLOGICAL MEASUREMENT METHOD AND IMMUNOLOGICALLY MEASURING KIT USING THE SAME - The anti-canine N-terminal pro-atrial natriuretic peptide antibodies (anti-canine NT-proANP antibodies) according to the present invention comprise anti-canine NT-proANP recognizing a partial portion or a whole portion of the amino acid sequence 31 to 67 of canine NT-proANP and anti-canine NT-proANP recognizing a partial portion or a whole portion of the amino acid sequence 68 to 98 thereof. The anti-canine NT-proANP antibodies are useful for immunologically measuring canine NT-proANP involved in heart diseases and infections of companion animals such as dogs, such as heart failure, mitral valve insufficiency and filariasis. The immunochromatographic assay using the immunochromatographic means such as immunochromatographic strip is extremely convenient and simple for measuring canine NT-proANP and is used as hand-carried and simple devices. | 10-09-2014 |
20140302535 | PROCESS FOR DETECTION OF ALZHEIMER'S DISEASE FROM A SERUM SAMPLE - Disclosed is a method of detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI). Also disclosed is a process for detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI) comprising (a) detecting a first concentration of lipocalin-PDS/TTR complex in a blood sample or urine sample from the subject, (b) determining a second concentration of PDS/TTR complex in a blood sample or urine sample from an unaffected individual, and (c) comparing the first and second concentrations, wherein a lower first concentration as compared to the second concentration is indicative of the subject having or being at risk of developing Alzheimer's disease. | 10-09-2014 |
20140302536 | DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE - Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP. | 10-09-2014 |
20140302537 | Use of Female Mammal's Urine for Determination of Fetal Gender Related Characteristics - The present invention provides a method for determining the gender of a fetus by assaying the sex hormones, evaluating the overall reducing/oxidizing (redox) activity, and/or evaluating the radical scavenging capacity of the maternal urine or other body fluid. The method can be used to determine fetal gender at any time point during the entire pregnancy. The body fluid may be processed before assaying. Processing may involve aging the body fluid, or purification of various fractions. | 10-09-2014 |
20140302538 | MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided. | 10-09-2014 |
20140308683 | Compositions and Methods for Determining Risk of a Cardiovascular Occlusive Event - The present disclosure provides methods for assessing risk of a cardiovascular occlusive event in an individual. The methods find use in diagnostic and prognostic applications. The present disclosure provides a method for measuring the level of pre?-1 high density lipoprotein in a biological sample; and also provides kits for use in carrying out the method. | 10-16-2014 |
20140308684 | Quantification of Non-Reducing End Glycan Residual Compounds - Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. | 10-16-2014 |
20140308685 | ANTIBODY CAPABLE OF BINDING TO SPECIFIC REGION OF PERIOSTIN, AND METHOD FOR MEASURING PERIOSTIN USING SAME - The present invention provides a method and a reagent for measuring periostin contained in a sample with improved accuracy, a method for improving accuracy in measurement of periostin, and a method of testing for pulmonary fibrosis or interstitial pneumonia with improved accuracy. The antibody of the present invention binds to at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin or a cleavage product thereof. The method and the reagent for measuring periostin and the method for improving accuracy in periostin measurement of the present invention is characterized by detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin. The method of testing for pulmonary fibrosis or interstitial pneumonia of the present invention includes the steps of a) measuring the amount or concentration of periostin in a sample derived from a subject, which measuring includes detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin and b) comparing the amount or concentration of the periostin in the sample derived from the subject with an amount or concentration of periostin in a sample derived from a living body not suffering from pulmonary fibrosis and interstitial pneumonia. | 10-16-2014 |
20140308686 | BIOMARKER FOR ABDOMINAL AORTIC ANEURYSM - Methods for detecting abdominal aortic aneurysm (AAA) or predisposition to AAA in a apoE subject, methods for monitoring the efficacy of treatment of AAA in a subject, and methods for evaluating the severity of AAA or risk of AAA in a subject involve measuring the amount of tetrahydrobiopterin (H4B) present in the test sample and comparing it to the amount of H4B present in a standard or previous test sample. A decreased amount of H4B present in the test sample compared to the standard is indicative of AAA or predisposition to AAA. Treatment can be administered to the subject prior to a second time point, and an increased amount of H4B present in the second test sample compared to the first test sample is indicative of effective treatment of AAA. Candidates can be identified for further testing or monitoring for AAA, and/or for treatment for AAA. | 10-16-2014 |
20140308687 | Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy - Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided. | 10-16-2014 |
20140308688 | HUMAN EMULATED RESPONSE WITH MICROFLUIDIC ENHANCED SYSTEMS - A multiple flow-based microfluidic cell culture system that emulates mammalian physiology is provided. Tissue-mimicking cell cultures are connected by flow within a physiologically meaningful arrangement so that the pharmacokinetics of various agents to be tested in the system emulate in vivo conditions. The system includes at least two organ tissue modules, each organ tissue module including a first chamber containing an organ tissue cell, the first chamber including an inlet and an outlet for flow of an organ tissue cell-specific culture medium; a second chamber including an inlet and an outlet for flow of a blood material; and a semi-permeable membrane separating the first and second chambers. The flow of blood material through each organ tissue module is interconnected and the flow of tissue-cell specific culture medium is directed to a single organ tissue module. | 10-16-2014 |
20140315222 | METHOD FOR MEASURING SIALIC ACID IN IMMUNOGLOBULIN G AND IMMUNOGLOBULIN G ANTI-DOUBLE-STRANDED DNA ANTIBODIES - A method for measuring the amount of sialic acid in immunoglobulin G and immunoglobulin G anti-ds DNA antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin G in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin G. Also, using a mouse monoclonal antibody immunoglobulin G as a standard, which is diluted from 1000 ng/ml to 15.625 ng/ml in phosphate buffered saline (PBS), produces good results. The method for measuring the amount of sialic acid in immunoglobulin G anti-ds DNA antibodies has never been done and the present invention produces good results as well. | 10-23-2014 |
20140315223 | Method of Simultaneous Detection of Heparin-Induced Immunoglobulins Types G, A, and M - The invention provides a method for detecting heparin-induced antibodies comprising a) binding a PF4-heparin antigen to a solid surface; b) incubating the bound PF4-heparin with a sample comprising heparin-induced antibodies to be detected; c) contacting the sample with at least two labeled secondary antibodies, wherein the secondary antibodies bind to heparin-induced antibodies present in the sample; d) detecting the presence of the labeled secondary antibodies using flow cytometry or a suitable method, wherein the heparin-induced antibodies bound to the secondary antibodies are identified. In one embodiment, the at least two secondary antibodies are anti-human antibodies which specifically bind to heparin-induced antibodies and are selected from the group consisting of Ig, IgG, IgA, and IgM. | 10-23-2014 |
20140315224 | DETECTION DEVICE, DETECTION STRIP, AND DETECTION SYSTEM - A detection device applied for detecting body fluids includes a substrate and a plurality of anti-growth factor antibodies. The substrate includes at least one reaction portion. The reaction portion includes a fiber-based material. Anti-growth factor antibodies are disposed on the fiber-based material. The present invention further provides a detection strip and a detection system for detecting body fluids. The present invention is advantageous for easy operation, lower amount of reagents and rapid analysis. | 10-23-2014 |
20140315225 | METHODS AND COMPOSITIONS FOR DETECTING THE PRESENCE OF ONE OR MORE AUTOANTIBODIES - This disclosure describes methods and compositions for immunohistochemically detecting the presence of a SRP autoantibody in a biological sample. | 10-23-2014 |
20140315226 | Device And Method For Detecting Substances Present In Biological Or Chemical Samples - The present invention relates to a device and a method for detecting substances which are present in biological or chemical samples, each substance producing an optically detectable signal upon reaction with a reagent. The device further comprises a sample carrier with at least two receptacles for receiving samples and is characterized in that at least part of the receptacle is equipped to receive at least 2 reagents each, and in that a camera for recording an image which shows at least one receptacle filled with at least two reagents for the detection of different substances, and an evaluation device for evaluating the samples which device is designed such as to evaluate each image by analyzing the signals in the image. Said method comprises the following steps: Introducing at least two reagents into one receptacle of a sample carrier, and optionally immobilizing the reagents, adding the sample to the receptacle, recording an image by means of a camera such that the image shows the receptacle which is loaded with at least two reagents, and evaluating the image by analyzing the color spectrum of the samples in the image. | 10-23-2014 |
20140315227 | THERAPEUTIC AGENT FOR PRETERM DELIVERY OR ABORTION USING PLASMINOGEN ACTIVATOR INHIBITOR-1 - The present invention relates to a method for diagnosing the degree of risk for preterm delivery or miscarriage, comprising measuring plasminogen activator inhibitor activity or level in plasma. Specifically, the present invention relates to: a method for diagnosing the degree of risk for preterm delivery or miscarriage, wherein when the plasminogen activator inhibitor activity or level is lower than those of normal pregnant woman, the degree of risk for preterm delivery or miscarriage is determined to be high; a kit for the diagnosis of the degree of risk for preterm delivery or miscarriage; and a pharmaceutical composition for the prevention of preterm delivery or miscarriage, comprising plasminogen activator inhibitor-1. | 10-23-2014 |
20140322731 | AMYLOID BETA-DERIVED DIFFUSIBLE LIGANDS (ADDLs), ADDL-BINDING MOLECULES, AND USES THEREOF - The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders. | 10-30-2014 |
20140322732 | METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH - The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself. | 10-30-2014 |
20140322733 | OPTICAL METHOD AND DEVICE FOR IDENTIFYING AND QUANTIFYING ANALYTES - A method for analysing a metalloprotein and/or the interaction with its environment comprising the following steps: (a) Providing a medium that enhances the detection of the electromagnetic cross-section signal of metalloproteins, (b) Incorporating a metalloprotein to analyse into said medium, (c) Contacting said medium with electromagnetic radiation, (d) Obtaining the electromagnetic cross-section spectrum of said metalloprotein, (e) Determining from said electromagnetic cross-section spectrum at least one parameter related to one or several analytes of interest. | 10-30-2014 |
20140335546 | Devices and Methods for Determining the Risk of Developing a Serious Infection - A device for calculating risk of a patient developing a serious infection, the device comprising: a controller; storage storing electronic program instructions for controlling the controller; a display for displaying a user interface; and input means; wherein the controller is operable, under control of the electronic program instructions, to: receive input via the input means, the input comprising one or more values representing respective measures of one or more risk factors associated with biological sample(s) obtained from the patient; process the input to calculate the risk; and display an indication of the calculated risk via the display. | 11-13-2014 |
20140335547 | Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation - The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression. | 11-13-2014 |
20140342377 | METHOD FOR THE DETECTION OF AN ANALYTE IN A SAMPLE - A method for the detection of at least one analyte in a sample is disclosed, wherein it comprises the steps of: a) providing a layer comprising a porous matrix having at least one ligand bound thereto above a filter constituting the bottom of at least one well of an assay plate, wherein said filter does not allow passage of said porous matrix having a ligand bound thereto, b) adding a sample containing said at least one analyte to be detected, said at least one analyte having the ability to specifically bind to said at least one ligand, c) adding a wash solution with a view to washing out non-bound sample components from the assay plate through the filter, d) adding enzyme-linked antibodies or antigens having the ability to specifically bind to said at least one analyte, e) adding a wash solution with a view to washing out non-bound enzyme-linked antibodies or antigens from the analysis plate through the filter, f) adding a substrate specific for the enzyme, wherein a product is formed by a reaction between the enzyme and the substrate, determining the quantity of said at least one analyte by measuring a signal related to the product, as well as method for the diagnosis of an EHEC (enterohemorrhagic | 11-20-2014 |
20140342378 | PEPTIDES IMMUNOREACTIVE WITH AUTOANTIBODIES FROM PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS - The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies. | 11-20-2014 |
20140342379 | Means and Methods for Assessing Gonadal Toxicity - The present invention pertains to the field of diagnostics for gonadal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing gonadal toxicity. It also relates to a method for determining whether a compound is capable of inducing such gonadal toxicity in a subject and to a method of identifying a drug for treating gonadal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing gonadal toxicity. | 11-20-2014 |
20140342380 | VERIFYING THE SOURCE OF BIOLOGICAL SAMPLES; METHOD, COMPOSITION AND KIT THEREFOR - The present invention relates to a method, composition and a kit for verifying the source of biological samples when collected for testing, e.g., for the presence of drugs of abuse. The method generally involves providing a subject with a composition comprising at least one detectable consumable marker and optionally at least one metabolizable detectable consumable marker; obtaining a biological sample from the subject after consumption of the composition; and detecting the presence or absence of the detectable consumable marker in the sample; wherein the presence of the detectable marker indicates that the subject is the source of the sample, and wherein the absence of the detectable marker indicates that the subject is not the source of the biological sample. | 11-20-2014 |
20140349316 | USE OF TUMOR NECROSIS FACTOR (TNF) RECEPTOR-ASSOCIATED FACTOR 7 (TRAF7) AS BIOMARKER FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), METHOD AND KIT FOR DETECTING OF HUMAN WITH SLE - A use of tumor necrosis factor (TNF) receptor-associated factor 7 (TRAF7) as a biomarker for systemic lupus erythematosus (SLE) and a method and a kit for detecting human with SLE are provided. The kit for detecting human with SLE includes TRAF7 and anti-TRAF7 antibodies. The method for detecting human with SLE includes the following steps. A plasma sample is taken from a patient with suspected SLE. The ratio of TRAF7 to total protein in the plasma sample of the patient is compared with that in the plasma sample of normal people. If the ratio of TRAF7 to total protein in the plasma sample of the patient is higher than that of the normal people, then it is possible that the patient is suffering from SLE. TRAF7 can be used as a biomarker for SLE patients in active phase and with renal involvement. | 11-27-2014 |
20140349317 | IMMUNOASSAY METHOD AND IMMUNOASSAY KIT - An object of the present invention is to provide an immunoassay method and an immunoassay kit which have the excellent effect of producing enhanced measurement sensitivity and yet reduced non-specific reaction. An immunoassay method including performing immune reaction in the presence of 0.67 to 2.67% (W/V) of chondroitin sulfate and 3.5% (W/V) or more of sodium chloride is provided. | 11-27-2014 |
20140349318 | BIOMARKERS OF IONIZING RADIATION - The present invention provides novel radiation associated markers. The radiation associated markers may be one or more of albumin, LTGF-β, or any protein or peptide listed in any one of Tables 1, 2, 3, 4, 5, and 6 provided herein. The present invention also provides methods of assessing exposure to ionizing radiation by determining the presence of one or more radiation associated markers. The methods may optionally include quantifying one or more of the radiation associated markers. The methods may further include comparing the amount of one or more radiation associated markers in the sample determined to be present in the sample with either (i) the amount determined for temporally matched, normal samples or (ii) the amount determined for samples obtained from individuals or subjects that have not been exposed to an elevated level of ionizing radiation. | 11-27-2014 |
20140349319 | ANTIBODY SPECIFIC FOR TRANS-RESVERATROL AND USE THEREOF - The present invention provides a method of detecting or measuring trans-Resveratrol (tRV) in a sample, comprising: contacting a sample to be tested with an antibody against tRV, or an antigen binding fragment of such an antibody; and detecting or measuring any tRV bound by the antibody or antibody fragment. The invention also provides an antibody against trans-Resveratrol. | 11-27-2014 |
20140349320 | Using Adaptive Immunity to Detect Drug Resistance - The present invention relates to a method of using adaptive immunity to detect drug resistance in infectious diseases. The invention provides novel antigens associated with drug resistant MTB infection. | 11-27-2014 |
20140349321 | BINDING MOLECULES AGAINST DENGUE VIRUS AND USES THEREOF - The present invention relates to binding molecules suited to the diagnosis, prevention and/or treatment of dengue virus infection. | 11-27-2014 |
20140349322 | SYSTEM FOR DETERMINING UNPROCESSED AND PARTIALLY PROCESSED NEUROTOXIN TYPE A - The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed | 11-27-2014 |
20140356886 | METHOD FOR MEASURING BETA-GLUCAN, AND BETA-GLUCAN-BINDING PROTEIN FOR USE IN THE METHOD - Disclosed are a method for measuring βG comprising the steps of bringing a sample into contact with a βG-binding protein 1 and a βG-binding protein 2, each comprising an amino acid sequence which is identical or substantially identical to an amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20, and having the β-glucan binding activity, to form a complex of the βG-binding protein 1, βG in the sample and the βG-binding protein 2, measuring quantity of the complex, and determining βG concentration in the sample based on the quantity of the complex; a reagent and a kit for use in said method; a novel βG-binding protein; a nucleic acid molecule encoding the βG-binding protein; and a method for producing the aforementioned βG-binding protein. | 12-04-2014 |
20140363829 | METHOD FOR INCREASING SPECIFICITY OF DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASES - Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a DFS70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed. | 12-11-2014 |
20140363830 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME - The present invention relates to compositions and methods related to inhibitors of Hsp90, including substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. The invention further provides methods for designing and identifying inhibitors of Hsp90. | 12-11-2014 |
20140363831 | COMPOUNDS AND METHODS USEFUL FOR DETECTION AND TREATMENT OF CANCER - The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for prevention and curative treatment of cancers and pre-cancers. | 12-11-2014 |
20140363832 | MOLECULAR MARKER FOR THE EARLY DETECTION OF MALIGNANT PLEURAL MESOTHELIOMA AND THE METHODS OF ITS EXPRESSION ANALYSIS USING BLOOD AND PLEURAL EFFUSION SAMPLES - The present invention provides a method for testing mesothelioma comprising a step of determining a concentration of a human periostin protein in at least one type of sample of blood or pleural fluid of a subject. In the step of determining the concentration of human periostin protein, an antibody directed against human periostin protein may be used. The present invention further provides a kit for diagnosing mesothelioma, said kit comprising an antibody directed against human periostin protein. In the kit for diagnosing mesothelioma, the antibody directed against a human periostin protein may be an antibody that binds to a polypeptide consisting of an amino acid sequence set out in SE ID NO: 2. | 12-11-2014 |
20140370526 | DETECTING INCLUSION BODY MYOSITIS - Methods, devices, kits and systems for diagnosing inclusion body myositis (IBM) are provided. Methods, devices, kits and systems involves detecting the presence and/or level of autoantibodies that are reactive against at least a ˜43 kilodalton (kDa) protein or ˜43 kDa protein band from a muscle lysate or a mammalian cell lysate, or autoantibodies that are reactive against a cytosolic 5′-nucleotidase 1A protein (NT5C1A), or a cytosolic 5′-nucleotidase 1B protein (NT5C1B), or a NT5C1B isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of NT5C1A or NT5C1B. Such autoantibodies are only found in IBM patients and not in patients with other myopathies. | 12-18-2014 |
20140370527 | METHOD AND TOOL FOR PREDICTING CANCER AND OTHER DISEASES - The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes. | 12-18-2014 |
20140370528 | Proteasome Deubiquinating Inhibitor Screening - A method for screening a compound to determine whether the compound is a proteasome deubiquinating inhibitor of high specificity comprises contacting the compound with human 19S regulatory particles (19S RP) of 26S proteasome and determining whether the compound inhibits activity of deubiquinating (DUB) enzymes UCHL5 and USP14; inhibition of UCHL5 and USCP14 activities indicates that the compound is a proteasome deubiquinating inhibitor of high specificity. | 12-18-2014 |
20140370529 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE - The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, wherein the level of each of at least two catecholamines is measured in a sample of biological fluid from said subject. | 12-18-2014 |
20140370531 | METHOD OF DIAGNOSING MILD TRAUMATIC BRAIN INJURY - The present invention relates to a method of determining whether a subject has suffered a mild traumatic brain injury. The method comprises selecting a subject exposed to a head trauma and determining an apoA-1 level in a body fluid sample obtained from the selected subject, wherein a decreased apoA-1 level in the body fluid sample indicates that the subject has suffered a mild traumatic brain injury. The invention also relates to a kit for determining whether a subject has suffered a mild traumatic brain injury. | 12-18-2014 |
20140377784 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A MYOPATHY - The invention provides compositions, methods, and kits diagnosing, monitoring, and otherwise characterizing a myopathy and for detecting the presence of autoantibodies in a biological sample. | 12-25-2014 |
20140377785 | ASSEMBLY FOR SELECTIVELY PERFORMING A CLINICAL CHEMISTRY TEST OR AN ELISA ASSAY, USE OF SAID REAGENT CARTRIDGE AND ASSEMBLY - An assembly for selectively performing a clinical chemical test or an ELISA assay including a reagent cartridge with a housing | 12-25-2014 |
20140377786 | DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 12-25-2014 |
20150010925 | CO-TRANSLATIONAL ACTIVATION OF A TRANSCRIPTION FACTOR BY PORTEOLYTIC CLEAVAGE AND METHODS OF USE - A method for measuring expression of autoregulatory molecules within living cells is provided. An autoregulatory molecule and marker construct is expressed in vivo, where the marker is cleaved from the construct during translation. The method comprises the expression of a construct having an autoregulatory molecule bound to a measurable expression marker by a cleavable linker. The cleavable linker is the substrate of a protease, which acts on its substrate in vivo during translation. Cleavage during translation, allows the autoregulatory molecule to fold normally as it would in its native form. The measurable marker is released and available for detection upon cleavage by the protease. As a result, the concentration of the measurable marker is directly related to the level of expression of the autoregulatory molecule. | 01-08-2015 |
20150010926 | METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY - The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample. | 01-08-2015 |
20150010927 | DETECTING LATENT TUBERCULOSIS INFECTIONS - This document provides methods and materials related to identifying mammals having a LTBI. For example, methods and materials for using ELISpot assays to identify mammals (e.g., humans) having a LTBI are provided. | 01-08-2015 |
20150010928 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER - The present invention pertains to the field of diagnostics for an endocrine disease or disorder and assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing an endocrine disease or disorder. It also relates to a method for determining whether a compound is capable of inducing such an endocrine disease or disorder in a subject and to a method of identifying a drug for treating an endocrine disease or disorder. Furthermore, the present invention relates to a device and a kit for diagnosing an endocrine disease or disorder. | 01-08-2015 |
20150017664 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING THE SAME - The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved. | 01-15-2015 |
20150017665 | Peptides and Methods for Detecting MPO-ANCA - The present invention relates to disorder-specific epitopes recognized by myeloperoxidase-anti-neutrophil cytoplasmic autoantibodies and the use of polypeptides comprising the epitopes in methods of diagnosing and monitoring autoimmune disorders associated with the autoantibodies. | 01-15-2015 |
20150017666 | DIAGNOSTIC PEPTIDES FOR LYME DISEASE - The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1-SEQ ID NO:28 and/or SEQ ID NO:41-SEQ ID NO:47, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic | 01-15-2015 |
20150017667 | MEANS AND METHODS FOR ASSESSING LIVER DISORDERS - The present invention pertains to the field of diagnostics for liver disorders and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver disorders. It also relates to a method for determining whether a compound is capable of inducing such liver disorders in a subject and to a method of identifying a drug for treating liver disorders. Furthermore, the present invention relates to a device and a kit for diagnosing liver disorders. | 01-15-2015 |
20150024416 | CORRECTION METHOD FOR ESTIMATING FREE LIGHT CHAIN PRODUCTION - The invention provides a method of estimating free light chain production (FLC) in a subject comprising (i) determining an amount of FLC in a sample from the subject; and (ii) correcting the amount of FLC in the sample for FLC cleared from the source of the sample by glomerular filtration and by reticuloendothelial (RE) clearance. | 01-22-2015 |
20150024417 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to | 01-22-2015 |
20150024418 | METHOD FOR DIAGNOSING OR PREDIAGNOSING A BETA-AMYLOIDOPATHY OR AN ALPHA-SYNUCLEOPATHY - The invention relates to a method for the diagnosis or prediagnosis of a β-amyloidopathy or an α-synucleopathy accompanied by a cerebral protein deposit and a reduced activity of the cerebral ABCC1-transporter, or for determining the risk of a proband suffering from such an illness, the proband already having accumulated substances transported by the cerebral ABCC1 transporter. | 01-22-2015 |
20150024419 | METHOD FOR THE ASSAY OF SYNUCLEINS - The present invention provides a method for the assay of synucleins in a body fluid or tissue sample, wherein said method comprises the steps of contacting said sample with membrane lipids under conditions enabling binding of the synuclein to said lipids, and the detection of the lipid-bound synuclein by a synuclein-binding agent. | 01-22-2015 |
20150024420 | EXTRACELLULAR AND MEMBRANE-ASSOCIATED PROSTATE CANCER MARKERS - This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein. | 01-22-2015 |
20150031052 | METHOD FOR REDUCING ADSORPTION OF BUBBLES - Provided is a means for improving measurement accuracy in an immunoassay using a dry plastic cell. A method for reducing adsorption of bubbles onto a cell side surface in an immunoassay, the method including carrying out a reaction and/or measurement in a presence of a surfactant, wherein the immunoassay comprises carrying out an antigen-antibody reaction in a dry plastic cell using an immunoassay reagent which immunologically reacts with a substance to be measured in a sample and carrying out an optical measurement of a resultant reacted product. | 01-29-2015 |
20150031053 | ASSAY AND METHOD FOR DETERMINING INSULIN-RESISTANCE - The present invention provides for a home test or a point of care test device that can both detect blood glucose and insulin levels and methods using said device. The device and methods can be used to aid diabetic patients and medical practitioners to fine tune insulin administration, and to monitor disease progression or treatment. | 01-29-2015 |
20150031054 | METHOD AND SYSTEM FOR DIAGNOSING ALZHEIMER'S DISEASE - Disclosed herein is a method for diagnosing Alzheimer's disease capable of minimizing invasiveness to reduce the risk of infection. The method for diagnosing Alzheimer's disease includes the steps of: pretreating an intranasal specimen; detecting tau protein or amyloid beta peptide (Aβ) in the pretreated intranasal specimen; comparing a value of the tau protein or the Aβ obtained in the detection step with a predetermined value; and displaying a comparison result obtained in the comparison step. | 01-29-2015 |
20150031055 | NOVEL BIOACTIVE LIPID DERIVATIVES, AND METHODS OF MAKING AND USING THE SAME - Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described. | 01-29-2015 |
20150037820 | LUNG CANCER MARKERS AND USES THEREOF - Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods. | 02-05-2015 |
20150037821 | METHODS OF IDENTIFYING HIT-ANTIBODIES AND PF4 ANTAGONISTS AND CELL LINES FOR USE THEREIN - Methods and cells or cell lines for identifying antibodies or fragments thereof that activate heparin-induced thrombocytopenia (HIT) are described. The methods comprise contacting a hematopoietic cell or cell line that comprises, in operative association, the platelet receptor FcyRIIA under the control of a suitable promoter, and a reporter construct comprising a reporter gene under the control of a promoter and transcription factor, which transcription factor is regulated downstream of the signaling cascade of activated FcyRIIA, with a test sample from a mammalian subject; a platelet factor 4 (PF4), a wild-type or variant of PF4 or a fragment thereof; and heparin; and detecting or measuring the level of reporter gene expression. | 02-05-2015 |
20150037822 | MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES - Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex. In some embodiments, the proteomic profile may also include information on the expression of adiponectin, sex hormone binding globulin (SHBG), C-reactive protein (CRP), a ratio of human chorionic gonadotropin (hCG) to placental lactogen, or a combination thereof. | 02-05-2015 |
20150044699 | VIBRIO HARVEYI-SPECIFIC BINDING DOWN SYNDROME CELL ADHESION MOLECULE, METHOD FOR IDENTIFICATION THEREOF AND USE THEREOF - The present invention relates to a | 02-12-2015 |
20150044700 | Anti-Gap43 Antibody - An anti-GAP43 antibody which is capable of distinguishing a non-phosphorylated threonine residue at position 89 (T89) from a phosphorylated threonine residue at position 89 (pT89) of mouse GAP43 set forth in SEQ ID NO: 13, and which is capable of specifically detecting a growth cone; an anti-GAP43 antibody which is capable of distinguishing a non-phosphorylated serine residue at position 96 (S96) from a phosphorylated serine residue at position 96 (pS96) of mouse GAP43, and which is capable of specifically detecting a growth cone; an anti-GAP43 antibody which is capable of distinguishing a non-phosphorylated threonine residue at position 172 (T172) from a phosphorylated threonine residue at position 172 (pT172) of mouse GAP43, and which is capable of specifically detecting a growth cone; and an immunological analysis method using these anti-GAP43 antibodies. | 02-12-2015 |
20150044701 | IgA-BINDING PEPTIDE AND IgA PURIFICATION USING THE SAME - This invention provides a peptide that comprises an amino acid sequence consisting of 14 to 18 amino acid residues represented by Formula (I) and is capable of binding to human IgA: | 02-12-2015 |
20150044702 | MEANS AND METHODS FOR ASSESSING DISORDERS RELATED TO IMPAIRED IRON ADSORPTION OR ENERGY METABOLISM - The present invention pertains to the field of diagnostics for iron adsorption disorder or impaired energy metabolism and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing iron adsorption disorder or impaired energy metabolism. It also relates to a method for determining whether a compound is capable of inducing such iron adsorption disorder or impaired energy metabolism in a subject and to a method of identifying a drug for treating iron adsorption disorder or impaired energy metabolism. Furthermore, the present invention relates to a device and a kit for diagnosing iron adsorption disorder or impaired energy metabolism. | 02-12-2015 |
20150044703 | METHODS AND COMPOSITIONS FOR DETECTING ENDOMETRIAL OR OVARIAN CANCER - Some embodiments of the present invention relate to methods and compositions for detecting the presence of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided. | 02-12-2015 |
20150044704 | MONOCLONAL ANTIBODIES AND DIAGNOSTIC USES THEREOF - The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies. | 02-12-2015 |
20150044705 | PROTEIN DETECTION USING MODIFIED CYCLODEXTRINS - A method is provided for detecting a protein using a cyclodextrin covalently linked to at least one label. The cyclodextrin can associate with the protein by sequestering an aromatic amino acid side-chain of the protein in its hydrophobic cavity. After contacting the protein with the cyclodextrin, the label can be detected directly or can undergo a chemical interaction with a reagent to form a detectable product. The label can include an indole moiety, which can react with a halo-substituted organic compound upon exposure to UV light and thereby be rendered fluorescent. Alternatively, the label can include a biotin moiety, which can bind to a binding partner such as avidin, or variants thereof, to form a detectable molecular complex. A labeled cyclodextrin can be used in the present methods to detect a protein of interest in an electrophoresis gel or on a blotting membrane. Aromatic amino acid residues of the protein, in particular tryptophan, remain protected from chemical modification due to sequestration by the cyclodextrin, making these methods compatible with downstream applications that require intact protein. Also provided herein are compositions, kits, and electrophoresis gels for use in detecting proteins. | 02-12-2015 |
20150044706 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries. | 02-12-2015 |
20150044707 | At-Home Blood Pregnancy Test Kit - Disclosed is an at-home blood pregnancy test kit that can identify the presence of hCG in a blood sample to detect pregnancy in female mammals. The present kit includes a housing having a sample strip that is in fluid communication with a sample pad for holding a blood sample, a test pad, and a conjugate pad. The housing further includes a test window and a push button for releasing a reagent that can react with hCG. The reagent and the test pad include antibodies that can bind with hCG antigens to detect presence of the same. The test window is adapted to display a symbol that indicates a negative pregnancy test result in the absence of hCG, or display a symbol that indicates a positive pregnancy test result in the presence of hCG. | 02-12-2015 |
20150050671 | METHOD FOR SPECIES-INDEPENDENT MEASUREMENT OF COMPLEMENT ACTIVATION IN ANIMALS - A method for species-independent measurement of complement (C) activation in animals. The method comprises taking samples in the range of 3-100 microliter of anticoagulated blood, plasma or serum of an animal (specimen), mixing the specimen with a specificity converting protein matrix (SCM), mixing to the specimen/SCM mixture an activator of the C system (Act), incubating the specimen/SCM/Act mixture at a temperature between 36° C. to 38° C. for a time of 5-120 min and determining the production of one or more human proteins by ELISA or other analytical methods. | 02-19-2015 |
20150050672 | CATALYTIC MARKING NANOPARTICLES FOR ULTRASENSITIVE BIOASSAY APPLICATIONS - Disclosed herein is a composition for ultrasensitive bioassay applications. The composition includes a plurality of dispersible, nanoparticles having a size less than 500 nm. The nanoparticles are contain a metal catalyst or a metal catalyst precursor. The nanoparticles are conjugated to at least one biospecific binding reactant that is selectively reactive with a target analyte. The composition includes a dispersing medium. A method and a kit for conducting bioassays is described. | 02-19-2015 |
20150050673 | Fibrinogen Assay - The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring/applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody. | 02-19-2015 |
20150056637 | FECAL SAMPLING DEVICE AND METHOD - A collection device for use in connection with off-device testing of collected samples. The device includes a first panel having one or more apertures for receiving samples, a second panel opposite the first panel, and a removable tab having a first portion and a second portion. The first portion is aligned with at least one of apertures on the first panel and constructed such that depositing the sample through the at least one aperture causes the sample to be directly deposited on the first portion of the tab, and the second portion includes a sample-free grasping area accessible from an exterior of the device for removing the tab. A method of obtaining a sample is also disclosed. | 02-26-2015 |
20150056638 | NANOSCALE PROCESS TO GENERATE REAGENTS SELECTIVE FOR INDIVIDUAL PROTEIN VARIANTS - The present invention provides devices and methods to separate and concentrate target protein species at a microliter scale and to generate reagents to those variants with exquisite selectivity for specific protein isoforms using only picograms of target material. | 02-26-2015 |
20150056639 | DETECTING COMPLEMENT ACTIVATION - Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided. | 02-26-2015 |
20150056640 | REAGENTS AND METHODS FOR DETECTING A POLYMORPHIC PROTEIN - The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications. | 02-26-2015 |
20150064726 | Biochemical Markers for Neurodegenerative Conditions - A method of bioassay for the quantification of peptide fragments relevant to neurodegenerative conditions comprising a neo-epitope formed by cleavage of a Tau protein by a secretase such as ADAM10 comprises contacting a blood derived sample with an antibody specific for the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. Neo-epitope containing peptide levels are found to be inversely correlated to cognitive function. | 03-05-2015 |
20150064727 | Ectoparasite Detection - Ectoparasite infestation of a substrate like bedding is detected by contacting a sample from the substrate with a polyclonal ectoparasite antibody generated from a whole ectoparasite immunogen, under conditions wherein the antibody specifically binds ectoparasite antigen in the sample. | 03-05-2015 |
20150064728 | PROCESS FOR DETERMINING THE SUSCEPTIBILITY TO NOSOCOMIAL INFECTIONS - The invention relates to a process for determining the susceptibility to nosocomical infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample. | 03-05-2015 |
20150064729 | METHOD AND KIT FOR IMMUNOLOGICAL DETECTION OF MYCOBACTERIUM TUBERCULOSIS - Definitive diagnosis and early start of treatment cannot be made for tuberculosis since conventional methods for detecting a | 03-05-2015 |
20150064730 | Methods and Devices for Rapid Assessment of Severity of Injury - Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided. | 03-05-2015 |
20150072359 | METHOD FOR THE DETECTION OF FREE BINDING PARTNER OF A MULTISPECIFIC BINDER - Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody that specifically binds to a second binding site of the multispecific antibody, which is different from the first binding site, and thereby depleting the multispecific antibody from the sample. | 03-12-2015 |
20150072360 | BIOMARKERS OF PULMONARY HYPERTENSION - Methods are disclosed for predicting or diagnosing pulmonary artery hypertension (PAH) and for determining the efficacy of PAH therapy using biomarkers. | 03-12-2015 |
20150072361 | Lung Cancer Molecular Markers - The invention provides a method of diagnosis and/or prognosis of lung cancer, the method comprising the steps of: (a) determining the level of a C4 activation fragment in a test sample, and (b) comparing the level of the test sample with the level of a C4 activation fragment detected in a control sample, wherein if the level of C4 activation fragment is higher than the level in a reference control, it is indicative that the subject suffers lung cancer or has a bad prognosis. | 03-12-2015 |
20150072362 | DEVICES, SYSTEMS, METHODS, AND KITS FOR RECEIVING A SWAB - Methods, devices, systems, and kits useful for the collection and analysis of samples obtained by swabs are disclosed. Swab containers configured for receiving a swab containing a sample; cartridges for holding one or more of: a swab container, a swab, assay units, pipette tips, vessels, transport units, and implements; systems (which may include a sample processing device); kits; and methods for their use are disclosed. A swab container may include an entry port; an assay chamber having an assay port; a conduit comprising an interior channel connecting the entry port; and an interior channel providing fluidic communication between the entry port and assay chamber. An interior channel may be configured to squeeze a portion of a swab placed in or through the conduit. A cartridge may include a cartridge frame configured to receive one or more of swab containers, assay units, transport units, pipette tips, vessels or implements. | 03-12-2015 |
20150072363 | PHENYLACETYLGLUTAMINE AS A BIOMARKER FOR HEALTHY AGING - Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose an in vitro method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using phenylacetylglutamine (PAG) as biomarker. | 03-12-2015 |
20150072364 | METHODS AND KITS FOR DIAGNOSING OSTEOARTHRITIS AND PREDICTING PROGRESSION - This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject. | 03-12-2015 |
20150079612 | Assays, Antibodies, Immunogens and Compositions Related to 5-FU - The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-FU and/or 5-FU conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma. | 03-19-2015 |
20150079613 | ATYPICAL HEMOLYTIC UREMIC SYNDROME BIOMARKER PROTEINS - The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment. | 03-19-2015 |
20150079614 | Liquid Sampling, Storage, Transfer and Delivery Device - The present invention provides a liquid sampling, storage, transfer and delivery device comprising housing containing a porous nib. The porous nib in the device contacts the sample, collects the sample, stores the sample, transports the sample inside its porous matrix and releases the sample from the porous matrix upon demand. | 03-19-2015 |
20150093767 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS - The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy. | 04-02-2015 |
20150093768 | DETECTION OF PROSTATE AND BLADDER CANCER - The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage prostate cancer and bladder cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid. | 04-02-2015 |
20150104816 | MARKER FOR DETECTING PANCREATIC CANCER - A marker for detecting pancreatic cancer, said marker comprising a glycoprotein C4BPA or PIGR, whereby a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and thus specifically diagnosed. Also, the marker is usable in monitoring the postoperative prognosis of a pancreatic cancer patient. When the aforesaid marker is used in combination with another pancreatic cancer marker such as CA19-9, furthermore, a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and diagnosed more specifically. | 04-16-2015 |
20150104817 | HYDROXYCHOLESTEROL IMMUNOASSAY - Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective. | 04-16-2015 |
20150104818 | GEMCITABINE IMMUNOASSAY - The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids. | 04-16-2015 |
20150111228 | OPTICAL BIOSENSOR - The present disclosure provides an optical biosensor including a complex including a porous support and an enzyme supported inside the pores of the porous support and a method for preparing the same. Since a dye does not flow but is concentrated in one place, the optical biosensor of the present disclosure has remarkably improved sensitivity. In addition, it is possible to carry out quantitative determination and qualitative analysis since color intensity increases with time. | 04-23-2015 |
20150111229 | Method for Searching for Inhibitor of Odor Cause By Furaneol - It is intended to identify a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. The present invention provides a method for searching for an inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone, comprising: adding a test substance and 2,5-dimethyl-4-hydroxy-3(2H)-furanone to an olfactory receptor OR5K1 or a polypeptide having at least 80% amino acid sequence identity thereto; measuring the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2H)-furanone; and identifying a test substance inhibiting the response of the olfactory receptor or the polypeptide, on the basis of the measured response. | 04-23-2015 |
20150111230 | METHOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLON TUMORS - The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response. | 04-23-2015 |
20150118695 | PORTABLE POCKET-SIZED BIOSENSOR - Disclosed herein is a portable biosensor, wherein a fluidic channel, comprising a porous solid matrix on which a capture recognition material of an analyte is fixed, is in contact with a signal detection sensor, wherein the signal detection sensor is a lens-free complementary metal oxide-semiconductor (CMOS) image sensors (CISs) for measuring a light signal generated by the reaction between the analyte and the capture recognition material. | 04-30-2015 |
20150118696 | LIQUID DIAGNOSTIC ASSAYS UTILIZING MARANGONI FLOW - The present invention provides simple and inexpensive assays for the detection of virtually any analyte in any sample that is in liquid form or that can be solubilized. The assays utilize the fluid dynamics of drop evaporation whereby soluble materials, including analytes and particles binding thereto, are drawn to the center of the drop by Marangoni flow and ultimately form a concentrated residual spot. The presence or absence of certain reagents can then be detected through a number of different approaches. | 04-30-2015 |
20150118697 | DEVICE AND METHOD FOR THE EXAMINATION OF A SAMPLE FLUID - A device for the examination of a sample fluid in a bioanalytical detection method comprises at least one receiving space for the sample fluid and a wall confining the receiving space. The wall is provided with at least one microstructured portion that faces the receiving space and has a multitude of regularly arranged structural elements. The structural elements are shaped in such a way that they form a three-phase border with an aqueous fluid. At the three-phase border at least one biomolecule can be permanently physically adsorbed. The device is in particular a cuvette, a microfluidic chip or a microtiter plate. | 04-30-2015 |
20150125885 | RTN4B POLYPEPTIDE, MONOCLONAL ANTIBODY THEREOF, MONOCLONAL ANTIBODY-PRODUCING HYBRIDOMA CELL STRAIN, AND, PREPARATION AND APPLICATION THEREOF - The present invention relates to a RTN4B-related polypeptide, a monoclonal antibody thereof, a monoclonal antibody-producing hybridoma cell strain, and, preparation and applications thereof The RTN4B polypeptide comprises an amino acid sequence presented by SEQ ID NO: 1. The invention further discloses a monoclonal antibody, a hybridoma cell strain to produce the monoclonal antibody prepared by the RTN4B polypeptide, and the related application in the treatment or prevention of tumors thereof. | 05-07-2015 |
20150132779 | Method for Determining Ubiqutin Chain Length - Protein ubiquitylation, an essential post-translational modification, regulates almost every cellular process including protein degradation, protein trafficking, signal transduction, and DNA damage response in eukaryotic cells. The diverse functions of ubiquitylation are thought to be mediated by distinct chain topologies resulting from eight different ubiquitin linkages, chain lengths, and complexities. Currently, ubiquitin linkages are generally thought to be a critical determinant of ubiquitin signaling. However, ubiquitin chain lengths, another key element of ubiquitin signaling, have not been well documented especially in vivo situation during past three decades from the discovery of ubiquitin. The reason of this was simply because no method has been available for determination of ubiquitin chain length in endogenous ubiquitylated substrates. In the present invention, a practical technique for determining the actual length of substrate-attached polyubiquitin chains from biological samples is established. Using the method, the mean length of substrate-attached polyubiquitin chains was determined and the robustness of ubiquitin chain length regulation in cells is investigated. The following is a summary of findings in this invention: 1. A method for determining ubiquitin chain length was developed and this method was named ‘ubiquitin protection from trypsinization’ (Ub-ProT). 2. Using Ub-ProT, it was determined that the mean length of substrate-attached ubiquitin chains is in the dimer to decamer range. 3. By quantitative proteomics, it was found that the mean lengths of five major types of ubiquitin chains can be divided into two groups. 4. Proteasome-inhibition did not alter the mean length of substrate-attached polyubiquitin chains, indicating that cells have a robust system for regulating ubiquitin chain length. | 05-14-2015 |
20150132780 | MELITTIN PEPTIDE CONJUGATES AND METHODS EMPLOYING SAME - Methods and reagents are disclosed for conducting assays for IgE specific for honey bee venom allergen. A reagent comprises a conjugate of a small molecule linked to a terminal glycine amino acid of a synthetic 26 amino acid melittin peptide. In the method a combination is provided that comprises a sample and the aforementioned reagent. The combination is subjected to conditions for binding of IgE specific for honey bee venom allergen to the reagent to form a complex. One or both of the presence and amount of the complex is detected and related to one or both of the presence and amount in the sample of IgE specific for honey bee venom allergen. | 05-14-2015 |
20150140580 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 05-21-2015 |
20150140581 | MICROFLUIDIC DEVICE FOR GENERATING NEURAL CELLS TO SIMULATE POST-STROKE CONDITIONS - This application provides devices for modeling ischemic stroke conditions. The devices can be used to culture neurons and to subject a first population of the neurons to low-oxygen conditions and a second population of neurons to normoxic conditions. The neurons are cultured on a porous barrier, and on the other side of the barrier run one or more fluid-filled channels. By flowing fluid with different oxygen levels through the channels, one can deliver desired oxygen concentrations to the cells nearest those channels. | 05-21-2015 |
20150147765 | SEROLOGICAL MARKERS FOR CANCER DIAGNOSIS USING BLOOD SAMPLE - The present invention relates to a method for diagnosing cancer using information on the aberrant glycosylation of a glycoprotein involved in cancer progress. More particularly, the present invention relates to a cancer diagnosis peptide marker which is screened by the steps of: separating a glycoprotein aberrantly glycosylated according to the occurrence and progress of cancer from the blood of a lung cancer patient by using lectin; and selecting a marker peptide produced by the hydrolysis of the glycoprotein isolated by lectin. The marker peptide can be effectively used as a cancer diagnosis marker and for the diagnosis of cancer. | 05-28-2015 |
20150147766 | METHOD FOR DETERMINING DISEASE SEVERITY IN TAUOPATHY-RELATED NEURODEGENERATIVE DISORDERS - A method for determining disease severity in a subject afflicted with a tauopathy-related neurodegenerative disease comprises detecting the level of a PINCH protein or isoform thereof in a test sample comprising brain tissue or cerebrospinal fluid. The PINCH protein level in the test sample indicates the relative severity of the tauopathy-related neurodegenerative disease afflicting the subject. | 05-28-2015 |
20150147767 | BAG3 AS BIOCHEMICAL SERUM AND TISSUE MARKER - The present invention concerns the field of diagnostic biological markers. Specifically the invention relates to anti-BAG3 antibodies for use as biological markers for the diagnosis of a pathological state. Furthermore, the invention involves specific ELISA methods and kits, for detecting and evaluating, anti-BAG3 antibodies or BAG3/antibody complexes in a biological sample. | 05-28-2015 |
20150293087 | ADDITIVE FOR MEASURING DILUTED SAMPLE IN NON-DILUTION-TYPE IMMUNOCHROMATOGRAPHIC METHOD REAGENT - Provided are: an immunoassay method in which the deviation from a theoretical value (hereinafter also referred to as “a reference value”), which may be caused when a diluted blood specimen is used as a sample, is reduced in an immunochromatographic method that is so designed that a blood specimen (whole blood, serum or plasma) is used directly as a sample without subjecting the blood specimen to any pretreatment such as a dilution treatment; and a reagent for use in the method. An immunochromatographic method performed on a blood specimen using an immunochromatographic device equipped with (1) a sample pad and (2) a membrane on which a component capable of specifically binding to an analyte is immobilized, arranged in the order of (1) and (2) from upstream, wherein hydroxyethyl starch is present in the measurement system. | 10-15-2015 |
20150293088 | SIGNAL AMPLIFICATION IN LATERAL FLOW AND RELATED IMMUNOASSAYS - The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays. | 10-15-2015 |
20150293090 | RECOMBINANT GRA ANTIGENS AND THE USE OF SAME FOR EARLY DIAGNOSIS OF TOXOPLASMOSIS - The present disclosure relates to a method for identifying the presence or absence of anti- | 10-15-2015 |
20150293101 | TUMOR CELL-DERIVED MICROVESICLES - The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer. | 10-15-2015 |
20150293102 | Detecting low-abundant analyte in microfluidic droplets - A method to produce aqueous droplets in oil and to manipulate the droplets for storage in the microfluidic device for certain amount of time to accumulate detectable amount of product produced by a single copy or plural copies of enzyme enclosed in the droplets, and to detect and measure the biomarkers in the antibody binding assay is disclosed. The method comprises: (1) generation of droplets in the microfluidic device, (2) storage of droplets in the microfluidic device, (3) measurement of activity of a single copy or plural copies of enzyme in the droplets, (4) individual molecule-counting immunoassay using the droplets. | 10-15-2015 |
20150293103 | Methods of Renal Cancer Detection - Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with, a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein, and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer. | 10-15-2015 |
20150293110 | COMPOSITIONS AND METHODS FOR IN VITRO DIAGNOSTIC TESTS INCLUDING ZWITTERIONIC SOLUBILIZATION REAGENT - The disclosure is directed to compositions, kits, and methods for performing colorimetric analysis. A composition for a colorimetric assay can be prepared that includes an aromatic amine chromogenic substrate and a zwitterionic solubilization reagent that is N,N,N-trimethylglycine (betaine). The zwitterionic solubilization reagent is highly useful as a non-encapsulating solubilization reagent and provided faster kinetics and increased dye content of an aromatic amine chromogenic substrate in an enzymatic reaction. In turn, this can result in improvements in detection of an analyte in a sample and also can increase the sample throughput. The aromatic amine chromogenic substrate and N,N,N-trimethylglycine solubilization reagent can be used in assays such as ELISAs in order to provide a more accurate and faster detection of analytes in a biological sample. | 10-15-2015 |
20150293117 | DETECTION DEVICE, DETECTION METHOD AND DETECTION STRIP - A detection device applied for detecting body fluids includes a substrate and a plurality of antigens of type XVII collagen. The substrate includes at least one reaction portion. The reaction portion includes a fiber-based material. Antigens of type XVII collagen are disposed on the fiber-based material. The present invention further provides a detection method and a detection strip for detecting body fluids. The present invention is advantageous for easy operation, lower amount of reagents and rapid analysis. | 10-15-2015 |
20150293118 | CROSS-REACTIVE DETERMINANTS AND METHODS FOR THEIR IDENTIFICATION - Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive | 10-15-2015 |
20150293122 | USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7. | 10-15-2015 |
20150293125 | METHOD FOR DETECTING NEUROLOGICAL DISEASE ACCOMPANIED BY INFLAMMATION AND/OR DEMYELINATION - Novel means useful for definitive diagnosis of a neurological disease accompanied by at least one of inflammation and demyelination, such as multiple sclerosis or neuromyelitis optica, is disclosed. The method for detecting a neurological disease (excluding cerebral infarction) accompanied by at least one of inflammation and demyelination provided by the present invention comprises measuring Crtac1B protein in a sample separated from a subject. The presence of the neurological disease is detected based on a low value of the Crtac1B protein level. | 10-15-2015 |
20150293132 | INTEGRITY TESTING OF HAIR SAMPLES - Methods for assessing the condition of keratinized structures, including hair, in particular methods to determine the condition of keratinized structures in relation to suitability for analysis of analytes of interest in a test sample, are presented. The methods comprise contacting the keratinized structure with a non-proteolytic reducing agent and an optional proteolytic agent. The methods further include inspection of the hair sample, or measurement of free protein eluted from the keratinized structure, after reduction and optional proteolysis to determine condition prior to analyte identification and quantitation by known techniques such as immunoassays. | 10-15-2015 |
20150298118 | Test Device and Sample Carrier - A test device ( | 10-22-2015 |
20150299244 | TESTOSTERONE DERIVATIVES WITH A CARBOXYALKYL SUBSTITUTION IN POSITION 3 AND USE THEREOF FOR THE PRODUCTION OF LABELLED STEROIDS FOR DETERMINING THE CONCENTRATION OF TESTOSTERONE IN A BIOLOGICAL SAMPLE - A testosterone derivative of formula (I): | 10-22-2015 |
20150301025 | PREDICTING HUMAN DEVELOPMENTAL TOXICITY OF PHARMACEUTICALS USING HUMAN STEM-LIKE CELLS AND METABOLOMIC RATIOS - This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound. | 10-22-2015 |
20150301035 | CALIBRATION STRIP FOR AN IMMUNOBLOT - An apparatus for detecting antibodies in a patient sample includes at least one incubation channel for accommodating a patient strip and for incubating the patient strip with a patient sample, a conjugate and a substrate and a control mechanism for visual inspection of incubation quality. A separate calibration strip has at least two control zones which are implemented in such a way that, owing to incubation with a reference sample, a conjugate and a substrate, a control band becomes visible in each case in the control zones in such a way that the color intensities of the control bands differ. An evaluation unit generates a calibration curve taking the different color intensities into account and ascertains, on the basis of the calibration curve, a quality value for an antibody-pathogen protein reaction which took place on the patient strip and information about antibody concentration in the patient sample examined. | 10-22-2015 |
20150301036 | METHOD FOR ENHANCING ENZYME ASSAYS - Additives capable of controlling the reaction rate between substrate and enzyme to form a dye in enzyme assays with absorbance, chemiluminescence, and fluorescence are effective tools for optimizing enzyme assays. A dye can be formed rapidly from the reaction between enzyme and substrate in the presence of a catalyst. Using relatively high concentration of dye formed from the rapid reaction, trace levels of analytical materials can be quantified using absorbance, chemiluminecence and fluorescence detection. A dye can be formed from a relatively slow reaction between enzyme and substrate in the presence of a surfactant such as Triton® X-100 and β-cyclodextrin. Using relatively low concentration of dye from the slow reaction, a high concentration of analytical material can be quantified without any dilution using absorbance, chemiluminescence, and fluorescence. | 10-22-2015 |
20150309017 | NON-COMPETITIVE IMMUNOASSAYS TO DETECT SMALL MOLECULES USING NANOPEPTAMERS - The present invention is directed to noncompetitive methods for detecting small analytes using nanopeptamers, and to devices useful for performing the methods. Nanopeptamers include a self-associating oligomeric protein that is attached to peptides that bind to an immune complex between the target analyte and a capture antibody. The noncompetitive methods allow for the direct detection of small analytes with increased sensitivity over competitive methods directed to the same target analyte, and provide a positive readout which is useful for rapid tests and on-site detection of small analytes such as such as pesticides, persistent organic pollutants, explosives, toxins, medicinal and abused drugs, and hormones. | 10-29-2015 |
20150309028 | METHODS AND COMPOSITIONS FOR SCREENING AND DETECTING BIOMARKERS - The present invention is concerned with a novel antigens associated with human tumors, including carcinomas of the colon or lung, as well as novel monoclonal antibodies which specifically bind to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antigens include 100 kDa glycoprotein that has a colorectal cancer membrane bound and a soluble form, has a UV absorbance peak at about 228 nm, an isoelectric point of about 3.5 to 4, a sialic acid content of about 20%, and does not substantially bind to an antibody specific for ACT. The antibodies find use both in methods such as the detection of malignant cells associated with tumors and in monitoring therapeutic treatment of humans with tumors. | 10-29-2015 |
20150309029 | Methods for Cancer Diagnosis, Anti-Cancer Drug Screening, and Test of Drug Effectiveness on the Basis of Phoshorylation of Ras at Thr-144 and Thr-148 - Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites. By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested. | 10-29-2015 |
20150330989 | METHOD AND SYSTEM FOR DIAGNOSING AND TREATING PREECLAMPSIA - Described herein are methods, systems and kits of the diagnosis of preeclampsia and HELLP syndrome, as well as the selection of a preeclampsia or HELLP syndrome treatment. These are based, at least in part, on the finding that proximal tubule injury, as measured by urinary KIM-1, is increased in severe preeclampsia and correlates with complement activation. The detection of complement proteins correlate with kidney injury in severe preeclampsia and/or HELLP syndrome and terminal complement blockage is a therapeutic approach taken as described in various embodiments of the present invention. | 11-19-2015 |
20150330999 | VEGF-A121 ASSAY - The invention provides a method for enriching the level of VEGF-A | 11-19-2015 |
20150338396 | GLYCOFORM DETECTION METHOD AND GLYCOFORM DETECTION DEVICE - It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts. | 11-26-2015 |
20150338405 | VACCINES AND DIAGNOSTICS FOR THE EHRLICHIOSES - The present invention concerns VLPT immunoreactive compositions for | 11-26-2015 |
20150338406 | IMMUNOREACTIVE GLYCOPROTEIN GP19 OF EHRLICHIA CANIS - The present invention concerns gp19 immunoreactive compositions for | 11-26-2015 |
20150338420 | DIAGNOSTIC METHOD FOR DETERMINING THE PRESENCE AND AMOUNT OF HUMAN INTERLEUKIN-3 IN A SAMPLE USING NOVEL IL-3 ANTIBODIES - For determining the presence and amount of human IL-3 in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3- antibody, fr agment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necesary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11. | 11-26-2015 |
20150344590 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 12-03-2015 |
20150346194 | Deglycosylation Reagents and Methods - Compositions and methods are provided for efficiently preparing a completely deglycosylated antibody where efficiency is measured in relative amounts of reagents in soluble or lyophilized form, and time and temperature of the reaction. Compositions and methods are also provided for separating substantially all N-linked glycans from a glycosylated antibody and for preserving functionality of the antibody. The methods are compatible with glycan labeling and protease digestion without the need for prior purification steps. | 12-03-2015 |
20150346195 | SCREENING OF CONJUGATED ANTIBODIES - Provided is a method for the functionalization of immunoglobulins through the use of transglutaminase, including methods for screening functionalized antibodies for characteristics of interest, antibody compositions comprising a plurality of functionalized antibodies, and functionalized antibodies with rodent constant regions. | 12-03-2015 |
20150346224 | PROCESS FOR THE PRODUCTION OF A HYBRIDOMA AND ANTIBODY OBTAINED THEREFROM, ABLE TO RECOGNIZE MORE THAN ONE VITAMIN D METABOLITE - The invention concerns a process for the production of a hybridoma, and of a monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D | 12-03-2015 |
20150355177 | DIAGNOSIS OF A NEUROLOGICAL DISEASE - The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide. | 12-10-2015 |
20150355196 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure. | 12-10-2015 |
20150361177 | SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. | 12-17-2015 |
20150361478 | ANIMAL FEED ENZYME EXTRACTION - An in-feed assay and buffers for extracting an enzyme from a feed pellet treated at high temperature is provided. Another embodiment of the invention is measuring the enzyme activity of the enzyme additive extracted from the animal feed, measuring the quantity of enzyme extracted from the animal feed, or measuring both. In one embodiment the enzyme is an animal feed additive, such as a phytase. | 12-17-2015 |
20150362502 | RAPID TEST FOR CELLULAR FIBRONECTIN - A rapid assay for detection of human cellular fibronectin (c-Fn) where ELISA-based assays have previously been developed for detecting and measuring cellular fibronectin in biological fluids, but these methods are too time-consuming for practical clinical diagnostic use. The assay of the present invention enables prediction of bleeding events on a rapid timescale. Described as well are high affinity human monoclonal antibodies, particularly those directed against isotopic determinants of cellular fibronectin (c-Fn), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than they do to plasma fibronectin, and enable assays to be created that detect c-Fn in less than 30 minutes in a variety of detection formats, and in some detection formats less than 15 minutes. These antibodies are useful for diagnostics, particularly prediction of bleeding events, prophylaxis and treatment of disease. | 12-17-2015 |
20150362510 | Biomarkers Related to Insulin Resistance Progression and Methods Using the Same - Biomarkers relating to insulin resistance and insulin resistance-related disorders are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. In addition, methods for monitoring the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. | 12-17-2015 |
20150368608 | METHOD FOR THE THREE-DIMENSIONAL CO-CULTURE OF PODOCYTES AND ENDOTHELIAL CELLS AND RELATIVE IN VITRO CO-CULTURE SYSTEM - The present invention relates to a new three-dimensional co-culture method of podocytes and endothelial cells, and a relative co-culture system. Furthermore, the invention relates to the use of said co-culture system as an in vitro study model of pathologies affecting the kidneys, and in particular the renal glomerular filtration barrier. | 12-24-2015 |
20150368692 | ANALYSIS OF THE ESTERIFICATION LEVEL OF CEREBROSTEROL AS A TOOL FOR DIAGNOSIS AND/OR PROGNOSIS OF NEURODEGENERATION - The present invention relates to a method for diagnosis and/or prognosis or for monitoring the activity of the enzyme LCAT in the central nervous system, comprising the steps of measuring the amount of non-esterified cerebrosterol ([24(S)OH—C | 12-24-2015 |
20150369799 | METHOD FOR SUPPRESSING FALSE NEGATIVE IN IMMUNOASSAY FOR DERIVED FROM BIOLOGICAL MUCOUS MEMBRANE - The problem to be solved is accurately and specifically detecting a target substance by suppressing the action of an immunoassay inhibitory substance contained in a specimen derived from a biological mucous membrane. A false negative can be suppressed by treating a specimen with a specimen treatment solution containing a compound having two or more sulfate groups in immunoassay for analyzing a target substance in a specimen derived from a biological mucous membrane. | 12-24-2015 |
20150369807 | METHODS AND DEVICES FOR DETERMINING A DISEASE STATE - The present invention, in some embodiments thereof, relates to methods and devices for determining a disease state in a patient. In some embodiments, human serum albumin may be analyzed for associated molecules, wherein the associated molecules are related to a disease such as cancer. Certain aspects of the invention are generally directed to devices and methods for determining a disease state as a function of the three-dimensional structure of a blood protein, human serum albumin (HSA) or its complex with other ligands, e.g., due to binding to disease-specific ligands. HSA interacts with biomolecules associated with a disease presence, and liganded HSA may differentially partition between aqueous phases of a predetermined partitioning system, wherein the partitioning behavior differs between HSA from healthy individuals and HSA from people harboring the predetermined disease, such as breast cancer. | 12-24-2015 |
20150369821 | NOVEL LIPOCALIN-MUTEIN ASSAYS FOR MEASURING HEPCIDIN CONCENTRATION - The present invention relates to lipocalin-mutein assays for measuring hepcidin concentration as well as methods preparing and utilizing and kits leveraging the lipocalin-mutein assays. | 12-24-2015 |
20150377876 | DIAGNOSTIC TOOLS TO PREDICT ONSET OF PREECLAMPSIA - Assays, kits, methods, and devices for diagnosing or predicting the likelihood of occurrence preeclampsia in a subject are disclosed. | 12-31-2015 |
20150377878 | DEVICES, METHODS, AND KITS FOR DETECTING AN ANALYTE IN A SAMPLE - One aspect of the invention provides a device for detecting an analyte in a sample. The device includes: a sample loading region, an imaging window, a well, and an absorbent pad. The sample loading region is in fluid communication with the well. The well is in fluid communication with the absorbent pad, such that when a fluid sample comprising solid support structures and a liquid carrier are applied to the sample loading region, the fluid sample travels to the well and at least part of the liquid carrier is absorbed into the absorbent pad. | 12-31-2015 |
20150377881 | METHODS AND COMPOSITIONS FOR IMPROVING DETECTION AND/OR CAPTURE OF A TARGET ENTITY - Embodiments of various aspects described herein are directed to methods, compositions, kits and systems for detecting and/or capturing a target entity in a sample. In particular, the methods, compositions and kits described herein relate to pretreatment of target-binding agents with a blocking agent described herein to reduce non-target binding in a complex matrix (e.g., blood). In some embodiments, methods and compositions for detecting and/or capturing a microbe in a test sample, including bodily fluids such as blood and tissues of a subject, food, water, and environmental surfaces are also provided herein. | 12-31-2015 |
20150377890 | METHOD OF DIAGNOSING NEOPLASTIC CONDITIONS - The present invention relates generally to a method for detecting an aberrant cell, and more particularly an apoptotic cell, in a subject or in a biological sample from said subject, and agents useful for same. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition. More particularly, the present invention contemplates a method for detecting an apoptotic cell by detecting the presence of extranuclear nuclear molecules, in particular La, or a relative increase in extranuclear nuclear molecule levels. The present invention further provides a method for diagnosing or monitoring conditions characterised by aberrant, unwanted or otherwise inappropriate cellular apoptosis in a subject or in a biological sample from said subject by screening for up-regulation of extranuclear nuclear molecule levels in a cell or group of cells. The present invention provides diagnostic agents useful for detecting these molecules. Such diagnostic agents include immunointeractive molecules, such as antibodies. | 12-31-2015 |
20160003810 | A METHOD FOR ESTIMATING GFR (GLOMERULAR FILTRATION RATE) FROM MEASURED VALUE OF MEGALIN IN URINE - The object of the present invention is to provide a method for estimating the glomerular renal function in a convenient and non-invasive manner. As a result of intensive studies to achieve the above object, the present inventors found that there is a high correlation between the urinary megalin excretion rate and the estimated glomerular filtration rate (eGFR) in renal disease patients, and the glomerular filtration rate (GFR) can be estimated with high probability in a non-invasive manner by measuring the megalin level in the urine. This has led to the completion of the present invention. | 01-07-2016 |
20160003834 | Reagent For Diagnosing Tumor, Pharmaceutical Composition, And Screening Method - The present invention provides antibodies useful for diagnosing and treating tumors as well as methods of screening for antitumor agents . More specifically, tumors can be diagnosed and treated using an anti-phosphorylated p62 antibody that recognizes phosphorylation of serine at position 351 of an amino acid sequence of SEQ ID No. 1 or at a position corresponding thereto. An antitumor agent can be obtained by screening for a substance that inhibits the phosphorylation or that dephosphorylates the phosphorylated serine. | 01-07-2016 |
20160003851 | Treatment of Acute Tubular Necrosis or Acute Tubule-Interstitial Nephropathy - Methods for treating, monitoring and diagnosing renal disorders including measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided. | 01-07-2016 |
20160008629 | CLINICAL DECISION SUPPORT (CDS) FOR RADIOTHERAPY IN PROSTATE CANCER | 01-14-2016 |
20160009795 | Anti-p40 Antibodies Systems and Methods | 01-14-2016 |
20160011181 | PSA ASSAY AND REAGENT THEREFOR | 01-14-2016 |
20160011192 | METHOD AND KIT FOR CYTOKINE ANALYSIS FROM A HUMAN WHOLE BLOOD SAMPLE | 01-14-2016 |
20160011210 | TROPONIN AND BNP BASED DIAGNOSIS OF RISK PATIENTS AND CAUSE OF STROKE | 01-14-2016 |
20160011217 | ANTIBODY AGAINST INSOLUBLE FIBRIN | 01-14-2016 |
20160011218 | ANALYSIS OF DIRECT FACTOR Xa INHIBITORS | 01-14-2016 |
20160018418 | HMGB1 AND ANTI-HMGB1 ANTIBODIES FOR THE PROGNOSTIC OF NEUROLOGICAL DISORDERS - The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient. | 01-21-2016 |
20160018419 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 01-21-2016 |
20160022190 | MULTI LUMEN CATHETER - A multi lumen catheter comprising a proximal end and distal end said catheter further comprising; a first lumen for a first fluid said first lumen having a first proximal opening and a first distal opening for receiving a fluid, second lumen for a second fluid said second lumen having a second proximal opening and a second distal opening for delivering a second fluid, a third lumen having a third proximal opening and a third distal opening, wherein the first distal opening is arranged with respect to the second distal opening so that when in use at least part of the first fluid which enters the first lumen through the first distal opening has passed across the second distal opening such that the first fluid which enters the first lumen comprise at least a part of the second fluid. | 01-28-2016 |
20160025707 | PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE - The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use. | 01-28-2016 |
20160025721 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 01-28-2016 |
20160025723 | MICROFLUIDIC DEVICE FOR IMMUNOBLOTTING - The present invention provides microfluidic devices, systems, and methods for use in immunoblotting applications. I particular, devices and methods provided herein have the advantages of traditional Western blotting with increased throughput and multiplex ability, and decreased time, sample, and reagent requirements. | 01-28-2016 |
20160025749 | PROTEIN FORMULATIONS - The present disclosure provides stable, solid protein formulations. The present disclosure also provides methods of using these formulations in protein detection kits that are stable over a variety of temperatures for extended time periods. | 01-28-2016 |
20160033412 | PARTIALLY ENCAPSULATED WAVEGUIDE BASED SENSING CHIPS, SYSTEMS AND METHODS OF USE - Optical readers and alignment tools for detecting the level of an analyte. Described herein are small, disposable partially-encapsulated sensing chips for detecting an analyte level from a fluid sample (e.g., a blood sample) having an edge of the integrated sensing chip exposed to directly expose a plurality of excitation and a collection waveguides, as well as optical readers and methods of operating them. A fluid sample maybe applied to a sensing surface of the sensing chip in the housing so that an analyte level can be optically detected. Also described are methods of sensing an analyte using these devices and systems including an optical detector. | 02-04-2016 |
20160033482 | BIOLOGICAL SPECIMEN EVALUATION METHODS USING CYTOLOGY AND IMMUNOLOGY - Information on cytokines and cytology obtained from a biological specimen are combined as a method of predicting the risk that dysplasia will progress to cancer. Methods are disclosed herein to augment the evaluation of biological samples from subjects being tested for cancer. In addition to the cell types that are traditionally considered in the morphology-based cytological screening of specimens, methods disclosed herein add evaluations of certain cell types and cytokines that are traditionally discounted or ignored during screening. | 02-04-2016 |
20160033501 | TEST KIT - The present invention provides a test kit capable of rapid and highly sensitive detection. | 02-04-2016 |
20160033510 | ANTIBODIES FOR THE IDENTIFICATION OF PANCREATIC DISORDERS - Levels of VEGF-A, VEGF-C and PGE | 02-04-2016 |
20160033512 | DIAGNOSIS OF CARCINOMAS - The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages. | 02-04-2016 |
20160033523 | PHARMACOKINETIC ANIMAL MODEL - The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species, the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants. | 02-04-2016 |
20160033529 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME - The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers. | 02-04-2016 |
20160038936 | LATERAL-FLOW ASSAY DEVICE HAVING FLOW CONSTRICTIONS - A lateral-flow assay device includes a substrate having a sample addition zone and a wash addition zone downstream thereof along a fluid flow path through which a sample flows. The fluid flow path is configured to receive a wash fluid in the wash addition zone. A hydrophilic surface is arranged in the wash addition zone. Flow constriction(s) are spaced apart from the fluid flow path and arranged to define, with the hydrophilic surface, a reservoir configured to retain the wash fluid by formation of a meniscus between the hydrophilic surface and the flow constriction(s). The fluid flow path draws the wash fluid from the reservoir by capillary pressure. Apparatus for analyzing a fluidic sample and methods of displacing a fluidic sample in a fluid flow path of an assay device are also described. | 02-11-2016 |
20160038937 | LATERAL-FLOW ASSAY DEVICE WITH FILTRATION FLOW CONTROL - A lateral-flow assay device includes a substrate with a sample addition zone and a fluid flow path. A cover supports a filter having a portion contacting the substrate to create a contact area that at least partly overlaps the sample addition zone. Another portion extends from the contact portion to the supported periphery of the filter to define with the substrate a reservoir configured to retain the filtrate by capillary pressure between the substrate and the extending portion. The reservoir volume is based on an acute angle formed between the substrate and the extending portion of the filter and on a fluid meniscus of the filtrate. The filter and sample addition zone are configured to provide capillary pressure drawing the filtrate from the reservoir to the sample addition zone. Methods for controlling flow characteristics in a lateral-flow assay device are also described. | 02-11-2016 |
20160041154 | IMMUNOASSAYS OF S-ADENOSYLMETHIONINE AND METHYLATION INDEX IN PERSONALIZED MEDICINE AND HEALTH EVALUATION - The invention provides a method of detecting the presence, absence or severity of a disease in a patient wherein said disease is accompanied by decreased level of S-adenosylmethionine, or increased level of S-adenosylhomocysterine, or reduced methylation index comprising: identifying any individual or a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of SAM in said biological sample using an antibody derived from a hapten analog of SAM, SAH; and correlating the levels of SAM, SAH and MI in said biological sample with the presence, absence, or severity of said disease. The invention also provides methods for determining methylation index in biological fluids which is indicative of the health status of an individual. Additionally, the invention includes colloidal gold test strips and homogenous enzyme immunoassays which are useful for determining S-adenosylmethionine and S-adenosylhomocysteine. | 02-11-2016 |
20160041157 | Method for the site-specific covalent cross-linking of antibodies to surfaces - This invention relates to conjugate antibody, drug and nanoparticle compositions and methods of generating the same. This invention further relates to methods of using same for imaging, diagnosing or treating a disease. | 02-11-2016 |
20160041175 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS - The invention described herein relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX from a biological sample. | 02-11-2016 |
20160041186 | Immunogenicity Assay - Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described. | 02-11-2016 |
20160046695 | METHOD FOR ALTERING THE BINDING SPECIFICITY OF PLASMA PROTEINS BY OXIDATION - The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity. | 02-18-2016 |
20160047807 | Method for Detection of Legionella Bacteria Employing Purified Antigen-Specific Antibodies - The present invention involves extracting from | 02-18-2016 |
20160061825 | Kits for Fecal Neopterin Concentration Measurement as an Indicator of Disease Activity in Inflammatory Bowel Disease - Disclosed are methods for determining disease activity in a patient having or at risk for developing inflammatory bowel disease (IBD) which include measuring neopterin concentration in a fecal sample from the patient. | 03-03-2016 |
20160061832 | Biomarkers for Inflammatory Bowel Disease with Ankylosing Spondylitis - There is provided herein a method for categorizing a patient having inflammatory bowel disease as being at risk for developing ankylosing spondylitis. The method comprises the use of a patient level of auto-antibodies directed against noggin (NOG) and/or sclerostin (SOST) to determine a risk for the patient developing ankylosing spondylitis. There is also provided methods of monitoring ankylosing spondylitis treatment using these auto-antibodies. | 03-03-2016 |
20160069869 | Ectoparasite Detection - Ectoparasite infestation of a substrate like bedding is detected by contacting a sample from the substrate with a polyclonal ectoparasite antibody generated from a whole ectoparasite immunogen, under conditions wherein the antibody specifically binds ectoparasite antigen in the sample. | 03-10-2016 |
20160069885 | Detection of Early-Stage Pancreatic Adenocarcinoma - Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. | 03-10-2016 |
20160069886 | BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER - Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules. | 03-10-2016 |
20160069888 | METHOD FOR THE DIAGNOSTIC OF CANCER AND ENZYME-LINKED IMMUNOASSAY (ELISA) KIT FOR ITS APPLICATION - The invention relates to the field of medical diagnostics, immunology and oncology, in particular to the new tumor markers, useful in the early diagnosis of cancer and methods for cancer diagnostics. A new antigen for ELISA to detect antibodies associated with malignancies, namely, mature human plasminogen or human plasminogen fragments containing kringles. We propose a method of diagnosing cancer at an early stage by detecting autoantibodies of type IgA, IgG, IgM to human plasminogen or its fragments in a samples of human blood plasma or sera. | 03-10-2016 |
20160069905 | Compositions and Methods for Detection of Defensins in a Patient Sample - Methods, devices and compositions for diagnosing, predicting and monitoring a urinary tract infection in a subject are described. The detection, prediction and monitoring of a urinary tract infection in a subject by detection of HD5 in the urine of a subject is described. | 03-10-2016 |
20160069910 | DETECTING ENDOCRINE DISRUPTING COMPOUNDS - A method and a detection device for detecting endocrine disrupting compounds are provided. The detection device includes a support structure and ligand binding domains (LBD) of at least one sex hormone receptor, immobilised on the support structure. The detection device further includes a linker molecule between the support structure and the ligand binding domains, for immobilising the LBD's on the support structure. | 03-10-2016 |
20160077089 | Platelet Allo-Antigen Typing And Platelet Antibody Tests - The present invention relates to methods for the detection of human platelet alloantigens (HPAs) on human platelets, methods for the detection of human antibodies against HPAs, and diagnostic test devices for carrying our said methods. | 03-17-2016 |
20160077092 | METHODS FOR ANALYSIS OF FREE AND AUTOANTIBODY-BOUND BIOMARKERS AND ASSOCIATED COMPOSITIONS, DEVICES, AND SYSTEMS - The present invention provides methods, compositions, and kits associated with analyzing, enriching, and/or isolating a biomarker or analyte in a biological sample. In one aspect, for example, a method for determining a concentration of a biomarker in a biological sample can include binding any unbound biomarker with an antibody specific for the biomarker to form antibody-bound biomarker, enriching the antibody-bound biomarker and any endogenous autoantibody-bound biomarker to form an enriched fraction, identifying the biomarker in the enriched fraction, and determining the concentration of the biomarker in the biological sample. In one aspect, the concentration of the biomarker is derived from initially unbound biomarker and autoantibody-bound biomarker in the biological sample. | 03-17-2016 |
20160077093 | METHODS FOR DETECTING EHRLICHIA INFECTION - The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against | 03-17-2016 |
20160077109 | CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF HUMAN SERUM PROTEIN BIOMARKERS - The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analysed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-α-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and β2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers. | 03-17-2016 |
20160077110 | Detection of Misfolded Amyloid Beta Protein - Methods and kits are provided for amplifying and detecting Aβ proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded Aβ protein may include contacting the sample with a monomeric, folded Aβ protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded Aβ protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded Aβ protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded Aβ aggregate present; and determining the presence of the soluble, misfolded Aβ protein in the sample by detecting at least a portion of the amplified portion of misfolded Aβ protein. | 03-17-2016 |
20160077111 | Detection of Misfolded Alpha Synuclein Protein - Methods and kits are provided for amplifying and detecting αS proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded αS protein may include: contacting the sample with a monomeric, folded αS protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded αS protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded αS protein in the presence of the soluble, misfolded αS protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded αS aggregate present; and determining the presence of the soluble, misfolded αS protein in the sample by detecting at least a portion of the soluble, misfolded αS protein. | 03-17-2016 |
20160077112 | Detection of Misfolded Proteins - Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof. | 03-17-2016 |
20160083735 | PROMOTER - The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5′ shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers. | 03-24-2016 |
20160084821 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CANCER SUSCEPTIBILITIES AND DEFECTIVE DNA REPAIR MECHANISMS AND TREATMENT THEREOF - Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway. | 03-24-2016 |
20160084836 | IMMUNOREACTIVE PROTEIN ORTHOLOGS OF EHRLICHIA CANIS AND E. CHAFFEENSIS - The present invention concerns gp36 immunoreactive compositions for | 03-24-2016 |
20160084841 | Method for Predicting Clinical Effect of Immunotherapy - Provided is a method for predicting a clinical effect on a subject in a WT1 peptide immunotherapy, said method comprising: a) a step for contacting a sample derived from the subject with WT1 antigen peptide or a variant thereof; and b) a step for detecting the binding of the sample to the WT1 antigen peptide or a variant thereof and thus measuring anti-WT1 antigen peptide IgG antibody titer existing in the sample, characterized in that an increase in the anti-WT1 antigen peptide IgG antibody titer in the subject determines the achievement of a favorable clinical effect. Also provided is a kit for performing the method according to the present invention, said kit containing WT1 antigen peptide or a variant thereof. | 03-24-2016 |
20160091486 | GLATIRAMER ACETATE HUMAN MONOCYTIC CELL LINE-BASED POTENCY ASSAY - The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon gamma (IFNγ), exposing said cells to said batch of glatiramer acetate, and determining the expression of the monocyte anti-inflammatory cytokine sIL-1Ra or the viability of said cells induced by glatiramer acetate. | 03-31-2016 |
20160091502 | TEXT NOT AVAILABLE - Methods of diagnosis or of quantitation of fibrosis are provided that comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope. The protein is collagen type III, collagen type I, collagen type IV, collagen type V, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein. | 03-31-2016 |
20160097776 | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND METHODS FOR USE OF SAME - Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided. | 04-07-2016 |
20160097777 | IMMUNOLOGICAL METHOD - The present invention relates to an in vitro method for the detection of an anti-drug antibody (ADA) against a therapeutic drug antibody (TDA) in a biological sample. The in vitro method comprises detecting and capturing said ADA using affinity moieties obtained from an intact therapeutic drug antibody, or a Fab fragment thereof, in a certain manner. Avoiding using only intact therapeutic drug antibodies or only Fab fragments thereof as reagents in such a method has been proven as an efficient way of increasing sensitivity, decreasing unspecific binding and the formation of large protein complexes. Such a method has great utility in therapeutic drug development or in the evaluation of a particular treatment of a patient. | 04-07-2016 |
20160097779 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta-1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries. | 04-07-2016 |
20160097784 | DETECTION OF POLYMYXINS - The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers. | 04-07-2016 |
20160101046 | POSTERIOR SEGMENT DRUG DELIVERY - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. | 04-14-2016 |
20160102124 | VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA SPECIES AND STRAINS - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic | 04-14-2016 |
20160103128 | NOVEL IMMUNOGENIC PROTEINS OF LEPTOSPIRA - The invention provides novel immunogenic proteins LigA and LigB from | 04-14-2016 |
20160103141 | COMPOSITIONS AND METHODS FOR DETECTING VITAMIN D - Compounds include carbamate derivatives of vitamin D including vitamin D | 04-14-2016 |
20160107141 | SOLID SUPPORT INCLUDING A POLYMER AND USE THEREOF - A solid support with a polymer, and a method of using the solid support are provided. | 04-21-2016 |
20160107157 | Specimen Acceptance Devices and Attachable Disposable Assay Cartridges - An apparatus includes a device for storing a liquid sample, in which the device has a sample acceptance well, one or more storage chambers, and one or more fluidic channels fluidly coupling the sample acceptance well to the one or more storage chambers. The apparatus also includes a well plate having a plate and multiple wells formed in the plate, in which the device and the well plate are configured to be attached to one another. | 04-21-2016 |
20160108117 | Anti-CXCL1, CXCL7 and CXCL8 Antibodies and their Applications - The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (K | 04-21-2016 |
20160109449 | ANTIBODIES OR FRAGMENTS THEREOF DIRECTED AGAINST A STAPHYLOCOCCUS AUREUS EPITOPE OF ISAA OR ISAB - The invention concerns antibodies or fragments thereof that are directed against a | 04-21-2016 |
20160109452 | LUNG CANCER BIOMARKER - The present invention relates to a lung cancer biomarker for diagnosing early stage lung cancers or predicting prognosis of lung cancers, which comprises a GM2AP protein. The present invention also relates to a method for diagnosing early stage lung cancers or predicting prognosis of lung cancers in vitro by detection of the biomarker. | 04-21-2016 |
20160109457 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF ANAPLASMA ANTIBODIES - The invention provides populations of isolated peptides useful for the detection of antibodies that bind to | 04-21-2016 |
20160109460 | Methods And Compositions For Determining Fortilin Levels - Certain embodiments are directed to method of measuring fortilin in a serum sample as a biomarker of in vivo apoptosis, which can be utilized to noninvasively assess the status of in vivo apoptosis in a subject. | 04-21-2016 |
20160109464 | GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients - The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide. | 04-21-2016 |
20160116463 | METHOD FOR MEASURING THE PLASMA CONCENTRATION OF AN ANALYTE DIRECTLY ON A WHOLE BLOOD SAMPLE - A method of measuring an analyte amount in a whole blood sample, including:
| 04-28-2016 |
20160121330 | CENTRIFUGE/MAGNET-BASED ANALYZERS AND METHOD OF OPERATING THEREOF - The present invention provides centrifuge/magnet-based analyzers and methods of operating thereof. The analyzer comprises three discs sandwiched together, in which each disc has difference functions. The top disc comprises magnetic units configured in patterns, whereas the bottom disc comprises tracks and magnetic units free to move in the tracks. The magnetic field co-generated by the top disc and the bottom disc attracts the magnetic beads in the intermediate disc to move and thus facilitates the reactions in the intermediate disc. | 05-05-2016 |
20160122423 | BLOOD MARKERS FOR DIAGNOSING EPITHELIUM DERIVED CANCERS AND MONOCLONAL ANTIBODIES THEREOF - The present invention provides uses of cytokeratins as markers for diagnosing epithelium derived cancers. The present invention provides cancer-related epitopes of cytokeratins and monoclonal antibodies which specifically recognize the epitopes. The present invention also provides methods for the early screen, diagnosis or prognosis of epithelium derived cancers in subjects, methods for the evaluation of therapeutic effect of related medicaments or therapies, and kits for accomplishing the methods. | 05-05-2016 |
20160123965 | REAGENTS, METHODS AND DEVICES TO PREVENT AGGREGATION IN PARTICLE BASED TESTS FOR THE DETECTION OF MULTIMERIC TARGET MOLECULES - The present invention relates to a method for preventing aggregation of detection particles in a test for detecting a multi-epitope target analyte comprising two or more similar or identical epitopes in a sample and/or for determining the concentration of the multi-epitope target analyte in a sample wherein the method comprises the step of applying a first capture entity which can specifically bind to at least one epitope on the multi-epitope analyte, characterized in that the first capture entity blocks the at least one epitope from binding to a detection particle. The invention further relates to a method wherein the detection of the multi-epitope target analyte comprises the use of a second capture entity, which can specifically bind to the same or similar epitope of the multi-epitope target analyte as the first capture entity. Also envisaged is a method for the detection of said multi-epitope target analyte, the performance of the method in a system comprising a sensor surface and the use of a first capture entity to block the at least one epitope from binding to a detection particle such as a magnetic detection particle. | 05-05-2016 |
20160123986 | METHOD FOR DIAGNOSING CANCER USING SECRETED RIBOSOMAL PROTEIN S3 - A method for diagnosing cancer using secreted ribosomal protein S3 (rpS3) is described, and more particularly, a method for diagnosing cancer or cancer metastasis using ribosomal protein S3 (rpS3) that is expressed in and secreted from cancer cells. Measuring the amount of extracellularly secreted rpS3 protein according to the present disclosure is highly useful for diagnosing cancer or cancer metastasis in a rapid and convenient manner using a biological sample such as blood. | 05-05-2016 |
20160123995 | Biomarker of Rehospitalization After Heart Failure - The invention relates to a method for establishing if a heart failure patient is susceptible to be hospitalized and/or rehospitalized, wherein said method comprises measuring the concentration of IGFBP | 05-05-2016 |
20160131661 | PHOSPHORYLCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES - In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. Pharmaceutical compositions comprising a phosphorylcholine conjugate or antibody preparations, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate is proposed as is use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis. | 05-12-2016 |
20160139145 | DIAGNOSTIC BLOOD TEST FOR SARCOIDOSIS - Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. The present invention discloses kits and a system for a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis. | 05-19-2016 |
20160139156 | APPARATUSES, METHODS, AND SYSTEMS FOR HOME MONITORING OF PHYSIOLOGICAL STATES AND CONDITIONS - Methods, systems and apparatuses for monitoring a physiological condition of a user. The apparatus includes a housing, a processor, a power source, a receptacle configured to receive an inserted test strip, an imaging unit configured to image the inserted test strip, and a communication unit configured to communicate data received from the imaging unit to a communication network. The apparatus is configured to read color change results produced by more than one different type test strip, and the more than one different type of test strip each produce a different color to indicate the presence of an analyte. The apparatus may include two separate but connectable units: an analyte sensing unit and a base unit. The apparatus may further include a temperature sensing unit which may alternatively connect with the base unit. The apparatus may communicate with a mobile application on a hand held device. | 05-19-2016 |
20160146795 | POROUS MEMBRANES WITH A POLYMER GRAFTING, METHODS AND USES THEREOF - A modified porous membrane comprising a polymer coating grafted to a porous membrane is described. A method for analyte detection from a biological sample using an immunoassay is also provided using the modified membrane, wherein the method comprises a) providing a modified porous membrane having the structure of Formula (I), b) incubating the modified porous membrane with a first biomolecule, wherein the first biomolecule binds to the modified porous membrane to form a first biomolecule bound modified porous membrane; and c) adding a biological sample comprising at least an analyte to the first biomolecule bound modified porous membrane for analyte detection by binding the analyte to the first biomolecule bound to the modified porous membrane. | 05-26-2016 |
20160146808 | APPARATUSES AND METHODS FOR GENERATING AND MEASUIRNG ENVIRONMENTAL LEVELS OF ALLERGENS - The present disclosure provides an apparatus comprising an air circulating device, an allergen source comprising an allergen, and a housing. The housing can be collapsible, portable, disposable and configurable. The present disclosure also provides a method comprising positioning an allergen source comprising an allergen in a chamber, distributing at least a portion of the allergen from the allergen source within the chamber, and collecting at least a portion of the distributed allergen. In an embodiment, the level of the shed allergen can be used to measure the effectiveness of various measures implemented to reduce airborne Fel d1 that is emitted from soiled cat litter. In another embodiment, the allergen can be introduced at a desired level in the chamber, and the resultant symptoms of a subject (e.g. a human) within the chamber can be identified and correlated with the amount of allergen. | 05-26-2016 |
20160153024 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS FOR DETERMINGING THE PRESENCE, IDENTITY, OR SEVERITY OF A DISEASE OR CONDITION | 06-02-2016 |
20160153971 | METHOD FOR DETERMINIG AGGLUTINATION | 06-02-2016 |
20160153982 | Controlling Fluid Flow Through An Assay Device | 06-02-2016 |
20160154007 | MONOCLONAL ANTIBODY RECOGNIZING HUMAN PAPILLOMAVIRUS (HPV) L2 PROTEIN AND METHOD FOR MEASURING HPV-NEUTRALIZING ANTIBODY TITER USING THE SAME | 06-02-2016 |
20160154014 | METHOD FOR DETERMINING DEPRESSION, KIT FOR ANALYZING SEROTONIN TRANSPORTER, AND KIT FOR ANALYZING UBIQUITINATED SEROTONIN TRANSPORTER IN BLOOD | 06-02-2016 |
20160161509 | METHODS FOR PREDICTING EMBRYO VIABILITY - The present invention provides methods for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence or absence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample. In many instances, the invention is applicable to embryos generated by in vitro fertilization techniques, for instance, to embryos developing in a growth media. The present invention further provides methods for determining the amount of a pregnancy associated markers such as molecular isoforms of hCG (hCG) in a sample. The present invention also provides a diagnostic kit for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample. | 06-09-2016 |
20160167848 | STORAGE CONTAINER FOR LIQUIDS | 06-16-2016 |
20160168236 | ANTI-GALECTIN-1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF | 06-16-2016 |
20160168614 | SCREENING FOR L-FORM BACTERIA | 06-16-2016 |
20160169883 | SENSOR CHIP, DETECTION SYSTEM, AND METHOD OF DETECTING TARGET SUBSTANCE IN ANALYTE | 06-16-2016 |
20160169906 | METHODS FOR IDENTIFYING AUTOIMMUNE ARTHRITIS AND FOR SCREENING FOR INHIBITOR OF ACTIVATION OF AUTOIMMUNE ARTHRITOGENIC T CELLS | 06-16-2016 |
20160169910 | Non-Glycosylated suPar Biomarkers and Uses Thereof | 06-16-2016 |
20160169911 | MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE | 06-16-2016 |
20160178633 | TUMOR BIOMARKER | 06-23-2016 |
20160178634 | METHOD FOR PREDICTING CANCER SENSITIVITY | 06-23-2016 |
20160178645 | DIAGNOSTIC AND MONITORING SYSTEM FOR HUNTINGTON'S DISEASE | 06-23-2016 |
20160178647 | Gum Condition Assessment | 06-23-2016 |
20160178650 | COMPOSITIONS AND METHODS FOR DETECTING CORTISOL | 06-23-2016 |
20160187357 | COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION - A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. | 06-30-2016 |
20160194377 | Crystal Structure of Staphylococcus Aureus Clumping Factor A in Complex with Fibrinogen Derived Peptide and Uses Thereof | 07-07-2016 |
20160195527 | BORRELIA DIAGNOSTICS AND SCREENING METHODS | 07-07-2016 |
20160195528 | Method for the Detection of H. Pylori Infection | 07-07-2016 |
20160195542 | METHOD FOR EVALUATING THE RISK OF MORTALITY IN PATIENTS WHO EXHIBIT A SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) OR SEPSIS | 07-07-2016 |
20160195551 | METHOD FOR EVALUATING SALIVARY ADIPONECTIN LEVEL AND KIT FOR MEASURING SALIVARY ADIPONECTIN LEVEL | 07-07-2016 |
20160202183 | SPECTRAL SHIFTS AND MODIFICATIONS IN METAL-ENHANCED FLUORESCENCE, PHOSPHORESCENCE AND ALPHA-FLUORESCENCE | 07-14-2016 |
20160202245 | Means and Methods for the determination of the biological activity of Neurotoxin polypeptides in cells | 07-14-2016 |
20160202274 | CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS | 07-14-2016 |
20160251450 | PROTEIN-POLYMER COMPLEX, TGase SUBSTRATE-CONTAINING POLYMER, TGase SUBSTRATE-CONTAINING MONOMER, METHOD FOR PRODUCING PROTEIN-POLYMER COMPLEX, AND METHOD FOR IMPROVING PROTEIN FUNCTION AT SOLID-LIQUID INTERFACE OR IN VICINITY OF SOLID-LIQUID INTERFACE | 09-01-2016 |
20160252533 | DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES | 09-01-2016 |
20160376331 | ELECTROACTIVE BIOPOLYMER OPTICAL AND ELECTRO-OPTICAL DEVICES AND METHOD OF MANUFACTURING THE SAME - A method of manufacturing a biopolymer optical device includes providing a polymer, providing a substrate, casting the polymer on the substrate, and enzymatically polymerizing an organic compound to generate a conducting polymer between the provided polymer and the substrate. The polymer may be a biopolymer such as silk and may be modified using organic compounds such as tyrosines to provide a molecular-level interface between the provided bulk biopolymer of the biopolymer optical device and a substrate or other conducting layer via a tyrosine-enzyme polymerization. The enzymatically polymerizing may include catalyzing the organic compound with peroxidase enzyme reactions. The result is a carbon-carbon conjugated backbone that provides polymeric “wires” for use in polymer and biopolymer optical devices. An all organic biopolymer electroactive material is thereby provided that provides optical functions and features. | 12-29-2016 |
20160377594 | METHOD FOR ASSESSMENT OF HEPATIC FUNCTION AND PORTAL BLOOD FLOW - A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease. | 12-29-2016 |
20160377613 | Diagnostic Test Of Streptococcus Agalactiae Infections - The method of the invention allows confirmation of infections caused by | 12-29-2016 |
20160377624 | COMPOSITION AND METHOD FOR DETECTING MALIGNANT NEOPLASTIC DISEASE - The present invention provides a composition comprising at least two targeting agents, wherein at least one first targeting agent recognizes a keratin 7 peptide and/or fragment(s) thereof, and at least one second targeting agent recognizes a keratin 19 peptide and/or fragment(s) thereof. Said first and second targeting agents are capable of binding specifically and simultaneously to a heterotypic complex of keratin 7 with keratin 19, and/or fragment(s) thereof. The composition of the invention may be used in methods for diagnosing and/or prognosing, predicting efficacy of treatment, assessing outcome of treatment of assessing recurrence of malignant neoplastic disease, such as e.g. lung cancer, bladder cancer, esophagus cancer, and ovarian cancer in a subject. | 12-29-2016 |
20160377629 | Methods and Apparatus for Detection of Gluten Sensitivity, and its Differentiation from Celiac Disease - Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of α-gliadin 33-mer, α-gliadin-17-mer, γ-gliadin-15-mer, ω-gliadin-17-mer, and glutenin 21-mer. Test plates and kits can advantageously test for antibodies to at least three, five, seven or all of mixed wheat antigens, α-gliadin, γ-gliadin, ω-gliadin, glutenin, α-glutenin, wheat germ agglutinin, gluteomorphin, prodynorphins, transglutaminase-2, transglutaminase-3, transglutaminase-6, and gliadin-bound transglutaminase. | 12-29-2016 |
20170233787 | METHODS AND COMPOSITIONS FOR ANALYZING GLUCOSE-6-PHOSPHATE DEHYDROGENASE ACTIVITY IN BLOOD SAMPLES | 08-17-2017 |
20170234862 | METHODS FOR BINDING BIOLOGICALLY ACTIVE MOLECULES TO SURFACES | 08-17-2017 |
20170234869 | ANTI-CARBAMYLATED PROTEIN ANTIBODIES AND THE RISK FOR ARTHRITIS | 08-17-2017 |
20170234901 | Modular Fluid Dispensing Devices | 08-17-2017 |
20180022782 | VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA SPECIES AND STRAINS | 01-25-2018 |
20180024129 | LATERAL FLOW DEVICE AND METHOD OF USE | 01-25-2018 |
20180024142 | IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINS | 01-25-2018 |
20180024145 | METHODS AND COMPOSITIONS FOR DIAGNOSING BRAIN INJURY OR NEURODEGENERATION | 01-25-2018 |
20190145957 | METHODS FOR EVALUATING THE PROTECTION EFFICACY OF A SUNSCREEN AGENT | 05-16-2019 |
20190145989 | METHODS OF MEASURING ADAMTS 13 ACTIVITY | 05-16-2019 |
20220135656 | Anti-Gliadin Antibodies - The present invention provides anti-gliadin antibodies and antibody fragments, and polypeptides encoding the antibodies or fragment. Also disclosed are methods and Kits for the use of such antibodies, fragments, or polypeptides in detection of gliadin. Further provided are heavy chain and light chain variable sequences and associated sequences of complementarity-determining regions (CDRs). | 05-05-2022 |
20220137037 | DEVICE AND METHOD FOR DETECTING PROTEIN-BASED MARKER, AND METHOD FOR MANUFACTURING CHIP - A detection device and method for detecting a protein-based marker, and method for manufacturing a chip are provided. The detection device includes a first cover plate, in which a liquid inlet and a liquid outlet are provided; a second cover plate attached to the first cover plate to form a chamber; and a chip in the chamber. The chip includes a glass substrate and a micro-hole array layer on a side of the glass substrate. The micro-hole array layer includes a plurality of micro-holes arranged in an array, with each of the micro-holes being a nano micro-hole. The liquid inlet and the liquid outlet are configured such that a solution containing a plurality of magnetic particles enters the chamber via the liquid inlet, flows through at least a portion of the plurality of micro-holes of the micro-hole array layer, and discharges from the liquid outlet. | 05-05-2022 |
20220137041 | DEVICE FOR METHODS OF DETECTING CANCER - A lateral flow assay device for testing a biological sample includes housing, a sample receiving pad, a conjugate test pad, and a nitrocellulose membrane. The sample receiving pad and conjugate test pad, as well as the nitrocellulose membrane, are enclosed within an interior portion of the housing. The sample receiving pad is in fluid communication with an opening defined in an outer surface of the housing for receiving the biological sample. At least a portion of the conjugate test pad is in contact with the sample receiving pad and is configured to test the biological sample. At least one window is defined in the outer surface of the housing adjacent the conjugate test pads such that the results of the test performed on the conjugate test pads are visible from outside of the housing. | 05-05-2022 |
20220137073 | DETECTION OF MISFOLDED TAU PROTEIN - Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like. | 05-05-2022 |